text
san diego ca accesswire may 5 2022 ensysce biosciences inc ensysce or the company nasdaq ensc otc pink enscw a clinical stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose today announced the release of its 2021 annual shareholder letter authored by chief executive officer dr lynn kirkpatrick to view the letter please visit about ensysce biosciences ensysce biosciences based in san diego ca is a clinical stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs leveraging its trypsin activated abuse protection taap and multi pill abuse resistance mpar platforms the company is developing next generation tamper proof opioids that prevent both drug abuse and overdoses ensysce s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse reducing the human and economic costs the platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs for more information please visit www ensysce com forward looking statements statements contained in this press release that are not purely historical may be deemed to be forward looking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of 1995 and other federal securities laws without limiting the foregoing the use of words such as may intends can might will expect plan and other similar expressions are intended to identify forward looking statements the product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and or efficacy that ensysce will not encounter problems or delays in clinical development or that any product candidate will ever receive regulatory approval or be successfully commercialized all forward looking statements are based on estimates and assumptions by ensysce s management that although ensysce believes to be reasonable are inherently uncertain all forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that ensysce expected in addition ensysce s business is subject to additional risks and uncertainties including among others the initiation and conduct of preclinical studies and clinical trials the timing and availability of data from preclinical studies and clinical trials expectations for regulatory submissions and approvals potential safety concerns related to or efficacy of ensysce s product candidates the availability or commercial potential of product candidates the ability of ensysce to fund its continued operations including its planned clinical trials the dilutive effect of stock issuances from our fundraising and ensysce s and its partners ability to perform under their license collaboration and manufacturing arrangements these statements are also subject to a number of material risks and uncertainties that are described in ensysce s most recent annual report on form 10 k and current reports on form 8 k which are available free of charge at the sec s website at www sec gov any forward looking statement speaks only as of the date on which it was made ensysce undertakes no obligation to publicly update or revise any forward looking statement whether as a result of new information future events or otherwise except as required under applicable law ensysce biosciences company contact lynn kirkpatrick ph d chief executive officer 858 263 4196 ensysce biosciences investor relations contact shannon devine mz north america main 203 741 8811 source ensysce biosciences inc view source version on accesswire com
rttnews the malaysia stock market on thursday ended the two day winning streak in which it had advanced almost 15 points or 0 9 percent the kuala lumpur composite index now rests just above the 1 580 point plateau and the losses may accelerate on friday the global forecast for the asian markets suggests consolidation on concerns for the outlook for interest rates and the global economy the european and u s markets were solidly lower and the asian bourses are tipped to open in similar fashion the klci finished sharply lower on thursday following losses from the telecoms financials and glove makers while the plantations offered mild support for the day the index dropped 17 45 points or 1 09 percent to finish at 1 582 98 after trading between 1 576 84 and 1 615 17 volume was 2 682 billion shares worth 2 379 billion ringgit there were 628 decliners and 380 gainers among the actives axiata tumbled 3 13 percent while cimb group retreated 1 73 percent dialog group shed 0 80 percent digi com plummeted 5 50 percent genting climbed 1 08 percent genting malaysia jumped 1 31 percent hartalega holdings slid 0 45 percent ihh healthcare eased 0 15 percent inari plunged 4 93 percent ioi corporation advanced 1 07 percent kuala lumpur kepong stumbled 1 90 percent maybank sank 0 88 percent maxis dropped 1 32 percent misc was up 0 38 percent mrdiy and sime darby plantations both gained 0 57 percent petronas chemicals added 0 78 percent ppb group lost 0 70 percent press metal declined 2 50 percent public bank slumped 1 28 percent rhb capital tanked 3 20 percent sime darby rose 0 43 percent telekom malaysia surrendered 3 01 percent tenaga nasional and hong leong bank both skidded 1 33 percent and top glove fell 0 60 percent the lead from wall street is broadly negative as the major averages opened under pressure and saw the losses accelerate as the day progressed finishing deep in the red the dow plummeted 1 063 points or 3 12 percent to finish at 32 997 97 while the nasdaq plunged 647 16 points or 4 99 percent to close at 12 317 16 and the s p 500 tumbled 153 30 points or 3 56 percent to end at 4 146 87 the sell off on wall street came as traders cashed in on the rally that followed the federal reserve s monetary policy announcement on wednesday which was less hawkish than some had feared but concerns about higher rates inflation the economic outlook and the ongoing war in ukraine remain contributing to the sharp pullback on wall street a sharp increase in treasury yields also weighed as the yield on the benchmark ten year note hit to its highest levels in three years traders were also looking ahead to the release of the labor department s closely watched monthly jobs report later today crude oil futures settled higher thursday benefitting from the european union proposal to impose sanctions on russian oil although prices pared some gains as the dollar rebounded on safe haven buying west texas intermediate crude oil futures for june ended higher by 0 45 or 0 4 percent at 108 26 a barrel
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
calgary alberta may 05 2022 globe newswire gran tierra energy inc gran tierra or the company nyse american gte tsx gte lse gte today announced the voting results from the company s annual meeting of stockholders held on may 4 2022 final voting results of gran tierra s annual meeting of stockholders stockholders elected all nine individuals nominated by gran tierra in addition stockholders voted for the ratification of the appointment of kpmg llp as gran tierra s independent registered public accounting firm for the fiscal year ending december 31 2022 for the approval on an advisory basis of the compensation of gran tierra s named executive officers every year as the preferred frequency of solicitation of stockholder advisory votes on the compensation of gran tierra s named executive officers and for the approval of the 2007 equity incentive plan as amended the detailed results of the vote are as follows proposal 1 election of directors for against abstain non votes gary s guidry 103 665 849 97 5 2 705 019 335 573 70 556 916 peter dey 87 911 653 84 0 16 790 829 2 003 958 70 556 916 evan hazell 101 024 231 96 5 3 687 499 1 994 709 70 556 916 robert b hodgins 99 364 937 95 0 5 271 675 2 069 828 70 556 916 alison redford 102 220 046 97 8 2 277 191 2 209 202 70 556 916 ronald royal 102 253 165 97 8 2 332 143 2 121 131 70 556 916 sondra scott 99 637 172 95 2 4 984 846 2 084 421 70 556 916 david p smith 102 123 557 97 5 2 587 313 1 995 570 70 556 916 brooke wade 99 835 833 95 4 4 866 966 2 003 641 70 556 916 proposal 2 for against abstain non votes ratification of appointment of the independent registered public accounting firm 170 088 249 96 0 6 495 233 679 874 0 proposal 3 for against abstain non votes approval of named executive officer compensation 94 910 820 88 9 10 923 981 871 640 70 556 915 proposal 4 every year every two years every three years abstain non votes approval of the preferred 88 490 938 1 655 691 9 191 649 7 353 011 70 572 067 frequency of solicitation of stockholders advisory votes on the compensation of gran tierra s named executive officers proposal 5 for against abstain non votes approval of 2007 equity incentive plan as amended 71 854 873 67 3 33 685 877 1 165 690 70 556 916 about gran tierra energy inc gran tierra energy inc together with its subsidiaries is an independent international energy company currently focused on oil and natural gas exploration and production in colombia and ecuador the company is currently developing its existing portfolio of assets in colombia and ecuador and will continue to pursue additional growth opportunities that would further strengthen the company s portfolio the company s common stock trades on the nyse american the toronto stock exchange and the london stock exchange under the ticker symbol gte additional information concerning gran tierra is available at www grantierra com information on the company s website including the sustainability report does not constitute a part of this press release investor inquiries may be directed to info grantierra com or 403 265 3221 gran tierra s securities and exchange commission filings are available on the sec website at the company s canadian securities regulatory filings are available on sedar at and uk regulatory filings are available on the national storage mechanism website at contact information for investor and media inquiries please contact gary guidry chief executive officer ryan ellson executive vice president chief financial officer rodger trimble vice president investor relations 1 403 265 3221 info grantierra com
the federal reserve on wednesday announced its biggest rate hike since 2000 with a half percentage point increase as it works to crush soaring us inflation with inflation at the highest rate in four decades federal reserve chair jerome powell sent a message directly to the american people expressing concern for the pain caused by rising prices and pledging to use all available tools to bring them down but he told reporters he remains confident the economy is strong enough to withstand rate increases without tipping into a recession after a quarter point hike in march the us central bank s policy setting federal open market committee fomc pushed the benchmark interest rate above 0 75pc as it works to cool the economy and confirmed more increases will be appropriate the hike will raise the costs of all types of borrowing from mortgages to credit cards to car loans cooling demand and business activity inflation has become an overriding concern after the world s largest economy saw annual consumer prices surge 8 5pc over the 12 months to march the biggest jump since december 1981 policymakers continue to believe inflation will gradually return to the fed s 2pc target as it raises borrowing costs but in a statement following the conclusion of its two day meeting the fomc said it will be highly attentive to inflation risks in an unusual move powell opened his news conference speaking to the american people inflation is much too high and we understand the hardship that is causing he said promising to use all tools available to bring it down expeditiously he acknowledged that higher interest rates also bring their share of pain but everyone would be better off if we can get this job done the sooner the better to achieve that aim he said additional 50 basis point increases should be on the table at the next couple of meetings however a more aggressive three quarter point hike is not under consideration the fed s goal is to engineer a soft landing reining in inflation while avoiding a contraction in economic activity and powell said that outcome is likely it s a strong economy and nothing about it suggested that it s close to or vulnerable to a recession he said but with china s pandemic lockdowns worsening global supply snarls and the war in ukraine pushing commodity prices higher analysts fear factors beyond the central bank s control could undermine that goal and perhaps plunge the us economy into a recession the fomc acknowledged the highly uncertain impact of russia s invasion of ukraine and western sanctions on moscow which are creating additional upward pressure on inflation and are likely to weigh on economic activity in addition covid lockdowns in china are likely to exacerbate supply chain disruptions the statement said though it contracted in the first quarter powell said the economy was healthy enough to withstand higher rates and pointed to robust job gains and strong household and business spending however central bankers cannot engineer a solution for the worker shortages that have challenged businesses and raised fears of a wage price spiral when employees demand higher salaries and fuel price increases powell downplayed those concerns saying some of the inflation is due to price shocks while fed policy can help address the imbalance in the labor market on wednesday payroll services firm adp reported private employers added a weaker than expected 247 000 workers in april a sign that companies are struggling to find available labor while government data released tuesday showed there are nearly two openings for every job seeker the fomc also said it would begin reducing its massive bond holdings starting june 1 beginning at the pace of 47 5b a month and then doubling after three months also aimed at removing stimulus from the economy the decision was widely expected and many economists believe the fomc will again hike rates by a half point in june though ian shepherdson of pantheon economics said after that we think all bets are off given the likelihood of a steep sustained drop in inflation a clear softening in manufacturing and a meltdown in housing market activity stock markets cheered the fed move closing sharply higher with big gains in interest sensitive tech shares
the u s air force s next generation air dominance ngad fighter will be the most expensive fighter jet ever built ngad will also be the first sixth generation fighter designed to fight china in the pacific the crewed fighter will also control robotic wingmen each of which will cost more than an f 35 the u s air force is bracing the public and congress for the highly anticipated next generation air dominance ngad fighter and the sticker shock wave the world s first sixth generation jet will leave in its wake the ngad fighter set to begin replacing the f 22 raptor in 2030 will cost multiple hundreds of millions of dollars easily two or three times the cost of the f 35 the fighter is being optimized for the asia pacific theater and will be accompanied into battle by robotic sidekicks air force secretary frank kendall in remarks reported by defense news told lawmakers that the crewed version of the ngad fighter jet would cost multiple hundreds of millions of dollars ngad includes both crewed and uncrewed fighters the uncrewed version would cost no more than half as much as the crewed version a per unit cost of 200 million would easily make crewed ngad fighters the most expensive fighter jet of all time and to be clear kendall s statement leaves plenty of room for the jet to actually cost in excess of 300 million for context the f 35a costs 77 million while the new updated f 15ex super eagle costs 80 million if a crewed ngad costs 300 million and the uncrewed version 150 million that same pot of money could buy nearly six f 35as ngad is a fundamentally different aircraft than the f 35a the f 35a was designed in the 1990s as an economical replacement for several fighters including the f a 18c av 8b harrier f 16 and a 10 thunderbolt the f 35 was designed to fulfill multiple missions including traditional fighter air to air roles air to ground strike roles and close air support the new fighter is better compared to and will replace the f 22a raptor the world s first fifth generation fighter designed purely for the air superiority mission nurphoto getty images a u s air force f 35 assigned to raf lakenheath flies a low altitude run through the mach loop wales january 2022 we don t know a lot about ngad other than that it was designed and flown in less than a year the strategic environment has changed a lot since the late 1980s when the raptor was first envisioned and ngad will reflect that the aircraft is likely to be laser focused on china which means operating over the sweeping expanse of the asia pacific region a war with beijing will involve moving tactical aircraft across thousands of miles operating from remote bases carved out of tiny islands and flying long range missions against enemy air and ground defenses an ngad might for example fly 1 400 miles from guam to kadena air base on the japanese island of okinawa there it could bolster the island s air defenses protecting the american and japanese bases on the island from chinese fighters attempting to establish air superiority and strike aircraft pummeling allied bases on the way there and back it could use its range to skirt around chinese warships with long range surface to air missile systems loop images getty images an f 22 raptor at raf fairford july 2017 the f 35 can t do that but that s not what the f 35 was meant for the f 22 however can t do that either and that s what the f 22 was meant for in the first place what will ngad look like stephen trimble defense editor at aviation week space technology spelled out some ideas at the check six podcast trimble suggests a long range fighter with the ability to cruise at 70 000 feet much higher than current fighters above the speed of sound using breakthrough technologies such as daytime or optical stealth usaf getty images f 111 assigned to raf upper heyford dropping 500 pound mk 82 practice blue band bombs the f 111 was one of the largest tactical jets flown by the u s air force one thing we can infer about the new fighter is that it will be big previous generation fighters used external fuel tanks to extend their range on combat missions allowing aerial refueling tankers to stay out of harm s way external fuel and weapons however ruin an aircraft s stealthy profile making it much more visible to radar as a result ngad will have to store a large amount of fuel and air to air missiles under the skin buried within the fuselage of the aircraft trimble suggests ngad could be as large as the f 111 a large long range strike aircraft that served from the late 1960s to the 1990s the f 111 was 73 feet long could fly from treetop level to 60 000 feet had a maximum takeoff weight of 100 000 pounds and with internal fuel alone had a range of 2 600 nautical miles usaf getty images an f 111 parked alongside an f 4 phantom 63 f 15 65 and mirage iii the f 22 is 62 feet long flies at up to 65 000 feet has a maximum takeoff weight of 83 000 pounds and has a range of 1 600 nautical miles while carrying 10 000 pounds of fuel in external tanks this number suggests that if the air force wanted an air superiority fighter with a 2 000 nautical mile range enough to fly from guam to okinawa an f 111 sized aircraft is not far from the mark no matter what ngad actually looks like it will probably be unlike anything we ve ever seen before it will also cost a lot more than we ve ever paid for a fighter jet before but in the wake of russia s invasion of ukraine which many predicted would never happen it seems likely that the u s will indeed pay whatever it costs both to deter china from launching a similar attack on taiwan or if deterrence fails clearing the skies of people s liberation army air force fighters now watch this
greenwich conn ap _ associated capital group inc ac on thursday reported a first quarter loss of 16 2 million after reporting a profit in the same period a year earlier the greenwich connecticut based company said it had a loss of 73 cents per share the asset manager posted revenue of 2 6 million in the period associated capital shares have fallen nearly 10 since the beginning of the year in the final minutes of trading on thursday shares hit 38 76 an increase of slightly more than 8 in the last 12 months _____ this story was generated by automated insights using data from zacks investment research access a zacks stock report on ac at
fort washington pa may 05 2022 globe newswire toll brothers apartment living the rental division of toll brothers inc nyse tol the nation s leading builder of luxury homes has been named one of the largest multifamily developers in the united states by the national multifamily housing council s nmhc 2022 nmhc 50 the annual ranking of the nation s largest apartment owners managers developers builders and syndicators toll brothers apartment living is now ranked as the 11th largest multifamily developer in the united states with 3 621 units started during the year of 2021 we re extremely honored to earn the recognition as one of the top multifamily developers nationwide said charles elliott president of toll brothers apartment living this ranking underscores the extraordinary results of our national growth strategy helping us to attract and retain the very best from the multifamily industry throughout many of the key markets in which we are expanding the number of units started in 2021 by toll brothers apartment living represents a 416 increase over the previous year the greatest single year growth period in the firm s history in addition to significant growth the firm started projects in more markets than ever before continuing the expansion of its national platform this year marks the 33rd edition of the nmhc top 50 lists nmhc partners with kingsley associates a leading real estate research and consulting firm for the nmhc 50 s research and analysis all apartment owners managers developers builders and syndicators are invited to answer a survey questionnaire that asks about their prior year s activities apartment owners managers and syndicators are ranked based on their portfolio holdings either owned or managed as of january 1 2022 while developers and builders are ranked based on the number of units started in 2021 for more details about the nmhc 50 visit nmhc org the nmhc 50 about toll brothers apartment living toll brothers apartment living is the apartment development division of toll brothers inc nyse tol an award winning fortune 500 company and the nation s leading builder of luxury homes toll brothers apartment living brings the same quality luxury and service for which toll brothers is known to its exceptional rental and mixed use communities in select markets including atlanta boston dallas los angeles new york philadelphia phoenix and washington dc toll brothers apartment living communities combine the energy of vibrant locations with unparalleled amenities resident services design and the expertise of america s luxury home builder in 2022 nmhc ranked toll brothers apartment living the 11th largest apartment developer in the united states today the firm has developed nearly 8 500 units has nearly 4 500 units under management and controls a national pipeline of more than 20 500 units for more information visit tollbrothersapartmentliving com about toll brothers toll brothers inc a fortune 500 company is the nation s leading builder of luxury homes the company was founded 55 years ago in 1967 and became a public company in 1986 its common stock is listed on the new york stock exchange under the symbol tol the company serves first time move up empty nester active adult and second home buyers as well as urban and suburban renters toll brothers builds in over 60 markets in 24 states arizona california colorado connecticut delaware florida georgia idaho illinois maryland massachusetts michigan nevada new jersey new york north carolina oregon pennsylvania south carolina tennessee texas utah virginia and washington as well as in the district of columbia the company operates its own architectural engineering mortgage title land development golf course development smart home technology and landscape subsidiaries the company also operates its own lumber distribution house component assembly and manufacturing operations toll brothers was named the world s most admired homebuilder in fortune magazine s 2022 survey of the world s most admired companies the seventh year it has been so honored toll brothers has also been named builder of the year by builder magazine and is the first two time recipient of builder of the year from professional builder magazine for more information visit tollbrothers com toll brothers discloses information about its business and financial performance and other matters and provides links to its securities filings notices of investor events and earnings and other news releases on the investor relations section of its website investors tollbrothers com 2022 fortune media ip limited all rights reserved used under license fortune and fortune media ip limited are not affiliated with and do not endorse the products or services of toll brothers about the national multifamily housing council based in washington d c the national multifamily housing council nmhc is the leadership of the trillion dollar apartment industry we bring together the prominent owners managers and developers who help create thriving communities by providing apartment homes for 40 million americans nmhc provides a forum for insight advocacy and action that enables both members and the communities they help build to thrive for more information visit nmhc org
san diego may 5 2022 prnewswire tusimple nasdaq tsp a global self driving technology company based in san diego california today announced its participation in the following investor conferences on wednesday may 18 2022 at 12 00 p m eastern time management will present in a panel at the bank of america 2022 transportation airlines and industrials conference in boston ma on tuesday may 24 2022 at 1 00 p m beijing hong kong time management will present in a virtual track presentation at the morgan stanley virtual china summit 2022 on tuesday may 24 2022 at 2 50 p m eastern time management will present in a fireside chat at the j p morgan 50th annual global technology media and communications conference in boston ma on wednesday may 25 2022 management will virtually participate in the 2022 ubs global truck commercial vehicle and powertrain conference on thursday may 26 2022 at 1 05 p m eastern time management will present in a virtual panel at the wolfe 15th annual global transportation industrials conference management will be available for one on one or group meetings with institutional investors at all the conferences above portfolio managers and analysts who wish to request a meeting should contact their institutional sales representative at each sponsoring bank about tusimple tusimple is a global autonomous driving technology company headquartered in san diego california with operations in arizona texas europe and china founded in 2015 tusimple is developing a commercial ready fully autonomous sae level 4 driving solution for long haul heavy duty trucks tusimple aims to transform the 4 trillion global truck freight industry through the company s leading ai technology which makes it possible for trucks to drive safely autonomously operate nearly continuously and reduce fuel consumption by 10 relative to manually driven trucks global achievements include the world s first fully autonomous driver out semi truck run on open public roads and development of the world s first autonomous freight network afn visit us at www tusimple com view original content to download multimedia source tusimple holdings inc
sean pavone shutterstock colleges where acceptance rates have decreased the most since 2001 each fall thousands of high school students and their families begin the nerve racking process of applying to college whether families are navigating the admissions process for the first time or for the fifth time it s still a journey that requires a slew of research and patience while college enrollment has gone down over the last several years throughout the 2000s and 2010s enrollment in public and private universities reached record highs edsmart identified 10 colleges that have shown the greatest decline in acceptance rates between the 2001 admissions cycle and 2020 data came from the integrated postsecondary education data system at the national center for education statistics only colleges and universities with at least 1 000 applicants were included in the analysis for each college we ve included offerings that potentially make a school more attractive to applicants from affordability to academic programs determining the exact reasons why these colleges have seen a record setting growth of applications over the last 20 years is difficult to quantify for many students over the decades pursuing a secondary degree is a path to improve career and earning opportunities indeed a 2018 college board report found that the median annual earnings for workers with a bachelor s degree was 24 900 higher than those whose highest degree was a high school diploma while there are many factors at play in addition to education attainment such as the type of career field and personal characteristics the report also found that the unemployment rate for workers age 25 and older with at least a bachelor s degree has consistently been half the rate of high school graduates the growing interest in applying to college may also be influenced by the widespread adoption of the common application a single standardized online application form introduced in 1988 more than 900 colleges accept the common app which sees a 10 increase in applications for the schools once they adopt this system the common app makes the process streamlined for both colleges and applicants as prospective students can fill out one form for several institutions for high schoolers saving time during the process can be appealing it can also lead to applying to more schools since they don t need to spend extra time to add a few more safety or reach institutions to widen their chances each school on this list allows applicants to apply with the common app the conversation around the decreasing acceptance rates has spurred discourse among the higher education community several ivy league schools are looking to downplay their single digit admission rates by withholding their admission data stanford university began the same practice in 2018 in hopes of making students feel less anxious to apply even as many institutions experience a rise in popularity with record numbers of applications they continue to improve their offerings from student life to academic rigor read on to see the list of schools that have seen the biggest change in competitive admission rates and learn more background about each institution katherine carey shutterstock 10 pitzer college claremont california acceptance rate 2020 16 6 per 100 69 2 decrease from 2001 applicants 2020 4 260 86 6 increase from 2001 freshmen enrollment 2020 219 1 8 decrease from 2001 pitzer college is one of the 5cs five undergraduate colleges in a consortium located in claremont california it joins pomona college another 5c on this list of colleges with decreasing acceptance rates pitzer is a private institution and while the annual cost runs around 57 000 before financial aid pitzer is known for its strength in majors like neuroscience environmental analysis and critical global studies pitzer is noted for student led policy initiatives this influence has spurred such actions as the adoption of gender neutral residence halls and bathrooms recognition of indigenous peoples day and the selection of the college s first african american president environmental impact has also been a focus with pitzer being the first college in california to divest endowments from fossil fuel stocks and placing a campus wide ban on plastic water bottles popova valeriya shutterstock 9 colby college waterville maine acceptance rate 2020 10 3 per 100 69 7 decrease from 2001 applicants 2020 13 922 256 2 increase from 2001 freshmen enrollment 2020 566 16 0 increase from 2001 colby college claims to be on a mission to eliminate barriers for students topping this list is a pledge to meet 100 of each admitted student s demonstrated financial needs without loans colby has also simplified its application process with the common app the current student body equals 2 100 students providing a small school experience the liberal arts college offers 56 majors ranging from environmental computation to global studies anthropology to astrophysics and 35 minors something appealing to those intimidated by maine winters is colby s jan plan which encourages students to spend the winter term with one primary focus such as conducting research in belize or filming a documentary in patagonia ken wolter shutterstock 7 tie grinnell college grinnell iowa acceptance rate 2020 19 2 per 100 70 3 decrease from 2001 applicants 2020 8 137 311 0 increase from 2001 freshmen enrollment 2020 360 0 6 increase from 2001 on campus the grinnellian community consists of a 9 1 student faculty ratio with most classes having 20 or fewer students something enticing for students looking for a small midwest college experience grinnell offers 27 majors including biological chemistry digital studies and linguistics plus 16 concentrations founded by abolitionists in 1846 grinnell has devoted itself to positive social change and encourages volunteerism within the community and around the globe deborah kekone shutterstock 7 tie pomona college claremont california acceptance rate 2020 8 6 per 100 70 3 decrease from 2001 applicants 2020 10 388 179 8 increase from 2001 freshmen enrollment 2020 399 1 5 increase from 2001 as mentioned earlier pomona college is part of the consortium of california colleges that make up the 5cs pomona college students are then a part of an 8 000 student community between these five schools and like its cohort pitzer pomona is seeing decreasing acceptance rates the student to faculty ratio sits at 8 1 giving classes a more intimate experience amid the 48 majors offered are specialties like late antique medieval studies cognitive science and molecular biology wangkun jia shutterstock 6 northeastern university boston massachusetts acceptance rate 2020 20 5 per 100 70 9 decrease from 2001 applicants 2020 64 459 336 7 increase from 2001 freshmen enrollment 2020 3 128 6 6 increase from 2001 something the university strongly promotes is experiential learning with a focus on knowledge and skills gained from both the classroom and through work research and international study over 90 majors are offered at northeastern raising social awareness takes center stage at the university with standout programs like their civil rights and restorative justice project center on crime and community resilience institute on race and dukakis center for urban and regional policy art is another form of action northeastern takes in uniting students and the community its public art initiative brings art to public spaces throughout the campus and nearby boston neighborhoods canva 5 northwestern university evanston illinois acceptance rate 2020 9 3 per 100 71 6 decrease from 2001 applicants 2020 39 263 166 6 increase from 2001 freshmen enrollment 2020 1 901 2 4 decrease from 2001 the university strives for an environment rich in diversity and inclusion global engagement and research opportunities northwestern boasts 90 school based research centers and more than 40 university research institutes and centers students from every u s state and from over 75 nations worldwide are undergraduates at northwestern the school s undergraduate offerings include over 120 majors and minors with subjects ranging from asian languages and cultures to computer engineering and from gender and sexuality studies to journalism campus life includes hundreds of clubs and organizations for students to join and the northwestern athletics program is held in high regard as a member of the big ten conference canva 4 vanderbilt university nashville tennessee acceptance rate 2020 11 6 per 100 74 9 decrease from 2001 applicants 2020 36 646 276 6 increase from 2001 freshmen enrollment 2020 1 693 8 8 increase from 2001 vanderbilt has extended its test scores non requirement through 2024 what is taken into consideration are academics leadership and engagement outside of the classroom the university has four undergraduate schools college of arts and science blair school of music school of engineering peabody school of education and human development and 70 majors based on reporting from the 2021 princeton review vanderbilt scored 2 on their lists for most beautiful campus and happiest students and 1 on the list for their students love these colleges eqroy shutterstock 3 colorado college colorado springs colorado acceptance rate 2020 13 6 per 100 76 1 decrease from 2001 applicants 2020 10 257 202 3 increase from 2001 freshmen enrollment 2020 538 12 3 increase from 2001 instead of following the usual two semesters a year structure colorado college adopted a block plan this allows for taking one class at a time in an intensive course 18 days from 9 a m to noon per the college this is equal to one class on a semester plan colorado college offers 80 majors which include political science geology economics sociology and environmental studies this institution also has an outdoor education program with 200 annual outdoor trips and more than 36 workshops and trainings fotoluminate llc shutterstock 2 tulane university new orleans louisiana acceptance rate 2020 11 1 per 100 81 8 decrease from 2001 applicants 2020 43 892 304 1 increase from 2001 freshmen enrollment 2020 1 801 18 7 increase from 2001 founded as the medical college of louisiana in 1834 tulane was sought after by students looking to enter the medical profession since then the university has become known as a top ranked research institution tulane offers over 70 majors in five different schools science and engineering architecture business liberal arts and public health at the heart of tulane s values is community service in 2021 the university saw members of the class body devoting 780 000 hours of civic service to tulane s hometown of new orleans perhaps this speaks to the university s motto non sibi sed suis not for one s self but for one s own canva 1 university of chicago chicago illinois acceptance rate 2020 7 3 per 100 83 3 decrease from 2001 applicants 2020 34 350 360 8 increase from 2001 freshmen enrollment 2020 1 848 71 0 increase from 2001 students can be found delving into the university of chicago s more than 50 majors including architectural studies and art history astrophysics biological sciences data science and human rights bringing inspiration to campus are regular speakers some who have hit the stage in the past supreme court justice elena kagan chance the rapper canadian prime minister justin trudeau senator bernie sanders jon stewart and former president barack obama bringing an emphasis on community service to the university of chicago back in 1996 was michelle obama the former first lady founded the university community service center which sees over 2 000 students giving back through more than 250 chicago organizations this story originally appeared on edsmart and was produced and distributed in partnership with stacker studio
new york new york reality returned to wall street thursday a day after an explosive rally triggered by a half percentage point increase in official interest rates the fed move was tempered by remarks from federal reserve governor jerome powell that more aggressive rate hikes may not be needed in the future yesterday s explosion higher was completely comical it was ridiculous his comments did not justify the move that we saw kenny polcari managing partner at kace capital advisors told reuters news agency thursday part of what people are recognizing very deep within his speech yesterday is the concern that inflation is out of control and the fed is behind the eight ball it is the concern that they may even have to make a more drastic move the nasdaq composite led thursday s firesale plummeting 647 16 points or 4 99 percent to 12 317 69 the dow jones industrials dived 1 063 09 points or 3 12 percent to 32 997 97 the standard and poor s 500 shed 153 30 points or 2 56 percent to 4 146 87 the u s dollar was steady thursday the euro fell from wednesday s 1 06 level to trade at 1 0550 around the new york close the british pound tumbled to 1 2365 the japanese yen weakened to 130 07 the swiss franc was sharply lower at 0 9846 the canadian dollar was little changed at 1 2834 the australian dollar dropped more than a cent and a half to 0 7113 the new zealand dollar weakened to 0 6430 on overseas equity markets the dax in germany advanced 0 49 percent the paris based cac 40 added 0 43 percent in london the ftse 100 edged up 0 13 percent the australian all ordinaries gained 74 40 points or 0 98 percent to 7 639 20 in new zealand the s p nzx 50 advanced 72 36 points or 0 62 percent to 11 747 57 china s shanghai composite rose 20 70 points or 0 68 percent to 3 067 76 in hong kong the hang seng went against the trend closing down 76 12 points or 0 36 percent at 20 793 40 japanese and south korean markets were closed thursday for public holidays
san diego may 5 2022 prnewswire tusimple nasdaq tsp a global self driving technology company based in san diego california today announced its participation in the following investor conferences on wednesday may 18 2022 at 12 00 p m eastern time management will present in a panel at the bank of america 2022 transportation airlines and industrials conference in boston ma at management will present in a panel at the bank of america 2022 transportation airlines and industrials conference in on tuesday may 24 2022 at 1 00 p m beijing hong kong time management will present in a virtual track presentation at the morgan stanley virtual china summit 2022 at hong kong time management will present in a virtual track presentation at the morgan stanley virtual china summit 2022 on tuesday may 24 2022 at 2 50 p m eastern time management will present in a fireside chat at the j p morgan 50th annual global technology media and communications conference in boston ma at management will present in a fireside chat at the j p morgan 50th annual global technology media and communications conference in on wednesday may 25 2022 management will virtually participate in the 2022 ubs global truck commercial vehicle and powertrain conference management will virtually participate in the 2022 ubs global truck commercial vehicle and powertrain conference on thursday may 26 2022 at 1 05 p m eastern time management will present in a virtual panel at the wolfe 15th annual global transportation industrials conference management will be available for one on one or group meetings with institutional investors at all the conferences above portfolio managers and analysts who wish to request a meeting should contact their institutional sales representative at each sponsoring bank about tusimple tusimple is a global autonomous driving technology company headquartered in san diego california with operations in arizona texas europe and china founded in 2015 tusimple is developing a commercial ready fully autonomous sae level 4 driving solution for long haul heavy duty trucks tusimple aims to transform the 4 trillion global truck freight industry through the company s leading ai technology which makes it possible for trucks to drive safely autonomously operate nearly continuously and reduce fuel consumption by 10 relative to manually driven trucks global achievements include the world s first fully autonomous driver out semi truck run on open public roads and development of the world s first autonomous freight network afn visit us at www tusimple com source tusimple holdings inc
being an active trader is crucial in this environment strategist volatility continued to dominate financial markets with stocks pushing lower as the latest u s jobs data cemented expectations the federal reserve will remain on its rate hike path to combat stubbornly high inflation at the end of a week marked by fickle trading quick reversals and heightened anxiety the s p 500 failed to stay in the green and fell to its lowest level in about a year the gauge posted its fifth straight weekly drop the longest losing streak since june 2011 the tech heavy nasdaq 100 underperformed treasury 10 year yields remained above 3 per cent while the dollar rose gasoline futures in new york settled at a record high the markets have been on a roller coaster ride said lindsey bell chief markets and money strategist at ally there is a significant amount of uncertainty a key question for many investors is how big of a hurdle a quickly rising interest rate environment is going to be for stocks to overcome the long awaited jobs report showed u s hiring advanced at a robust pace in april yet a smaller labor force may increase pressure on employers to boost wages even more to bring workers back that dynamic will likely complicate the fed s fight to tame decades high inflation as central bankers work to bring labor demand in line with supply more comments no big surprises from today s jobs report it largely confirms that the labor market remains tight affording the fed the flexibility to tackle its price stability mandate head on said jason pride chief investment officer of private wealth at glenmede investors just can t confidently buy stocks as too much uncertainty persists with what will happen with global growth and how far the fed will take tightening beyond the summer wrote ed moya senior market analyst at oanda some of the main moves in markets stocks the s p 500 fell 0 6 per cent as of 4 p m new york time the nasdaq 100 fell 1 2 per cent the dow jones industrial average fell 0 3 per cent the msci world index fell 1 per cent currencies the bloomberg dollar spot index rose 0 2 per cent the euro was little changed at us 1 0547 the british pound fell 0 2 per cent to us 1 2342 the japanese yen fell 0 3 per cent to 130 54 per dollar bonds the yield on 10 year treasuries advanced eight basis points to 3 12 per cent germany s 10 year yield advanced nine basis points to 1 13 per cent britain s 10 year yield advanced three basis points to 2 00 per cent commodities
new york ny may 05 2022 globe newswire cartesian growth corporation ii the company announced today the pricing of its initial public offering of 20 000 000 units at a price of 10 00 per unit the units are expected to commence trading on may 6 2022 on the nasdaq global market under the symbol reneu the company s sponsor is an affiliate of cartesian capital group llc a global private equity firm specializing in providing growth capital to transnational businesses each unit consists of one class a ordinary share and one third of one redeemable warrant with each whole warrant entitling the holder to purchase one class a ordinary share at a price of 11 50 per share once the securities comprising the units begin separate trading the class a ordinary shares and warrants are expected to be listed on the nasdaq global market under the symbols rene and renew respectively cantor fitzgerald co is serving as the sole book running manager for the offering and piper sandler co is acting as co manager the underwriters have been granted a 45 day option to purchase up to an additional 3 000 000 units at the initial public offering price to cover over allotments if any the offering is expected to close on or about may 10 2022 subject to customary closing conditions a registration statement relating to these securities has been declared effective by the securities and exchange commission the sec on may 5 2022 the offering is being made only by means of a prospectus copies of which may be obtained by contacting cantor fitzgerald co attention capital markets 499 park avenue new york ny 10022 or by e mail at prospectus cantor com this press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction about cartesian growth corporation ii cartesian growth corporation ii is a blank check company organized for the purpose of effecting a merger share exchange asset acquisition share purchase or reorganization or engaging in any other similar business combination with one or more businesses or entities the company is led by chairman and chief executive officer peter yu who is also the managing partner of cartesian capital group llc a global private equity firm and registered investment adviser headquartered in new york city new york the company s acquisition and value creation strategy is to identify and combine with an established high growth company that can benefit from both a constructive combination and continued value creation by the company s management the company is an emerging growth company as defined in the jumpstart our business startups act of 2012 for more information about cartesian growth corporation ii please visit www cartesiangrowth com cgc2 forward looking statements this press release includes forward looking statements that involve risks and uncertainties forward looking statements are statements that are not historical facts such forward looking statements including with respect to the initial public offering and the anticipated use of the proceeds thereof are subject to risks and uncertainties which could cause actual results to differ from the forward looking statements including those set forth in the risk factors section of the registration statement and preliminary prospectus for the company s initial public offering copies of these documents can be accessed through the sec s website at www sec gov no assurance can be given that the offering discussed above will be completed on the terms described or at all or that the net proceeds of the offering will be used as indicated the company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in the company s expectations with respect thereto or any change in events conditions or circumstances on which any statement is based except as required by law media contact cartesian growth corporation ii contact cartesiangrowth com
all dollar amounts are united states dollars unless otherwise stated vancouver bc may 5 2022 prnewswire galiano gold inc galiano or the company tsx gau nyse gau reports first quarter q1 operating and financial results for the company and the asanko gold mine agm located in ghana west africa the agm is a 50 50 joint venture jv with gold fields ltd jse gfi nyse gfi which is managed and operated by galiano all financial information contained in this release is unaudited and reported in us asanko gold mine key metrics 100 basis production gold production of 42 343 ounces in line with 2022 production guidance of 100 000 120 000 ounces of gold gold production of 42 343 ounces in line with 2022 production guidance of 100 000 120 000 ounces of gold cost performance total cash costs per ounce 1 of 1 361 and all in sustaining costs 1 aisc of 1 559 oz during the quarter resulting in positive cash flows from operations of 3 9 million and aisc margin 1 of 12 0 million total cash costs per ounce of and all in sustaining costs aisc of oz during the quarter resulting in positive cash flows from operations of and aisc margin of financial performance reported gold revenue of 77 4 million generated from 41 929 gold ounces sold at an average realized price of 1 846 oz reported a net loss of 13 6 million during the quarter following the recognition of a 21 0 million severance liability and adjusted ebitda 1 of 13 1 million reported gold revenue of generated from 41 929 gold ounces sold at an average realized price of oz reported a net loss of during the quarter following the recognition of a severance liability and adjusted ebitda of focus on exploration deep directional drilling commenced at the nkran deposit aimed at defining the continuity and extension of mineralization below the limits of observed mineral resources the results of this program will be used to evaluate the underground potential of nkran exploration drilling continued at greater midras south while additional resource definition drilling progressed at miradani and nkran cut 3 deep directional drilling commenced at the nkran deposit aimed at defining the continuity and extension of mineralization below the limits of observed mineral resources the results of this program will be used to evaluate the underground potential of nkran exploration drilling continued at greater midras south while additional resource definition drilling progressed at miradani and nkran cut 3 culture of safety strong safety performance with no lost time injuries lti nor total recordable injuries tri reported during the quarter resulting in 12 month rolling lti and tri frequency rates of 0 11 and 0 21 per million employee hours worked respectively the agm has now achieved 6 3 million employee hours worked without an lti strong safety performance with no lost time injuries lti nor total recordable injuries tri reported during the quarter resulting in 12 month rolling lti and tri frequency rates of 0 11 and 0 21 per million employee hours worked respectively the agm has now achieved 6 3 million employee hours worked without an lti stable liquidity 45 3 million in cash 13 1 million in gold sales receivables and 4 1 million in gold on hand and no debt as of march 31 2022 in cash in gold sales receivables and in gold on hand and no debt as of workforce optimization undertook a process of rationalizing the agm s workforce severance notifications were issued and personnel necessary to maintain current operations have been retained with new employment contracts management expects to realize near term and sustainable cost savings and a more streamlined and efficient operation over the remaining life of mine as a result of the rationalization 1 see non ifrs performance measures galiano gold highlights stable balance sheet cash on hand of 50 4 million and 8 7 million in receivables as at march 31 2022 while remaining debt free cash on hand of and in receivables as at while remaining debt free earnings reported a net loss of 1 5 million or 0 01 per share for q1 2022 reported a net loss of or per share for q1 2022 board and management changes marcel de groot and shawn wallace confirmed that they will not be standing for re election at the company s upcoming annual general meeting and greg martin former cfo of ssr mining inc will be nominated for election at that meeting on march 23 2022 the company announced that fausto di trapani had stepped down as cfo of the company to pursue another opportunity and the company appointed matt freeman svp finance as its new cfo in line with the company s succession plan production for the quarter was in line with expectations and is on track to meet 2022 production guidance said matt badylak president and chief executive officer we are nearing completion of mining at both esaase and akwasiso and have started to supplement mill feed with stockpile material which currently is performing in line with our expectations we continue to advance the technical work we have previously outlined and will provide periodic updates as we progress through these work programs we anticipate providing an update to the agm s mineral reserves post the completion of this work in q1 2023 finally during the quarter we successfully initiated a rationalization of the agm s workforce which despite an upfront cost will deliver immediate cost savings and enable a more streamlined and efficient operation going forward asanko gold mine summary of q1 2022 operational and financial results 100 basis asanko gold mine 100 basis q1 2022 q4 2021 q3 2021 q2 2021 q1 2021 ore mined 000t 1 075 1 623 1 464 1 333 1 841 waste mined 000t 5 279 8 752 10 017 9 073 9 552 total mined 000t 6 354 10 375 11 481 10 406 11 393 strip ratio w o 4 9 5 4 6 8 6 8 5 2 average gold grade mined g t 1 3 1 2 1 3 1 2 1 3 mining cost t mined 4 64 3 75 3 28 3 03 3 31 ore transportation from esaase 000 t 1 304 1 264 1 272 1 261 870 ore transportation cost t trucked 5 82 6 13 5 88 6 20 6 48 ore milled 000t 1 482 1 472 1 542 1 475 1 444 average mill head grade g t 1 3 1 2 1 1 1 1 1 4 average recovery rate 69 91 90 94 95 processing cost t treated 9 46 10 07 9 68 9 87 10 31 gold production oz 42 343 50 278 49 543 50 421 59 999 gold sales oz 41 929 51 368 48 435 53 348 62 925 average realized gold price oz 1 846 1 771 1 758 1 782 1 757 operating cash costs1 oz 1 268 1 168 1 185 1 147 901 total cash costs1 oz 1 361 1 257 1 273 1 236 989 all in sustaining costs1 oz 1 559 1 539 1 598 1 497 1 158 all in sustaining margin1 oz 287 232 160 285 599 asanko gold mine 100 basis q1 2022 q4 2021 q3 2021 q2 2021 q1 2021 all in sustaining margin1 m 12 0 11 9 7 8 15 2 37 7 revenue m 77 5 91 1 85 3 95 2 110 8 income loss from mine operations m 10 6 8 9 13 0 18 1 35 9 adjusted net income loss 1 m 7 4 11 4 7 7 12 7 29 7 cash provided by operating activities m 3 9 14 0 26 5 10 8 35 4 the agm produced 42 343 ounces of gold during the quarter as the processing plant achieved milling throughput of 1 5mt of ore processed at a grade of 1 3g t with metallurgical recovery averaging 69 refer to the company s news release dated february 25 2022 for further details on lower plant recovery for further details on lower plant recovery sold 41 929 ounces of gold in q1 2022 at an average realized gold price of 1 846 oz for total revenue of 77 5 million including 0 1 million of by product silver revenue a decrease of 33 3 million from q1 2021 the decrease in revenue quarter on quarter was a function of a 33 reduction in sales volumes partly offset by a 5 increase in realized gold prices relative to q1 2021 oz for total revenue of including of by product silver revenue a decrease of from q1 2021 the decrease in revenue quarter on quarter was a function of a 33 reduction in sales volumes partly offset by a 5 increase in realized gold prices relative to q1 2021 total cost of sales including depreciation and depletion and royalties amounted to 67 0 million in q1 2022 a decrease of 7 9 million from q1 2021 the decrease in cost of sales was primarily due to fewer gold ounces sold and a 4 5 million positive net realizable value nrv adjustment on stockpile inventory due to higher gold prices in q1 2022 which were partly offset by higher ore transportation costs 2 0 million increase in q1 2022 a decrease of from q1 2021 the decrease in cost of sales was primarily due to fewer gold ounces sold and a positive net realizable value nrv adjustment on stockpile inventory due to higher gold prices in q1 2022 which were partly offset by higher ore transportation costs increase total cash costs per ounce 1 were 1 361 in q1 2022 compared to 989 in q1 2021 a 38 increase cash costs were higher in q1 2022 due in part to lower gold sales volumes which had the effect of increasing fixed production costs on a per unit basis higher ore transportation costs and general inflationary pressures on fuel and consumables and government levies these factors were partially offset by the above mentioned positive nrv adjustment on stockpile inventory in q1 2022 that was credited against production costs were in q1 2022 compared to in q1 2021 a 38 increase cash costs were higher in q1 2022 due in part to lower gold sales volumes which had the effect of increasing fixed production costs on a per unit basis higher ore transportation costs and general inflationary pressures on fuel and consumables and government levies these factors were partially offset by the above mentioned positive nrv adjustment on stockpile inventory in q1 2022 that was credited against production costs income from mine operations for q1 2022 totaled 10 6 million compared to income from mine operations of 35 9 million in q1 2021 the reduction in income from mine operations was due to a 33 3 million decrease in revenue partly offset by a 7 9 million decrease in cost of sales as described above compared to income from mine operations of in q1 2021 the reduction in income from mine operations was due to a decrease in revenue partly offset by a decrease in cost of sales as described above the agm generated 3 9 million of cash flows from operating activities during q1 2022 compared to 35 4 million of cash flows from operating activities during q1 2021 the decrease in cash flows from operations was primarily due to lower revenues from lower gold production and higher aisc 1 of cash flows from operating activities during q1 2022 compared to of cash flows from operating activities during q1 2021 the decrease in cash flows from operations was primarily due to lower revenues from lower gold production and higher aisc in light of the changing nature of operations at the agm the jv has undertaken a process of rationalizing its workforce severance notifications were issued resulting in a 21 0 million severance liability recorded by the agm at march 31 2022 and personnel necessary to maintain current operations have been retained with new employment contracts despite the upfront cost associated with the restructuring management expects to realize near term and sustainable costs savings and a more streamlined and efficient operation going forward as well as ensuring the severance liability is permanently eliminated over the next two years galiano gold inc summary q1 2022 financial results galiano gold inc consolidated q1 2022 q4 2021 q3 2021 q2 2021 q1 2021 net loss income after tax m 1 5 91 0 4 1 5 0 13 0 net loss income after tax per share 0 01 0 40 0 02 0 02 0 06 adjusted net loss income1 m 1 5 14 5 4 1 5 0 13 0 adjusted net loss per share1 0 01 0 06 0 02 0 02 0 06 the company reported a net loss after tax of 1 5 million in q1 2022 compared to net income after tax of 13 0 million in q1 2021 the decrease in earnings during q1 2022 was due to a reduction in the jv s net earnings in q1 2022 compared to net income after tax of in q1 2021 the decrease in earnings during q1 2022 was due to a reduction in the jv s net earnings cash used in operating activities in q1 2022 was 3 2 million compared to 4 7 million in q1 2021 the decrease in cash used in operations was primarily due to an increase in accounts payable and accrued liabilities partly offset by an increase in receivables related to the company s jv service fee compared to in q1 2021 the decrease in cash used in operations was primarily due to an increase in accounts payable and accrued liabilities partly offset by an increase in receivables related to the company s jv service fee as at march 31 2021 the company had cash on hand of 50 4 million and 8 7 million in receivables for a gross liquidity position of 59 1 million and no debt this news release should be read in conjunction with galiano s management s discussion and analysis and the unaudited condensed consolidated interim financial statements for the three months ended march 31 2022 and 2021 which are available at www galianogold com and filed on sedar 1 non ifrs performance measures the company has included certain non ifrs performance measures in this press release these non ifrs performance measures do not have any standardized meaning accordingly these performance measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with ifrs refer to the non ifrs measures section of galiano s management s discussion and analysis for an explanation of these measures and reconciliations to the company s and the jv s reported financial results in accordance with ifrs operating cash costs per ounce and total cash costs per ounce operating cash costs are reflective of the cost of production adjusted for share based payments and by product revenue per ounce of gold sold total cash costs include production royalties of 5 excluded from operating cash costs are one time severance charges and net realizable value adjustments on stockpile inventory resulting from lower expected gold recovery recorded in q4 2021 as the magnitude of such adjustments are not indicative of current period costs operating cash costs are reflective of the cost of production adjusted for share based payments and by product revenue per ounce of gold sold total cash costs include production royalties of 5 excluded from operating cash costs are one time severance charges and net realizable value adjustments on stockpile inventory resulting from lower expected gold recovery recorded in q4 2021 as the magnitude of such adjustments are not indicative of current period costs all in sustaining costs per gold ounce the company has adopted the reporting of all in sustaining costs per gold ounce aisc as per the world gold council s guidance aisc include total cash costs corporate overhead expenses sustaining capital expenditure capitalized stripping costs reclamation cost accretion and lease payments made to and interest expense on the agm s mining and service contractors per ounce of gold sold the company has adopted the reporting of all in sustaining costs per gold ounce aisc as per the world gold council s guidance aisc include total cash costs corporate overhead expenses sustaining capital expenditure capitalized stripping costs reclamation cost accretion and lease payments made to and interest expense on the agm s mining and service contractors per ounce of gold sold adjusted ebitda ebitda provides an indication of the company s continuing capacity to generate income from operations before taking into account the company s financing decisions and costs of amortizing capital assets accordingly ebitda comprises net income loss excluding interest expense interest income amortization and depletion and income taxes adjusted ebitda adjusts ebitda to exclude non recurring items and to include the company s interest in the adjusted ebitda of the jv other companies and jv partners may calculate ebitda and adjusted ebitda differently ebitda provides an indication of the company s continuing capacity to generate income from operations before taking into account the company s financing decisions and costs of amortizing capital assets accordingly ebitda comprises net income loss excluding interest expense interest income amortization and depletion and income taxes adjusted ebitda adjusts ebitda to exclude non recurring items and to include the company s interest in the adjusted ebitda of the jv other companies and jv partners may calculate ebitda and adjusted ebitda differently adjusted net loss income the company has included the non ifrs performance measures of adjusted net loss income and adjusted net loss income per common share neither adjusted net loss income nor adjusted net loss income per share have any standardized meaning and are therefore unlikely to be comparable to other measures presented by other issuers adjusted net loss income excludes certain non cash items from net income or net loss to provide a measure which helps the company and investors to evaluate the results of the underlying core operations of the company and its ability to generate cash flows and is an important indicator of the strength of our operations and the performance of our core business about galiano gold inc galiano s vision is to build a sustainable business capable of long term value creation for its stakeholders through a combination of exploration accretive m a activities and the disciplined deployment of its financial resources the company currently operates and manages the asanko gold mine located in ghana west africa which is jointly owned with gold fields ltd the company is strongly committed to the highest standards for environmental management social responsibility and health and safety for its employees and neighbouring communities for more information please visit www galianogold com cautionary note regarding forward looking statements certain statements and information contained in this news release constitute forward looking statements within the meaning of applicable u s securities laws and forward looking information within the meaning of applicable canadian securities laws which we refer to collectively as forward looking statements forward looking statements are statements and information regarding possible events conditions or results of operations that are based upon assumptions about future conditions and courses of action all statements and information other than statements of historical fact may be forward looking statements in some cases forward looking statements can be identified by the use of words such as seek expect anticipate budget plan estimate continue forecast intend believe predict potential target may could would might will and similar words or phrases including negative variations suggesting future outcomes or statements regarding an outlook forward looking statements in this news release include but are not limited to the operating plans for the agm under the jv between the company and gold fields plans to transition from mining to processing stockpiles and the benefits that may arise therefrom and with respect to the re start of mining operations thereafter and activities to be completed while mining activities are temporarily paused such forward looking statements are based on a number of material factors and assumptions including but not limited to the company and gold fields will agree on the manner in which the jv will operate the agm including agreement on development plans and capital expenditures the price of gold will not decline significantly or for a protracted period of time the accuracy of the estimates and assumptions underlying mineral resources estimates the ability of the agm to continue to operate produce and ship dor from the agm site to be refined during the covid 19 pandemic or any other infectious disease outbreak the company s ability to raise sufficient funds from future equity financings to support its operations and general business and economic conditions the global financial markets and general economic conditions will be stable and prosperous in the future the ability of the jv and the company to comply with applicable governmental regulations and standards the mining laws tax laws and other laws in ghana applicable to the agm and the jv will not change and there will be no imposition of additional exchange controls in ghana the success of the jv and the company in implementing its development strategies and achieving its business objectives the jv will have sufficient working capital necessary to sustain its operations on an ongoing basis and the company will continue to have sufficient working capital to fund its operations and contributions to the jv and the key personnel of the company and the jv will continue their employment the foregoing list of assumptions cannot be considered exhaustive forward looking statements involve known and unknown risks uncertainties and other factors which may cause actual results performance or achievements to differ materially from those anticipated in such forward looking statements the company believes the expectations reflected in such forward looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and you are cautioned not to place undue reliance on forward looking statements contained herein some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward looking statements contained in this news release include but are not limited to the mineral resource estimates may change and may prove to be inaccurate mineral reserves may not be reinstated metallurgical recoveries may not be economically viable risks associated with the company ceasing its mining operations during 2022 the company does not currently have a lom estimate for the agm due to the withdrawal of the mineral reserve actual production costs returns and other economic and financial performance may vary from the company s estimates in response to a variety of factors many of which are not within the company s control agm has a limited operating history and is subject to risks associated with establishing new mining operations sustained increases in costs or decreases in the availability of commodities consumed or otherwise used by the company may adversely affect the company adverse geotechnical and geological conditions including geotechnical failures may result in operating delays and lower throughput or recovery closures or damage to mine infrastructure the ability of the company to treat the number of tonnes planned recover valuable materials remove deleterious materials and process ore concentrate and tailings as planned is dependent on a number of factors and assumptions which may not be present or occur as expected the company s operations may encounter delays in or losses of production due to equipment delays or the availability of equipment outbreaks of covid 19 and other infectious diseases may have a negative impact on global financial conditions demand for commodities and supply chains and could adversely affect the company s business financial condition and results of operations and the market price of the common shares of the company the company s operations are subject to continuously evolving legislation compliance with which may be difficult uneconomic or require significant expenditures the company may be unsuccessful in attracting and retaining key personnel labour disruptions could adversely affect the company s operations the company s business is subject to risks associated with operating in a foreign country risks related to the company s use of contractors the hazards and risks normally encountered in the exploration development and production of gold the company s operations are subject to environmental hazards and compliance with applicable environmental laws and regulations the effects of climate change or extreme weather events may cause prolonged disruption to the delivery of essential commodities which could negatively affect production efficiency the company s operations and workforce are exposed to health and safety risks unexpected costs and delays related to or the failure of the company to obtain necessary permits could impede the company s operations the company s title to exploration development and mining interests can be uncertain and may be contested geotechnical risks associated with the design and operation of a mine and related civil structures the company s properties may be subject to claims by various community stakeholders risks related to limited access to infrastructure and water the company s exploration programs may not successfully reinstate mineral reserves risks associated with establishing new mining operations the company s common shares may experience price and trading volume volatility the company has never paid dividends the company s revenues are dependent on the market prices for gold which have experienced significant recent fluctuations the company may not be able to secure additional financing when needed or on acceptable terms company shareholders may be subject to future dilution risks related to the control of agm cashflows and operation through a joint venture risks related to changes in interest rates and foreign currency exchange rates risks relating to credit rating downgrades changes to taxation laws applicable to the company may affect the company s profitability and ability to repatriate funds ability to repatriate funds risks related to the company s internal controls over financial reporting and compliance with applicable accounting regulations and securities laws non compliance with public disclosure obligations could have an adverse effect on the company s stock price the carrying value of the company s assets may change and these assets may be subject to impairment charges risks associated with changes in reporting standards the company s primary asset is held through a joint venture which exposes the company to risks inherent to joint ventures including disagreements with joint venture partners and similar risks the company may be liable for uninsured or partially insured losses the company may be subject to litigation damage to the company s reputation could result in decreased investor confidence and increased challenges in developing and maintaining community relations which may have adverse effects on the business results of operations and financial conditions of the joint venture and the company and the company s share price the company may be unsuccessful in identifying targets for acquisition or completing suitable corporate transactions and any such transactions may not be beneficial to the company or its shareholders the company must compete with other mining companies and individuals for mining interests risks related to information systems security threats the company s growth future profitability and ability to obtain financing may be impacted by global financial conditions and the risk factors described under the heading risk factors in the company s annual information form although the company has attempted to identify important factors that could cause actual results or events to differ materially from those described in the forward looking statements you are cautioned that this list is not exhaustive and there may be other factors that the company has not identified furthermore the company undertakes no obligation to update or revise any forward looking statements included in or incorporated by reference in this news release if these beliefs estimates and opinions or other circumstances should change except as otherwise required by applicable law neither toronto stock exchange nor the investment industry regulatory organization of canada accepts responsibility for the adequacy or accuracy of this release source galiano gold inc
example video title will go here for this video example video title will go here for this video some states previously passed laws banning or restricting access to abortions those laws are now set to go into effect on friday the supreme court ruled in favor of mississippi s anti abortion law in dobbs v jackson women s health organization overturning the 1973 roe v wade decision that made abortion legal nationwide a copy of the supreme court s decision leaked to politico in may led to questions from many of our verify viewers and people on social media asking whether this changes abortion access nationwide some claimed that the decision doesn t make abortion illegal throughout the country and instead sends the issue to individual states by the way if you actually read the decision it doesn t outlaw abortion it sends the legality question of abortion to states and their legislatures to decide tim young timrunshismouth may 3 2022 the question is abortion illegal in all states now that the supreme court overturned roe v wade the sources the answer no abortion isn t illegal in all states now that the supreme court overturned roe v wade states can still pass their own abortion laws to either restrict or guarantee the right to abortions what we found in its 1973 ruling on roe v wade the supreme court found that a fundamental right to privacy is inherent in the fourteenth amendment s due process clause and a person s right to choose whether to have an abortion falls within the right to privacy the court s 1973 decision made it illegal for states to regulate abortion in the first trimester of pregnancy in the second trimester states could impose some regulations on abortion that are reasonably related to maternal health once the fetus reached the point of viability in the third trimester or the point where it could survive outside the womb with medical support a state could regulate or ban abortions so long as the laws contain exceptions for cases when abortion is necessary to save the life or health of the mother however supreme court justice samuel alito wrote in the majority opinion on dobbs v jackson women s health organization which overturns roe v wade that the constitution makes no reference to abortion and no such right is implicitly protected by any constitutional provision including the fourteenth amendment now that roe v wade is overturned the right to an abortion in the first trimester is no longer federally protected but that doesn t mean abortion is illegal in every state in the u s liza fuentes a senior research assistant at the guttmacher institute previously told verify that individual states can make their own laws about abortions benjamin barton a law professor at the university of tennessee knoxville agrees if the draft opinion becomes the actual majority opinion there would no longer be a federal constitutional right to an abortion so the decision as to whether to allow abortions or not would be up to individual states he wrote in an email to verify before the supreme court issued its official ruling about a dozen states have trigger laws to ban all or nearly all abortions set to go into effect now that roe v wade is overturned according to the guttmacher institute more than two dozen u s states are certain or likely to ban abortions in the absence of roe on the other hand some states have passed laws guaranteeing the right to have an abortion without state interference south dakota gov kristi noem said in may that she will call for a special legislative session to restrict access to abortions the state already has a trigger law on the books to ban most abortions following the supreme court s decision in january 2022 new jersey gov phil murphy signed the freedom of reproductive choice act into law codifying the constitutional right to freedom of reproductive choice in the state
london uk accesswire may 5 2022 data knights acquisition corp data knights or the company nasdaq dkdca nasdaq dkdcw a special purpose acquisition company today announced the deposit of an aggregate of 1 150 000 into the company s trust account for its public stockholders representing 0 10 per public share which enables the company to extend the period of time it has to consummate its initial business combination by three months from may 11 2022 to august 11 2022 the extension the extension is the first of up to two three month extensions permitted under the company s governing documents the extension provides the company with additional time to complete its initial business combination the business combination with onemednet corporation a delaware corporation onemednet previously announced by the company and onemednet on april 25 2022 about data knights acquisition corp data knights acquisition corp is a blank check company formed for the purposes of effecting a merger capital stock exchange asset acquisition stock purchase reorganization or similar business combination with one or more tech or software businesses or entities about onemednet corporation founded in 2009 onemednet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers employing its proven onemednet irwd solution onemednet securely de identifies searches and curates a data archive locally bringing a wealth of internal and third party research opportunities to providers by leveraging this extensive federated provider network together with industry leading technology and in house clinical expertise onemednet successfully meets the most rigorous rwd life science requirements cautionary statement regarding forward looking statements certain statements contained in this press release constitute forward looking statements within the meaning of federal securities laws forward looking statements may include but are not limited to statements with respect to i trends in the real world medical data industry including changes in u s and state laws regulations and guidance related to onemednet s products and services ii onemednet s growth prospects and onemednet s market size iii onemednet projected financial and operational performance including relative to its competitors iv new product and service offerings onemednet may introduce in the future v the potential transaction including the implied enterprise value the expected post closing ownership structure and the likelihood and ability of the parties to consummate the potential transaction successfully vi the risk the proposed business combination may not be completed in a timely manner or at all which may adversely affect the price of data knights securities vii the failure to satisfy the conditions to the consummation of the proposed business combination including the approval of the proposed business combination by the stockholders of data knights acquisition corp viii the effect of the announcement or pendency of the proposed business combination on data knights or onemednet s business relationships performance and business generally ix the outcome of any legal proceedings that be instituted against data knights or onemednet related to the proposed business combination or any agreement related thereto x the ability to maintain the listing of data knights on nasdaq xi the price of data knights securities including volatility resulting from changes in the competitive and regulated industry in which onemednet operates variations in performance across competitors changes in laws and regulations affecting onemednet s business and changes in the combined capital structure xii the ability to implement business pans forecasts and other expectations after the completion of the proposed business combination and identify and realize additional opportunities and xiii other statements regarding data knights or onemednet s expectations hopes beliefs intentions and strategies regarding the future in addition any statements that refer to projections forecasts or other characterizations of future events or circumstances including any underlying assumptions are forward looking statements he words anticipate believe continue could estimate expect intends outlook may might plan possible potential predict project should would and similar expressions may identify forward looking statements but the absence of these words does not mean that a statement is not forward looking forward looking statements are predictions projections and other statements about future events that are based on current expectations and assumptions and as a result are subject are subject to risks and uncertainties you should carefully consider the risks and uncertainties described in the risk factors section of data knights acquisition corp s registration statement on form s 1 any proxy statement relating to the transaction which is expected to be filed by data knights acquisition corp with the sec other documents filed by data knights acquisition corp from time to time with sec and any risk factors made available to you in connection with data knights acquisition corp onemednet and the transaction these forward looking statements involve a number of risks and uncertainties some of which are beyond the control of onemednet and data knights acquisition corp and other assumptions that may cause the actual results or performance to be materially different from those expressed or implied by these forward looking statements contacts investor contact shannon devine mz group north america 203 741 8811 source data knights acquisition corp view source version on accesswire com
a co founder of arm has criticised britain s technology illiterate politicians amid fears the firm will list its shares in new york rather than london hermann hauser one of the entrepreneurs who spun off the chip designer from acorn computers in 1990 said mps have only recently woken up to the importance of supporting uk technology and he called on arm s owner softbank to float arm on the stock market in london as well as new york in a so called dual listing rather than just in the us arm co founder hermann hauser pictured said mps have only recently woken up to the importance of supporting uk technology the japanese group bought cambridge based arm for 24billion in 2016 but is planning to sell it through a stock market float having seen a proposed sale to us giant nvidia collapse new york is the favoured destination for the float but no formal decision has been made hauser told the bbc technology sovereignty has become a key issue for the decade and even the technology illiterate politicians like johnson and the majority of parliament have woken up to the fact that it is important to support the local technology companies with local stock exchanges
first quarter glaucoma franchise net revenues of 29 8 million up 30 over first quarter 2021 management reaffirms 2022 glaucoma franchise guidance of 130 million to 140 million first phase 3 registrational trial for ar 15512 on track for enrollment second quarter of 2022 durham n c business wire aerie pharmaceuticals inc nasdaq aeri a pharmaceutical company focused on the discovery development and commercialization of first in class ophthalmic therapies today reports financial results for the first quarter ended march 31 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022 we continue to execute well on our three strategic pillars to build out aerie version 2 0 i am pleased to report strong year over year revenue growth for our first in class glaucoma franchise products in line with our expectations we are also excited about the progress we have made with our potential best in class dry eye product candidate ar 15512 as we continue to drive efficiencies in our operations said raj kannan chief executive officer of aerie pharmaceuticals mr kannan continued the addition of chief medical officer dr gary sternberg and chief financial officer peter lang further strengthens our senior leadership team driving the growth of our novel commercial franchise unlocking the potential value in our pipeline and continuing to focus on reducing our net cash burn should position us well for the future first quarter financial results and highlights for the quarter ended march 31 2022 aerie reported results compared to the quarter ended march 31 2021 total glaucoma franchise net product revenues of 29 8 million up 30 compared to 23 0 million net loss of 35 9 million compared to a net loss of 42 0 million net loss per share diluted of 0 76 compared to a net loss per share diluted of 0 91 non gaap net loss of 31 3 million compared to non gaap net loss of 33 2 million non gaap net loss per share diluted of 0 66 compared to non gaap net loss per share diluted of 0 72 balance sheet and liquidity highlights cash cash equivalents and total investments were 199 2 million as of march 31 2022 compared to 139 8 million as of december 31 2021 cash cash equivalents and total investments as of march 31 2022 included 90 0 million of upfront payments received in january related to our licensing and collaboration agreement with santen executed in december 2021 during the first quarter of 2022 our net cash provided by operating activities was 61 9 million excluding the 90 0 million santen payment net cash used in operating activities was 28 1 million further an 8 0 million milestone payment was made in the first quarter of 2022 to the former shareholders of avizorex pharma s l which was acquired by aerie in 2019 outlook for 2022 business and pipeline objectives financial guidance aerie reaffirms the following business and pipeline objectives and full year guidance previously reported for 2022 glaucoma franchise net product revenues guidance 130 million to 140 million up 16 to 25 versus 2021 total net cash used a reduction of approximately 15 in 2022 versus 2021 is expected phase 3 registrational study initiation for ar 15512 in dry eye expected during the second quarter of 2022 investigational new drug application submission for ar 14034 in wet age related macular degeneration expected in the second half of 2022 conference call webcast information aerie management will host a live conference call and webcast at 5 00 p m eastern time today to discuss aerie s financial results and provide a general business update the live webcast and a replay may be accessed by visiting aerie s website at please connect to aerie s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast alternatively please call 888 734 0328 u s or 678 894 3054 international to listen to the live conference call the conference id number for the live call is 4696464 please dial in approximately 10 minutes prior to the call about aerie pharmaceuticals inc aerie is a pharmaceutical company focused on the discovery development and commercialization of first in class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open angle glaucoma dry eye diabetic macular edema dme and wet age related macular degeneration wet amd aerie s first novel product rhopressa netarsudil ophthalmic solution 0 02 a once daily eye drop approved by the u s food and drug administration fda for the reduction of elevated intraocular pressure iop in patients with open angle glaucoma or ocular hypertension was launched in the united states in april 2018 in clinical trials of rhopressa the most common adverse reactions were conjunctival hyperemia corneal verticillata instillation site pain and conjunctival hemorrhage more information about rhopressa including the product label is available at www rhopressa com aerie s second novel product for the reduction of elevated iop in patients with open angle glaucoma or ocular hypertension rocklatan netarsudil 0 02 and latanoprost ophthalmic solution 0 005 was launched in the united states in may 2019 in clinical trials of rocklatan the most common adverse reactions were conjunctival hyperemia corneal verticillata instillation site pain and conjunctival hemorrhage more information about rocklatan including the product label is available at www rocklatan com more information on aerie pharmaceuticals is available at www aeriepharma com forward looking statements this press release contains forward looking statements for purposes of the safe harbor provisions of the private securities litigation reform act of 1995 we may in some cases use terms such as predicts believes potential proposed continue estimates anticipates expects plans intends may could might will should exploring pursuing or other words that convey uncertainty of future events or outcomes to identify these forward looking statements forward looking statements in this release include statements regarding our intentions beliefs projections outlook analyses or current expectations concerning among other things our commercial franchise and our pipeline any guidance or timelines future liquidity cash balances or financing transactions our ongoing and anticipated preclinical studies and clinical trials fda or other regulatory approvals and effectiveness of any product product candidates or future product candidates and our expectations for full year 2022 by their nature forward looking statements involve risks and uncertainties because they relate to events competitive dynamics industry change and other factors beyond our control and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated we discuss many of these risks in greater detail under the heading risk factors in the quarterly and annual reports that we file with the securities and exchange commission sec forward looking statements are not guarantees of future performance and our actual results of operations financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release any forward looking statements that we make in this press release speak only as of the date of this press release in particular fda and european medicines agency ema approval of rhopressa and rocklatan and medicines and healthcare products regulatory agency mhra authorization of roclanda does not guarantee regulatory approval of rhopressa rocklatan or roclanda in other jurisdictions and there can be no assurance that we will receive regulatory approval for rhopressa rocklatan or roclanda in such other jurisdictions in addition fda approval of rhopressa and rocklatan does not guarantee fda approval of our product candidates or any future product candidates and there can be no assurance that we will receive fda approval for our product candidates or any future product candidates furthermore the acceptance of the investigational new drug applications by the fda for our product candidates does not guarantee fda approval of such product candidates and the outcomes of later clinical trials for our product candidates may not be sufficient to submit a new drug application nda with the fda or to receive fda approval we assume no obligation to update our forward looking statements whether as a result of new information future events or otherwise after the date of this press release non gaap financial measures to supplement our financial statements which are prepared and presented in accordance with generally accepted accounting principles gaap we use the following non gaap financial measures some of which are discussed above adjusted net loss and adjusted net loss per share also referred to herein as non gaap net loss and non gaap net loss per share for reconciliations of non gaap measures to the most directly comparable gaap measures please see the reconciliation of gaap to non gaap financial measures and reconciliation of gaap net loss per share to adjusted net loss per share non gaap tables in this press release we believe these non gaap financial measures provide investors with useful supplemental information about the financial performance of our business enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business the presentation of these financial measures is not intended to be considered in isolation from or as a substitute for financial information prepared and presented in accordance with gaap investors are cautioned that there are material limitations associated with the use of non gaap financial measures as an analytical tool in particular the adjustments to our gaap financial measures reflect the exclusion of stock based compensation expense which is recurring and will be reflected in our financial results for the foreseeable future in addition these measures may be different from non gaap financial measures used by other companies limiting their usefulness for comparison purposes we compensate for these limitations by providing specific information regarding the gaap amounts excluded from these non gaap financial measures aerie pharmaceuticals inc consolidated balance sheets unaudited in thousands march 31 2022 december 31 2021 assets current assets cash and cash equivalents 56 441 37 187 short term investments 138 807 102 614 accounts receivable net 63 617 68 828 inventory 40 190 40 410 licensing receivable 90 000 prepaid expenses and other current assets 17 911 16 611 total current assets 316 966 355 650 long term investments 3 985 property plant and equipment net 51 226 51 472 operating lease right of use assets 21 916 22 669 other assets 1 453 1 600 total assets 395 546 431 391 liabilities and stockholders deficit equity current liabilities accounts payable 7 877 8 285 accrued expenses and other current liabilities 102 950 112 341 operating lease liabilities 4 464 4 365 total current liabilities 115 291 124 991 convertible notes net 311 678 234 527 deferred revenue non current 70 000 64 315 operating lease liabilities non current 21 033 21 751 other non current liabilities 3 256 3 140 total liabilities 521 258 448 724 stockholders deficit common stock 48 48 additional paid in capital 1 016 510 1 136 656 accumulated other comprehensive loss 430 126 accumulated deficit 1 141 840 1 153 911 total stockholders deficit 125 712 17 333 total liabilities and stockholders deficit 395 546 431 391 aerie pharmaceuticals inc consolidated statements of operations unaudited in thousands except share and per share data three months ended march 31 2022 2021 product revenues net 29 835 22 970 total revenues net 29 835 22 970 costs and expenses cost of goods sold 6 780 6 700 selling general and administrative 31 524 32 598 research and development 25 174 17 891 total costs and expenses 63 478 57 189 loss from operations 33 643 34 219 other expense net 1 555 7 714 loss before income taxes 35 198 41 933 income tax expense 693 31 net loss 35 891 41 964 net loss per common share basic and diluted 0 76 0 91 weighted average number of common shares outstanding basic and diluted 47 520 045 46 109 080 aerie pharmaceuticals inc reconciliation of gaap to non gaap financial measures unaudited in thousands three months ended march 31 2022 2021 net loss gaap 35 891 41 964 add back stock based compensation expense 4 632 8 749 adjusted net loss 31 259 33 215 cost of goods sold gaap 6 780 6 700 less stock based compensation expense 162 507 adjusted cost of goods sold 6 618 6 193 selling general and administrative expenses gaap 31 524 32 598 less stock based compensation expense 3 134 6 255 adjusted selling general and administrative expenses 28 390 26 343 research and development expenses gaap 25 174 17 891 less stock based compensation expense 1 336 1 987 adjusted research and development expenses 23 838 15 904 total operating expenses gaap 56 698 50 489 less stock based compensation expense 4 470 8 242 adjusted total operating expenses 52 228 42 247 aerie pharmaceuticals inc reconciliation of gaap net loss per share to adjusted net loss per share non gaap unaudited three months ended march 31 2022 2021 net loss per common share basic and diluted gaap 0 76 0 91 add back stock based compensation expense 0 10 0 19 adjusted net loss per share basic and diluted non gaap 0 66 0 72 weighted average number of common shares outstanding basic and diluted 47 520 045 46 109 080 media carolyn mcauliffe cmcauliffe aeriepharma com 949 526 8733 investors lifesci advisors on behalf of aerie pharmaceuticals inc hans vitzthum hans lifesciadvisors com 617 430 7578
traders work on the floor of the new york stock exchange nyse in new york city u s may 4 2022 reuters brendan mcdermid by david french reuters u s stocks ended thursday sharply lower amid a broad sell off as investor sentiment cratered in the face of concerns that the federal reserve s interest rate hike the previous day would not be enough to tame surging inflation all three main wall street benchmarks erased gains made during a relief rally on wednesday with the nasdaq posting its biggest one day percentage decline since june 2020 and its lowest finish since november 2020 the dow s decline was its worst daily performance since october 2020 technology megacaps slumped google parent alphabet inc apple inc microsoft corp meta platforms tesla inc and amazon com all fell between 4 3 and 8 3 however it was not just high growth stocks which have struggled in 2022 as the prospect of rate rises had investors questioning their future earnings potential the selloff hit all areas of the market as traders headed for the exits investors aren t looking at fundamentals such as earnings right now and this is more of a sentiment issue said megan horneman chief investment officer at verdence capital advisors the u s central bank on wednesday raised interest rates by half a percentage point as expected and fed chair jerome powell explicitly ruled out a hike of 75 basis points in a coming meeting traders however on thursday raised their bets on a 75 basis point hike at the fed s june meeting worries about fed policy moves mixed earnings from some big growth companies the conflict in ukraine and pandemic related lockdowns in china have hammered wall street recently overshadowing a better than expected quarterly reporting season the dow jones industrial average fell 1 063 09 points or 3 12 to 32 997 97 the s p 500 lost 153 3 points or 3 56 to 4 146 87 and the nasdaq composite dropped 647 17 points or 4 99 to 12 317 69 only 19 of the s p 500 s constituents closed in positive territory one of which was twitter inc which ended 2 6 higher elon musk revealed on thursday that oracle s co founder larry ellison and sequoia capital were among investors that would back his takeover of the social media giant with 7 14 billion of financing all of the 11 major s p sectors declined with consumer discretionary leading the way with a 5 8 drop the index was dragged by etsy inc and ebay inc down 16 8 and 11 7 respectively after both forecast q2 revenue would be below wall street s estimates the technology sector was the next biggest loser down 4 9 with intuit inc among those weighing the heaviest it slipped 8 5 to its lowest finish in a year a day after agreeing to pay a 141 million settlement centered on deception claims around its turbotax product you re seeing those areas of the market which are purely discretionary they are the ones getting hit today because everyone is anticipating that this is going to be a challenging period for consumers over the next several quarters said horneman of verdence capital advisors the cboe volatility index also known as wall street s fear gauge climbed to 31 20 points the focus now shifts to the u s labor department s closely watched monthly employment report on friday for clues on labor market strength and its impact on monetary policy volume on u s exchanges was 13 45 billion shares compared with the 12 01 billion average for the full session over the last 20 trading days the s p 500 posted two new 52 week highs and 43 new lows the nasdaq composite recorded 20 new highs and 446 new lows reporting by devik jain and medha singh in bengaluru and david french in new york editing by shounak dasgupta sriraj kalluvila and cynthia osterman
houston may 5 2022 prnewswire salient midstream mlp fund the fund nyse smm today announced a distribution of 0 0875 per share for the second quarter ending may 31 2022 this distribution is payable to common stockholders on may 27 2022 at the close of business on april 30 2022 the fund s total assets were 223 6 million and the net asset value nav per share was 9 21 on april 30 2022 the closing share price of the fund was 7 94 which was trading at a 13 8 discount to the nav 1 for the month ending april 30 2022 the fund s nav and market price total returns were 3 3 and 3 6 respectively compared to 2 2 for the alerian midstream energy select total return index ameix 2 the fund s nav and market price total returns year to date ytd were 24 6 and 19 2 respectively compared to 18 9 for the ameix 2 the fund s second quarter distribution will be payable on may 27 2022 to common stockholders of record on may 19 2022 it is anticipated that this distribution will be a combination of return of capital and ordinary income for tax purposes the final tax status of the distribution may differ substantially from this preliminary information and the final determination of such amount will be made in early 2023 when the fund can determine its earnings and profits for the 2022 fiscal year the fund s quarterly distributions per share over the past year are shown below 3 amount increase payable date ex date record date 0 0875 may 27 2022 may 18 2022 may 19 2022 0 0875 25 0 february 25 2022 february 16 2022 february 17 2022 0 070 november 29 2021 november 15 2021 november 16 2021 0 070 16 7 august 30 2021 august 16 2021 august 17 2021 0 060 may 27 2021 may 17 2021 may 18 2021 total increase 45 8 past performance is not indicative of future results the fund distributions are comprised of distributable cash flow generated from its portfolio investments plus any realized capital gains the tax characteristics of the historical distributions can be found on since the fund s inception the portfolio management team has focused on generating top tier total returns rather than focusing on maximizing distributions the fund s performance over multiple time periods versus its peers is provided in the table below along with a ranking of smm vs peers market price nav name yield premium discount ytd 1 year 3 year annualized 5 year annualized 7 year annualized since inception annualized rank ytd 1 year 3 year annualized 5 year annualized 7 year annualized since inception annualized rank salient midstream mlp fund 4 4 13 8 19 2 54 9 2 5 3 3 7 2 2 0 2 24 4 33 9 0 7 2 8 7 8 0 8 3 manager a 8 4 16 3 25 6 41 5 17 2 13 5 11 9 4 7 8 19 3 28 3 16 3 12 6 12 3 3 9 9 manager b 8 0 19 0 16 3 28 4 5 1 5 5 10 8 3 3 4 14 5 26 0 3 7 4 0 10 2 2 6 7 average ric excluding smm 8 2 17 7 20 9 34 9 11 2 9 5 11 4 4 0 16 9 27 2 10 0 8 3 11 2 3 3 manager c 7 2 19 7 28 5 49 4 8 6 7 7 9 4 3 6 6 26 2 47 3 7 1 5 8 9 0 2 2 6 manager d 7 2 16 3 26 4 39 6 10 7 8 6 9 8 3 4 5 25 8 44 6 9 3 6 5 9 1 1 9 4 manager e 7 1 19 2 25 4 42 7 6 8 7 1 8 3 4 0 7 25 2 44 7 5 5 5 4 7 9 2 2 5 manager f 3 9 19 6 23 6 47 3 0 5 1 9 7 1 23 6 43 4 1 7 0 4 5 7 manager g 8 4 16 8 22 6 41 2 31 0 21 7 16 7 10 2 11 19 4 35 1 28 4 19 2 16 0 8 5 11 manager h 8 9 13 3 20 7 32 2 8 4 6 0 9 0 2 5 3 18 9 29 5 7 7 3 8 6 6 0 3 2 manager i 5 7 18 8 21 8 25 7 31 1 22 7 21 8 18 7 26 9 29 1 20 6 19 4 manager j 7 4 13 6 14 1 17 5 4 1 5 9 5 2 15 0 20 3 3 6 3 5 5 1 manger k 5 1 10 6 33 2 56 6 31 6 22 4 17 5 14 6 30 9 29 1 20 9 17 7 manager l 7 7 0 6 16 9 20 7 1 2 0 9 1 8 2 6 1 12 9 17 9 1 5 0 0 2 6 3 1 1 manger m 8 5 14 7 22 6 36 5 23 3 18 3 14 3 7 4 10 12 1 26 4 20 5 13 8 13 3 4 7 10 manager n 5 5 20 0 8 4 29 7 0 3 1 8 4 6 7 0 9 11 6 21 7 2 1 0 8 4 9 2 7 8 average c corp 6 9 15 2 22 0 36 6 13 1 10 4 10 5 4 4 18 7 32 4 11 5 8 4 9 8 2 4 cef universe average 6 9 15 4 21 7 37 6 11 8 9 8 10 4 4 1 18 8 31 8 10 5 8 0 9 8 2 4 source salient capital advisors llc april 30 2022 for illustrative purposes only past performance is not indicative of future results no investment strategy can guarantee performance results all investments are subject to investment risk including loss of principal invested since inception in 2012 smm is the second best performing closed end fund on market price and the third best on nav in the peer group of eleven funds smm s inception to date itd annualized total return based on market price of 2 0 has outperformed the ric average of 4 0 and c corp average of 4 4 likewise on a nav basis smm s itd return of 0 8 compares favorably to the 3 3 return for the peer group of ric funds and 2 4 for c corp funds april market commentary april began strong for energy infrastructure equities with a 5 return as of april 20 but a correction late in the month caused such equities to finish down 2 2 as measured by the alerian midstream energy select index ameix 2 4 april s correction came on the heels of energy demand fears with the threat that china would extend its lockdowns to include beijing and the potential for a global economic slowdown due to the war in ukraine and higher interest rates earnings announcements began in late april with a few large energy infrastructure companies announcing volume growth and healthy earnings increases compared to last year for the remainder of 2022 we remain positive on the industry as 1 free cash flow after distributions is poised to increase rapidly year over year for the industry 2 hydrocarbon volumes should grow as drilling activity improves and 3 capital allocation remains focused on returning excess cash to investors through buybacks and potential distribution increases 5 crude oil as measured by the west texas intermediate wti benchmark was up 7 9 for the month of april and is now up 35 3 for the year 4 crude oil prices have moved sharply higher due to the war in ukraine russia produces 10 million barrels per day mmbbls d of crude oil or about 10 of global supply and is the second largest crude oil exporter after saudi arabia 6 markets are worried that crude oil supplies may be disrupted which could lead to a spike in prices well above current levels while sanctions so far have avoided russian crude oil sanctioning russia s energy exports would likely lead to a further spike in global crude oil and natural gas prices even if crude oil sanctions are not implemented we would expect a geopolitical risk premium to remain in crude oil prices for the near future should things normalize we view crude oil prices in the 70 80 range as being positive for long term investment in the american energy industry while the ukrainian war will have an as yet unknown effect on crude oil supply fundamentals remain robust as energy consumption continues to rise post covid commodity analysts continue to see a tight supply environment for both crude oil and natural gas in 2022 and potentially into 2023 as energy demand appears to be on trend to exceed peak pre covid levels 7 we believe that current crude oil and natural gas prices are sufficient to lead to u s volume growth in 2022 and 2023 with increases in production already showing up in recent energy information administration eia data the promise of these incremental volumes should be supportive of midstream companies the fund s top ten holdings as of april 30 2022 are shown below 8 no symbol name country asset type weight 1 et energy transfer l p united states mlp 9 3 2 trgp targa resources corp united states c corp 7 4 3 lng cheniere energy inc united states c corp 6 0 4 emg utica offshore co investment lp united states c corp 6 0 5 enb enbridge inc canada c corp 5 6 6 ppl cn pembina pipeline corp united states c corp 5 6 7 mplx mplx l p united states mlp 5 3 8 wmb the williams companies inc canada c corp 4 7 9 oke oneok inc united states c corp 4 4 10 pagp plains gp holdings l p united states c corp 4 4 58 7 for illustrative purposes only current and future holdings are subject to change and risk and are not recommendations to buy or sell any security figures are based on the fund s gross assets ex cash source salient capital advisors llc april 30 2022 the fund s unaudited balance sheet as of april 30 2022 is shown below salient midstream mlp fund balance sheet april 30 2022 unaudited assets in millions investments 222 0 other assets 1 2 cash and cash equivalents 0 4 total assets 223 6 liabilities line of credit payable 60 0 other liabilities 0 4 total liabilities 60 4 net assets 163 2 the fund had 17 7 million common shares outstanding as of april 30 2022 past performance is not indicative of future results salient midstream mlp fund is a delaware statutory trust registered as a non diversified closed end management investment company under the investment company act of 1940 as amended the fund s investment objective is to provide a high level of total return with an emphasis on making quarterly cash distributions to its common shareholders the fund seeks to achieve that objective by investing at least 80 of its total assets in securities of mlps and midstream companies there can be no assurance that the fund will achieve its investment objective this press release contains forward looking statements as defined under the u s federal securities laws generally the words believe expect intend estimate anticipate project will and similar expressions identify forward looking statements which generally are not historical in nature forward looking statements are subject to certain risks and uncertainties that could cause actual future results to differ significantly from the fund s present expectations or projections indicated in any forward looking statements these risks include but are not limited to changes in economic and political conditions regulatory and legal changes leverage risk valuation risk interest rate risk tax risk the volume of sales and purchase of shares the continuation of investment advisory administration and other service arrangements and other risks discussed in the fund s filings with the securities and exchange commission you should not place undue reliance on forward looking statements which speak only as of the date they are made the fund undertakes no obligation to publicly update or revise any forward looking statements made herein there is no assurance that the fund s investment objective will be attained about salient salient partners l p salient is a real asset and alternative investment firm that offers a suite of strategies focused on energy and infrastructure real estate and tactical alternative investments institutions and investment advisors turn to salient to build smarter more efficient portfolios strategies are offered in the form of open and closed end funds and separately managed accounts salient was founded in 2002 and has offices in houston and san francisco learn more about salient at www salientpartners com _____________ 1 past performance is not indicative of future results current performance may be higher or lower than the data shown the data shown are unaudited returns do not reflect the deduction of taxes that shareholders may have to pay on fund distributions or upon the sale of fund shares 2 source salient capital advisors llc and alerian april 30 2022 alerian midstream energy select index alerian midstream energy select total return index amei and ameix are trademarks of alerian and their use is granted under a license from alerian past performance is not indicative of how the index will perform in the future the index reflects the reinvestment of distributions and income and does not reflect deductions for fees expenses or taxes the index is unmanaged and is not available for direct investment alerian midstream energy select total return index ameix is a total return composite of north american midstream energy infrastructure companies that are engaged in activities involving energy commodities the capped float adjusted capitalization weighted index is disseminated in real time on a price return basis inception date of the ameix is april 1 2013 3 the amount of distributions may vary depending on a number of factors as portfolio and market conditions change the rate of distributions on fund common shares could change a portion of the fund s returns may be comprised of ordinary income return of capital and net realized capital gains the fund will determine the tax characteristics of all fund distributions after the end of the calendar year and will provide shareholders such information at that time 4 source bloomberg april 30 2022 5 free cash flow after distributions 6 source energy information administration eia april 30 2022 7 source goldman sachs april 30 2022 8 fund shares do not represent a deposit or obligation of and are not guaranteed or endorsed by any bank or other insured depository institution and are not federally insured by the federal deposit insurance corporation the federal reserve board or any other government agency data are based on total market value of fund investments unless otherwise indicated the data provided are for informational purposes only and are not intended for trading purposes view original content to download multimedia source salient partners l p
why rosen law firm a global investor rights law firm reminds purchasers of the securities of volta inc f k a tortoise acquisition corp ii nyse vlta nyse vlta wt nyse snpr between august 2 2021 and march 28 2022 inclusive the class period of the important may 31 2022 lead plaintiff deadline so what if you purchased volta securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement what to do next to join the volta class action go to or call phillip kim esq toll free at 866 767 3653 or email or for information on the class action a class action lawsuit has already been filed if you wish to serve as lead plaintiff you must move the court no later than may 31 2022 a lead plaintiff is a representative party acting on behalf of other class members in directing the litigation why rosen law we encourage investors to select qualified counsel with a track record of success in leadership roles often firms issuing notices do not have comparable experience resources or any meaningful peer recognition many of these firms do not actually handle securities class actions but are merely middlemen that refer clients or partner with law firms that actually litigate the cases be wise in selecting counsel the rosen law firm represents investors throughout the globe concentrating its practice in securities class actions and shareholder derivative litigation rosen law firm has achieved the largest ever securities class action settlement against a chinese company rosen law firm was ranked no 1 by iss securities class action services for number of securities class action settlements in 2017 the firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors in 2019 alone the firm secured over 438 million for investors in 2020 founding partner laurence rosen was named by law360 as a titan of plaintiffs bar many of the firm s attorneys have been recognized by lawdragon and super lawyers details of the case according to the lawsuit defendants throughout the class period made false and or misleading statements and or failed to disclose that 1 volta had improperly accounted for restricted stock units issued in connection with the business combination 2 volta had understated its net loss for third quarter 2021 3 there were material weaknesses in volta s internal control over financial reporting that resulted in a material error 4 as a result of the foregoing volta would restate its financial statements 5 legacy volta s founders would imminently exit the company 6 volta s financial results would be adversely impacted and 7 as a result of the foregoing defendants positive statements about volta s business operations and prospects were materially misleading and or lacked a reasonable basis when the true details entered the market the lawsuit claims that investors suffered damages to join the volta class action go to or call phillip kim esq toll free at 866 767 3653 or email or for information on the class action no class has been certified until a class is certified you are not represented by counsel unless you retain one you may select counsel of your choice you may also remain an absent class member and do nothing at this point an investor s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff follow us for updates on linkedin on twitter or on facebook attorney advertising prior results do not guarantee a similar outcome contact information laurence rosen esq phillip kim esq the rosen law firm p a 275 madison avenue 40th floor new york ny 10016 tel 212 686 1060 toll free 866 767 3653 fax 212 202 3827 www rosenlegal com to view the source version of this press release please visit original source of the original story vlta notice rosen trusted investor counsel encourages volta inc f k a tortoise acquisition corp ii investors with losses in excess of 100k to secure counsel before important deadline in securities class action vlta vlta wt snpr this content is published on behalf of the above source please contact them directly for any concern related to the above
it was the governor s strongest signal yet that he might singlehandedly allow medical marijuana for kentuckians suffering from certain medical conditions example video title will go here for this video example video title will go here for this video frankfort ky gov andy beshear sounded increasingly confident thursday that he will have the leeway to take at least some executive action to make medical marijuana legally accessible in kentucky it was the governor s strongest signal yet that he might singlehandedly allow medical marijuana for kentuckians suffering from certain medical conditions his prediction comes as his legal team reviews his options on a long running issue that stalled in the legislature the democratic governor first floated the possibility of executive action about a month ago and since then the latest bill to legalize medical marijuana died in the republican dominated state senate the legal analysis is not yet finalized but i do think that there is going to be room for at least some executive action beshear said thursday when asked for an update at his weekly news conference the governor maintains that legalizing medical cannabis has strong support among kentuckians he didn t specify thursday what actions might be at his disposal to make it legally available whatever steps we re able to take we want them to be clear the governor said we want it to serve a purpose it is not a back end way to allow recreational marijuana so we want to make sure that we do it right beshear said there are folks out there suffering who could benefit from medical cannabis he said he spoke recently with a woman whose son suffers from post traumatic stress disorder after multiple deployments with the military that s the type of help we ought to be providing the governor said beshear didn t offer a new timetable for a decision having previously said a decision could come this summer on possible executive action he instructed his legal team to analyze potential options for executive action that could create a framework to allow medical cannabis in the state the governor s office set up a website for public comments on the issue and a medical cannabis advisory committee is being formed to gather public input the challenge is that there are thousands of people who want to be a part because there are thousands of people who feel very very strongly about this issue he said a bill aimed at allowing kentucky to join the majority of states that have legalized medical marijuana passed the kentucky house this year but died in the senate republicans have supermajorities in both chambers the bill would have strictly regulated the use of cannabis for a list of eligible conditions including cancer multiple sclerosis chronic pain epilepsy and chronic nausea instead a measure creating a cannabis research center at the university of kentucky won final approval from lawmakers key lawmakers resisting the legalization of medical cannabis pushed for the center as an alternative they said it would allow more time to study the effectiveness of marijuana in treating certain ailments the governor has said he sees value in the cannabis center s formation but said he won t wait for it to do cannabis studies before deciding whether to take action beshear has received pushback from some prominent republicans for considering executive action republican senate president robert stivers said recently that kentuckians should be concerned that the governor thinks he can change statute by executive order he simply can t legalize medical marijuana by executive order you can t supersede a statue by executive order because it s a constitutional separation of powers violation stivers said beshear has said he would prefer that lawmakers pass a measure legalizing medical marijuana but said they failed to get the job done make it easy to keep up to date with more stories like this download the whas11 news app now for apple or android users
is this the big one on wednesday i warned that the federal reserve had made a colossal mistake when it increased its benchmark interest rate by 50 basis points and it looks like investors on wall street fully agree we just witnessed one of the largest single day stock market crashes in history and of course this comes at a time when stock prices had already fallen quite dramatically even before the carnage on thursday stocks were off to their worst start to a year in decades so will things settle down soon or is this the beginning of a truly historic stock market collapse millions of americans better hope that it is the former because trillions upon trillions of dollars in paper wealth is on the line i have always warned my readers that you only make money in the stock market if you get out in time it doesn t matter if you were holding certain stocks when they soared to all time record highs what is going to determine if you make a profit or not is when you choose to sell and markets tend to go down a whole lot faster than they go up on thursday the dow was down more than 1 000 points the s p 500 plunged more than 3 5 percent and the nasdaq got absolutely crushed the dow jones industrial average lost 1 063 points or 3 12 to close at 32 997 97 the tech heavy nasdaq composite fell 4 99 to finish at 12 317 69 its lowest closing level since november 2020 both of those losses were the worst single day drops since 2020 the s p 500 fell 3 56 to 4 146 87 marking its second worst day of the year the reason why the nasdaq plummeted so dramatically was because tech stocks were in free fall mode once again large tech stocks were under pressure with facebook parent meta platforms and amazon falling 6 8 and 7 6 respectively microsoft dropped 4 4 salesforce tumbled 7 1 apple sank 5 6 if you think that those numbers are bad just look at what happened to etsy and ebay etsy and ebay dropped 16 8 and 11 7 respectively after issuing weaker than expected revenue guidance shopify fell nearly 15 after missing estimates on the top and bottom lines the declines dragged nasdaq to its worst day in nearly two years we have seen other bad days on wall street in recent years but this definitely feels different i think that kim forrest has done a better job than anyone else of summarizing what we just witnessed i expected some selloff but the great puking that s happening i didn t expect said kim forrest founder and chief investment officer at bokeh capital partners is this capitulation i remember what capitulation feels like this kind of feels like capitulation when everything even the good names are getting barfed out i could not have said it better myself so precisely what was the trigger that prompted this rush for the exits well a lot of analysts are pointing to the fed s decision to raise interest rates on wednesday here is one example it s going to be incredibly difficult for the fed to normalize interest rates without having a negative impact on growth and earnings said paul nolte portfolio manager at kingsview investment management so stock prices are too high if we re going to see a flattening or a decline in earnings per share because there is so much leverage in the market right now rapid declines could precipitate wave after wave of forced selling in fact it appears that this is already happening to a certain degree ultimately it certainly won t take too much to turn this market slide into a market avalanche meanwhile we continue to get more indications that the u s economy as a whole is really slowing down on thursday we learned that worker productivity declined at its fastest pace in nearly 75 years during the first quarter worker productivity fell to start 2022 at its fastest pace in nearly 75 years while labor costs soared as the u s struggled with surging covid cases the bureau of labor statistics reported thursday nonfarm productivity a measure of output against hours worked declined 7 5 from january through march the biggest fall since the third quarter of 1947 at the same time we continue to get more bad news on the inflation front one of the largest meatpackers in the western hemisphere is warning that steaks and burgers will get even more expensive in the months ahead beef will be getting even more expensive at u s grocery stores in the months ahead according to one of the country s biggest meatpackers national beef co controlled by the brazilian giant marfrig global foods sees relatively stable margins in the next two quarters according to tim klein who heads marfrig s u s operations that means even though their costs to buy cattle are increasing the company will ultimately be able to pass that on to consumers in the form of pricier steaks and burgers and the rapidly rising cost of fertilizer will inevitably make trips to the grocery store much more painful later this year a fertilizer shortage is putting the food supply at risk fertilizer prices have tripled from where they were in 2021 and it s forcing mid michigan farmers to change how they grow their crops you re cutting off one hand to save the other said seth cords so many things are simultaneously going wrong and the outlook for the second half of this year is exceedingly bleak but for a long time stock prices were able to defy economic reality even though economic conditions were rapidly deteriorating all around us investors just continued to party on as stock prices just kept going higher and higher of course now everything has changed trillions of dollars in paper wealth has already been wiped out and trillions more will likely be wiped out in the days ahead but wall street doesn t even realize that what we have been through so far is just a warm up act much more difficult days are coming and eventually we will see financial disaster on a scale that is absolutely unprecedented in our history hopefully that time can be put off for as long as possible but the clock is ticking and what happened on thursday should be a major league wake up call for all of us it is finally here michael s new book entitled 7 year apocalypse is now available in paperback and for the kindle on amazon about the author my name is michael and my brand new book entitled 7 year apocalypse is now available on amazon com in addition to my new book i have written five other books that are available on amazon com including lost prophecies of the future of america the beginning of the end get prepared now and living a life that really matters commissionsearned when you purchase any of these books you help to support the work that i am doing and one way that you can really help is by sending digital copies as gifts through amazon to family and friends time is short and i need help getting these warnings into the hands of as many people as possible i have published thousands of articles on the economic collapse blog end of the american dream and the most important news and the articles that i publish on those sites are republished on dozens of other prominent websites all over the globe i always freely and happily allow others to republish my articles on their own websites but i also ask that they include this about the author section with each article the material contained in this article is for general information purposes only and readers should consult licensed professionals before making any legal business financial or health decisions i encourage you to follow me on social media on facebook and twitter and any way that you can share these articles with others is a great help these are such troubled times and people need hope john 3 16 tells us about the hope that god has given us through jesus christ for god so loved the world that he gave his only begotten son that whosoever believeth in him should not perish but have everlasting life if you have not already done so i strongly urge you to ask jesus to be your lord and savior today
after years of documenting my design projects on the internet for the world to watch criticize and hopefully enjoy in 2018 i found myself once again crying in the shower we are renovating an old farmhouse in oregon and i was extremely frustrated with our renovation process i was so sick of feeling dumb being mansplained by my contractor and doubting every decision i knew so much about design and renovation and had been writing about it for years on my blog but i wished so badly that there was a book full of real life anecdotes to help educate and support me so i pitched the book the next day and four short years later it s here although the world has changed dramatically since that tearful shower the information in this book has become even more relevant as so many people staying indoors were focusing more on their homes so here are five tips from the new design rules the book guides you through the renovation and decoration process from my perspective with lots of stories and photos it reveals things like bathroom makes to avoid and how high should you really hang art my goal was to help people learn the rules of design so they can creatively break them thus making a choice not a mistake avoid the too small rug design by dee murphy the too small rug is such a common mistake but it can throw off the whole room in this living room dee murphy not only followed the rules by having at least the front two legs of all the furniture on the rug but she layered the vintage rug over a simpler sisal rug to ground the conversation area even more we wrote more about living room rulesand i also did a super dated but still fun video about rug size here vary the art configuration on each wall art direction by emily hendersondesign and styling assistance by emily bowser and julie rose this is a great styling tip that i ve used in almost every room what you want to avoid is every wall having one similar piece of art hung at the same height instead think about doing what we did here mixing a gallery wall mirror shelves leaning art diptychs or one large scale piece of art even if you like more minimal simple design which i do you want to vary the type or scale of art so it doesn t feel redundant and to give each piece its own moment don t chase every trend when it comes to permanent finishes design by ben mendansky you can absolutely bring stylish design ideas into your home but take those risks in lighting furniture and decor elements that don t require demo and hiring out to change do what ben mendansky did with the light fixtures here y all he ombre d the yellow from light to dark yes take risks but be really really careful leaning hard into trends in your permanent finishes like tile flooring windows and architectural details don t hang curtains too high off the floor design by rosa beltran high water curtains can make a room look silly but most big box stores only stock certain length ready made curtains 84 is almost always too short fyi always size up 90 96 usually works for 8 9 ceilings so the curtains hang long enough to touch or almost touch the floor you can hang the rod near the ceiling or halfway between window and ceiling like in this case not at the top of the window but always try to get as close to the floor as you can we have a fun graph and more photos in this post also please note there is a bunny on the bed don t overlook what you already have design by sara ruffin costello in this world of everything at our fingertips hello internet shopping it s tempting to replace something old with something new but before you do look at your pieces with new eyes if you like the shape and style but not the color or fabric you could do what sara ruffin costello did and reupholster a vintage chair in a patterned fabric if the above room tempts you know that the rest of her incredible home in new orleans is peppered through the book and knocks me down every time i see her creativity that green paint the floor tile the door you will make mistakes in the renovation or decoration process we all do it s part of the creative process but i hope this book can help you avoid as many as possible and unleash your creativity and maybe shed fewer shower tears thank you emily and congratulations on your beautiful book emily is also having a book signing in nyc on may 12th you can grab tickets here ps all our house toursand an apartment makeover for joanna s sister after her husband died top photo design by christa martin
bill gates hits back at elon musk says shorting tesla doesn t mean betting against the environment or electric cars responding to elon musk s claims that he is shorting tesla stock bill gates says such a position is just an investment not a move against helping solve climate change elon musk accused the microsoft billionaire in a tweet last week of betting as much as half a billion dollars that shares of the electric car company would fall in a text exchange between the two billionaires leaked online that musk said was authentic the tesla ceo asked gates if he was still shorting the stock gates said he was and that he wanted to talk to musk about philanthropy musk denied the request outright advertisement advertisement sorry i cannot take your philanthropy on climate change seriously when you have a massive short position against tesla the company doing the most to solve climate change musk reportedly said in the text exchange advertisement advertisement but gates told the bbc in an interview wednesday that his bet against tesla is unrelated to advocacy for pro environmental projects and government policies that has nothing to do with climate change i have ways of diversifying gates said in an interview he added that just because he was betting against tesla doesn t mean he was against the rise of electric cars the popularity of electric cars will lead to more competition for selling those cars so there s a difference between electric cars being adopted and companies becoming infinitely valuable he told the bbc musk and gates have a history of frosty relations and musk has attacked gates on twitter repeatedly after gates said he was concerned about the range and premium price of tesla vehicles in a 2020 video with youtuber marques brownlee musk said in a tweet that his conversations with the former microsoft ceo have been underwhelming tbh more recently amid musk s takeover of twitter the tesla and spacex ceo tweeted a picture of gates side by side with an emoji of a pregnant man saying in case u need to lose a boner fast gates told cnbc s squawk box in july 2020 that musk should cut back on his controversial vaccine comments and focus on electric cars and rockets in a new york times podcast later that year the tesla ceo responded to gates comments about musk s lack of experience with vaccines calling gates a knucklehead musk has also attacked gates in tweets regarding his vaccine advocacy in a tweet last week musk said he was moving on from attacking gates for shorting tesla but gates appears unruffled there s no need for him to be nice to me gates said of musk in the bbc interview disagreements and attacks between the two men have drawn outsize attention because of their immense wealth musk overtook gates as the world s second richest person in 2020 and later surpassed amazon founder jeff bezos to take the top spot the tesla ceo is currently the richest person in the world according to the bloomberg billionaires index while gates sits at fourth on the list gates has pledged to give away most of his fortune over his lifetime this story was originally featured on fortune com
net sales increased 5 4 and base business net sales increased 5 6 b g foods inc nyse bgs today announced financial results for the first quarter of 2022 summary q1 2022 in millions except per share data change vs amount q1 2021 net sales 532 4 5 4 base business net sales 1 532 2 5 6 diluted eps 2 0 34 17 1 adj diluted eps 1 0 34 34 6 net income 2 23 7 12 0 adj net income 1 23 6 30 8 adj ebitda 1 77 9 16 2 guidance for full year fiscal 2022 net sales increased to a range of 2 10 billion to 2 14 billion adjusted ebitda revised to a range of 348 million to 358 million adjusted diluted earnings per share revised to a range of 1 65 to 1 75 commenting on the results casey keller president and chief executive officer of b g foods stated first quarter results delivered strong sales growth behind pricing and elevated demand however inflation on key input costs was higher than expected primarily resulting from the war in ukraine and continued supply disruptions and had a significant impact on gross margins recent pricing actions are expected to recover higher costs in the second half of 2022 financial results for the first quarter of 2022 net sales for the first quarter of 2022 increased 27 3 million or 5 4 to 532 4 million from 505 1 million for the first quarter of 2021 the increase was primarily due to pricing initiatives including list price increases and trade spend reductions and the impact of product mix partially offset by volume declines primarily due to price elasticity and supply chain challenges in the first quarter of 2022 resulting from the covid 19 omicron variant base business net sales1 for the first quarter of 2022 increased 28 1 million or 5 6 to 532 2 million from 504 1 million for the first quarter of 2021 the increase in base business net sales was driven by an increase in net pricing and the impact of product mix of 36 2 million or 7 2 of base business net sales and the positive impact of foreign currency of 0 1 million partially offset by a decrease in unit volume of 8 2 million net sales of crisco increased 21 0 million or 36 2 net sales of back to nature increased 3 9 million or 32 1 net sales of clabber girl increased 3 6 million or 20 5 net sales of ortega increased 3 6 million or 9 3 net sales of green giant including le sueur increased 3 2 million or 2 4 net sales of cream of wheat increased 2 8 million or 15 5 and net sales of maple grove farms increased 1 2 million or 6 0 in the first quarter of 2022 as compared to the first quarter of 2021 net sales of the company s spices seasonings2 decreased 15 1 million or 14 7 in the first quarter of 2022 as compared to the first quarter of 2021 the decrease was driven in part by comparisons against a very strong first quarter of 2021 for the company s spices seasonings and supply chain challenges during the first quarter of 2022 compared to the first quarter of 2020 the company s spices seasonings increased 14 9 million or 20 4 base business net sales of all other brands in the aggregate increased 3 9 million or 3 7 for the first quarter of 2022 gross profit was 101 3 million for the first quarter of 2022 or 19 0 of net sales gross profit was 117 8 million for the first quarter of 2021 or 23 3 of net sales during the first quarter of 2022 the company s gross profit was negatively impacted by higher than expected input cost inflation including materially increased costs for raw materials and transportation the company expects input cost inflation will continue to have a significant industry wide impact during the remainder of fiscal 2022 the company is attempting to mitigate the impact of inflation on its gross profit by locking in prices through short term supply contracts and advance commodities purchase agreements and by implementing cost saving measures the company also announced list price increases in 2021 and again during the first and second quarters of 2022 and where appropriate has reduced trade promotions to its customers for certain of the company s products however increases in the prices the company charges its customers generally lag behind rising input costs as such the company did not fully offset the incremental costs that it faced in the first quarter of 2022 and may not fully offset the incremental costs that the company is facing and expects to continue to face in the remainder of fiscal 2022 selling general and administrative expenses decreased 3 6 million or 7 0 to 46 8 million for the first quarter of 2022 from 50 4 million for the first quarter of 2021 the decrease was composed of decreases in acquisition divestiture related and non recurring expenses of 4 0 million and consumer marketing expenses of 1 5 million partially offset by increases in selling expenses of 1 7 million general and administrative expenses of 0 1 million and warehousing expenses of 0 1 million expressed as a percentage of net sales selling general and administrative expenses improved by 1 2 percentage points to 8 8 for the first quarter of 2022 as compared to 10 0 for the first quarter of 2021 during the first quarter of 2022 the company completed the closure and sale of its portland maine manufacturing facility the company recorded a gain on the sale of the portland property plant and equipment of 7 1 million during the first quarter of 2022 the positive impact during the quarter of the gain on sale was partially offset by approximately 2 2 million of expenses incurred during the quarter relating to the closure of the facility and the transfer of manufacturing operations net interest expense decreased 0 2 million or 0 6 to 26 8 million for the first quarter of 2022 from 27 0 million in the first quarter of 2021 the decrease was primarily attributable to a slightly lower average long term debt outstanding during the first quarter of 2022 as compared to the first quarter of 2021 the company s net income was 23 7 million or 0 34 per diluted share for the first quarter of 2022 compared to net income of 26 9 million or 0 41 per diluted share for the first quarter of 2021 the company s adjusted net income for the first quarter of 2022 was 23 6 million or 0 34 per adjusted diluted share compared to 34 1 million or 0 52 per adjusted diluted share for the first quarter of 2021 the decreases in net income diluted earnings per share adjusted net income and adjusted diluted earnings per share were primarily attributable to industry wide input cost inflation and supply chain disruptions partially offset by list price increases trade spend reductions and a net benefit during the first quarter of 4 9 million resulting from the gain on sale of the portland maine manufacturing facility partially offset by expenses relating to the closure of the facility and the transfer of manufacturing operations for the first quarter of 2022 adjusted ebitda was 77 9 million a decrease of 15 0 million or 16 2 compared to 92 9 million for the first quarter of 2021 the decrease in adjusted ebitda was primarily attributable to industry wide input cost inflation and supply chain disruptions partially offset by list price increases trade spend reductions and a net benefit during the first quarter of 4 9 million resulting from the gain on sale of the portland maine manufacturing facility partially offset by expenses relating to the closure of the facility and the transfer of manufacturing operations adjusted ebitda as a percentage of net sales was 14 6 for the first quarter of 2022 compared to 18 4 in the first quarter of 2021 for the first quarter of 2022 adjusted ebitda before covid 19 expenses was 78 4 million a decrease of 17 4 million or 18 2 compared to 95 8 million for fiscal 2021 covid 19 expenses were 0 5 million and 2 9 million for the first quarter of 2022 and first quarter 2021 respectively adjusted ebitda before covid 19 expenses as a percentage of net sales was 14 7 for the first quarter of 2022 compared to 19 0 in the first quarter of 2021 full year fiscal 2022 guidance b g foods increased its net sales guidance for full year fiscal 2022 to a range of 2 10 billion to 2 14 billion b g foods revised its full year fiscal 2022 adjusted ebitda guidance to a range of 348 million to 358 million and adjusted diluted earnings per share to a range of 1 65 to 1 75 b g foods continues to see strong consumer demand for its products the company has also seen and expects to continue to see significant cost inflation for various inputs including ingredients packaging transportation and labor attributable to a number of factors including the covid 19 pandemic the war in ukraine climate and weather conditions supply chain disruptions including raw material shortages and labor shortages the company has initiated various revenue enhancing activities including list price increases and trade spend initiatives and cost savings initiatives to offset these costs but there can be no assurance at this point of the ultimate effectiveness of these activities and initiatives the company s management is not able to fully estimate the impact covid 19 industry wide supply chain disruptions cost inflation and the company s cost inflation mitigation efforts will have on the company s results for the remainder of fiscal 2022 and the company s guidance should be read in this context the ultimate impact of the covid 19 pandemic on the company s business will depend on many factors including among others how long social distancing and stay at home and work from home policies and recommendations remain in effect whether and the extent to which additional waves or variants of covid 19 will affect the united states and the rest of north america the company s ability to continue to operate its manufacturing facilities maintain its supply chain without material disruption procure ingredients packaging and other raw materials when needed the extent to which macroeconomic conditions resulting from the pandemic and the pace of the subsequent recovery may impact consumer eating and shopping habits and the extent to which consumers continue to work remotely even after the pandemic subsides and how that may impact consumer habits conference call b g foods will hold a conference call at 4 30 p m et today may 5 2022 to discuss first quarter 2022 financial results the live audio webcast of the conference call can be accessed at www bgfoods com investor relations a replay of the webcast will be available following the conference call through the same link about non gaap financial measures and items affecting comparability adjusted net income net income adjusted for certain items that affect comparability adjusted diluted earnings per share diluted earnings per share adjusted for certain items that affect comparability base business net sales net sales without the impact of acquisitions until the acquisitions are included in both comparable periods and without the impact of discontinued or divested brands ebitda net income before net interest expense income taxes depreciation and amortization and loss on extinguishment of debt adjusted ebitda ebitda as adjusted for cash and non cash acquisition divestiture related expenses gains and losses which may include third party fees and expenses integration restructuring and consolidation expenses amortization of acquired inventory fair value step up and gains and losses on the sale of certain assets and non recurring expenses gains and losses and adjusted ebitda before covid 19 expenses adjusted ebitda as adjusted for covid 19 expenses3 are non gaap financial measures a non gaap financial measure is a numerical measure of financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles in the united states gaap in b g foods consolidated balance sheets and related consolidated statements of operations comprehensive income changes in stockholders equity and cash flows non gaap financial measures should not be considered in isolation or as a substitute for the most directly comparable gaap measures the company s non gaap financial measures may be different from non gaap financial measures used by other companies the company uses non gaap financial measures to adjust for certain items that affect comparability this information is provided in order to allow investors to make meaningful comparisons of the company s operating performance between periods and to view the company s business from the same perspective as the company s management because the company cannot predict the timing and amount of these items that affect comparability management does not consider these items when evaluating the company s performance or when making decisions regarding allocation of resources additional information regarding ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses and a reconciliation of ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses to net income and to net cash provided by operating activities is included below for the first quarter of 2022 and 2021 along with the components of ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses also included below are reconciliations of the non gaap terms adjusted net income adjusted diluted earnings per share and base business net sales to the most directly comparable measure calculated and presented in accordance with gaap in the company s consolidated balance sheets and related consolidated statements of operations comprehensive income changes in stockholders equity and cash flows end notes please see about non gaap financial measures and items affecting comparability below for the definition of the non gaap financial measures base business net sales adjusted diluted earnings per share adjusted net income ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses as well as information concerning certain items affecting comparability and reconciliations of the non gaap terms to the most comparable gaap financial measures includes the spices seasoning brands acquired in the fourth quarter of 2016 as well as the company s legacy spices seasonings brands such as dash and ac cent covid 19 expenses include temporary enhanced compensation that ended on february 15 2021 for the company s manufacturing employees compensation the company continued to pay manufacturing employees while in quarantine which was incremental to the compensation the company paid to the manufacturing employees who produced the company s products while others were in quarantine and expenses relating to other precautionary health and safety measures about b g foods inc based in parsippany new jersey b g foods and its subsidiaries manufacture sell and distribute high quality branded shelf stable and frozen foods across the united states canada and puerto rico with b g foods diverse portfolio of more than 50 brands you know and love including back to nature b g b m bear creek cream of wheat crisco dash green giant las palmas le sueur mama mary s maple grove farms new york style ortega polaner spice islands and victoria there s a little something for everyone for more information about b g foods and its brands please visit www bgfoods com forward looking statements statements in this press release that are not statements of historical or current fact constitute forward looking statements the forward looking statements contained in this press release include without limitation statements related to b g foods expectations regarding net sales adjusted ebitda adjusted diluted earnings per share consumer demand input cost inflation list price increases cost savings initiatives the ability of the company to recover higher costs in the second half of 2022 through pricing actions and the company s overall expectations for the remainder of fiscal 2022 and beyond such forward looking statements involve known and unknown risks uncertainties and other unknown factors that could cause the actual results of b g foods to be materially different from the historical results or from any future results expressed or implied by such forward looking statements in addition to statements that explicitly describe such risks and uncertainties readers are urged to consider statements labeled with the terms believes belief expects projects intends anticipates assumes could should estimates potential seek predict may will or plans and similar references to future periods to be uncertain and forward looking factors that may affect actual results include without limitation the continuing impact of the covid 19 pandemic on the company s business including without limitation the ability of the company and its supply chain partners to continue to operate manufacturing facilities distribution centers and other work locations without material disruption and to procure ingredients packaging and other raw materials when needed despite disruption in the supply chain or labor shortages the duration of social distancing and stay at home and work from home policies and recommendations and whether and the extent to which additional waves or variants of covid 19 will affect the united states and the rest of north america and the extent to which macroeconomic conditions resulting from the pandemic and the pace of the subsequent recovery may impact consumer eating and shopping habits whether and when the company will be able to realize the expected financial results and accretive effect of the crisco acquisition and how customers competitors suppliers and employees will react to the acquisition the company s substantial leverage the effects of rising costs for the company s commodities ingredients packaging other raw materials distribution and labor crude oil prices and their impact on distribution packaging and energy costs the company s ability to successfully implement sales price increases and cost saving measures to offset any cost increases intense competition changes in consumer preferences demand for the company s products and local economic and market conditions the company s continued ability to promote brand equity successfully to anticipate and respond to new consumer trends to develop new products and markets to broaden brand portfolios in order to compete effectively with lower priced products and in markets that are consolidating at the retail and manufacturing levels and to improve productivity the company s ability to recruit and retain senior management and a highly skilled and diverse workforce at the company s corporate offices manufacturing facilities and other locations despite a very tight labor market and changing employee expectations as to fair compensation an inclusive and diverse workplace flexible working and other matters the risks associated with the expansion of the company s business the company s possible inability to identify new acquisitions or to integrate recent or future acquisitions or the company s failure to realize anticipated revenue enhancements cost savings or other synergies from recent or future acquisitions the company s ability to successfully complete the integration of recent or future acquisitions into the company s enterprise resource planning erp system tax reform and legislation including the effects of the infrastructure investment and jobs act u s tax cuts and jobs act and the u s cares act and future tax reform or legislation the company s ability to access the credit markets and the company s borrowing costs and credit ratings which may be influenced by credit markets generally and the credit ratings of the company s competitors unanticipated expenses including without limitation litigation or legal settlement expenses the effects of currency movements of the canadian dollar and the mexican peso as compared to the u s dollar the effects of international trade disputes tariffs quotas and other import or export restrictions on the company s international procurement sales and operations future impairments of the company s goodwill and intangible assets the company s ability to protect information systems against or effectively respond to a cybersecurity incident or other disruption the company s sustainability initiatives and changes to environmental laws and regulations the company s ability to successfully transition the operations of the portland maine manufacturing facility to third party co manufacturing facilities and existing company manufacturing facilities without significant disruption in production or customer service and the company s ability to achieve anticipated productivity improvements and cost savings and other factors that affect the food industry generally the forward looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in b g foods filings with the securities and exchange commission including under item 1a risk factors in the company s most recent annual report on form 10 k and in its subsequent reports on forms 10 q and 8 k investors are cautioned not to place undue reliance on any such forward looking statements which speak only as of the date they are made b g foods undertakes no obligation to publicly update or revise any forward looking statement whether as a result of new information future events or otherwise b g foods inc and subsidiaries consolidated balance sheets in thousands except share and per share data unaudited april 2 january 1 2022 2022 assets current assets cash and cash equivalents 41 470 33 690 trade accounts receivable net 164 190 145 281 inventories 612 768 609 794 assets held for sale 3 256 prepaid expenses and other current assets 40 307 38 151 income tax receivable 1 137 4 284 total current assets 859 872 834 456 property plant and equipment net 334 187 341 471 operating lease right of use assets 63 330 65 166 goodwill 644 949 644 871 other intangible assets net 1 922 090 1 927 119 other assets 7 081 6 916 deferred income taxes 7 842 8 546 total assets 3 839 351 3 828 545 liabilities and stockholders equity current liabilities trade accounts payable 152 309 129 861 accrued expenses 47 719 66 901 current portion of operating lease liabilities 13 502 12 420 income tax payable 2 093 2 557 dividends payable 32 721 32 548 total current liabilities 248 344 244 287 long term debt 2 281 195 2 267 759 deferred income taxes 312 604 310 641 long term operating lease liabilities net of current portion 52 628 55 607 other liabilities 30 614 29 997 total liabilities 2 925 385 2 908 291 stockholders equity preferred stock 0 01 par value per share authorized 1 000 000 shares no shares issued or outstanding common stock 0 01 par value per share authorized 125 000 000 shares 68 885 801 and 68 521 651 shares issued and outstanding as of april 2 2022 and january 1 2022 respectively 689 685 additional paid in capital 3 547 accumulated other comprehensive loss 15 469 18 169 retained earnings 928 746 934 191 total stockholders equity 913 966 920 254 total liabilities and stockholders equity 3 839 351 3 828 545 b g foods inc and subsidiaries consolidated statements of operations in thousands except per share data unaudited first quarter ended april 2 april 3 2022 2021 net sales 532 407 505 134 cost of goods sold 431 119 387 340 gross profit 101 288 117 794 operating income and expenses selling general and administrative expenses 46 840 50 379 amortization expense 5 223 5 436 gain on sales of assets 7 099 operating income 56 324 61 979 other income and expenses interest expense net 26 802 26 969 other income 1 839 1 091 income before income tax expense 31 361 36 101 income tax expense 7 705 9 223 net income 23 656 26 878 weighted average shares outstanding basic 68 630 64 583 diluted 69 017 65 210 earnings per share basic 0 34 0 42 diluted 0 34 0 41 cash dividends declared per share 0 475 0 475 b g foods inc and subsidiaries items affecting comparability reconciliation of ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses to net income and to net cash provided by operating activities in thousands unaudited first quarter ended april 2 april 3 2022 2021 net income 23 656 26 878 income tax expense 7 705 9 223 interest expense net 26 802 26 969 depreciation and amortization 19 825 20 291 ebitda 1 77 988 83 361 acquisition divestiture related and non recurring income expenses 2 87 4 510 amortization of acquisition related inventory step up 3 5 054 adjusted ebitda 1 77 901 92 925 covid 19 expenses 4 500 2 891 adjusted ebitda before covid 19 expenses 1 78 401 95 816 income tax expense 7 705 9 223 interest expense net 26 802 26 969 acquisition divestiture related and non recurring income expenses 2 87 4 510 amortization of acquisition related inventory step up 3 5 054 gain on sales of assets 7 113 26 deferred income taxes 2 913 6 188 amortization of deferred debt financing costs and bond discount premium 1 169 1 141 share based compensation expense 1 090 723 changes in assets and liabilities net of effects of business combinations 16 309 29 175 net cash provided by operating activities 25 231 26 020 1 ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses are non gaap financial measures used by management to measure operating performance a non gaap financial measure is defined as a numerical measure of the company s financial performance that excludes or includes amounts so as to be different from the most directly comparable measure calculated and presented in accordance with gaap in the company s consolidated balance sheets and related consolidated statements of operations comprehensive income changes in stockholders equity and cash flows the company defines ebitda as net income before net interest expense income taxes depreciation and amortization and loss on extinguishment of debt the company defines adjusted ebitda as ebitda adjusted for cash and non cash acquisition divestiture related expenses gains and losses which may include third party fees and expenses integration restructuring and consolidation expenses amortization of acquired inventory fair value step up and gains and losses on the sale of certain assets and non recurring expenses gains and losses the company defines adjusted ebitda before covid 19 expenses as adjusted ebitda adjusted for covid 19 expenses management believes that it is useful to eliminate these items because it allows management to focus on what it deems to be a more reliable indicator of ongoing operating performance and the company s ability to generate cash flow from operations the company uses ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses in the company s business operations to among other things evaluate the company s operating performance develop budgets and measure the company s performance against those budgets determine employee bonuses and evaluate the company s cash flows in terms of cash needs the company also presents ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses because the company believes they are useful indicators of the company s historical debt capacity and ability to service debt and because covenants in the company s credit agreement and the company s senior notes indentures contain ratios based on these measures as a result reports used by internal management during monthly operating reviews feature the ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses metrics however management uses these metrics in conjunction with traditional gaap operating performance and liquidity measures as part of its overall assessment of company performance and liquidity and therefore does not place undue reliance on these measures as its only measures of operating performance and liquidity ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses are not recognized terms under gaap and do not purport to be alternatives to operating income net income or any other gaap measure as an indicator of operating performance ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses are not complete net cash flow measures because ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses are measures of liquidity that do not include reductions for cash payments for an entity s obligation to service its debt fund its working capital capital expenditures and acquisitions and pay its income taxes and dividends rather ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses are potential indicators of an entity s ability to fund these cash requirements ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses are not complete measures of an entity s profitability because they do not include certain costs and expenses and gains and losses described above because not all companies use identical calculations this presentation of ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses may not be comparable to other similarly titled measures of other companies however ebitda adjusted ebitda and adjusted ebitda before covid 19 expenses can still be useful in evaluating the company s performance against the company s peer companies because management believes these measures provide users with valuable insight into key components of gaap amounts 2 acquisition divestiture related and non recurring expenses for the first quarter of 2021 of 4 5 million primarily includes acquisition and integration expenses for the crisco and clabber girl acquisitions and certain cost savings initiatives 3 for the first quarter of 2021 amortization of acquisition related inventory step up of 5 1 million relates to the purchase accounting adjustments made to inventory acquired in the crisco acquisition 4 covid 19 expenses of 0 5 million for the first quarter of 2022 and 2 9 million for the first quarter of 2021 primarily includes temporary enhanced compensation for the company s manufacturing employees that ended on february 15 2021 compensation the company continued to pay manufacturing employees while in quarantine which was incremental to the compensation the company paid to the manufacturing employees who produced the company s products while others were in quarantine and expenses relating to other precautionary health and safety measures b g foods inc and subsidiaries items affecting comparability reconciliation of adjusted net income and adjusted diluted earnings per share to net income in thousands except per share data unaudited first quarter ended april 2 april 3 2022 2021 net income 23 656 26 878 acquisition divestiture related and non recurring income expenses net of tax 1 66 3 405 amortization of acquisition related inventory step up net of tax 2 3 816 adjusted net income 23 590 34 099 adjusted diluted earnings per share 0 34 0 52 1 acquisition divestiture related and non recurring expenses for the first quarter of 2021 primarily includes acquisition and integration expenses for the crisco and clabber girl acquisitions and certain cost savings initiatives 2 for the first quarter of 2021 amortization of acquisition related inventory step up of 5 1 million or 3 8 million net of tax relates to the purchase accounting adjustments made to inventory acquired in the crisco acquisition b g foods inc and subsidiaries items affecting comparability reconciliation of base business net sales 1 to net sales in thousands unaudited first quarter ended april 2 april 3 2022 2021 net sales 532 407 505 134 net sales from discontinued brands 2 239 1 002 base business net sales 532 168 504 132 1 base business net sales is a non gaap financial measure used by management to measure operating performance the company defines base business net sales as the company s net sales excluding 1 the net sales of acquisitions until the net sales from such acquisitions are included in both comparable periods and 2 net sales of discontinued or divested brands the portion of current period net sales attributable to recent acquisitions for which there is no corresponding period in the comparable period of the prior year is excluded for each acquisition the excluded period starts at the beginning of the most recent fiscal period being compared and ends on the first anniversary of the acquisition date for discontinued or divested brands the entire amount of net sales is excluded from each fiscal period being compared the company has included this financial measure because management believes it provides useful and comparable trend information regarding the results of the company s business without the effect of the timing of acquisitions and the effect of discontinued or divested brands 2 reflects net sales of the snackwell s and farmwise brands which are being discontinued view source version on businesswire com
elon musk s deal to acquire has had its ups and downs much like the stock price of most of his companies but it seems like a final arrangement is approaching and that once it arrives musk will be pulling the strings of the social networking platform where he spends a great deal of his time cnbc reported on thursday that musk is expected to serve as twitter s temporary ceo as soon as the deal is official it was previously reported that musk had selected a ceo to his newly acquired social media platform and the news that musk will be taking over until his preferred choice comes aboard likely spells the end of current ceo parag agrawal s tenure it s anybody s guess how all of this will actually shake out though this is elon musk after all the bigger question is how musk is financing the takeover musk has backed a good amount of the deal with funding based on his own shares of tesla stock and bank loans but to foot the massive 44 billion bill he also needed a ton of outside investor money which it appears he got from some unlikely or very likely depending on whom you ask places based on new sec filings musk recently secured more than 7 billion in equity funding from around 19 sources which include sums in the hundreds of millions from various hedge funds as well as some more notable sources like the saudi royal family per the filing saudi prince alwaleed bin talal bin abdulaziz alsaud has agreed to purchase 34 948 975 shares of twitter at 54 20 upon completion of the deal with musk which is notable because prince alwaleed had previously said nuts to a similar offer popular on rolling stone musk is also getting 375 million from qatar which is a little curious considering musk has repeatedly claimed that his twitter will be a bastion of free speech qatar is not really a fan elon musk files new paperwork showing he s got more than 7bn of equity financing to roll into his twitter purchase including binance some qatari group and a saudi billionaire pic twitter com h1jtbzunjp mark di stefano markdistef may 5 2022 musk landing massive investments from wealthy overseas nations isn t surprising but the list of musk s financiers does raise the question of huh what s going on here for example many of the names on this list are all nebulously or tangibly connected to the wider trump universe this may simply be due to the fact that nearly all of america s megarich are all in business together in order to make each other more rich still maggie haberman at the times points out that zach witkoff the son of witkoff capital founder steve witkoff 100 million investment in musktwitter recently got married at mar a lago with trump in attendance steve witkoff in turn used to be one of trump s real estate lawyers editor s picks oracle ceo larry ellison is also a big investor forking over 1 billion ellison is good friends with musk apparently he s also one of trump s wealthiest supporters meanwhile brookfield a canadian asset management company and a new 250 million investor in twitter is also deeply linked to the trumps in 2019 brookfield took out a 99 year lease on 666 fifth avenue which was owned by the kushner family paying the entire lease s 1 1 billion sum up front and massively bailing out the kushners struggling business in return strangely brookfield subsidiary westinghouse electric which is the only u s company that makes large nuclear reactors like say the ones that the saudi government was actively pursuing as part of its nuclear power plan how are twitter s new financiers going to affect twitter as we know it it is as yet unclear what seems like a safe bet right now is that trump will get his account back thanks to a new ceo who truly understands the poster s heart
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
los angeles business wire puma biotechnology inc nasdaq pbyi a biopharmaceutical company announced financial results for the first quarter ended march 31 2022 unless otherwise stated all comparisons are for the first quarter of 2022 compared to the first quarter of 2021 product revenue net consists entirely of revenue from sales of nerlynx puma s first commercial product product revenue net in the first quarter of 2022 was 40 7 million compared to product revenue net of 45 8 million in the first quarter of 2021 based on accounting principles generally accepted in the united states gaap puma reported net loss of 3 4 million or 0 08 per basic and diluted share for the first quarter of 2022 compared to net income of 16 5 million or 0 41 per basic share and 0 40 per diluted share for the first quarter of 2021 non gaap adjusted net loss was 0 3 million or 0 01 per basic and diluted share for the first quarter of 2022 compared to non gaap adjusted net income of 22 4 million or 0 56 per basic share and 0 55 per diluted share for the first quarter of 2021 non gaap adjusted net income excludes stock based compensation expense for a reconciliation of gaap net income loss to non gaap adjusted net income loss and gaap net income loss per share to non gaap adjusted net income loss per share please see the financial tables at the end of this news release net cash used in operating activities for the first quarter of 2022 was 26 9 million compared to 15 7 million provided by operating activities in the first quarter of 2021 at march 31 2022 puma had cash cash equivalents and marketable securities of 73 9 million compared to cash cash equivalents and marketable securities of 82 1 million at december 31 2021 2021 was an important year for puma as we made operational changes to maximize the efficiency of the puma team and the environment with which we operate said alan h auerbach chairman chief executive officer and president of puma we remain committed to increasing awareness of and access to nerlynx as an option to reduce the risk of recurrence for patients battling her2 positive breast cancer the inclusion of nerlynx in the updated nccn guidelines is an important step to expanding the awareness and utilization of neratinib for high risk patients mr auerbach added we anticipate the following key milestones over the next 12 months i reporting phase ii data from the cohort of patients in the summit basket trial of neratinib in her2 mutated hr positive breast cancer h1 2022 ii reporting phase ii data from the cohort of patients in the summit basket trial of neratinib in her2 mutated biliary tract cancer h1 2022 iii reporting phase ii data from the cohort of patients in the summit basket trial of neratinib in non small cell lung cancer patients with egfr exon 18 mutations h2 2022 iv conducting a pre nda meeting with the fda to discuss the potential for an accelerated approval pathway of neratinib in her2 mutated hr positive breast cancer h2 2022 v conducting a meeting with the fda to discuss the potential for an accelerated approval pathway for neratinib in non small cell lung cancer patients with egfr exon 18 mutations who have previously been treated with an egfr tyrosine kinase inhibitor 2022 vi reporting phase ii tbcrc 022 trial data from cohort 4b and 4c of the combination of kadcyla plus neratinib in patients with her2 positive breast cancer with brain metastases who have previously been treated with kadcyla h2 2022 and vii reporting phase ii data from the summit trial of neratinib in cervical cancer patients with her2 mutations h2 2022 revenue total revenue consists of product revenue net from sales of nerlynx puma s first commercial product license revenue from puma s sub licensees and royalty revenue for the first quarter ended march 31 2022 total revenue was 45 7 million of which 40 7 million was net product revenue and 5 0 million was royalty revenue this compares to total revenue of 98 2 million in the first quarter of 2021 of which 45 8 million was net product revenue 50 0 million was license revenue and 2 4 million was royalty revenue operating costs and expenses total operating costs and expenses were 46 4 million for the first quarter of 2022 compared to 78 0 million for the first quarter of 2021 cost of sales cost of sales was 10 8 million for the first quarter of 2022 compared to 29 6 million for the first quarter of 2021 cost of sales in the first quarter of 2021 included 20 0 million for a termination fee paid to a former sub licensee for the return of commercial rights to nerlynx in greater china partially offset by higher royalties due on increased non u s partner sales selling general and administrative expenses selling general and administrative expenses were 20 4 million for the first quarter of 2022 compared to 28 2 million for the first quarter of 2021 the 7 8 million decrease resulted primarily from decreases of approximately 3 1 million in professional fees and expenses primarily related to a decrease in consulting costs for marketing and commercialization support 2 9 million in payroll and related costs due to reduced headcount and 1 4 million in stock based compensation also due to reduced headcount research and development expenses research and development expenses were 15 2 million for the first quarter of 2022 compared to 20 2 million for the first quarter of 2021 the 5 0 million decrease resulted primarily from decreases of 2 5 million in internal r d costs related primarily to reduced payroll costs 1 3 million in stock based compensation due to the impact of headcount reductions in 2021 0 7 million in consultants and contractors due to the close of the control study and the winding down of the summit study and 0 5 million in clinical trial expenses due to reduced study costs as noted above total other income expenses total other expenses were 2 7 million for the first quarter of 2022 compared to total other expenses of 3 7 million for the first quarter of 2021 the 1 0 million decrease in other expenses resulted primarily from lower interest expense on the milestone installment payments to pfizer as well as lower costs related to our outstanding debt conference call puma biotechnology will host a conference call to report its first quarter 2022 financial results and provide an update on the company s business and outlook at 1 30 p m pdt 4 30 p m edt on thursday may 5 2022 the call may be accessed by dialing 866 682 6100 domestic or 862 298 0702 international please dial in at least 10 minutes in advance and inform the operator that you would like to join the puma biotechnology conference call a live webcast of the conference call and presentation slides may be accessed on the investors section of the puma biotechnology website at a replay of the call will be available approximately one hour after completion of the call and will be archived on puma s website for 90 days about puma biotechnology puma biotechnology inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care puma in licenses the global development and commercialization rights to pb272 neratinib oral pb272 neratinib intravenous and pb357 neratinib oral was approved by the u s food and drug administration in 2017 for the extended adjuvant treatment of adult patients with early stage her2 overexpressed amplified breast cancer following adjuvant trastuzumab based therapy and is marketed in the united states as nerlynx neratinib tablets in february 2020 nerlynx was also approved by the fda in combination with capecitabine for the treatment of adult patients with advanced or metastatic her2 positive breast cancer who have received two or more prior anti her2 based regimens in the metastatic setting nerlynx was granted marketing authorization by the european commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor positive her2 overexpressed amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab based therapy nerlynx is a registered trademark of puma biotechnology inc further information about puma biotechnology can be found at www pumabiotechnology com important safety information regarding nerlynx neratinib u s indication nerlynx neratinib tablets for oral use indications and usage nerlynx is a kinase inhibitor indicated as a single agent for the extended adjuvant treatment of adult patients with early stage her2 positive breast cancer to follow adjuvant trastuzumab based therapy in combination with capecitabine for the treatment of adult patients with advanced or metastatic her2 positive breast cancer who have received two or more prior anti her2 based regimens in the metastatic setting contraindications none warnings and precautions diarrhea manage diarrhea through either nerlynx dose escalation or loperamide prophylaxis if diarrhea occurs despite recommended prophylaxis treat with additional antidiarrheals fluids and electrolytes as clinically indicated withhold nerlynx in patients experiencing severe and or persistent diarrhea permanently discontinue nerlynx in patients experiencing grade 4 diarrhea or grade 2 diarrhea that occurs after maximal dose reduction hepatotoxicity monitor liver function tests monthly for the first 3 months of treatment then every 3 months while on treatment and as clinically indicated withhold nerlynx in patients experiencing grade 3 liver abnormalities and permanently discontinue nerlynx in patients experiencing grade 4 liver abnormalities embryo fetal toxicity nerlynx can cause fetal harm advise patients of potential risk to a fetus and to use effective contraception adverse reactions the most common adverse reactions reported in 5 of patients were as follows nerlynx as a single agent diarrhea nausea abdominal pain fatigue vomiting rash stomatitis decreased appetite muscle spasms dyspepsia ast or alt increased nail disorder dry skin abdominal distention epistaxis weight decreased and urinary tract infection nerlynx in combination with capecitabine diarrhea nausea vomiting decreased appetite constipation fatigue asthenia weight decreased dizziness back pain arthralgia urinary tract infection upper respiratory tract infection abdominal distention renal impairment and muscle spasms to report suspected adverse reactions contact puma biotechnology inc at 1 844 nerlynx 1 844 637 5969 or fda at 1 800 fda 1088 or drug interactions gastric acid reducing agents avoid concomitant use with proton pump inhibitors separate nerlynx by at least 3 hours with antacids separate nerlynx by at least 2 hours before or 10 hours after h 2 receptor antagonists or separate nerlynx by at least 3 hours with antacids receptor antagonists or separate nerlynx by at least 3 hours with antacids strong cyp3a4 inhibitors avoid concomitant use p gp and moderate cyp3a4 dual inhibitors avoid concomitant use strong or moderate cyp3a4 inducers avoid concomitant use certain p gp substrates monitor for adverse reactions of p gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with nerlynx use in specific populations lactation advise women not to breastfeed please see full prescribing information for additional safety information to help ensure patients have access to nerlynx puma has implemented the puma patient lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance more information on the puma patient lynx program can be found at or 1 855 816 5421 forward looking statements this press release contains forward looking statements including statements regarding puma s anticipated milestones all forward looking statements involve risks and uncertainties that could cause puma s actual results to differ materially from the anticipated results and expectations expressed in these forward looking statements these statements are based on current expectations forecasts and assumptions and actual outcomes and results could differ materially from these statements due to a number of factors which include but are not limited to any adverse impact on puma s business or the global economy and financial markets generally from the global covid 19 pandemic and the risk factors disclosed in the periodic and current reports filed by puma with the securities and exchange commission from time to time including puma s annual report on form 10 k for the year ended december 31 2021 and subsequent filings readers are cautioned not to place undue reliance on these forward looking statements which speak only as of the date hereof puma assumes no obligation to update these forward looking statements except as required by law puma biotechnology inc and subsidiaries consolidated statements of operations in millions except share and per share data three months ended march 31 2022 2021 unaudited unaudited revenues product revenue net 40 7 45 8 license revenue 50 0 royalty revenue 5 0 2 4 total revenue 45 7 98 2 operating costs and expenses cost of sales 10 8 29 6 selling general and administrative 20 4 28 2 research and development 15 2 20 2 total operating costs and expenses 46 4 78 0 income loss from operations 0 7 20 2 other expenses interest expense 2 7 3 5 legal verdict expense 0 2 total other expenses 2 7 3 7 net income loss before income taxes 3 4 16 5 income tax expense net income loss 3 4 16 5 net income loss per share of common stock basic 0 08 0 41 net income loss per share of common stock diluted 0 08 0 40 weighted average shares of common stock outstanding basic 42 207 709 40 260 864 weighted average shares of common stock outstanding diluted 42 207 709 40 894 868 puma biotechnology inc and subsidiaries liquidity and capital resources in millions march 31 december 31 2022 2021 unaudited cash and cash equivalents 63 9 63 1 marketable securities 10 0 19 0 working capital 42 8 30 4 stockholders equity deficit 7 1 2 4 three months three months ended ended march 31 march 31 2022 2021 unaudited unaudited cash provided by used in operating activities 26 9 15 7 investing activities 9 0 5 3 financing activities 9 8 increase decrease in cash and cash equivalents and restricted cash 8 1 10 4 use of non gaap measures in addition to operating results as calculated in accordance with gaap puma uses certain non gaap financial measures when planning monitoring and evaluating operational performance the following table presents the company s net income loss and net income loss per share calculated in accordance with gaap and as adjusted to remove the impact of stock based compensation expense for the three months ended march 31 2022 stock based compensation represented approximately 8 8 of operating expenses and 12 1 for the same period in 2021 in each case excluding cost of sales puma s management believes that these non gaap financial measures are useful to enhance understanding of puma s financial performance are more indicative of its operational performance and facilitate a better comparison among fiscal periods these non gaap financial measures are not and should not be viewed as substitutes for gaap reporting measures puma biotechnology inc and subsidiaries reconciliation of gaap net income loss to non gaap adjusted net income loss and gaap net income loss per share to non gaap adjusted net income loss per share in millions except share and per share data unaudited three months ended march 31 2022 2021 gaap net income loss 3 4 16 5 adjustments stock based compensation selling general and administrative 2 2 3 6 1 research and development 0 9 2 3 2 non gaap adjusted net income loss 0 3 22 4 gaap net income loss per share basic 0 08 0 41 adjustment to net income loss as detailed above 0 07 0 15 non gaap adjusted basic net income loss per share 0 01 0 56 3 gaap net income loss per share diluted 0 08 0 40 adjustment to net income loss as detailed above 0 07 0 15 non gaap adjusted diluted net income loss per share 0 01 4 0 55 5 1 to reflect a non cash charge to operating expense for selling general and administrative stock based compensation 2 to reflect a non cash charge to operating expense for research and development stock based compensation 3 non gaap adjusted basic net income loss per share was calculated based on 42 207 709 and 40 260 864 weighted average shares of common stock outstanding for the three months ended march 31 2022 and 2021 respectively 4 potentially dilutive common stock equivalents stock options restricted stock units and warrants were not included in this non gaap adjusted diluted net loss per share for the three months ended march 31 2022 as these shares would be considered anti dilutive 5 non gaap adjusted diluted net income per share was calculated based on 40 894 868 weighted average shares of common stock outstanding for the three months ended march 31 2021 alan h auerbach or mariann ohanesian puma biotechnology inc 1 424 248 6500 info pumabiotechnology com ir pumabiotechnology com david schull russo partners 1 212 845 4200 david schull russopartnersllc com
continued to advance clinical gene therapy programs for the treatment of danon disease fanconi anemia fa leukocyte adhesion deficiency i lad i and pyruvate kinase deficiency pkd updates on all four programs to be presented at the 2022 annual meeting of the american society of gene and cell therapy asgct this month trials on track for 2022 data readouts appointed internationally recognized cardiovascular physician scientist and biopharmaceutical executive fady malik m d ph d to board of directors named experienced commercial leader carlos martin to chief commercial officer and proven biotech executive jessie yeung to vice president of investor relations and corporate finance cash position of 346 6m operational runway extended into first half of 2024 cranbury n j business wire rocket pharmaceuticals inc nasdaq rckt a leading late stage clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need today reports financial results for the quarter ending march 31 2022 and updates from the company s key pipeline developments business operations and upcoming milestones i am pleased with our first quarter progress as we maintained our strong focus on execution across each of our clinical programs in house aav manufacturing readiness and overall business operations said gaurav shah m d chief executive officer of rocket pharma we are looking forward to this month s asgct meeting where we will present updates from all four clinical programs we also remain on track to deliver full data readouts through the rest of the year as planned dr shah continued in the first quarter we also bolstered our company leadership team with the appointments of fady malik m d ph d an internationally recognized physician scientist to our board of directors global commercial executive carlos martin to chief commercial officer and capital markets expert jessie yeung to vice president investor relations and corporate finance furthermore we continued to scale up our in house manufacturing facility and remain on track for aav cgmp manufacturing initiation in q2 finally we extended our cash runway from the second half of 2023 into the first half of 2024 and have a strong balance sheet with liquidity through potential regulatory filings and approvals said dr shah taken together we have generated tremendous momentum with our best in class gene therapies utilizing both ex vivo lentiviral and in vivo aav platforms in our pursuit of cures for patients facing these rare and truly devastating diseases key pipeline and operational updates danon fa lad i and pkd trials have continued to progress and remain on track all 2022 milestones remain on track including potential top line readouts for phase 2 trials in lad i and fa in q2 and q3 respectively pediatric efficacy readout for the phase 1 danon disease trial in q3 and the phase 1 readout for pkd in q4 all 2022 milestones remain on track including potential top line readouts for phase 2 trials in lad i and fa in q2 and q3 respectively pediatric efficacy readout for the phase 1 danon disease trial in q3 and the phase 1 readout for pkd in q4 updated clinical data to be presented at asgct updates from all four clinical programs to be presented at the 2022 annual meeting of the american society of gene and cell therapy asgct at the walter e washington convention center in washington d c may 16 19 details for oral presentations are as follows title extended results from first in human clinical trial of rp a501 aav9 lamp2b gene therapy treatment for danon disease session cardiovascular and pulmonary diseases presenter barry greenberg m d fhfsa university of california san diego medical center la jolla ca date monday may 16 2022 session time 10 15 a m 12 00 p m et presentation time 10 45 a m 11 00 a m et location room 206 abstract number 24 title ex vivo lentiviral mediated gene therapy for patients with fanconi anemia updated results from global rp l102 clinical trials session hematopoietic stem cell gene therapy presenter agnieszka czechowicz m d ph d center for definitive and curative medicine stanford university school of medicine stanford ca date monday may 16 2022 session time 3 45 p m 5 30 p m et presentation time 4 15 p m 4 30 p m et location room 202 abstract number 108 title interim results from an ongoing phase 1 2 study of lentiviral mediated ex vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency i lad i session clinical trials spotlight symposium presenter donald b kohn m d broad stem cell research center ucla los angeles and recipient of asgct s 2022 outstanding achievement award date thursday may 19 2022 session time 8 00 a m 9 45 a m et presentation time 8 00 a m 8 15 a m et location ballroom c abstract number 1188 details for the poster presentation are as follows title changing the treatment paradigm for pyruvate kinase deficiency with lentiviral mediated gene therapy interim results from an ongoing global phase 1 study presenter ami shah m d center for definitive and curative medicine stanford university school of medicine stanford ca date monday may 16 2022 time 5 30 p m 6 30 p m et location hall d abstract number 357 in house aav current good manufacturing practice cgmp manufacturing initiation anticipated in q2 the company s state of the art 103 720 ft 2 manufacturing facility in cranbury n j is being scaled up to manufacture aav drug product for a planned phase 2 study in danon disease the company s state of the art 103 720 ft manufacturing facility in cranbury n j is being scaled up to manufacture aav drug product for a planned phase 2 study in danon disease broadened cardiovascular experience of rocket s board of directors the company announced the appointment of fady malik m d ph d to its board of directors dr malik brings nearly 25 years of experience as an internationally recognized cardiovascular physician scientist and highly successful biopharmaceutical executive dr malik is executive vice president of research and development at cytokinetics a late stage biopharmaceutical company where he has worked in a variety of positions since he joined the founders to launch the company the company announced the appointment of fady malik m d ph d to its board of directors dr malik brings nearly 25 years of experience as an internationally recognized cardiovascular physician scientist and highly successful biopharmaceutical executive dr malik is executive vice president of research and development at cytokinetics a late stage biopharmaceutical company where he has worked in a variety of positions since he joined the founders to launch the company named chief commercial officer in march 2022 carlos martin was appointed to senior vice president chief commercial officer mr martin brings over 20 years of global commercial leadership gained at novartis schering plough and eli lilly mr martin will lead the go to market entry models in the u s and eu and build out of key commercial capabilities to pave the way for potential patient access reimbursement and treatment of rocket s gene therapies in march 2022 carlos martin was appointed to senior vice president chief commercial officer mr martin brings over 20 years of global commercial leadership gained at novartis schering plough and eli lilly mr martin will lead the go to market entry models in the u s and eu and build out of key commercial capabilities to pave the way for potential patient access reimbursement and treatment of rocket s gene therapies appointed vice president investor relations corporate finance in march 2022 jessie yeung joined the company as vice president investor relations ms yeung brings more than 15 years of investor relations corporate finance and capital market experience across industries including the biopharmaceutical and financial sectors prior to rocket ms yeung was the head of corporate finance and investor relations at legend biotech ms yeung also has experience as an equity research analyst at bank of america merrill lynch wells fargo and j p morgan in march 2022 jessie yeung joined the company as vice president investor relations ms yeung brings more than 15 years of investor relations corporate finance and capital market experience across industries including the biopharmaceutical and financial sectors prior to rocket ms yeung was the head of corporate finance and investor relations at legend biotech ms yeung also has experience as an equity research analyst at bank of america merrill lynch wells fargo and j p morgan published peer reviewed expanded categorization of severe pkd who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency pkd toward an expanded definition of severe pkd was published in the american journal of hematology the publication summarizes the natural history of the disease and proposes an expanded categorization of severe pkd to help identify the most optimal patients for ongoing gene and cell based evaluations who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency pkd toward an expanded definition of severe pkd was published in the the publication summarizes the natural history of the disease and proposes an expanded categorization of severe pkd to help identify the most optimal patients for ongoing gene and cell based evaluations recognized rare disease day with an event at nasdaq tower in new york city on february 28 2022 rocket hosted its annual rare disease day celebration highlighting the theme rare but not alone more than 250 members of the global rare disease community and rocket team gathered in person and virtually to hear about the impact of rare disease and clinical research from patients families advocacy groups and scientific collaborators and innovators including dr moris danon founder of danon disease the event concluded with the lighting of the empire state building as well as other global landmarks in rare disease day colors anticipated 2022 milestones rp a501 for danon disease aav report data from pediatric patient cohort of phase 1 trial q3 2022 initiate pivotal phase 2 trial activities q4 2022 rp l201 for leukocyte adhesion deficiency i lvv report top line data from pivotal phase 2 trial q2 2022 rp l102 for fanconi anemia lvv report top line data from pivotal phase 2 trial q3 2022 rp l301 for pyruvate kinase deficiency lvv report preliminary phase 1 data q4 2022 initiate pivotal phase 2 trial activities q4 2022 manufacturing facility in cranbury new jersey achieve in house aav current good manufacturing practice cgmp manufacturing readiness q2 2022 upcoming investor conference kinnari patel pharm d mba president and chief operating officer will deliver an in person company presentation at the bank of america securities healthcare conference on wednesday may 11 at 2 20 p m et at the encore hotel in las vegas first quarter financial results cash position cash cash equivalents and investments as of march 31 2022 were 346 6 million cash cash equivalents and investments as of march 31 2022 were 346 6 million r d expenses research and development expenses were 30 8 million for the three months ended march 31 2022 compared to 28 3 million for the three months ended march 31 2021 the increase in research and development expense was primarily driven by an increase in compensation and benefits expense due to increased r d headcount an increase in laboratory supplies and manufacturing development expenses offset by a decrease in non cash stock compensation expense research and development expenses were 30 8 million for the three months ended march 31 2022 compared to 28 3 million for the three months ended march 31 2021 the increase in research and development expense was primarily driven by an increase in compensation and benefits expense due to increased r d headcount an increase in laboratory supplies and manufacturing development expenses offset by a decrease in non cash stock compensation expense g a expenses general and administrative expenses were 11 7 million for the three months ended march 31 2022 compared to 10 9 million for the three months ended march 31 2021 the increase in general and administrative expenses was primarily driven by an increase in compensation and benefits expense due to increased g a headcount and an increase in commercial preparation expenses offset by a decrease in non cash stock compensation expense general and administrative expenses were 11 7 million for the three months ended march 31 2022 compared to 10 9 million for the three months ended march 31 2021 the increase in general and administrative expenses was primarily driven by an increase in compensation and benefits expense due to increased g a headcount and an increase in commercial preparation expenses offset by a decrease in non cash stock compensation expense net loss net loss was 43 0 million or 0 67 per share basic and diluted for the three months ended march 31 2022 compared to 40 2 million or 0 65 per share basic and diluted for the three months ended march 31 2021 net loss was 43 0 million or 0 67 per share basic and diluted for the three months ended march 31 2022 compared to 40 2 million or 0 65 per share basic and diluted for the three months ended march 31 2021 shares outstanding 64 522 057 shares of common stock were outstanding as of march 31 2022 financial guidance cash position as of march 31 2022 we had cash cash equivalents and investments of 346 6 million in april 2022 the company sold 1 3 million shares of common stock for net proceeds of 17 3 million under the at the market facility with the at the market facility proceeds and other efficiencies the company expects such resources will be sufficient to fund its operating expenses and capital expenditure requirements into the first half of 2024 including the continued buildout and initiation of aav cgmp manufacturing capabilities at our cranbury new jersey r d and manufacturing facility and continued development of our four clinical programs as well as future pipeline programs about rocket pharmaceuticals inc rocket pharmaceuticals inc nasdaq rckt is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders the company s platform agnostic approach enables it to design the best therapy for each indication creating potentially transformative options for patients afflicted with rare genetic diseases rocket s clinical programs using lentiviral vector lvv based gene therapy are for the treatment of fanconi anemia fa a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer leukocyte adhesion deficiency i lad i a severe pediatric genetic disorder that causes recurrent and life threatening infections which are frequently fatal and pyruvate kinase deficiency pkd a rare monogenic red blood cell disorder resulting in increased red cell destruction and mild to life threatening anemia rocket s first clinical program using adeno associated virus aav based gene therapy is for danon disease a devastating pediatric heart failure condition for more information about rocket please visit www rocketpharma com rocket cautionary statement regarding forward looking statements various statements in this release concerning rocket s future expectations plans and prospects including without limitation rocket s expectations regarding its guidance for 2022 in light of covid 19 the safety and effectiveness of product candidates that rocket is developing to treat fanconi anemia fa leukocyte adhesion deficiency i lad i pyruvate kinase deficiency pkd and danon disease the expected timing and data readouts of rocket s ongoing and planned clinical trials rocket s plans for the advancement of its danon disease program following the lifting of the fda s clinical hold and the safety effectiveness and timing of related pre clinical studies and clinical trials may constitute forward looking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of 1995 and other federal securities laws and are subject to substantial risks uncertainties and assumptions you should not place reliance on these forward looking statements which often include words such as believe expect anticipate intend plan will give estimate seek will may suggest or similar terms variations of such terms or the negative of those terms although rocket believes that the expectations reflected in the forward looking statements are reasonable rocket cannot guarantee such outcomes actual results may differ materially from those indicated by these forward looking statements as a result of various important factors including without limitation rocket s ability to monitor the impact of covid 19 on its business operations and take steps to ensure the safety of patients families and employees the interest from patients and families for participation in each of rocket s ongoing trials our expectations regarding the delays and impact of covid 19 on clinical sites patient enrollment trial timelines and data readouts our expectations regarding our drug supply for our ongoing and anticipated trials actions of regulatory agencies which may affect the initiation timing and progress of pre clinical studies and clinical trials of its product candidates rocket s dependence on third parties for development manufacture marketing sales and distribution of product candidates the outcome of litigation and unexpected expenditures as well as those risks more fully discussed in the section entitled risk factors in rocket s annual report on form 10 k for the year ended december 31 2021 filed february 28 2022 with the sec accordingly you should not place undue reliance on these forward looking statements all such statements speak only as of the date made and rocket undertakes no obligation to update or revise publicly any forward looking statements whether as a result of new information future events or otherwise three months ended march 31 2022 2021 operating expenses research and development 30 794 28 309 general and administrative 11 770 10 913 total operating expenses 42 564 39 222 loss from operations 42 564 39 222 research and development incentives 500 interest expense 464 1 729 interest and other income net 623 911 amortization of premium accretion of discount on investments net 577 639 total other expense net 418 957 net loss 42 982 40 179 net loss per share attributable to common stockholders basic and diluted 0 67 0 65 weighted average common shares outstanding basic and diluted 64 509 721 61 574 405 march 31 december 31 2022 2021 cash cash equivalents and investments 346 593 388 740 total assets 460 150 497 020 total liabilities 42 530 42 296 total stockholders equity 417 620 454 724 media kevin giordano director corporate communications kgiordano rocketpharma com investors jessie yeung m b a vice president investor relations and corporate finance investors rocketpharma com
laval qc and vaughan on may 5 2022 prnewswire bausch lomb corporation bausch lomb a wholly owned subsidiary of bausch health companies inc nyse tsx bhc bausch health today announced the pricing of its initial public offering ipo of 35 000 000 common shares at a public offering price of 18 00 per share a wholly owned subsidiary of bausch health the selling shareholder is offering all of the common shares and bausch lomb will not receive any of the proceeds from the ipo the selling shareholder has granted the underwriters a 30 day option to purchase up to an additional 5 250 000 common shares of bausch lomb to cover over allotments if any at the initial public offering price less underwriting commissions the common shares have been approved for listing on the new york stock exchange nyse and conditionally approved for listing on the toronto stock exchange tsx the common shares are expected to begin trading on the nyse and on an if as and when issued basis on the tsx on may 6 2022 in each case under the ticker symbol blco the offering is expected to close on may 10 2022 subject to customary closing conditions following the ipo bausch health together with its subsidiaries will hold approximately 90 of the common shares of bausch lomb or 88 5 of the common shares of bausch lomb if the underwriters over allotment option is exercised in full morgan stanley and goldman sachs co llc are acting as joint lead book running managers for the ipo citigroup j p morgan barclays bofa securities guggenheim securities jefferies evercore isi wells fargo securities and deutsche bank securities are acting as joint book running managers for the ipo and dnb markets hsbc truist securities amerivet securities loop capital markets ramirez co inc r seelaus co llc siebert williams shank and stern are acting as co managers for the ipo a registration statement relating to these securities has been filed with and declared effective by the u s securities and exchange commission sec on may 5 2022 and a receipt has been obtained for a final base prep prospectus that has been filed with the securities regulatory authorities in each of the provinces and territories of canada other than quebec on may 5 2022 the ipo is only being made by means of a prospectus when available copies of the final prospectus and the supplemented prep prospectus containing pricing information and other important information relating to the common shares and the offering may be obtained from morgan stanley co llc attn prospectus department 180 varick street 2nd floor new york n y 10014 or goldman sachs co llc attn prospectus department 200 west street new york n y 10282 by telephone at 866 471 2526 or by email at a copy of the supplemented prep prospectus will be filed and will become available on sedar at www sedar com by may 9 2022 no securities regulatory authority has either approved or disapproved of the contents of this news release this news release does not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state province territory or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state province territory or jurisdiction about bausch lomb bausch lomb a leading global eye health business of bausch health companies inc is dedicated to protecting and enhancing the gift of sight for millions of people around the world from the moment of birth through every phase of life its comprehensive portfolio of more than 400 products includes contact lenses lens care products eye care products ophthalmic pharmaceuticals over the counter products and ophthalmic surgical devices and instruments founded in 1853 bausch lomb has a significant global research and development manufacturing and commercial footprint with more than 12 000 employees and a presence in nearly 100 countries bausch lomb is headquartered in vaughan ontario with corporate offices in bridgewater new jersey about bausch health bausch health companies inc nyse tsx bhc bausch health is a global company whose mission is to improve people s lives with our health care products bausch health develops manufactures and markets a range of pharmaceutical medical device and over the counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology bausch health is delivering on its commitments as it builds an innovative company dedicated to advancing global health forward looking statements this news release may contain forward looking statements about the potential distribution of the common shares of bausch lomb that bausch health will continue to hold following completion of the bausch lomb ipo which may generally be identified by the use of the words anticipates hopes expects intends plans should could would may believes subject to and variations or similar expressions including statements about the closing of the ipo whether the underwriters will exercise their over allotment option the number of shares to be held by bhc following the ipo and the expectations relating to the listing of the common shares on the nyse and tsx these statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward looking statements in addition actual results are subject to other risks and uncertainties that relate more broadly to bausch health s overall business including those more fully described in bausch health s most recent annual report on form 10 k and detailed from time to time in bausch health s other filings with the u s securities and exchange commission and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forward looking statements these forward looking statements speak only as of the date hereof bausch health undertakes no obligation to update any of these forward looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes unless required by law source bausch lomb corporation bausch health companies inc
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
enrollment continues in phase 1 dose escalation immunicy 1 trial for lead shrna based allogeneic car t candidate cyad 211 for relapsed refractory multiple myeloma r r mm dialogue continues with regulatory agencies concerning cyad 101 002 phase 1b trial which remains on clinical hold mont saint guibert belgium business wire regulatory news celyad oncology sa brussels cyad paris cyad nasdaq cyad euronext nasdaq cyad the company a clinical stage biotechnology company focused on the discovery and development of chimeric antigen receptor t cell car t therapies for cancer today announced an update on its financial results and recent business developments for the fiscal quarter ended march 31 2022 the first quarter of 2022 brought us both challenges and opportunities that we are facing head on while we continue to investigate the recent developments in the cyad 101 phase 1b trial we are making great progress with our shrna based allogeneic programs including cyad 211 for which we anticipate announcing additional data during the second half of the year commented filippo petti chief executive officer of the company we are truly thankful for our hardworking team and the support of our shareholders while we advance towards our milestones for the year and further enhance our allogeneic car t investigational therapies with our proprietary non gene edited technologies update on clinical and preclinical programs cyad 211 allogeneic shrna based anti bcma car t candidate for r r mm the dose escalation phase 1 immunicy 1 trial is evaluating the tolerability and clinical activity of a single infusion of cyad 211 following preconditioning with cyflu cyclophosphamide and fludarabine in patients with relapsed refractory multiple myeloma r r mm the current segment of the immunicy 1 study is evaluating cyad 211 following enhanced lymphodepleting eld regimens with the aim to improve cell expansion and persistence and potentially maximize the clinical activity of cyad 211 in addition the immunicy 1 protocol allows for redosing of cyad 211 in certain patients enrollment in the eld cohorts of the immunicy 1 trial continues with additional data expected from the program in the second half of 2022 cyad 101 allogeneic tim based nkg2d car t candidate for metastatic colorectal cancer mcrc in february 2022 the company voluntarily paused the phase 1b trial of cyad 101 after two fatalities occurred that presented with similar pulmonary findings subsequently in march 2022 the company was informed by the u s food and drug administration that the cyad 101 002 phase 1b trial had been placed on clinical hold phase 1b trial had been placed on clinical hold the company continues to investigate these findings in the cyad 101 002 phase 1b trial and is evaluating any similar events in additional patients treated in the study while also working with appropriate regulatory authorities the company expects to provide additional updates on the trial in the future shrna armored car sharc franchise research continues in multiple discovery programs focused on the co expression of interleukin 18 il 18 in conjunction with our short hairpin rna shrna technology platform also known as our sharc shrna armored car franchise in april the company decided to stop the development of cyad 203 an allogeneic shrna based il 18 armored nkg2d car t candidate following the analysis of preclinical data from multiple investigational new drug application ind enabling studies the company continues to explore back up allogeneic nkg2d receptor car t candidates currently in discovery stage that leverage the company s sharc platform first quarter 2022 financial review as of march 31 2022 the company had cash and cash equivalents of 20 6 million 23 0 million net cash burn during the first quarter of 2022 amounted to 9 4 million 10 5 million in line with expectations the company confirms its previous guidance that its existing cash and cash equivalents combined with the remaining access to the equity purchase agreement established with lincoln park capital fund llc should be sufficient to fund operating expenses and capital expenditure requirements until mid 2023 financial calendar first half 2022 financial results august 5 2022 third quarter 2022 financial results november 10 2022 about celyad oncology sa celyad oncology sa is a clinical stage biotechnology company focused on the discovery and development of chimeric antigen receptor t cell car t therapies for cancer the company is developing a pipeline of allogeneic off the shelf and autologous personalized car t cell therapy candidates for the treatment of both hematological malignancies and solid tumors celyad oncology was founded in 2007 and is based in mont saint guibert belgium and new york ny the company has received funding from the walloon region belgium to support the advancement of its car t cell therapy programs for more information please visit www celyad com forward looking statements this release contains forward looking statements within the meaning of applicable securities laws including the private securities litigation reform act of 1995 as amended forward looking statements include without limitation statements regarding the cyad 101 002 trial including the clinical hold the timing and outcomes of additional data from phase 1 immunicy 1 trial of cyad 211 safety and clinical activity of the product candidates in celyad oncology s pipeline celyad oncology s financial condition and cash runway and expected results of operations and business outlook the words may might will could would should plan anticipate intend believe expect estimate future potential continue target and similar words or expressions are intended to identify forward looking statements although not all forward looking statements contain these identifying words forward looking statements are based on management s current expectations and may involve known and unknown risks and uncertainties which might cause actual results financial condition performance or achievements of celyad oncology to differ materially from those expressed or implied by such forward looking statements such risk and uncertainty includes without limitation the timing duration and outcome of the clinical hold on the cyad 101 002 phase 1b trial celyad oncology s ability to continue to access to the equity purchase agreement with lincoln park capital fund llc our financial and operating results the duration and severity of the covid 19 pandemic and global economic uncertainty including with respect to geopolitical conditions and attendant sanctions resulting from the conflict in ukraine a further list and description of these risks uncertainties and other risks can be found in celyad oncology s u s securities and exchange commission sec filings and reports including in the latest annual report on form 20 f filed with the sec and subsequent filings and reports of celyad oncology these forward looking statements speak only as of the date of publication of this document and celyad oncology s actual results may differ materially from those expressed or implied by these forward looking statements celyad oncology expressly disclaims any obligation to update any forward looking statements in this document to reflect any change in its expectations with regard thereto or any change in events conditions or circumstances on which any such statement is based unless required by law or regulation investor and media contact sara zelkovic communications investor relations director celyad oncology investors celyad com
the food and drug administration on thursday announced it was limiting access to johnson johnson s covid 19 vaccine because of the risk of a blood clotting disorder that was discovered weeks after the vaccine was first put into use in the spring of 2021 going forward the single dose vaccine will only be available to people 18 and older who cannot take one of the other available vaccines for medical reasons or who simply will not agree to be vaccinated with one of the messenger rna vaccines made by moderna and by pfizer and its partner biontech advertisement peter marks the fda s vaccines lead told stat the agency reached its decision after a recent review of the data on the vaccine revealed another person in this country had died after receiving it the ninth such death in the first quarter of the year the vaccine is made by j j s vaccines division janssen if we see deaths and there is an alternative vaccine that is not associated with deaths but is associated with similar efficacy we felt it was time at this point to make a statement on the fact sheet that this was not a first line vaccine said marks who is director of the fda s center for biologics evaluation and research newsletters sign up for morning rounds your daily dose of news in health and medicine please enter a valid email address privacy policy the clotting disorder called thrombosis with thrombocytopenia or tts is rare occurring at a rate of about 3 25 cases per million doses administered but the condition can be fatal or life altering if an individual survives with one death for every 2 million doses given in this country the fda decided that is a risk most people don t need to take marks said advertisement the prospect of a single dose vaccine held enormous promise when j j announced its approach the vaccine doesn t require the complicated cold chain needed for the mrna vaccines a single dose product is attractive to people who don t like to be vaccinated and cheaper to use for low and middle income countries but the level of protection the vaccine offered was not as high as that induced by the messenger rna and in the u s people who received the j j vaccine have since been urged to get mrna boosters when the clotting risk was identified in mid april of 2021 the fda paused use of the vaccine though the pause was lifted 10 days later confidence in the vaccine had been shaken and demand for it plummeted in december the independent panel that advises the centers for disease control and prevention on vaccines issued a preferential recommendation for the mrna vaccines over the j j product of the 577 million doses of covid vaccine administered in the united states only 18 7 million were the j j vaccine the company said it has updated its product sheet to reflect the fda s restrictions in a statement it said data continue to show that the benefits of the vaccine outweigh its risks when compared to going unvaccinated johnson johnson continues to collaborate with health authorities and regulators around the world to ensure healthcare professionals and individuals are warned and fully informed about reports of tts enabling correct diagnosis appropriate treatment and expedited reporting it said marks stressed that people who received the j j vaccine in the past do not need to worry tts when it occurs develops a week or two after vaccination people who were vaccinated months ago are not in danger of developing the condition he said he acknowledged the latest announcement won t change much on the ground in the united states where few vaccination sites stock the j j vaccine at this point but it could have implications abroad where countries still struggling to vaccinate their populaces could be influenced by the u s decision in the united states this is probably not going to have that much of an effect marks said we re trying to be cautious and we ve informed our global partners at for instance about this and tried to work with them because we don t want our global partners to be panicked we re not saying that it s a bad vaccine we re just saying that for our population where there s an alternative we feel that the alternative should be used
london uk accesswire may 5 2022 data knights acquisition corp data knights or the company nasdaq dkdca nasdaq dkdcw a special purpose acquisition company today announced the deposit of an aggregate of 1 150 000 into the company s trust account for its public stockholders representing 0 10 per public share which enables the company to extend the period of time it has to consummate its initial business combination by three months from may 11 2022 to august 11 2022 the extension the extension is the first of up to two three month extensions permitted under the company s governing documents the extension provides the company with additional time to complete its initial business combination the business combination with onemednet corporation a delaware corporation onemednet previously announced by the company and onemednet on april 25 2022 about data knights acquisition corp data knights acquisition corp is a blank check company formed for the purposes of effecting a merger capital stock exchange asset acquisition stock purchase reorganization or similar business combination with one or more tech or software businesses or entities about onemednet corporation founded in 2009 onemednet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers employing its proven onemednet irwd solution onemednet securely de identifies searches and curates a data archive locally bringing a wealth of internal and third party research opportunities to providers by leveraging this extensive federated provider network together with industry leading technology and in house clinical expertise onemednet successfully meets the most rigorous rwd life science requirements cautionary statement regarding forward looking statements certain statements contained in this press release constitute forward looking statements within the meaning of federal securities laws forward looking statements may include but are not limited to statements with respect to i trends in the real world medical data industry including changes in u s and state laws regulations and guidance related to onemednet s products and services ii onemednet s growth prospects and onemednet s market size iii onemednet projected financial and operational performance including relative to its competitors iv new product and service offerings onemednet may introduce in the future v the potential transaction including the implied enterprise value the expected post closing ownership structure and the likelihood and ability of the parties to consummate the potential transaction successfully vi the risk the proposed business combination may not be completed in a timely manner or at all which may adversely affect the price of data knights securities vii the failure to satisfy the conditions to the consummation of the proposed business combination including the approval of the proposed business combination by the stockholders of data knights acquisition corp viii the effect of the announcement or pendency of the proposed business combination on data knights or onemednet s business relationships performance and business generally ix the outcome of any legal proceedings that be instituted against data knights or onemednet related to the proposed business combination or any agreement related thereto x the ability to maintain the listing of data knights on nasdaq xi the price of data knights securities including volatility resulting from changes in the competitive and regulated industry in which onemednet operates variations in performance across competitors changes in laws and regulations affecting onemednet s business and changes in the combined capital structure xii the ability to implement business pans forecasts and other expectations after the completion of the proposed business combination and identify and realize additional opportunities and xiii other statements regarding data knights or onemednet s expectations hopes beliefs intentions and strategies regarding the future in addition any statements that refer to projections forecasts or other characterizations of future events or circumstances including any underlying assumptions are forward looking statements he words anticipate believe continue could estimate expect intends outlook may might plan possible potential predict project should would and similar expressions may identify forward looking statements but the absence of these words does not mean that a statement is not forward looking forward looking statements are predictions projections and other statements about future events that are based on current expectations and assumptions and as a result are subject are subject to risks and uncertainties you should carefully consider the risks and uncertainties described in the risk factors section of data knights acquisition corp s registration statement on form s 1 any proxy statement relating to the transaction which is expected to be filed by data knights acquisition corp with the sec other documents filed by data knights acquisition corp from time to time with sec and any risk factors made available to you in connection with data knights acquisition corp onemednet and the transaction these forward looking statements involve a number of risks and uncertainties some of which are beyond the control of onemednet and data knights acquisition corp and other assumptions that may cause the actual results or performance to be materially different from those expressed or implied by these forward looking statements contacts investor contact shannon devine mz group north america 203 741 8811 source data knights acquisition corp view source version on accesswire com
laval qc and vaughan on may 5 2022 prnewswire bausch lomb corporation bausch lomb a wholly owned subsidiary of bausch health companies inc nyse tsx bhc bausch health today announced the pricing of its initial public offering ipo of 35 000 000 common shares at a public offering price of 18 00 per share a wholly owned subsidiary of bausch health the selling shareholder is offering all of the common shares and bausch lomb will not receive any of the proceeds from the ipo the selling shareholder has granted the underwriters a 30 day option to purchase up to an additional 5 250 000 common shares of bausch lomb to cover over allotments if any at the initial public offering price less underwriting commissions the common shares have been approved for listing on the new york stock exchange nyse and conditionally approved for listing on the toronto stock exchange tsx the common shares are expected to begin trading on the nyse and on an if as and when issued basis on the tsx on may 6 2022 in each case under the ticker symbol blco the offering is expected to close on may 10 2022 subject to customary closing conditions following the ipo bausch health together with its subsidiaries will hold approximately 90 of the common shares of bausch lomb or 88 5 of the common shares of bausch lomb if the underwriters over allotment option is exercised in full morgan stanley and goldman sachs co llc are acting as joint lead book running managers for the ipo citigroup j p morgan barclays bofa securities guggenheim securities jefferies evercore isi wells fargo securities and deutsche bank securities are acting as joint book running managers for the ipo and dnb markets hsbc truist securities amerivet securities loop capital markets ramirez co inc r seelaus co llc siebert williams shank and stern are acting as co managers for the ipo a registration statement relating to these securities has been filed with and declared effective by the u s securities and exchange commission sec on may 5 2022 and a receipt has been obtained for a final base prep prospectus that has been filed with the securities regulatory authorities in each of the provinces and territories of canada other than quebec on may 5 2022 the ipo is only being made by means of a prospectus when available copies of the final prospectus and the supplemented prep prospectus containing pricing information and other important information relating to the common shares and the offering may be obtained from morgan stanley co llc attn prospectus department 180 varick street 2nd floor new york n y 10014 or goldman sachs co llc attn prospectus department 200 west street new york n y 10282 by telephone at 866 471 2526 or by email at a copy of the supplemented prep prospectus will be filed and will become available on sedar at www sedar com by may 9 2022 no securities regulatory authority has either approved or disapproved of the contents of this news release this news release does not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state province territory or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state province territory or jurisdiction about bausch lomb bausch lomb a leading global eye health business of bausch health companies inc is dedicated to protecting and enhancing the gift of sight for millions of people around the world from the moment of birth through every phase of life its comprehensive portfolio of more than 400 products includes contact lenses lens care products eye care products ophthalmic pharmaceuticals over the counter products and ophthalmic surgical devices and instruments founded in 1853 bausch lomb has a significant global research and development manufacturing and commercial footprint with more than 12 000 employees and a presence in nearly 100 countries bausch lomb is headquartered in vaughan ontario with corporate offices in bridgewater new jersey about bausch healthbausch health companies inc nyse tsx bhc bausch health is a global company whose mission is to improve people s lives with our health care products bausch health develops manufactures and markets a range of pharmaceutical medical device and over the counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology bausch health is delivering on its commitments as it builds an innovative company dedicated to advancing global health forward looking statementsthis news release may contain forward looking statements about the potential distribution of the common shares of bausch lomb that bausch health will continue to hold following completion of the bausch lomb ipo which may generally be identified by the use of the words anticipates hopes expects intends plans should could would may believes subject to and variations or similar expressions including statements about the closing of the ipo whether the underwriters will exercise their over allotment option the number of shares to be held by bhc following the ipo and the expectations relating to the listing of the common shares on the nyse and tsx these statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward looking statements in addition actual results are subject to other risks and uncertainties that relate more broadly to bausch health s overall business including those more fully described in bausch health s most recent annual report on form 10 k and detailed from time to time in bausch health s other filings with the u s securities and exchange commission and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forward looking statements these forward looking statements speak only as of the date hereof bausch health undertakes no obligation to update any of these forward looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes unless required by law view original content to download multimedia source bausch lomb corporation bausch health companies inc
stamford conn business wire may 5 2022 more u s enterprises are seeking a single platform to manage all the functions in their organization and many are finding it through servicenow and its thriving ecosystem of partners according to a new research report published today by information services group isg nasdaq iii a leading global technology research and advisory firm the 2022 isg provider lens servicenow ecosystem partners report for the u s finds companies face several challenges managing a growing number of applications and business requirements they include the complexity of integrating separate applications for each function rising security concerns with remote work and the need to manage performance and service levels the cost of technology operations including support maintenance and licenses is also a growing burden the report says the need to rely on multiple software platforms can result in a degraded view of the overall technology and services environment and is hindering digital business transformation at some companies said bill huber isg partner digital platforms and solutions a unified approach can help them move forward there is a growing appetite among u s enterprises for solutions to transform business processes especially in transaction driven industries such as insurance retail health care and banking and finance isg says companies are transforming their workflows to simplify activities inputs and outputs servicenow is one of the fastest growing vendors of such platforms and its largest market is the u s the wide adoption of servicenow is driven by the company s strong ecosystem of consulting implementation integration and managed services providers through its partners and by making acquisitions servicenow is increasingly targeting specific industries with accelerators that meet unique business requirements servicenow s goal is to deliver products for every persona portfolio and industry sector said jan erik aase partner and global leader isg provider lens research it has a discrete strategy to carry out this mission for enterprises and service providers in the u s the report reviews how servicenow and partners are using new technologies such as ai to expand the platform s capabilities plus how servicenow s partnership programs help providers deliver value to enterprises the 2022 isg provider lens servicenow ecosystem partners report for the u s evaluates the capabilities of 29 providers across three quadrants servicenow consulting services servicenow implementation and integration services and servicenow managed services providers the report names accenture capgemini cask cognizant deloitte genpact hcl infosys lti tcs and wipro as leaders in three quadrants each it names trianz as a leader in two quadrants and hexaware and kpmg as leaders in one quadrant each in addition hexaware and mindtree are named as rising stars companies with a promising portfolio and high future potential by isg s definition in two quadrants each tech mahindra and trianz are named as rising stars in one quadrant each customized versions of the report are available from cask hexaware and trianz the 2022 isg provider lens servicenow ecosystem partners report for the u s is available to subscribers or for one time purchase on this webpage about isg provider lens research the isg provider lens quadrant research series is the only service provider evaluation of its kind to combine empirical data driven research and market analysis with the real world experience and observations of isg s global advisory team enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners while isg advisors use the reports to validate their own market knowledge and make recommendations to isg s enterprise clients the research currently covers providers offering their services globally across europe as well as in the u s canada brazil the u k france benelux germany switzerland the nordics australia and singapore malaysia with additional markets to be added in the future for more information about isg provider lens research please visit this webpage a companion research series the isg provider lens archetype reports offer a first of its kind evaluation of providers from the perspective of specific buyer types about isg isg information services group nasdaq iii is a leading global technology research and advisory firm a trusted business partner to more than 800 clients including more than 75 of the world s top 100 enterprises isg is committed to helping corporations public sector organizations and service and technology providers achieve operational excellence and faster growth the firm specializes in digital transformation services including automation cloud and data analytics sourcing advisory managed governance and risk services network carrier services strategy and operations design change management market intelligence and technology research and analysis founded in 2006 and based in stamford conn isg employs more than 1 300 digital ready professionals operating in more than 20 countries a global team known for its innovative thinking market influence deep industry and technology expertise and world class research and analytical capabilities based on the industry s most comprehensive marketplace data for more information visit www isg one com view source version on businesswire com contact press will thoretz isg 1 203 517 3119 arvidson matter communications for isg 1 617 874 5214 keyword connecticut united states north america industry keyword professional services data management security technology software consulting internet source information services group inc copyright business wire 2022 pub 05 05 2022 11 00 am disc 05 05 2022 11 02 am
shares in asia pacific declined on friday hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 shares on wall street declined sharply overnight with the dow jones industrial average seeing its worst day since 2020 singapore shares in asia pacific largely declined on friday after an overnight drop on wall street sent the dow jones industrial average to its worst day since 2020 hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 in mainland china the shanghai composite slipped 2 16 to end the trading day at 3 001 56 while the shenzhen component shed 2 141 to 10 809 88 in asia of course we re very much influenced by what the u s fed does and the u s economy but now we face the zero covid problem from china richard martin a business consultant and managing director at ima asia told cnbc s street signs asia on friday get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters data shows china s recent covid lockdowns are hitting more than just beijing and shanghai where the bulk of new infections have been found a lot of the components and materials come out of china so in addition to weak demand from china we re going to have a shortage of components from china which on the supply side into the markets across asia will stop factories running martin said technology stocks in the region sold off following the tech heavy nasdaq composite s nearly 5 drop overnight stateside shares of tencent declined 4 69 while alibaba fell 6 57 and meituan slipped 4 68 hong kong s hang seng tech index dropped 5 23 to 4 036 26 the broader risk off sentiment also extended to electric vehicle stocks with xpeng plunging 9 84 while nio shed 11 47 in japan shares of conglomerate softbank group dropped 2 27 south korea s kakao slipped 5 28 while industry heavyweight samsung electronics declined 2 06 other asia pacific markets mostly dip south korea s kospi dropped 1 23 on the day to 2 644 51 the s p asx 200 in australia shed 2 16 to close at 7 205 60 singapore s straits times index slipped 1 39 as of 4 20 p m local time japanese stocks bucked the overall trend regionally as they returned to trade on friday after being closed for holidays much of this week the nikkei 225 closed 0 69 higher at 27 003 56 while the topix index gained 0 93 to 1 915 91 msci s broadest index of asia pacific shares outside japan fell 2 74 overnight on wall street the dow jones industrial average plunged 1 063 09 points or 3 12 to 32 997 97 the s p 500 fell 3 56 to 4 146 87 thursday s moves on wall street were a sharp reversal from a wednesday rally after the u s federal reserve increased its benchmark interest rate by half a percentage point in line with market expectations and also the biggest hike in two decades fed chairman powell also indicated raising rates by 75 basis points at a time is not something the committee is actively considering with no obvious news flow to explain the sharp reversal it seems instead that the relief of powell indicating 75bp moves were likely a step too far gave way to a renewed focus on high inflation and a challenging growth outlook taylor nugent an economist at national australia bank wrote in a friday note currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 103 617 after a recent jump from below 103 the japanese yen traded at 130 50 per dollar weaker as compared to levels below 130 seen against the greenback earlier in the week the australian dollar was at 0 7081 after yesterday s decline from levels above 0 721 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 54 to 111 50 per barrel u s crude futures also gained 0 49 to 108 79 per barrel
the investment eases some of the financial pressure mr musk has absorbed in pursuit of the social media platform the investments mean mr musk s margin loan which lets him borrow against the value of securities he already owns has halved to us6 25 billion from us12 5 billion the securities and exchange commission filing shows free speech platform however mr musk still must come up with us21 billion in cash he does not yet have or yet explained publicly how he will obtain most of his us268 billion fortune is tied up in his stock holdings including tesla though he recently sold more than us8 billion of his shares in the electric carmaker mr musk s twitter focus has investors worried about his day job at tesla the automaker s shares slid 7 9 per cent amid a broader market sell off on thursday twitter stock climbed nearly 3 per cent twitter s board signed off on the us44 billion deal late last month giving the world s richest person command of a highly influential platform the acquisition followed weeks of evangelising on the necessity of free speech as mr musk seized on twitter s role as the de facto town square and took umbrage with content moderation efforts he views as an escalation toward censorship mr musk s positions on free speech and how to police the site have put him relatively at odds with current twitter leadership raising questions about how he will steer his changes through and whether they will affect the executive suite advertisement mr musk is expected to step in as temporary ceo after he completes the takeover us tv channel cnbc reported on thursday citing unnamed sources the current ceo parag agrawal succeeded jack dorsey last november twitter declined to comment to steer this ship mr musk may lean on the expertise of his new backers mr ellison who committed us1 billion co founded the business software company oracle in the 1970s and grew it into one of the world s biggest tech companies in the past decade he gave up the ceo role purchased the hawaiian island of lanai and spent more of his time backing an america s cup sailing team sequoia capital which committed us800 million to the twitter deal has a long history with mr musk besides backing two of his current projects spacex and the boring sequoia helped him launch one of his first companies x com which eventually merged with another start up to become paypal elon s brilliance for over two decades we ve had a front row seat to elon s business and technical prowess a sequoia spokesman said in a statement we see as he does the opportunity to drive meaningful product innovation that will help unlock twitter s full potential as a global platform that connects the world advertisement ben horowitz investor and co founder of andreessen horowitz which contributed us400 million to the new deal said in a twitter feed that the venture capital firm believes in elon s brilliance to make twitter what it was meant to be mr musk has become one of the leading champions of cryptocurrency which perhaps explains why binance plans to invest us500 million toward the twitter purchase the world s largest crypto trading platform reached out to mr musk after he made his initial bid and the billionaire welcomed a discussion on how crypto technologies could be harnessed to improve the social media site according to patrick hillman a binance spokesman other investors include qatar s sovereign wealth fund and saudi prince alwaleed bin talal bin abdulaziz alsaud who originally rejected mr musk s us54 20 a share offer saying in a tweet that he didn t think it came close to the intrinsic value of the company now the prince has agreed to convert his stake in twitter worth nearly us2 billion into a stake in the private company washington post
cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation while scotts miracle gro might seem cheap on a price to earnings basis management doesn t have a handle on how bad it s going to get the mad money host said cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation historically this is a great time of year for anything garden related because it s planting season and scotts is a name that we used to get a ton of questions about but over the past thirteen months these shares have been obliterated the mad money host said get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters while scottsmiracle gro might seem cheap on a price to earnings basis the problem is that the earnings forecast keeps coming down and management doesn t have a handle on how bad it s going to get he later added scottsmiracle gro stock fell 6 on thursday the company reported better than expected earnings in its previous quarter two days before jpmorgan upgraded scottsmiracle gro to overweight from neutral on wednesday pointing to the stock s valuation high margins and market leadership stifel downgraded the stock from overweight to hold cramer said that he agrees with stifel s more bearish stance on scotts particularly because of the company s struggles with rising raw costs lack of confidence regarding an earnings target of 8 a share and his concerns with the performance of scotts hawthorne division hawthorne operates in cannabis an industry cramer says has been beaten down for the last year on top of that scotts has an ugly enough balance sheet that they don t see management embracing an aggressive buyback either in short business is bad and there s not much scotts can do to make it better cramer said sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
racine an alleged racine drug dealer has been accused of having ammo marijuana and oxycodone in a room shared with a toddler kalib p crandall 21 of the 900 block of peck avenue was charged with six felony counts of bail jumping two felony counts of possession of firearm by adjudicated delinquent felony counts of possession with intent to deliver narcotics possession with intent to deliver distribute manufacture marijuana less than or equal to 200 grams maintaining a drug trafficking place and a misdemeanor count of obstructing an officer according to a criminal complaint an investigator with the racine special investigations unit reported that in march and april he conducted an investigation into the sale of controlled substances and possession of firearms at the 900 block of peck avenue the suspect was identified as crandall on tuesday a search warrant was executed on the residence and crandall was seen leaving the driveway as crandall saw officers approaching he produced a handgun and turned away crandall then fled on foot before being stopped at a metal fence and detained a search of crandall found two baggies containing 4 5 grams of marijuana six 5mg oxycodone pills a handgun with a round in the chamber and five in the magazine an ar 15 with the butt stick removed a round in the chamber and 30 rounds in the magazine officers made contact with a woman and a toddler at the residence the woman said she rented the residence and that crandall lived there with the toddler the south bedroom belonged to crandall and the toddler a search of the bedroom found an empty prescription bottle for oxycodone a baggie with marijuana weighing 22 5 grams the butt stock piece belonging to the ar 15 a laser tactical attachment for the rifle a rifle magazine a loose rifle cartridge a digital black scale with marijuana residue 660 in cash a small glass pipe with marijuana residue an open box of rifle ammunition additional boxes of ammunition in the closet crandall was later interviewed at the racine county jail where he said he was leaving the house to meet with someone and wishes he had never answered the phone call crandall was given a 15 000 cash bond in racine county circuit court on thursday a preliminary hearing is on may 12 at the racine county law enforcement center 717 wisconsin ave online court records show
highlights developer of cbd based treatments for multiple skin care applications new e commerce marketing team with experienced industry veterans exclusive worldwide rights to patented shark repellent technologies novel cannabidiol aspartame combination treatment significantly reduces isga score in atopic dermatitis exclusive worldwide rights for unique formulas addressing jellyfish and man o war stings sea lice and swimmer s itch with 4 patents pending double blind placebo controlled clinical trial of jw 200 for the treatment of actinic keratosis merger partner next frontier s executive chairman interviewed with benzinga jupw board approval of 5 0 million share buyback program jupw will present data for jupiter s jw 300 a cannabidiol topical treatment for first degree burns at scale 2022 aesthetic medicine plastic surgery medical dermatology conference to take place may 11 15 2022 in nashville tennessee in a clinical trial of 36 patients a controlled area of skin was exposed to uv irradiation the percentage of subjects who experienced burns measured by erythema in patients treated with jw 300 was significantly lower p 0 047 than in subjects who received the placebo lotion the percent of subjects who were burned in the placebo arm was 61 compared to 27 in patients treated with jw 300 in addition in patients n 18 treated with jw 300 the average erythema score was 0 388 after radiation compared to 0 722 in the placebo arm n 18 dr glynn wilson chief scientist of jupiter wellness commented these statistically significant results demonstrate jw 300 s potential as either a prescription or over the counter topical cream to help prevent sunburn and its more harmful consequences such as skin cancer we look forward to presenting these important data to leading dermatology and aesthetic medicine physicians at scale jupiter ceo brian john added jw 300 complements our current over the counter skincare products including canisun as well as our prescription product photocil serving a large market that needs more effective solutions jupw recently announced it has concluded an asset purchase agreement with ascent clinical research inc through which it has acquired certain clinical assets including clinical trial research contracts worth 3 million in annual revenues for a purchase price of 5 royalties on future net revenues generated by the assets about jupw jupiter wellness inc nasdaq jupw is a leading developer of cannabidiol cbd based medical therapeutics and wellness products the jupw clinical pipeline of prescription cbd enhanced skin care therapeutics address indications including eczema burns herpes cold sores and skin cancer jupw generates revenues from a growing line of proprietary over the counter skincare products including its flagship canisun sunscreen and other wellness brands sold through its robust distribution platform over the past two years jupw has built a portfolio of award winning wellness brands including canisun jack wellness 1937 black belt and felix ambrosia as well prescription therapeutics such as photosil that have been featured in numerous media outlets including the today show cnn abc cbs animal planet adweek bloomberg the washington post vogue buzzfeed and forbes jupw to launch canisun for shark defense sunscreen with patented shark repellents exclusive worldwide rights to patented shark repellent technologies for the sun and skin market licensed from shark defense technologies view discovery channel videos on the shark repellent technology here on april 7th jupw announced the upcoming launch of canisun for shark defense the latest addition to the company s reef friendly sunscreen line through a licensing agreement with shark defense technologies llc the leading researcher of chemical electrochemical and magnetic shark repellents jupw has the exclusive worldwide rights to patents formulas and production methods for shark repellent technologies for use in sun and skincare products novel treatment jw 100 significantly reduces isga score in atopic dermatitis results from a randomized double blinded placebo controlled interventional study on april 6th jupw announced the publication of clinical study results to investigate the safety and efficacy of jw 100 its proprietary lotion formulation for the treatment of atopic dermatitis eczema in the journal of cosmetic dermatology vol 21 issue 4 april 2022 pp 1647 1650 jupw launches nostingz jellyfish protective sunscreen backed by patent pending formula in 13 b sunscreen market exclusive worldwide rights for unique formulas addressing jellyfish and man o war stings sea lice and swimmer s itch with 4 patents pending on april 5th jupw announced the launch of nostingz a proprietary line of sunscreen designed to protect against jellyfish and man o war stings sea lice and swimmer s itch all while continuing to protect ocean lovers skin from uva uvb in a range of spfs jupw has signed a license agreement with shark defense technologies for the exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds including 4 patents pending the agreement includes future collaboration to develop and refine additional formulas for more on the jupw nostingz product or to purchase visit jupw board approval of 5 0 million share buyback program on january 25th jupw announced it its board of directors approved a 5 0 million share buyback program which expires on june 30 2022 under the share buyback program shares of jupw common stock may be repurchased periodically in open market or privately negotiated transactions for additional information on jupiter wellness inc jupw visit www jupiterwellnessinc com the products mentioned are thc free and or compliant with the 2018 farm bill disclaimer this article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks media contact company name jupiter wellness inc contact person brian john ceo email send email phone 561 244 7100 country united states website
calgary alberta may 05 2022 globe newswire gran tierra energy inc gran tierra or the company nyse american gte tsx gte lse gte today announced the voting results from the company s annual meeting of stockholders held on may 4 2022 final voting results of gran tierra s annual meeting of stockholders stockholders elected all nine individuals nominated by gran tierra in addition stockholders voted for the ratification of the appointment of kpmg llp as gran tierra s independent registered public accounting firm for the fiscal year ending december 31 2022 for the approval on an advisory basis of the compensation of gran tierra s named executive officers every year as the preferred frequency of solicitation of stockholder advisory votes on the compensation of gran tierra s named executive officers and for the approval of the 2007 equity incentive plan as amended the detailed results of the vote are as follows proposal 1 election of directors for against abstain non votes gary s guidry 103 665 849 97 5 2 705 019 335 573 70 556 916 peter dey 87 911 653 84 0 16 790 829 2 003 958 70 556 916 evan hazell 101 024 231 96 5 3 687 499 1 994 709 70 556 916 robert b hodgins 99 364 937 95 0 5 271 675 2 069 828 70 556 916 alison redford 102 220 046 97 8 2 277 191 2 209 202 70 556 916 ronald royal 102 253 165 97 8 2 332 143 2 121 131 70 556 916 sondra scott 99 637 172 95 2 4 984 846 2 084 421 70 556 916 david p smith 102 123 557 97 5 2 587 313 1 995 570 70 556 916 brooke wade 99 835 833 95 4 4 866 966 2 003 641 70 556 916 proposal 2 for against abstain non votes ratification of appointment of the independent registered public accounting firm 170 088 249 96 0 6 495 233 679 874 0 proposal 3 for against abstain non votes approval of named executiveofficer compensation 94 910 820 88 9 10 923 981 871 640 70 556 915 proposal 4 every year every two years every three years abstain non votes approval of the preferred 88 490 938 1 655 691 9 191 649 7 353 011 70 572 067 frequency of solicitation of stockholders advisory votes on the compensation of gran tierra s named executive officers proposal 5 for against abstain non votes approval of 2007 equity incentive plan as amended 71 854 873 67 3 33 685 877 1 165 690 70 556 916 about gran tierra energy inc gran tierra energy inc together with its subsidiaries is an independent international energy company currently focused on oil and natural gas exploration and production in colombia and ecuador the company is currently developing its existing portfolio of assets in colombia and ecuador and will continue to pursue additional growth opportunities that would further strengthen the company s portfolio the company s common stock trades on the nyse american the toronto stock exchange and the london stock exchange under the ticker symbol gte additional information concerning gran tierra is available at www grantierra com information on the company s website including the sustainability report does not constitute a part of this press release investor inquiries may be directed to or 403 265 3221 gran tierra s securities and exchange commission filings are available on the sec website at the company s canadian securities regulatory filings are available on sedar at and uk regulatory filings are available on the national storage mechanism website at contact information for investor and media inquiries please contact gary guidry chief executive officer ryan ellson executive vice president chief financial officer rodger trimble vice president investor relations 1 403 265 3221 source gran tierra energy inc
data knights acquisition corp nasdaq dkdca nasdaq dkdcw a special purpose acquisition company today announced the deposit of an aggregate of 1 150 000 into the company s trust account for its public stockholders representing 0 10 per public share which enables the company to extend the period of time it has to consummate its initial business combination by three months from may 11 2022 to august 11 2022 the extension the extension is the first of up to two three month extensions permitted under the company s governing documents the extension provides the company with additional time to complete its initial business combination the business combination with onemednet corporation a delaware corporation onemednet previously announced by the company and onemednet on april 25 2022
hauppauge n y may 05 2022 globe newswire chembio diagnostics inc chembio or the company nasdaq cemi a leading point of care diagnostics company focused on infectious diseases today reported financial results for the quarter ended march 31 2022 recent highlights achieved total revenue of 18 8 million including record quarterly product revenue of 18 5 million in the first quarter of 2022 representing growth of 116 and 360 respectively compared to the prior year period u s product revenue of 4 5 million representing growth of 530 compared to the prior year period latin america product revenue of 12 5 million compared to 0 3 million in the prior year period completed shipments under the 28 3 million purchase order from bio manguinhos for dpp sars cov 2 antigen tests in brazil and continued shipments on the 4 million hiv test purchase order supported by the global fund which are expected to be completed in the second quarter of 2022 improved gross product margin to 18 in the first quarter of 2022 from negative 9 in the fourth quarter of 2021 reduced cash usage in the first quarter of 2022 to 4 4 million from 8 7 million in the prior year period and 7 2 million in the preceding quarter expanded distributor relationships in europe to supply the sure check hiv self tests in the uk and france enhanced operations at chembio diagnostics brazil by increasing low cost manufacturing capabilities for over the counter packaging to support sure check self test supply for state local and retail pharmacies we are pleased with our first quarter performance which included record quarterly product sales and substantial sequential gross product margin improvement said richard eberly chembio s president and chief executive officer in light of decreasing international demand for covid 19 testing we are repositioning our commercial focus toward our core products the hiv self testing market continues to grow across europe brazil and africa and with renewed marketing efforts we believe our sure check products can address the needs of this patient population and further penetrate this market going forward we will continue to prioritize use of our resources to drive more profitable growth and operational efficiency in accordance with our previously announced global competitiveness program first quarter 2022 financial results total revenue for the first quarter of 2022 was 18 8 million an increase of 116 compared to the prior year period net product sales for the first quarter of 2022 were 18 5 million an increase of 360 compared to the prior year period government grant license and royalty and r d revenue for the first quarter of 2022 totaled 0 3 million a decrease of 94 compared to the prior year period gross product margin for the first quarter of 2022 was 3 3 million compared to 0 5 million for the prior year period gross product margin percentage for the first quarter of 2022 was 18 compared to 12 for the prior year period gross product margin in the first quarter of 2022 was driven by increased product volume sold in us and latin america at higher average selling prices and operational productivity research and development expenses decreased by 1 2 million or 42 in the first quarter of 2022 compared to the prior year period selling general and administrative expenses increased by 0 9 million or 14 in the first quarter of 2022 compared to the prior year period impairment restructuring severance and related costs for the first quarter of 2022 totaled 3 0 million including an impairment of goodwill net loss for the first quarter of 2022 was 8 8 million or 0 29 per diluted share compared to a net loss of 4 5 million or 0 22 per diluted share for the prior year period the net loss includes impairment restructuring severance and related costs of 3 0 million or 0 10 per share for the first quarter of 2022 compared to a de minimis amount in the prior year period cash and cash equivalents as of march 31 2022 totaled 24 4 million compared to 28 8 million at december 31 2021 going concern considerations the company continued to experience market clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of covid 19 test systems during the continuing but evolving uncertainty caused by covid 19 for the three months ended march 31 2022 the company continued to incur significant expenses in connection with pending legal matters the company performed an assessment to determine whether there were conditions or events that considered in the aggregate raised substantial doubt about the company s ability to continue as a going concern within one year after the date the company s unaudited condensed consolidated financial statements for the three months ended march 31 2022 are being issued the q1 financials issuance date initially this assessment did not consider the potential mitigating effect of management s plans that had not been fully implemented because as described below substantial doubt was determined to exist as the result of this initial assessment management then assessed the mitigating effect of its plans to determine if it is probable that the plans 1 would be effectively implemented within one year after the q1 financials issuance date and 2 when implemented would mitigate the relevant conditions or events that raise substantial doubt about the company s ability to continue as a going concern the company achieved significant revenue growth in recent years while profitability has not been at levels as expected it has taken steps including investments in automation to mitigate headwinds such as labor availability volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth during the three months ended march 31 2022 the company undertook measures to increase its total revenues and improve its liquidity position by implementing the global competitiveness program the main pillars of the global competitiveness program include the following focus on higher margin business in growth markets lower manufacturing costs reduce infrastructure costs strategic review of non core businesses and assets in addition the company will continue to focus on regulatory approvals for its dpp sars cov 2 antigen test system dpp respiratory antigen panel and dpp hiv syphilis test system these measures and other plans and initiatives have been designed to provide the company with adequate liquidity to meet its obligations for at least the twelve month period following the q1 financials issuance date the company s execution of those measures and its other plans and initiative continue to depend however on factors and uncertainties that are beyond the company s control or that may not be addressable on terms acceptable to the company or at all the company considered in particular how the ongoing healthcare and economic impacts of covid 19 on the global customer base for the company s non covid 19 products continue to negatively affect the timing and rate of recovery of the company s revenues from those products by for example decreasing the allocation of funding for hiv testing thereby continuing to adversely affect the company s liquidity although the company has entered into agreements to distribute third party covid 19 products in the united states its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products the company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in its existing credit agreement those obligations include covenants requiring i minimum cash balance of 3 0 million and ii minimum total revenue amounts for the twelve months preceding each quarter end for the next year the minimum total revenue requirements range from 43 8 million for the twelve months ending june 30 2022 to 48 8 million for the twelve months ending march 31 2023 upon an event of default under the credit agreement the lender could elect to declare all amounts outstanding thereunder together with accrued interest to be immediately due and payable in such an event there can be no assurance that the company would have sufficient liquidity to fund payment of the amounts that would be due under the credit agreement or that if such liquidity were not available the company would be successful in raising additional capital on acceptable terms or at all or in completing any other endeavor to continue to be financially viable and continue as a going concern the company s inability to raise additional capital on acceptable terms in the near future whether for purposes of funding payments required under the credit agreement or providing additional liquidity needed for its operations could have a material adverse effect on its business prospects results of operations liquidity and financial condition accordingly management determined the company could not be certain that the company s plans and initiatives would be effectively implemented within one year after the q1 financials issuance date without giving effect to the prospect of raising additional capital pursuant to the company s existing at the market offering agreement increasing product revenue in the near future or executing other mitigating plans many of which are beyond the company s control it is unlikely that the company will be able to generate sufficient cash flows to meet its required financial obligations including its debt service and other obligations due to third parties the existence of these conditions raises substantial doubt about the company s ability to continue as a going concern for the twelve month period following the q1 financials issuance date the company s unaudited condensed consolidated financial statements for the three months ended march 31 2022 have been prepared assuming the company will continue as a going concern which contemplates continuity of operations realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the q1 financials issuance date as such those unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts or the amount and classification of liabilities that may result should the company be unable to continue as a going concern conference call chembio will host a conference call today beginning at 4 30 pm et to discuss its financial results and recent business highlights investors interested in listening to the call may do so by dialing 888 506 0062 from the united states or 973 528 0011 from outside the united states and providing entry code 898553 to listen to a live webcast of the call please visit the investor relations section of chembio s website at www chembio com following the call a replay will be available on the investor relations section of chembio s website a telephone replay will be available until 4 30 pm et on may 19 2022 by dialing 877 481 4010 from the united states or 919 882 2331 from outside the united states and using passcode 45278 about chembio diagnostics chembio is a leading diagnostics company focused on developing and commercializing point of care tests used for the rapid detection and diagnosis of infectious diseases including sexually transmitted disease insect vector and tropical disease covid 19 and other viral and bacterial infections enabling expedited treatment coupled with chembio s extensive scientific expertise its novel dpp technology offers broad market applications beyond infectious disease chembio s products are sold globally directly and through distributors to hospitals and clinics physician offices clinical laboratories public health organizations government agencies and consumers learn more at www chembio com forward looking statements certain statements contained in the second bulleted item under recent highlights above and in the paragraph following the bulleted items under recent highlights above are not historical facts and may be forward looking statements within the meaning of the private securities litigation reform act of 1995 forward looking statements include statements regarding the intent belief or current expectations with respect to the chembio s r d investments development of certain products and registration of existing products in new geographies such statements which are expectations only reflect management s current views are based on certain assumptions and involve risks and uncertainties actual results events or performance may differ materially from forward looking statements due to a number of important factors and will be dependent upon a variety of factors including but not limited to the following any of which could be exacerbated even further by the continuing covid 19 outbreak in the united states and globally the ability of chembio to continue to generate revenue from the hiv test purchase order supported by the global fund or other product orders and the margins it can realize from that revenue or its ability to develop new products will depend on the availability and cost of human material and other resources required to build and deliver the tests which factors are largely outside chembio s control the ability of chembio to maintain existing and timely obtain additional regulatory approvals which approvals are subject to processes that can change recurringly without notice the highly competitive and rapidly developing diagnostics market which includes a number of competing companies with strong relationships with current and potential customers including governmental authorities and with significantly greater financial and other resources that are available to chembio and the risks of doing business with foreign governmental entities including geopolitical international and other challenges as well as potential material adverse effects of tariffs and other changes in u s trade policy chembio undertakes no obligation to publicly update forward looking statements in this release to reflect events or circumstances that occur after the date hereof or to reflect any change in chembio s expectations with regard to the forward looking statements or the occurrence of unanticipated events factors that may impact chembio s success are more fully disclosed in chembio s periodic public filings with the u s securities and exchange commission including its annual report on form 10 k for the fiscal year ended december 31 2021 particularly under the heading risk factors dpp is chembio s registered trademark and the chembio logo is chembio s trademark for convenience these trademarks appear in this release without or symbols but that practice does not mean that chembio will not assert to the fullest extent under applicable law its rights to the trademarks all other trademarks appearing in this release are the property of their respective owners investor relations contact philip taylor gilmartin group 415 937 5406 investor chembio com chembio diagnostics inc and subsidiaries condensed consolidated statements of operations for the three months ended unaudited march 31 2022 march 31 2021 revenues product revenue 18 527 456 4 024 662 r d revenue 18 173 1 106 639 government grant income 3 350 000 license and royalty revenue 270 982 243 058 total revenues 18 816 611 8 724 359 costs and expenses cost of product revenue 15 223 861 3 548 441 research and development expenses 1 653 706 2 863 338 selling general and administrative expenses 6 946 271 6 085 067 impairment restructuring severance and related costs 3 043 179 83 087 total costs and expenses 26 867 017 12 579 933 loss from operations 8 050 406 3 855 574 other expense interest expense net 733 561 712 477 loss before income taxes 8 783 967 4 568 051 income tax expense benefit 6 327 67 888 net loss 8 790 294 4 500 163 basic and diluted loss per share 0 29 0 22 weighted average number of shares outstanding basic and diluted 30 090 045 20 163 386 chembio diagnostics inc and subsidiaries condensed consolidated balance sheets as of march 31 2022 december 31 2021 assets current assets cash and cash equivalents 24 399 388 28 772 892 accounts receivable 9 879 954 11 441 107 inventories net 11 844 121 12 920 451 prepaid expenses and other current assets 2 097 491 2 096 399 total current assets 48 220 954 55 230 849 fixed assets property plant and equipment net 8 414 313 8 556 773 finance lease right of use asset net 190 526 191 870 total fixed assets net 8 604 839 8 748 643 other assets operating lease right of use assets net 5 693 482 5 891 906 goodwill 3 022 787 deposits and other assets 370 940 358 010 total assets 62 890 215 73 252 195 liabilities and stockholders equity current liabilities accounts payable and accrued liabilities 10 542 851 13 127 993 current portion of long term debt 2 100 000 1 200 000 operating lease liabilities 916 524 886 294 finance lease liabilities 72 203 68 176 total current liabilities 13 631 578 15 282 463 other liabilities long term operating lease liabilities 5 733 214 5 976 151 long term finance lease liabilities 134 955 139 678 long term debt less current portion net 16 855 322 17 589 003 total liabilities 36 355 069 38 987 295 stockholders equity common stock 0 01 par value 302 699 301 050 additional paid in capital 166 483 376 165 772 636 accumulated deficit 139 800 154 131 009 860 treasury stock 206 554 206 554 accumulated other comprehensive loss 244 221 592 372 total stockholders equity 26 535 146 34 264 900 total liabilities and stockholders equity 62 890 215 73 252 195 chembio diagnostics inc and subsidiaries condensed consolidated statements of cash flows for the three months ended unaudited march 31 2022 march 31 2021 net cash used in operating activities 4 368 959 7 261 260 net cash used in investing activities 286 544 1 239 168 net cash used by financing activities 55 444 129 341 effect of exchange rate changes on cash 337 442 85 579 increase in cash and cash equivalents 4 373 504 8 715 348 cash and cash equivalents beginning of the period 28 772 892 23 066 301 cash and cash equivalents end of the period 24 399 388 14 350 953
shares in asia pacific declined on friday hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 shares on wall street declined sharply overnight with the dow jones industrial average seeing its worst day since 2020 singapore shares in asia pacific largely declined on friday after an overnight drop on wall street sent the dow jones industrial average to its worst day since 2020 hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 in mainland china the shanghai composite slipped 2 16 to end the trading day at 3 001 56 while the shenzhen component shed 2 141 to 10 809 88 in asia of course we re very much influenced by what the u s fed does and the u s economy but now we face the zero covid problem from china richard martin a business consultant and managing director at ima asia told cnbc s street signs asia on friday feeling out of the loop we ll catch you up on the chicago news you need to know sign up for the weekly chicago catch up newsletter here data shows china s recent covid lockdowns are hitting more than just beijing and shanghai where the bulk of new infections have been found a lot of the components and materials come out of china so in addition to weak demand from china we re going to have a shortage of components from china which on the supply side into the markets across asia will stop factories running martin said technology stocks in the region sold off following the tech heavy nasdaq composite s nearly 5 drop overnight stateside shares of tencent declined 4 69 while alibaba fell 6 57 and meituan slipped 4 68 hong kong s hang seng tech index dropped 5 23 to 4 036 26 the broader risk off sentiment also extended to electric vehicle stocks with xpeng plunging 9 84 while nio shed 11 47 in japan shares of conglomerate softbank group dropped 2 27 south korea s kakao slipped 5 28 while industry heavyweight samsung electronics declined 2 06 other asia pacific markets mostly dip south korea s kospi dropped 1 23 on the day to 2 644 51 the s p asx 200 in australia shed 2 16 to close at 7 205 60 singapore s straits times index slipped 1 39 as of 4 20 p m local time japanese stocks bucked the overall trend regionally as they returned to trade on friday after being closed for holidays much of this week the nikkei 225 closed 0 69 higher at 27 003 56 while the topix index gained 0 93 to 1 915 91 msci s broadest index of asia pacific shares outside japan fell 2 74 overnight on wall street the dow jones industrial average plunged 1 063 09 points or 3 12 to 32 997 97 the s p 500 fell 3 56 to 4 146 87 thursday s moves on wall street were a sharp reversal from a wednesday rally after the u s federal reserve increased its benchmark interest rate by half a percentage point in line with market expectations and also the biggest hike in two decades fed chairman powell also indicated raising rates by 75 basis points at a time is not something the committee is actively considering with no obvious news flow to explain the sharp reversal it seems instead that the relief of powell indicating 75bp moves were likely a step too far gave way to a renewed focus on high inflation and a challenging growth outlook taylor nugent an economist at national australia bank wrote in a friday note currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 103 617 after a recent jump from below 103 the japanese yen traded at 130 50 per dollar weaker as compared to levels below 130 seen against the greenback earlier in the week the australian dollar was at 0 7081 after yesterday s decline from levels above 0 721 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 54 to 111 50 per barrel u s crude futures also gained 0 49 to 108 79 per barrel
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed corecivic inc let s just stay away inmode ltd if you want med tech you just want edwards lifesciences western midstream partners lp this one s got a great yield really good story get connecticut local news weather forecasts and entertainment stories to your inbox sign up for nbc connecticut newsletters sghc limited they are doing well and i don t say that idly enterprise products partners lp they are the best in what they do united states steel corp if you re going to own a steel company which i don t honestly recommend right now you re going to own nucor teva pharmaceutical industries ltd i would prefer to see you in something like a ast spacemobile inc i do not know that company but we will do homework on it sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
example video title will go here for this video example video title will go here for this video some states previously passed laws banning or restricting access to abortions those laws are now set to go into effect on friday the supreme court ruled in favor of mississippi s anti abortion law in dobbs v jackson women s health organization overturning the 1973 roe v wade decision that made abortion legal nationwide a copy of the supreme court s decision leaked to politico in may led to questions from many of our verify viewers and people on social media asking whether this changes abortion access nationwide some claimed that the decision doesn t make abortion illegal throughout the country and instead sends the issue to individual states by the way if you actually read the decision it doesn t outlaw abortion it sends the legality question of abortion to states and their legislatures to decide tim young timrunshismouth may 3 2022 the question is abortion illegal in all states now that the supreme court overturned roe v wade the sources the answer no abortion isn t illegal in all states now that the supreme court overturned roe v wade states can still pass their own abortion laws to either restrict or guarantee the right to abortions what we found in its 1973 ruling on roe v wade the supreme court found that a fundamental right to privacy is inherent in the fourteenth amendment s due process clause and a person s right to choose whether to have an abortion falls within the right to privacy the court s 1973 decision made it illegal for states to regulate abortion in the first trimester of pregnancy in the second trimester states could impose some regulations on abortion that are reasonably related to maternal health once the fetus reached the point of viability in the third trimester or the point where it could survive outside the womb with medical support a state could regulate or ban abortions so long as the laws contain exceptions for cases when abortion is necessary to save the life or health of the mother however supreme court justice samuel alito wrote in the majority opinion on dobbs v jackson women s health organization which overturns roe v wade that the constitution makes no reference to abortion and no such right is implicitly protected by any constitutional provision including the fourteenth amendment now that roe v wade is overturned the right to an abortion in the first trimester is no longer federally protected but that doesn t mean abortion is illegal in every state in the u s liza fuentes a senior research assistant at the guttmacher institute previously told verify that individual states can make their own laws about abortions benjamin barton a law professor at the university of tennessee knoxville agrees if the draft opinion becomes the actual majority opinion there would no longer be a federal constitutional right to an abortion so the decision as to whether to allow abortions or not would be up to individual states he wrote in an email to verify before the supreme court issued its official ruling about a dozen states have trigger laws to ban all or nearly all abortions set to go into effect now that roe v wade is overturned according to the guttmacher institute more than two dozen u s states are certain or likely to ban abortions in the absence of roe on the other hand some states have passed laws guaranteeing the right to have an abortion without state interference south dakota gov kristi noem said in may that she will call for a special legislative session to restrict access to abortions the state already has a trigger law on the books to ban most abortions following the supreme court s decision in january 2022 new jersey gov phil murphy signed the freedom of reproductive choice act into law codifying the constitutional right to freedom of reproductive choice in the state
clinical programs continue progressing with multiple phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self amplifying mrna samrna vaccines against viruses expected over the next 18 months recent presentations reinforce expertise in vaccine design and delivery and potential of gritstone s platform technologies in oncology and infectious diseases cash cash equivalents marketable securities and restricted cash of 186 8 million as of march 31 2022 emeryville calif may 05 2022 globe newswire gritstone bio inc nasdaq grts a clinical stage biotechnology company that aims to develop the world s most potent vaccines today reported financial results for the first quarter ended march 31 2022 and reviewed business highlights clinical data out of our cancer and viral disease vaccine programs are expected to be flowing steadily through year end and over the next 18 months said andrew allen m d ph d co founder president and chief executive officer of gritstone our individualized neoantigen vaccine candidate for solid tumors granite is now in a randomized phase 2 3 trial in newly diagnosed metastatic colorectal cancer building on the exciting molecular response survival data shown at esmo 2021 in end stage colorectal cancer patients multiple phase 1 trials are ongoing in coral 2nd generation covid 19 vaccine program with data from all studies expected throughout 2h2022 and initial data from the phase 2 study of slate kras kras specific off the shelf vaccine candidate is also expected in 2h2022 our recent presentations at aacr underscore the unique capabilities of our novel self amplifying mrna samrna vector which has demonstrated potency and dose sparing potential along with a favorable safety and tolerability profile in the clinic the data we are generating with sars cov 2 as the target are providing validation for the entire samrna platform and provide clear rationale to pursue additional viral pathogens we look forward to sharing more data and continuing to demonstrate the value we are bringing to patients and all stakeholders as the year progresses clinical program updates tumor specific neoantigen tsna oncology programs granite individualized tsna directed vaccine based immunotherapyusing an adenoviral priming vector and samrna boost vector to deliver relevant neoantigens following success in late line studies gritstone intends to continue advancing granite through randomized controlled trials and evaluate these candidates in earlier lines of treatment where immune responses may be stronger and the potential benefits could be further accentuated in january gritstone announced the first patient was enrolled for inclusion in granite crc 1l a randomized controlled phase 2 3 trial evaluating granite in combination with immune checkpoint blockade for frontline maintenance treatment of newly diagnosed patients with metastatic microsatellite stable colorectal cancer mss crc preliminary data molecular response and progression free survival from the phase 2 portion of the trial are expected in 2h2023 in march gritstone announced the first patient was enrolled for inclusion in granite crc adjuvant a randomized controlled phase 2 trial in patients with high risk mss crc and stage ii iii disease who are circulating tumor dna ctdna after definitive surgery in april gritstone shared two poster presentations at the american association for cancer research aacr annual meeting poster 1238 further demonstrated the correlation between patient survival and ctdna in metastatic crc poster 4149 demonstrated lower doses of samrna drive superior neoantigen specific cd8 t cell responses in cancer patients versus high doses in phase 1 2 trials for granite and slate in patients with advanced solid tumors slate off the shelf shared neoantigen directed vaccine based immunotherapy using an adenoviral priming vector and samrna boost vector to deliver a cassette of shared tsna gritstone intends to continue advancing its existing candidate slate kras and has a long term objective of developing a suite of off the shelf product candidates that target tumor specific targets across a number of patient populations and cancer types in april gritstone presented an oral presentation at aacr detailing how translational immunology data and the company s cassette design capabilities enabled development of slate kras an optimized kras specific version of slate that is now in phase 2 study in patients with advanced non small cell lung cancer nsclc and crc early signals from the ongoing phase 2 study support the potential of slate kras to drive stronger cd8 t cell responses to mutant kras than our original candidate slate v1 initial data from the ongoing phase 2 study of slate kras trial are expected in 2h2022 infectious disease programs gritstone s infectious disease programs aim to deliver vaccine candidates that drive both b cell and t cell immunity with the potential to provide either a protective or therapeutic effect across a broad array of viral diseases this approach has demonstrated the ability to generate robust cd8 t cells and neutralizing antibodies against sars cov 2 in multiple preclinical and clinical studies and is being evaluated against multiple other pathogens in gritstone owned and partnered studies coral second generation sars cov 2 vaccine program delivering both spike and highly conserved non spike t cell epitopes tces with a focus on the samrna vector this approach offers potential for more durable clinical protection and broader immunity against sars cov 2 variants than first generation products by inducing potent cd8 t cells in addition to neutralizing antibody responses gritstone is currently evaluating five distinct sars cov 2 product candidates across four different clinical trials containing spike plus additional non spike tce sequences and also full length nucleocapsid these studies include homologous and heterologous prime boost regimens all four of these studies are ongoing and initial data from all are expected during the second half of 2022 the coral boost study a phase 1 study evaluating a t cell enhanced samrna vaccine as a booster against sars cov 2 is ongoing in the united kingdom in january gritstone announced positive clinical data from the first cohort and subsequently expanded the study the data which demonstrated both strong neutralizing antibody responses to spike and robust cd8 t cell responses provided human proof of concept of the samrna vector in viral diseases and the company s approach to infectious disease the coral cepi trial is ongoing in south africa with support from the coalition for epidemic preparedness innovations cepi and is evaluating t cell enhanced omicron and beta spike constructs in virus nave convalescent and hiv patients the coral immunocompromised trial is ongoing in the united kingdom evaluating t cell enhanced samrna and chimpanzee adenovirus chad vaccines in b cell deficient subjects the coral nih trial which is being sponsored and executed by the national institute of allergy and infectious disease niaid is ongoing in the united states evaluating t cell enhanced samrna and or chad vaccines in previously vaccinated healthy volunteers hiv collaboration with gilead sciences inc gilead under gilead s hiv cure program to research and develop vaccine based hiv immunotherapy treatment an investigational new drug application ind was cleared in december 2021 first quarter 2022 financial results cash cash equivalents marketable securities and restricted cash were 186 8 million as of march 31 2022 compared to 223 5 million as of december 31 2021 research and development expenses were 28 2 million for the three months ended march 31 2022 compared to 24 9 million for the three months ended march 31 2021 the increase of 3 3 million for the three months ended march 31 2022 compared to the three months ended march 31 2021 was primarily due to increases in personnel related expenses outside services and facilities related costs offset by decreases in laboratory supplies and milestone and license payments general and administrative expenses were 8 0 million for the three months ended march 31 2022 compared to 6 9 million for the three months ended march 31 2021 the increase of 1 1 million was primarily attributable to increases in personnel related expenses and in facilities related costs offset by a decrease in outside services collaboration and license revenue was 4 7 million for the three months ended march 31 2022 compared to 39 7 million for the three months ended march 31 2021 during the three months ended march 31 2022 we recognized 4 0 million in collaboration revenue related to the 2seventy agreement 0 7 million in collaboration revenue related to the gilead collaboration agreement 2 2 million in grant revenue from the cepi funding agreement and 0 2 million in grant revenue from the gates foundation during the three months ended march 31 2021 we recorded 38 6 million in license revenue and 0 3 million in collaboration revenue related to the gilead collaboration agreement and 0 7 million in collaboration revenue related to the 2seventy agreement about gritstone gritstone bio inc nasdaq grts is a clinical stage biotechnology company that aims to create the world s most potent vaccines experts in vaccine design and development we leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets independently and with our collaborators we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease www gritstonebio com gritstone forward looking statements this press release contains forward looking statements including but not limited to statements related to the potential of gritstone s therapeutic programs the advancements in the company s ongoing clinical trials the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials such forward looking statements involve substantial risks and uncertainties that could cause gritstone s research and clinical development programs future results performance or achievements to differ significantly from those expressed or implied by the forward looking statements such risks and uncertainties include among others the uncertainties inherent in the drug development process including gritstone s programs early stage of development the process of designing and conducting preclinical and clinical trials the regulatory approval processes the timing of regulatory filings the challenges associated with manufacturing drug products gritstone s ability to successfully establish protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations gritstone undertakes no obligation to update or revise any forward looking statements for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward looking statements as well as risks relating to the business of the company in general see gritstone s most recent quarterly report on form 10 q filed on may 5 2022 and any current and periodic reports filed with the securities and exchange commission gritstone contacts media dan budwick 1ab 973 271 6085 dan 1abmedia com investors george e macdougall director investor relations corp comms gritstone bio inc ir gritstone com gritstone bio inc condensed consolidated statements of operations unaudited in thousands except share and per share amounts three months ended march 31 2022 2021 collaboration and license revenues 4 745 39 693 grant revenues 2 446 total revenues 7 191 39 693 operating expenses research and development 28 199 24 856 general and administrative 7 955 6 941 total operating expenses 36 154 31 797 income loss from operations 28 963 7 896 interest income net 47 27 net income loss 28 916 7 923 net income loss per common share basic 0 34 0 10 weighted average number of shared used in computing net income loss per share basic 87 277 599 75 987 372 net income loss per share diluted 0 34 0 10 weighted average number of shared used in computing net income loss per share diluted 87 277 599 77 464 356 gritstone bio inc condensed consolidated balance sheets unaudited in thousands
at lifehacker we independently select and write about stuff we love and think you ll like too we have affiliate and advertising partnerships which means we may collect a share of sales or other compensation from the links on this page btw prices are accurate and items in stock at the time of posting ever since disney entered the playing field we ve been spoiled for choice with marvel content the streaming service s arrival also offers many a chance to go through an entire mcu rewatch with nearly all the films and series conveniently in one place if you re considering taking on one of these rewatches yourself you may wonder how long it will take we re here to get the maths out of the way for you let s figure out just how long it takes to watch every marvel movie and series what is the runtime of every movie and series image marvel studios let s start by breaking down the time needed for every marvel movie and show that is part of the mcu i ve placed the titles in release order rather than chronologically and gathered their runtimes as per imdb phase 1 iron man 126 minutes the incredible hulk 112 minutes iron man 2 124 minutes thor 115 minutes captain america the first avenger 124 minutes the avengers 143 minutes phase 2 iron man 3 130 minutes thor the dark world 112 minutes captain america the winter soldier 136 minutes guardians of the galaxy 121 minutes avengers age of ultron 141 minutes ant man 117 minutes phase 3 captain america civil war 147 minutes doctor strange 115 minutes guardians of the galaxy vol 2 136 minutes spider man homecoming 133 minutes thor ragnarok 130 minutes black panther 134 minutes avengers infinity war 149 minutes ant man and the wasp 118 minutes captain marvel 123 minutes avengers endgame 181 minutes spider man far from home 129 minutes phase 4 wandavision 9 episodes 357 minutes the falcon and the winter soldier 6 episodes 324 minutes loki 6 episodes 297 minutes black widow 134 minutes what if 9 episodes 315 minutes shang chi and the legend of the ten rings 132 minutes eternals 157 minutes hawkeye 6 episodes 294 minutes spider man no way home 148 minutes doctor strange in the multiverse of madness 126 minutes moon knight 6 episodes 287 minutes thor love and thunder 119 minutes ms marvel 6 episodes 271 minutes i am groot 5 episodes 25 minutes she hulk attorney at law 9 episodes 300 minutes werewolf by night 54 minutes black panther wakanda forever 161 minutes guardians of the galaxy holiday special 41 minutes phase 5 ant man and the wasp quantumania 124 minutes guardians of the galaxy vol 3 150 minutes secret invasion 6 episodes 266 minutes i am groot season 2 5 eisodes 25 minutes loki season 2 6 episodes 307 minutes the marvels 105 minutes what if season 2 9 episodes 289 minutes here are some interesting statistics out of all that if you re interested longest marvel movie avengers endgame avengers endgame shortest marvel movie the marvels the marvels longest marvel series wandavision 9 episodes wandavision 9 episodes shortest marvel series secret invasion 6 episodes how long does it take to binge watch all of the mcu image marvel disney the marvel cinematic universe currently stands at 45 different titles with many more on the way be prepared this is not a binge watch to take lightly by my calculations the total of all the above runtimes adds up to be 7804 minutes that s about 130 hours of marvel movies and tv series to watch watching them back to back with no breaks would take over 5 days that s a whole lot of marvel dozens more projects will soon be added to this list including echo deadpool 3 and many more to come in 2023 so make sure you re up to date before those come out if you need help finding where to stream all these mcu projects we ve got a guide that will help you as for which movie is the best that s a different debate what about other marvel projects image netflix marvel with disney reacquiring the rights to many of the projects under the marvel studios umbrella a lot of titles are suddenly in the same realm as the mcu although many aren t considered canon just yet if you want to watch everything marvel related we ve broken down some more runtimes below marvel one shots marvel studios has released a bunch of one shot shorts over the years which are considered canon in the mcu if you want to check them out it s a pretty easy watch the consultant 2011 3 minutes a funny thing happened on the way to thor s hammer 2011 3 minutes item 47 2012 11 minutes agent carter 2013 15 minutes all hail the king 2014 13 minutes team thor part 1 2016 3 minutes team thor part 2 2016 4 minutes team darryl 2017 6 minutes in total the one shots will take you 58 minutes so a nice easy watch the defenders saga daredevil 39 episodes 2099 minutes jessica jones 39 episodes 2029 minutes luke cage 26 episodes 1467 minutes iron fist 23 episodes 1252 minutes the defenders 8 episodes 400 minutes the punisher 26 episodes 1384 minutes the total time to watch the defenders saga comes out at 8631 minutes which is roughly 144 hours that s more than the entire mcu if you need the proper watch order for these ex marvel netflix series you can find that here spider man movies image sony marvel is a large brand with a lot of characters under its umbrella which means many companies have vied for those rights over time one of these characters is spider man who remains under sony s jurisdiction despite their agreement for tom holland s iteration to appear in the mcu this all came to a head in spider man no way home which may have inspired you to take on a full spider man rewatch if so we ve gathered the runtime of tobey maguire and andrew garfield s superhero movies for you below as well as the other adjacent movies in sony s spider man universe spider man 121 minutes spider man 2 127 minutes spider man 3 139 minutes the amazing spider man 136 minutes the amazing spider man 2 142 minutes venom 112 minutes venom let there be carnage 97 minutes morbius 104 minutes spider man into the spider verse 117 minutes spider man across the spider verse 140 minutes overall we re looking at 1235 minutes for sony s universe of marvel movies so far which equates to about 20 hours agents of shield i can t believe i lost so much of my life figuring this out but here it is the runtimes for all of agents of shield agents of shield season 1 22 episodes 978 minutes agents of shield season 2 22 episodes 983 minutes agents of shield season 3 22 episodes 981 minutes agents of shield season 4 22 episodes 977 minutes agents of shield season 5 22 episodes 975 minutes agents of shield season 6 13 episodes 576 minutes agents of shield season 7 13 episodes 573 minutes in total that comes to 6043 minutes which is roughly 101 hours agent carter let s not forget agent carter featuring hayley atwell as her character peggy carter from the captain america movies there were only two seasons of this one which come out at agent carter season 1 8 episodes 349 minutes agent carter season 2 10 episodes 445 minutes the total watch time for this one is a more manageable 794 minutes or just over 13 hours fox marvel movies image fox disney since disney officially acquired fox studios and deadpool 3 is now on the mcu slate we can probably consider the previous fox superhero movies somewhat essential viewing here s a breakdown of those runtimes x men 105 minutes x2 134 minutes x men the last stand 105 minutes x men first class 133 minutes x men days of future past 132 minutes x men apocalypse 145 minutes x men dark phoenix 116 minutes x men origins wolverine 108 minutes the wolverine 127 minutes logan 139 minutes deadpool 110 minutes deadpool 2 121 minutes in total a rewatch of the fox marvel movies comes to 1475 minutes or roughly 24 5 hours other marvel tv series image disney under the many disney umbrellas including hulu and freeform some other mcu adjacent ya focused tv shows were released that adapted comic books like runaways and cloak dagger the series are set in the same universe and even had a crossover episode here are their runtimes runaways season 1 10 episodes 495 minutes season 2 13 episodes 610 minutes season 3 10 episodes 475 minutes cloak dagger season 1 10 episodes 421 minutes season 2 10 episodes 415 minutes combined these two come out at 2416 minutes which is around 40 hours unfortunately disney pulled runaways from streaming as part of a cost cutting exercise so you ll have a hard time finding that one to watch cloak dagger is still available to stream on disney for now marvel also released its attempt at the inhumans in a tv show which never passed one season however one character does have a crossover in doctor strange in the multiverse of madness meaning you could consider the events of the show canon in one of the universes inhumans season 1 8 episodes 354 minutes the whole series comes in at just under 6 hours we ll continue adding to this list as more marvel projects are released so keep checking for updated runtimes until then enjoy your marvel movie and tv show binge watch once you re done there you can weigh up how long a star wars marathon will take you this article has been updated since its original release date lead image credit marvel studios disney
broomfield colo business wire swisslog healthcare a top supplier in healthcare technology combining pharmacy and transport automation has announced anthony pugliese as its new chief commercial officer of medication management previously serving as the senior vice president of sales and marketing pugliese is experienced in supporting swisslog healthcare s commitment to enable better patient outcomes and customer satisfaction in his new role pugliese will be responsible for overseeing the global sales and marketing efforts for the medication management division as well as serving as the commercial leader for the north american medication management activities anthony has been with swisslog for over 10 years and has shown dedication to the organization and its customers for a long time i m very pleased to now have him on our executive team said hans schuler ceo of swisslog healthcare medication management anthony s expertise and knowledge in the industry will continue to make a positive impact on swisslog healthcare s continued success worldwide pugliese initially joined swisslog healthcare in 2012 as its vice president and general manager overseeing all canadian sales marketing and operations after three years in that role pugliese was promoted to senior vice president of sales in north america and later to senior vice president of sales and marketing he holds a bachelor of science in industrial engineering from the university at buffalo as a company swisslog healthcare has a unique combination of being a strong and stable organization while still pushing the boundaries of innovation said anthony pugliese i m excited to carry on with swisslog healthcare s reputation and commitment to enhancing quality of care enabling better patient outcomes and increasing efficiency through automation this announcement comes following the recent restructuring of swisslog healthcare s focused divisions medication management and translogic pneumatic tube systems as part of the kuka group a leading global supplier of intelligent automation solutions swisslog healthcare continues to expand its global reach and the leadership required to manage it about swisslog healthcare swisslog healthcare is a leading provider of healthcare solutions including hardware software and services delivering transport and pharmacy automation supports medication management for hospitals pharmacies and healthcare institutions swisslog healthcare has installed facility wide automation systems in more than 3 000 healthcare institutions worldwide the company offers single source integrated solutions from consulting to design implementation to lifetime customer service for more information visit www swisslog healthcare com swisslog healthcare is a member of the kuka group a leading global supplier of intelligent automation solutions view source version on businesswire com erica fetherston 10 to 1 public relations 480 676 9141 source swisslog healthcare
new york new york reality returned to wall street thursday a day after an explosive rally triggered by a half percentage point increase in official interest rates the fed move was tempered by remarks from federal reserve governor jerome powell that more aggressive rate hikes may not be needed in the future yesterday s explosion higher was completely comical it was ridiculous his comments did not justify the move that we saw kenny polcari managing partner at kace capital advisors told reuters news agency thursday part of what people are recognizing very deep within his speech yesterday is the concern that inflation is out of control and the fed is behind the eight ball it is the concern that they may even have to make a more drastic move the nasdaq composite led thursday s firesale plummeting 647 16 points or 4 99 percent to 12 317 69 the dow jones industrials dived 1 063 09 points or 3 12 percent to 32 997 97 the standard and poor s 500 shed 153 30 points or 2 56 percent to 4 146 87 the u s dollar was steady thursday the euro fell from wednesday s 1 06 level to trade at 1 0550 around the new york close the british pound tumbled to 1 2365 the japanese yen weakened to 130 07 the swiss franc was sharply lower at 0 9846 the canadian dollar was little changed at 1 2834 the australian dollar dropped more than a cent and a half to 0 7113 the new zealand dollar weakened to 0 6430 on overseas equity markets the dax in germany advanced 0 49 percent the paris based cac 40 added 0 43 percent in london the ftse 100 edged up 0 13 percent the australian all ordinaries gained 74 40 points or 0 98 percent to 7 639 20 in new zealand the s p nzx 50 advanced 72 36 points or 0 62 percent to 11 747 57 china s shanghai composite rose 20 70 points or 0 68 percent to 3 067 76 in hong kong the hang seng went against the trend closing down 76 12 points or 0 36 percent at 20 793 40 japanese and south korean markets were closed thursday for public holidays
laval qc and vaughan on may 5 2022 prnewswire bausch lomb corporation bausch lomb a wholly owned subsidiary of bausch health companies inc nyse tsx bhc bausch health today announced the pricing of its initial public offering ipo of 35 000 000 common shares at a public offering price of 18 00 per share a wholly owned subsidiary of bausch health the selling shareholder is offering all of the common shares and bausch lomb will not receive any of the proceeds from the ipo the selling shareholder has granted the underwriters a 30 day option to purchase up to an additional 5 250 000 common shares of bausch lomb to cover over allotments if any at the initial public offering price less underwriting commissions the common shares have been approved for listing on the new york stock exchange nyse and conditionally approved for listing on the toronto stock exchange tsx the common shares are expected to begin trading on the nyse and on an if as and when issued basis on the tsx on may 6 2022 in each case under the ticker symbol blco the offering is expected to close on may 10 2022 subject to customary closing conditions following the ipo bausch health together with its subsidiaries will hold approximately 90 of the common shares of bausch lomb or 88 5 of the common shares of bausch lomb if the underwriters over allotment option is exercised in full morgan stanley and goldman sachs co llc are acting as joint lead book running managers for the ipo citigroup j p morgan barclays bofa securities guggenheim securities jefferies evercore isi wells fargo securities and deutsche bank securities are acting as joint book running managers for the ipo and dnb markets hsbc truist securities amerivet securities loop capital markets ramirez co inc r seelaus co llc siebert williams shank and stern are acting as co managers for the ipo a registration statement relating to these securities has been filed with and declared effective by the u s securities and exchange commission sec on may 5 2022 and a receipt has been obtained for a final base prep prospectus that has been filed with the securities regulatory authorities in each of the provinces and territories of canada other than quebec on may 5 2022 the ipo is only being made by means of a prospectus when available copies of the final prospectus and the supplemented prep prospectus containing pricing information and other important information relating to the common shares and the offering may be obtained from morgan stanley co llc attn prospectus department 180 varick street 2nd floor new york n y 10014 or goldman sachs co llc attn prospectus department 200 west street new york n y 10282 by telephone at 866 471 2526 or by email at a copy of the supplemented prep prospectus will be filed and will become available on sedar at www sedar com by may 9 2022 no securities regulatory authority has either approved or disapproved of the contents of this news release this news release does not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state province territory or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state province territory or jurisdiction about bausch lomb bausch lomb a leading global eye health business of bausch health companies inc is dedicated to protecting and enhancing the gift of sight for millions of people around the world from the moment of birth through every phase of life its comprehensive portfolio of more than 400 products includes contact lenses lens care products eye care products ophthalmic pharmaceuticals over the counter products and ophthalmic surgical devices and instruments founded in 1853 bausch lomb has a significant global research and development manufacturing and commercial footprint with more than 12 000 employees and a presence in nearly 100 countries bausch lomb is headquartered in vaughan ontario with corporate offices in bridgewater new jersey about bausch healthbausch health companies inc nyse tsx bhc bausch health is a global company whose mission is to improve people s lives with our health care products bausch health develops manufactures and markets a range of pharmaceutical medical device and over the counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology bausch health is delivering on its commitments as it builds an innovative company dedicated to advancing global health forward looking statementsthis news release may contain forward looking statements about the potential distribution of the common shares of bausch lomb that bausch health will continue to hold following completion of the bausch lomb ipo which may generally be identified by the use of the words anticipates hopes expects intends plans should could would may believes subject to and variations or similar expressions including statements about the closing of the ipo whether the underwriters will exercise their over allotment option the number of shares to be held by bhc following the ipo and the expectations relating to the listing of the common shares on the nyse and tsx these statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward looking statements in addition actual results are subject to other risks and uncertainties that relate more broadly to bausch health s overall business including those more fully described in bausch health s most recent annual report on form 10 k and detailed from time to time in bausch health s other filings with the u s securities and exchange commission and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forward looking statements these forward looking statements speak only as of the date hereof bausch health undertakes no obligation to update any of these forward looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes unless required by law view original content to download multimedia source bausch lomb corporation bausch health companies inc
cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation while scotts miracle gro might seem cheap on a price to earnings basis management doesn t have a handle on how bad it s going to get the mad money host said cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation historically this is a great time of year for anything garden related because it s planting season and scotts is a name that we used to get a ton of questions about but over the past thirteen months these shares have been obliterated the mad money host said feeling out of the loop we ll catch you up on the chicago news you need to know sign up for the weekly chicago catch up newsletter here while scottsmiracle gro might seem cheap on a price to earnings basis the problem is that the earnings forecast keeps coming down and management doesn t have a handle on how bad it s going to get he later added scottsmiracle gro stock fell 6 on thursday the company reported better than expected earnings in its previous quarter two days before jpmorgan upgraded scottsmiracle gro to overweight from neutral on wednesday pointing to the stock s valuation high margins and market leadership stifel downgraded the stock from overweight to hold cramer said that he agrees with stifel s more bearish stance on scotts particularly because of the company s struggles with rising raw costs lack of confidence regarding an earnings target of 8 a share and his concerns with the performance of scotts hawthorne division hawthorne operates in cannabis an industry cramer says has been beaten down for the last year on top of that scotts has an ugly enough balance sheet that they don t see management embracing an aggressive buyback either in short business is bad and there s not much scotts can do to make it better cramer said sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
reaffirms financial outlook for fiscal 2022 franchising momentum continues delaware ohio may 05 2022 globe newswire franchise group inc nasdaq frg franchise group frg or the company today announced the financial results of its fiscal 2022 first quarter for the first quarter of fiscal 2022 total reported revenue for franchise group was 1 1 billion net income from continuing operations was 12 3 million or 0 25 per fully diluted share adjusted ebitda was 112 3 million and non gaap eps was 1 29 per share on march 26 2022 total cash on hand was approximately 149 6 million and outstanding term debt was approximately 1 3 billion the outstanding term debt balance does not include repayments from the net proceeds received from the 94 million sale of the w s badcock corporation badcock retail real estate portfolio which closed on march 31 2022 frg anticipates closing the previously announced 150 million sale of the badcock distribution centers and the 18 5 million sale of the badcock corporate headquarters by the end of its fiscal second quarter as well as an additional sale of other badcock real estate for approximately 5 6 million by the end of fiscal 2022 frg intends to use the net cash proceeds from these real estate sales to repay the remaining 175 million of badcock acquisition financing brian kahn franchise group s president and ceo stated i am proud of frg s overall performance in the first quarter frg s diversification across various discretionary and non discretionary products and services continued to serve us well mr kahn continued i can t stress enough how resilient and nimble our management teams have been while staying true to our brands ethos and value propositions their collective success is strengthening the foundation of frg as we seek to further diversify and scale through strategic internal and external investment opportunities the company has six reportable segments american freight the vitamin shoppe pet supplies plus buddy s sylvan and badcock the following table summarizes revenue adjusted ebitda and net income loss for each of these segments reconciliations of adjusted ebitda non gaap net income and non gaap eps to their respective most comparable gaap measures are included below under non gaap financial measures and key metrics for the three months ended march 26 2022 adjusted net revenue ebitda income loss in thousands american freight 241 416 15 879 1 434 vitamin shoppe 310 953 40 493 21 405 pet supplies plus 301 214 24 221 8 125 buddy s 15 585 5 235 2 564 sylvan learning 10 043 2 828 166 badcock 256 259 26 111 2 859 corporate 2 429 15 650 total 1 135 470 112 338 12 317 outlook franchise group is reaffirming its previously announced financial outlook for fiscal year 2022 of revenue of approximately 4 45 billion adjusted ebitda of approximately 450 million and non gaap eps of approximately 5 00 per share in formulating its outlook the company expects to reduce net debt to below 1 1 billion by the end of its fiscal year 2022 in calculating eps the company is using approximately 41 0 million weighted average shares outstanding non gaap eps is calculated by adding the tax effected impact of adjustments to ebitda to net income on a per share basis in calculating gaap and non gaap eps the company is currently using an effective tax rate of approximately 27 the company does not provide a quantitative reconciliation of forward looking non gaap financial measures such as forecasted adjusted ebitda or non gaap eps to the most directly comparable gaap financial measures because it is difficult to reliably predict or estimate the relevant components without unreasonable effort due to future uncertainties that may potentially have significant impact on such calculations and providing them may imply a degree of precision that would be confusing or potentially misleading estimates exclude potential acquisitions divestitures or refranchising activities see non gaap financial measures and key metrics conference call information franchise group will conduct a conference call on may 5th at 4 30 p m et to discuss its business review financial results for its fiscal 2022 first and discuss its outlook for the balance of fiscal year 2022 a real time webcast of the conference call will be available on the events page of franchise group s website at www franchisegrp com the conference call can also be accessed live via telephone at 866 374 5140 the passcode is 42926723 please dial in 5 10 minutes prior to the scheduled start time about franchise group inc franchise group is an owner and operator of franchised and franchisable businesses that continually looks to grow its portfolio of brands while utilizing its operating and capital allocation philosophy to generate strong cash flow for its shareholders franchise group s business lines include pet supplies plus american freight the vitamin shoppe badcock home furniture more buddy s home furnishings and sylvan learning on a combined basis franchise group currently operates over 3 000 locations predominantly located in the u s that are either company run or operated pursuant to franchising and dealer agreements franchise group inc and subsidiaries consolidated balance sheets in thousands except share count and per share data march 26 2022 december 25 2021 assets unaudited unaudited current assets cash and cash equivalents 149 597 292 714 current receivables net 110 368 118 698 current securitized receivables net 386 886 369 567 inventories net 779 279 673 170 current assets held for sale 203 679 other current assets 28 403 24 063 total current assets 1 658 212 1 478 212 property plant and equipment net 237 056 449 886 non current receivables net 11 156 11 755 non current securitized receivables net 48 355 47 252 goodwill 806 697 806 536 intangible assets net 125 222 127 951 tradenames 222 687 222 687 operating lease right of use assets 713 820 714 741 investment in equity securities 11 626 35 249 other non current assets 18 578 18 902 total assets 3 853 409 3 913 171 liabilities and stockholders equity current liabilities current installments of long term obligations 487 957 486 170 current operating lease liabilities 173 295 173 101 accounts payable and accrued expenses 458 776 410 552 other current liabilities 51 572 50 833 total current liabilities 1 171 600 1 120 656 long term obligations excluding current installments 1 286 972 1 383 725 non current operating lease liabilities 552 412 557 071 other non current liabilities 90 739 88 888 total liabilities 3 101 723 3 150 340 stockholders equity common stock 0 01 par value per share 180 000 000 shares authorized 40 353 865 and 40 296 688 shares issued and outstanding at march 26 2022 and december 25 2021 respectively 404 403 preferred stock 0 01 par value per share 20 000 000 shares authorized and 4 541 125 issued and outstanding at march 26 2022 and december 25 2021 45 45 additional paid in capital 480 628 475 396 retained earnings 270 609 286 987 total equity 751 686 762 831 total liabilities and equity 3 853 409 3 913 171 franchise group inc and subsidiaries consolidated statements of operations three months ended in thousands except share count and per share data march 26 2022 march 27 2021 unaudited unaudited revenues product 979 164 583 816 service and other 148 282 28 576 rental 8 024 8 953 total revenues 1 135 470 621 345 operating expenses cost of revenue product 616 585 339 414 service and other 8 663 405 rental 2 861 3 005 total cost of revenue 628 109 342 824 selling general and administrative expenses 376 995 225 545 total operating expenses 1 005 104 568 369 income from operations 130 366 52 976 other expense bargain purchase gain 67 other 21 977 36 726 interest expense net 92 327 47 435 income loss from continuing operations before income taxes 15 995 31 185 income tax expense benefit 3 678 2 851 income loss from continuing operations 12 317 28 334 income loss from discontinued operations net of tax 42 147 net income attributable to franchise group inc 12 317 13 813 income loss per share from continuing operations basic 0 25 0 76 diluted 0 25 0 76 net income loss per share basic 0 25 0 29 diluted 0 25 0 29 weighted average shares outstanding basic 40 307 412 40 110 084 diluted 41 107 793 40 110 084 franchise group inc and subsidiaries consolidated statements of cash flows three months ended in thousands march 26 2022 march 27 2021 unaudited unaudited operating activities net income 12 317 13 813 adjustments to reconcile net income to net cash provided by used in operating activities provision for doubtful accounts 15 103 710 depreciation amortization and impairment charges 22 033 14 176 amortization of deferred financing costs and prepayment penalties 71 679 67 699 stock based compensation expense 5 447 2 550 change in fair value of investment 23 723 gain on bargain purchases and sales of company owned stores 2 206 623 other non cash items 2 227 62 changes in other assets and liabilities 83 716 22 512 net cash provided by operating activities 62 153 75 751 investing activities purchases of property plant and equipment 9 752 11 667 proceeds from sale of property plant and equipment 2 554 277 acquisition of business net of cash and restricted cash acquired 3 930 463 753 issuance of operating loans to franchisees 17 058 payments received on operating loans to franchisees 21 644 net cash used in investing activities 11 128 470 557 financing activities dividends paid 27 315 15 620 issuance of long term debt and other obligations 124 358 1 306 724 repayment of long term debt and other obligations 290 202 854 665 issuance of common stock 24 issuance of preferred stock 79 541 principal payments of finance lease obligations 768 payment for debt issue costs and prepayment penalty on extinguishment 87 490 other stock compensation transactions 239 336 net cash provided by used in financing activities 194 142 428 154 effect of exchange rate changes on cash net 56 net increase decrease in cash equivalents and restricted cash 143 117 33 404 cash cash equivalents and restricted cash at beginning of period 292 714 151 502 cash cash equivalents and restricted cash at end of period 149 597 184 906 supplemental cash flow disclosure cash paid for taxes net of refunds 274 65 cash paid for interest 21 424 39 730 accrued capital expenditures 3 177 3 019 tax receivable agreement included in other long term liabilities 16 775 non gaap financial measures and key metrics adjusted ebitda non gaap net income and non gaap eps are financial measures that are not prepared in accordance with gaap management believes the presentation of these measures is useful to investors as supplemental measures in evaluating the aggregate performance of the company s operating businesses and in comparing its results from period to period because they exclude items that the company does not believe are reflective of its core or ongoing operating results these measures are used by management to evaluate the company s performance and make resource allocation decisions each period these metrics are also used in the determination of executive management s compensation adjusted ebitda non gaap net income and non gaap eps should not be considered in isolation or as a substitute for net income or other income statement information prepared in accordance with gaap and our presentation of these non gaap measures may not be comparable to similarly titled measures used by other companies management defines and calculates adjusted ebitda as net income loss from continuing operations before interest income taxes depreciation and amortization adjusted for certain non core or non operational items related to executive severance and related costs stock based compensation shareholder litigation costs corporate governance costs accrued judgments and settlements net of estimated revenue store closures rebranding costs acquisition costs inventory fair value step up amortization and prepayment penalty on early debt repayment adjusted ebitda is a financial measure that is not prepared in accordance with gaap management defines and calculates non gaap net income and non gaap eps as net income loss and net income loss per diluted share from continuing operations adjusted for non core or non operational items related to executive severance and related costs stock based compensation non cash executive compensation expense shareholder litigation costs prepayment penalties on early debt repayment non cash amortization of debt issuance costs store closures rebranding costs acquisition costs inventory fair value step up amortization and amortization of acquired intangible assets although amortization of acquired intangible assets is excluded from these non gaap measures it is important for investors to understand that such intangible assets support revenue generation management excludes amortization of intangible assets because these are non cash amounts for which the amount and frequency are significantly impacted by the timing and size of our acquisitions which vary from period to periods and across companies the tax effect on the related non gaap adjustments was calculated based on an estimated annual non gaap effective tax rate of 27 reconciliation of adjusted ebitda below are reconciliations of net income loss from continuing operations to adjusted ebitda for the three months ended march 26 2022 for the three months ended march 26 2022 in thousands buddy s pet supplies plus american freight vitamin shoppe sylvan badcock corporate total net income loss from continuing operations 2 564 8 125 1 434 21 405 166 2 859 15 650 12 317 add back interest expense 808 4 731 7 568 6 398 719 72 030 73 92 327 income tax expense benefit 693 4 165 5 078 7 550 60 993 14 862 3 678 depreciation and amortization charges 757 6 129 2 559 6 863 1 856 3 870 22 033 total adjustments 2 258 15 025 15 205 20 811 2 635 76 893 14 789 118 038 ebitda 4 822 23 150 13 771 42 216 2 801 74 034 30 439 130 355 adjustments to ebitda executive severance and related costs 6 102 96 stock based compensation 70 875 294 9 5 377 6 626 litigation costs and settlements 343 1 082 550 1 745 230 corporate compliance costs 51 51 store closures 120 238 575 933 securitized receivables net 50 871 50 871 prepayment penalty on early debt repayment right of use asset impairment 375 375 integration costs 44 105 18 297 464 divestiture costs 2 273 1 936 337 acquisition costs 38 14 546 29 626 loss on investment in equity securities 23 723 23 723 acquisition bargain purchase gain 67 67 total adjustments to ebitda 413 1 071 2 108 1 723 27 47 923 28 010 18 017 adjusted ebitda 5 235 24 221 15 879 40 493 2 828 26 111 2 429 112 338 reconciliation of non gaap net income and eps below are reconciliations of net income loss from continuing operations to non gaap net income and net income loss from continuing operations per diluted share to non gaap eps for the three months ended march 26 2022 for the three months ended in thousands except share count and per share data march 26 2022 net income loss from continuing operations net income loss from continuing operations per diluted share 12 317 0 30 less preferred dividend declared 2 128 0 05 adjusted net income available to common stockholder 10 189 0 25 add back executive severance and related costs 96 stock based compensation 6 626 0 16 litigation costs and settlements 230 0 01 corporate compliance costs 51 store closures 933 0 02 securitized receivables net 50 871 1 24 prepayment penalty on early debt repayment right of use asset impairment 375 0 01 integration costs 464 0 01 divestiture costs 337 0 01 acquisition costs 626 0 02 loss on investment in equity securities 23 723 0 58 acquisition bargain purchase gain 67 adjustments to ebitda 18 017 0 44 non cash amortization of debt issuance costs 6 379 0 15 amortization of acquisition related intangibles 4 086 0 10 securitized receivables interest expense 65 300 1 59 tax impact 14 887 0 36 impact of diluted share count assuming non gaap net income total adjustments to net income loss from continuing operations 42 860 1 04 non gaap net income from continuing operations non gaap diluted eps from continuing operations 53 049 1 29 basic weighted average shares 40 307 412 non gaap diluted weighted average shares outstanding 41 107 793 forward looking statements this press release contains forward looking statements within the meaning of the private securities litigation reform act of 1995 forward looking statements include without limitation projections predictions expectations or beliefs about future events or results and are not statements of historical fact such statements may include statements regarding the company s results of operation and financial condition its outlook for fiscal 2022 the expected timing of the completion of the sale leaseback of badcock s real estate portfolio and the use of proceeds therefrom such forward looking statements are based on various assumptions as of the time they are made and are inherently subject to known and unknown risks uncertainties and other factors that may cause actual results performance or achievements to be materially different from any future results performance or achievements expressed or implied by such forward looking statements forward looking statements are often accompanied by words that convey projected future events or outcomes such as expect believe estimate plan project anticipate intend will may view opportunity potential or words of similar meaning or other statements concerning opinions or judgment of the company or its management about future events although the company believes that its expectations with respect to forward looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations there can be no assurance that actual results performance or achievements of the company will not differ materially from any projected future results performance or achievements expressed or implied by such forward looking statements actual future results performance or achievements may differ materially from historical results or those anticipated depending on a variety of factors many of which are beyond the control of the company the company refers you to the risk factors and management s discussion and analysis of financial condition and results of operations sections of the company s form 10 k for the fiscal year ended december 25 2021 and comparable sections of the company s quarterly reports on form 10 q and other filings which have been filed with the sec and are available on the sec s website at www sec gov all of the forward looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein the actual results or developments anticipated may not be realized or even if substantially realized they may not have the expected consequences to or effects on the company or its business or operations readers are cautioned not to rely on the forward looking statements contained in this press release forward looking statements speak only as of the date they are made and the company does not undertake any obligation to update revise or clarify these forward looking statements whether as a result of new information future events or otherwise investor relations contact andrew f kaminsky evp chief administrative officer franchise group inc akaminsky franchisegrp com 914 939 5161
shanghai china may 05 2022 globe newswire nio inc nyse nio hkex 9866 nio or the company a pioneer and a leading company in the premium smart electric vehicle market today announced the proposed secondary listing of its class a ordinary shares par value us 0 00025 per share the shares by way of introduction on the main board of the singapore exchange securities trading limited the sgx st the company s american depositary shares the adss each representing one share will continue to be primarily listed and traded on the new york stock exchange the nyse the company has received a conditional eligibility to list letter etl from the sgx st on may 5 2022 for the listing and quotation of the shares on the main board of the sgx st the etl is not an indication of the merits of the proposed secondary listing of the company s shares on the sgx st the company its subsidiaries the adss and or the company s shares an introductory document relating to the proposed secondary listing by way of introduction of the shares on the main board of the sgx st is targeted to be issued later this month prior to the listing on the main board of the sgx st upon listing on the main board of the sgx st the shares listed on the main board of the sgx st will be fully fungible with the adss listed on the nyse this press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities of the company nor shall there be any offer or sale of the securities in any state or other jurisdiction in which such offer solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction about nio inc nio inc is a pioneer and a leading company in the premium smart electric vehicle market founded in november 2014 nio s mission is to shape a joyful lifestyle nio aims to build a community starting with smart electric vehicles to share joy and grow together with users nio designs develops jointly manufactures and sells premium smart electric vehicles driving innovations in next generation technologies in autonomous driving digital technologies electric powertrains and batteries nio differentiates itself through its continuous technological breakthroughs and innovations such as its industry leading battery swapping technologies battery as a service or baas as well as its proprietary autonomous driving technologies and autonomous driving as a service or adaas nio launched the es8 a seven seater flagship premium smart electric suv in december 2017 and began deliveries of the es8 in june 2018 and its variant the six seater es8 in march 2019 nio launched the es6 a five seater high performance premium smart electric suv in december 2018 and began deliveries of the es6 in june 2019 nio launched the ec6 a five seater premium smart electric coupe suv in december 2019 and began deliveries of the ec6 in september 2020 nio launched the et7 a flagship premium smart electric sedan in january 2021 and began deliveries of the et7 in march 2022 nio launched the et5 a mid size premium smart electric sedan in december 2021 safe harbor statement this press release contains statements that may constitute forward looking statements pursuant to the safe harbor provisions of the u s private securities litigation reform act of 1995 these forward looking statements can be identified by terminology such as will expects anticipates aims future intends plans believes estimates likely to and similar statements nio may also make written or oral forward looking statements in its periodic reports to the u s securities and exchange commission the sec in its annual report to shareholders in press releases and other written materials and in oral statements made by its officers directors or employees to third parties statements that are not historical facts including statements about nio s beliefs plans and expectations are forward looking statements forward looking statements involve inherent risks and uncertainties a number of factors could cause actual results to differ materially from those contained in any forward looking statement including but not limited to the following nio s strategies nio s future business development financial condition and results of operations nio s ability to develop and manufacture a car of sufficient quality and appeal to customers on schedule and on a large scale its ability to ensure and expand manufacturing capacities including establishing and maintaining partnerships with third parties its ability to provide convenient and comprehensive power solutions to its customers the viability growth potential and prospects of the newly introduced baas and adaas its ability to improve the technologies or develop alternative technologies in meeting evolving market demand and industry development nio s ability to satisfy the mandated safety standards relating to motor vehicles its ability to secure supply of raw materials or other components used in its vehicles its ability to secure sufficient reservations and sales of the es8 es6 ec6 et7 and et5 its ability to control costs associated with its operations its ability to build the nio brand general economic and business conditions globally and in china and assumptions underlying or related to any of the foregoing further information regarding these and other risks is included in nio s filings with the sec the listing document issued with the sehk and the introductory document issued with the sgx st all information provided in this press release is as of the date of this press release and nio does not undertake any obligation to update any forward looking statement except as required under applicable law for more information please visit investor relations contact press contact
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
new york new york reality returned to wall street thursday a day after an explosive rally triggered by a half percentage point increase in official interest rates the fed move was tempered by remarks from federal reserve governor jerome powell that more aggressive rate hikes may not be needed in the future yesterday s explosion higher was completely comical it was ridiculous his comments did not justify the move that we saw kenny polcari managing partner at kace capital advisors told reuters news agency thursday part of what people are recognizing very deep within his speech yesterday is the concern that inflation is out of control and the fed is behind the eight ball it is the concern that they may even have to make a more drastic move the nasdaq composite led thursday s firesale plummeting 647 16 points or 4 99 percent to 12 317 69 the dow jones industrials dived 1 063 09 points or 3 12 percent to 32 997 97 the standard and poor s 500 shed 153 30 points or 2 56 percent to 4 146 87 the u s dollar was steady thursday the euro fell from wednesday s 1 06 level to trade at 1 0550 around the new york close the british pound tumbled to 1 2365 the japanese yen weakened to 130 07 the swiss franc was sharply lower at 0 9846 the canadian dollar was little changed at 1 2834 the australian dollar dropped more than a cent and a half to 0 7113 the new zealand dollar weakened to 0 6430 on overseas equity markets the dax in germany advanced 0 49 percent the paris based cac 40 added 0 43 percent in london the ftse 100 edged up 0 13 percent the australian all ordinaries gained 74 40 points or 0 98 percent to 7 639 20 in new zealand the s p nzx 50 advanced 72 36 points or 0 62 percent to 11 747 57 china s shanghai composite rose 20 70 points or 0 68 percent to 3 067 76 in hong kong the hang seng went against the trend closing down 76 12 points or 0 36 percent at 20 793 40 japanese and south korean markets were closed thursday for public holidays
san diego ca accesswire may 5 2022 ensysce biosciences inc ensysce or the company nasdaq ensc otc pink enscw a clinical stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose today announced the release of its 2021 annual shareholder letter authored by chief executive officer dr lynn kirkpatrick to view the letter please visit about ensysce biosciences ensysce biosciences based in san diego ca is a clinical stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs leveraging its trypsin activated abuse protection taap and multi pill abuse resistance mpar platforms the company is developing next generation tamper proof opioids that prevent both drug abuse and overdoses ensysce s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse reducing the human and economic costs the platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs for more information please visit www ensysce com forward looking statements statements contained in this press release that are not purely historical may be deemed to be forward looking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of 1995 and other federal securities laws without limiting the foregoing the use of words such as may intends can might will expect plan and other similar expressions are intended to identify forward looking statements the product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and or efficacy that ensysce will not encounter problems or delays in clinical development or that any product candidate will ever receive regulatory approval or be successfully commercialized all forward looking statements are based on estimates and assumptions by ensysce s management that although ensysce believes to be reasonable are inherently uncertain all forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that ensysce expected in addition ensysce s business is subject to additional risks and uncertainties including among others the initiation and conduct of preclinical studies and clinical trials the timing and availability of data from preclinical studies and clinical trials expectations for regulatory submissions and approvals potential safety concerns related to or efficacy of ensysce s product candidates the availability or commercial potential of product candidates the ability of ensysce to fund its continued operations including its planned clinical trials the dilutive effect of stock issuances from our fundraising and ensysce s and its partners ability to perform under their license collaboration and manufacturing arrangements these statements are also subject to a number of material risks and uncertainties that are described in ensysce s most recent annual report on form 10 k and current reports on form 8 k which are available free of charge at the sec s website at www sec gov any forward looking statement speaks only as of the date on which it was made ensysce undertakes no obligation to publicly update or revise any forward looking statement whether as a result of new information future events or otherwise except as required under applicable law ensysce biosciences company contact lynn kirkpatrick ph d chief executive officer 858 263 4196 ensysce biosciences investor relations contact shannon devine mz north america main 203 741 8811 source ensysce biosciences inc view source version on accesswire com
new york a sharp sell off left the dow jones industrial average more than 1 000 points lower thursday wiping out the gains from wall street s biggest rally in two years as worries grow that the higher interest rates the federal reserve is using in its fight against inflation will derail the economy the benchmark s p 500 fell 3 6 marking its biggest loss in nearly two years a day after it posted its biggest gain since may 2020 the nasdaq slumped 5 its worst drop since june 2020 the losses by the dow and the other indexes offset the gains from a day earlier yesterday s sharp rally was not rooted in reality and today s dramatic selloff is a reversal of that misplaced exuberance said ben kirby co head of investments at thornburg investment management wall street s breakneck day to day reversal reflects the degree of investors uncertainty and unease over the array of threats the economy is facing starting with inflation running at the highest level in four decades and how effective the federal reserve s bid to tame higher prices by jacking up interest rates will be file u s federal reserve board chairman jerome powell speaks on capitol hill in washington jan 11 2022 on wednesday the federal reserve announced a widely expected half percentage point increase in its short term interest rate stocks bounced around following the move but then sharply rose as bond yields fell after fed chair jerome powell reassured investors by saying the central bank wasn t considering shifting to more aggressive three quarter point rate hikes as the fed continues with further rate increases in coming months but whatever relief powell s remarks gave stock investors vanished thursday stocks slumped and bond yields climbed the yield on the 10 year treasury note rose to 3 04 rising yields are sure to put upward pressure on mortgage rates which are at their highest level since 2009 investors remain uneasy about whether the fed can do enough to tame inflation without tipping the economy which is showing signs of slowing into a recession in addition to high inflation and rising interest rates investors are grappling with uncertainty over lingering supply chain disruptions and geopolitical tensions the biggest issue is there are just a lot of moving parts and the unanswered question is to what extent as the fed attempts to tame inflation will that result in economic slowing and perhaps a recession said terry sandven chief equity strategist at u s bank wealth management the s p 500 fell 153 30 points to 4 146 87 while the nasdaq slid 647 16 points to 12 317 69 the dow briefly skidded 1 375 points before closing down 1 063 09 points or 3 1 to 32 997 97 smaller company stocks also fell sharply the russell 2000 fell 78 77 points or 4 to 1 871 15
shanghai china may 05 2022 globe newswire nio inc nyse nio hkex 9866 nio or the company a pioneer and a leading company in the premium smart electric vehicle market today announced the proposed secondary listing of its class a ordinary shares par value us 0 00025 per share the shares by way of introduction on the main board of the singapore exchange securities trading limited the sgx st the company s american depositary shares the adss each representing one share will continue to be primarily listed and traded on the new york stock exchange the nyse the company has received a conditional eligibility to list letter etl from the sgx st on may 5 2022 for the listing and quotation of the shares on the main board of the sgx st the etl is not an indication of the merits of the proposed secondary listing of the company s shares on the sgx st the company its subsidiaries the adss and or the company s shares an introductory document relating to the proposed secondary listing by way of introduction of the shares on the main board of the sgx st is targeted to be issued later this month prior to the listing on the main board of the sgx st upon listing on the main board of the sgx st the shares listed on the main board of the sgx st will be fully fungible with the adss listed on the nyse this press release shall not constitute an offer to sell or the solicitation of an offer or an invitation to buy any securities of the company nor shall there be any offer or sale of the securities in any state or other jurisdiction in which such offer solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction about nio inc nio inc is a pioneer and a leading company in the premium smart electric vehicle market founded in november 2014 nio s mission is to shape a joyful lifestyle nio aims to build a community starting with smart electric vehicles to share joy and grow together with users nio designs develops jointly manufactures and sells premium smart electric vehicles driving innovations in next generation technologies in autonomous driving digital technologies electric powertrains and batteries nio differentiates itself through its continuous technological breakthroughs and innovations such as its industry leading battery swapping technologies battery as a service or baas as well as its proprietary autonomous driving technologies and autonomous driving as a service or adaas nio launched the es8 a seven seater flagship premium smart electric suv in december 2017 and began deliveries of the es8 in june 2018 and its variant the six seater es8 in march 2019 nio launched the es6 a five seater high performance premium smart electric suv in december 2018 and began deliveries of the es6 in june 2019 nio launched the ec6 a five seater premium smart electric coupe suv in december 2019 and began deliveries of the ec6 in september 2020 nio launched the et7 a flagship premium smart electric sedan in january 2021 and began deliveries of the et7 in march 2022 nio launched the et5 a mid size premium smart electric sedan in december 2021 safe harbor statement this press release contains statements that may constitute forward looking statements pursuant to the safe harbor provisions of the u s private securities litigation reform act of 1995 these forward looking statements can be identified by terminology such as will expects anticipates aims future intends plans believes estimates likely to and similar statements nio may also make written or oral forward looking statements in its periodic reports to the u s securities and exchange commission the sec in its annual report to shareholders in press releases and other written materials and in oral statements made by its officers directors or employees to third parties statements that are not historical facts including statements about nio s beliefs plans and expectations are forward looking statements forward looking statements involve inherent risks and uncertainties a number of factors could cause actual results to differ materially from those contained in any forward looking statement including but not limited to the following nio s strategies nio s future business development financial condition and results of operations nio s ability to develop and manufacture a car of sufficient quality and appeal to customers on schedule and on a large scale its ability to ensure and expand manufacturing capacities including establishing and maintaining partnerships with third parties its ability to provide convenient and comprehensive power solutions to its customers the viability growth potential and prospects of the newly introduced baas and adaas its ability to improve the technologies or develop alternative technologies in meeting evolving market demand and industry development nio s ability to satisfy the mandated safety standards relating to motor vehicles its ability to secure supply of raw materials or other components used in its vehicles its ability to secure sufficient reservations and sales of the es8 es6 ec6 et7 and et5 its ability to control costs associated with its operations its ability to build the nio brand general economic and business conditions globally and in china and assumptions underlying or related to any of the foregoing further information regarding these and other risks is included in nio s filings with the sec the listing document issued with the sehk and the introductory document issued with the sgx st all information provided in this press release is as of the date of this press release and nio does not undertake any obligation to update any forward looking statement except as required under applicable law for more information please visit investor relations contact press contact source nio inc
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed corecivic inc let s just stay away inmode ltd if you want med tech you just want edwards lifesciences western midstream partners lp this one s got a great yield really good story feeling out of the loop we ll catch you up on the chicago news you need to know sign up for the weekly chicago catch up newsletter here sghc limited they are doing well and i don t say that idly enterprise products partners lp they are the best in what they do united states steel corp if you re going to own a steel company which i don t honestly recommend right now you re going to own nucor teva pharmaceutical industries ltd i would prefer to see you in something like a ast spacemobile inc i do not know that company but we will do homework on it sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
new line cinema movie the hollywood walk of fame inductee teased about the possibility of a fourth austin power movie in 2018 saying well you re gonna see dr evil soon somewhere in the culture may 6 2022 aceshowbiz mike myers would love to do a fourth austin powers movie having starred as both the titular comedic parody of suave spy james bond and his arch nemesis dr evil in the previous movies the 58 year old actor would be up for reprising the roles again but couldn t confirm whether or not another film is in the works i can neither confirm nor deny the existence or non existence of such a project should it exist or not exist the austin powers in goldmember star said on the matter when it was suggested his comment felt like a confirmation he told siriusxm s jess cagle it was a non confirmed confirmation confirmation myers who also wrote and produced the trilogy spoke about the possibility of a fourth austin powers movie back in november 2018 admitting it was looking good he said at the time well you re gonna see dr evil soon somewhere in the culture but the movie you know i ve had three kids under the age of seven they take a long time to write they always have jay s been super crazy he added he s doing a fantastic movie right now that he s working on but it s looking good myers also previously claimed he would love to make a fourth movie in the franchise as he explained the film series was created as a tribute to his father who passed away in 1991 he said after my dad died in 1991 i was taking stock of his influence on me as a person and his influence on me with comedy in general so austin powers was a tribute to my father who james bond peter sellers the beatles the goodies peter cook and dudley moore he elaborated further i would love to do another but you just have to see i was devastated by my father s death but to have that turn into something that makes people happy is unbelievably satisfying it s that kind of stuff you never get used to or get tired of
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
bill com nyse bill a leading provider of cloud based software that simplifies digitizes and automates financial operations for small and midsize businesses smbs announced today that aida lvarez has joined the company s board of directors lvarez is a former head of the u s small business administration experienced public board member accomplished investment banker award winning journalist and distinguished public servant aida s extensive experience in running the u s small business administration and serving on boards of global corporations is a valuable combination that will bring great perspective as we grow the company said ren lacerte ceo and founder of bill com i am honored to welcome aida her passion for smbs and unique background to our board of directors lvarez was the first latino woman to be appointed to a cabinet position for a u s president she entered the clinton administration as the first director of the office of federal housing enterprise oversight and later headed the u s small business administration from 1997 to 2001 she has more than a decade of experience in investment banking working as a vice president in public finance for both bear stearns and first boston prior to this lvarez served as vice president public affairs of the new york city health and hospitals she was also an award winning print and television news journalist in the new york city metropolitan market across the united states small and midsize businesses are at the heart of our local communities i witnessed this first hand during my time leading the u s small business administration i also know from personal experience about the dreams and challenges faced by entrepreneurs because as a young teenager i worked alongside my mother running two small restaurants in brooklyn said ms lvarez what attracted me to bill com is that they are a mission driven company focused on helping small businesses i view my board service as another way to support these important businesses that are so vital to our economy lvarez previously served on boards of walmart pacificare united health and mufg union bank she currently serves on the board of hp inc among others lvarez is the founding chair emerita of the latino community foundation in california she s on the san francisco symphony board of governors and the board of the deyoung and the legion of arts museums lvarez was formerly a commissioner for the smithsonian american art museum she holds a bachelor of arts degree from harvard college and was on the harvard board of overseers she has honorary doctorates from bethany college iona college mercy college and the inter american university of puerto rico
jamestown a celebration of a project like applied blockchain inc s state of the art hosting facility does not happen unless there are entrepreneurs and risk takers willing to get the capital together to execute a plan and collaboration among many entities and partners according to gov doug burgum you can t celebrate a project like this that is on the cutting edge of innovation unless you ve got entrepreneurs unless you have risk takers unless you have people that are willing to get out and try to do things with new models in places where people say it will never work he said applied blockchain hosted a ribbon cutting ceremony thursday may 5 for its hosting facility that is located about 7 miles north of jamestown near the substation owned by otter tail power co the hosting facility is co located with the substation plans in september called for applied blockchain s hosting facility to provide 100 megawatts of capacity in early 2022 construction on the hosting facility began in september north dakota gov doug burgum looks to the mountain high rack of computers thursday may 5 2022 inside one of the buildings at applied blockchain s hosting facility north of jamestown john m steiner the jamestown sun applied blockchain which is headquartered in dallas is a publicly traded builder and operator of next generation data centers across north america which provide substantial compute power to blockchain infrastructure and support bitcoin mining according to the company s website applied blockchain s hosting facility mines bitcoin ethereum and other cryptocurrency assets advertisement wes cummins co founder and ceo of applied blockchain said it is amazing what his team and the contractors have done he said applied blockchain came to the right location we just got really lucky that we made this match he said we found the right partner with otter tail north dakota governor doug burgum speaks during a ribbon cutting ceremony at applied blockchain data center north of jamestown on thursday may 5 2022 john m steiner the jamestown sun irene gao head of global business development at bitmain said applied blockchain s hosting facility has very high end mining infrastructure we really cherish this partnership with them applied blockchain she said we are very happy to see how it runs efficiently the facility includes eight buildings with a total square footage of about 65 000 square feet each of the first four buildings is about 33 feet by 280 feet and each of the second set of four buildings is about 33 feet by 205 feet the eight buildings will host anywhere between 30 000 to 35 000 mining machines the facility in jamestown has 30 full time employees burgum toured one of the facility s 33 by 205 foot buildings that had about 4 500 computers used as mining machines stacked on top of each other along a straight line all the way down the center of the building one side of the building was noticeably cooler than the other side because of the fans pushing the heat from the computers from one side to the other a wall of computers as seen from the backside seems to go on endlessly inside one of the buildings at applied blockchain s hosting facility north of jamestown john m steiner the jamestown sun burgum said the digital economy needs power like electricity to run on whether it is running a server farm that manages transactions online managing emails or even businesses such as banks or health care providers advertisement you need power and you need data centers to run all that he said companies like applied blockchain want to be in north dakota because of its reliable and affordable power supplies the climate and the state having the right policies he said north dakota has a solution for energy policies that no state in the nation has he said we are the first state in the nation that has primacy away from the epa u s environmental protection agency north dakota has a combination of cold dry weather and cheap electricity costs that attract data center operators to the state two montana companies have a 1 9 billion data center planned near williston north dakota and another company is building one in grand forks burgum said another company is thinking about using power from the garrison dam as a carbon free source of power for a data center it is happening here because in north dakota unlike the federal government we believe that innovation is the solution to the problems not regulation he said regulation is backward looking regulation adds costs to companies like applied blockchain and then they don t get to do the work that they are doing but when we lead with innovation we can solve almost any problem burgum said the state of north dakota could become a customer of high performance computing for blockchain he said the state government has data for every citizen including licenses health care and medicaid cryptocurrency is a digital currency that can be used for payments or held as an investment similar to the stock market cryptocurrency is not a government currency and doesn t have a central bank interstate rates or a long history of exchange rates against other currencies advertisement cryptocurrencies are stored in virtual wallets such as klever or coinbase multi cryptocurrency wallets cryptocurrency can be purchased and sold on exchanges and each cryptocurrency system is separate and not interchangeable other than through these exchanges cryptocurrency transactions are recorded and kept through a ledger called blockchain each block is connected to those before and behind it making it more difficult for hackers to tamper with the blockchain because the block containing the record and all other blocks linked to it would need to be changed to avoid detection
all dollar amounts are united states dollars unless otherwise stated vancouver bc may 5 2022 prnewswire galiano gold inc galiano or the company tsx gau nyse gau reports first quarter q1 operating and financial results for the company and the asanko gold mine agm located in ghana west africa the agm is a 50 50 joint venture jv with gold fields ltd jse gfi nyse gfi which is managed and operated by galiano all financial information contained in this release is unaudited and reported in us asanko gold mine key metrics 100 basis production gold production of 42 343 ounces in line with 2022 production guidance of 100 000 120 000 ounces of gold gold production of 42 343 ounces in line with 2022 production guidance of 100 000 120 000 ounces of gold cost performance total cash costs per ounce 1 of 1 361 and all in sustaining costs 1 aisc of 1 559 oz during the quarter resulting in positive cash flows from operations of 3 9 million and aisc margin 1 of 12 0 million total cash costs per ounce of and all in sustaining costs aisc of oz during the quarter resulting in positive cash flows from operations of and aisc margin of financial performance reported gold revenue of 77 4 million generated from 41 929 gold ounces sold at an average realized price of 1 846 oz reported a net loss of 13 6 million during the quarter following the recognition of a 21 0 million severance liability and adjusted ebitda 1 of 13 1 million reported gold revenue of generated from 41 929 gold ounces sold at an average realized price of oz reported a net loss of during the quarter following the recognition of a severance liability and adjusted ebitda of focus on exploration deep directional drilling commenced at the nkran deposit aimed at defining the continuity and extension of mineralization below the limits of observed mineral resources the results of this program will be used to evaluate the underground potential of nkran exploration drilling continued at greater midras south while additional resource definition drilling progressed at miradani and nkran cut 3 deep directional drilling commenced at the nkran deposit aimed at defining the continuity and extension of mineralization below the limits of observed mineral resources the results of this program will be used to evaluate the underground potential of nkran exploration drilling continued at greater midras south while additional resource definition drilling progressed at miradani and nkran cut 3 culture of safety strong safety performance with no lost time injuries lti nor total recordable injuries tri reported during the quarter resulting in 12 month rolling lti and tri frequency rates of 0 11 and 0 21 per million employee hours worked respectively the agm has now achieved 6 3 million employee hours worked without an lti strong safety performance with no lost time injuries lti nor total recordable injuries tri reported during the quarter resulting in 12 month rolling lti and tri frequency rates of 0 11 and 0 21 per million employee hours worked respectively the agm has now achieved 6 3 million employee hours worked without an lti stable liquidity 45 3 million in cash 13 1 million in gold sales receivables and 4 1 million in gold on hand and no debt as of march 31 2022 in cash in gold sales receivables and in gold on hand and no debt as of workforce optimization undertook a process of rationalizing the agm s workforce severance notifications were issued and personnel necessary to maintain current operations have been retained with new employment contracts management expects to realize near term and sustainable cost savings and a more streamlined and efficient operation over the remaining life of mine as a result of the rationalization 1 see non ifrs performance measures galiano gold highlights stable balance sheet cash on hand of 50 4 million and 8 7 million in receivables as at march 31 2022 while remaining debt free cash on hand of and in receivables as at while remaining debt free earnings reported a net loss of 1 5 million or 0 01 per share for q1 2022 reported a net loss of or per share for q1 2022 board and management changes marcel de groot and shawn wallace confirmed that they will not be standing for re election at the company s upcoming annual general meeting and greg martin former cfo of ssr mining inc will be nominated for election at that meeting on march 23 2022 the company announced that fausto di trapani had stepped down as cfo of the company to pursue another opportunity and the company appointed matt freeman svp finance as its new cfo in line with the company s succession plan production for the quarter was in line with expectations and is on track to meet 2022 production guidance said matt badylak president and chief executive officer we are nearing completion of mining at both esaase and akwasiso and have started to supplement mill feed with stockpile material which currently is performing in line with our expectations we continue to advance the technical work we have previously outlined and will provide periodic updates as we progress through these work programs we anticipate providing an update to the agm s mineral reserves post the completion of this work in q1 2023 finally during the quarter we successfully initiated a rationalization of the agm s workforce which despite an upfront cost will deliver immediate cost savings and enable a more streamlined and efficient operation going forward asanko gold mine summary of q1 2022 operational and financial results 100 basis asanko gold mine 100 basis q1 2022 q4 2021 q3 2021 q2 2021 q1 2021 ore mined 000t 1 075 1 623 1 464 1 333 1 841 waste mined 000t 5 279 8 752 10 017 9 073 9 552 total mined 000t 6 354 10 375 11 481 10 406 11 393 strip ratio w o 4 9 5 4 6 8 6 8 5 2 average gold grade mined g t 1 3 1 2 1 3 1 2 1 3 mining cost t mined 4 64 3 75 3 28 3 03 3 31 ore transportation from esaase 000 t 1 304 1 264 1 272 1 261 870 ore transportation cost t trucked 5 82 6 13 5 88 6 20 6 48 ore milled 000t 1 482 1 472 1 542 1 475 1 444 average mill head grade g t 1 3 1 2 1 1 1 1 1 4 average recovery rate 69 91 90 94 95 processing cost t treated 9 46 10 07 9 68 9 87 10 31 gold production oz 42 343 50 278 49 543 50 421 59 999 gold sales oz 41 929 51 368 48 435 53 348 62 925 average realized gold price oz 1 846 1 771 1 758 1 782 1 757 operating cash costs1 oz 1 268 1 168 1 185 1 147 901 total cash costs1 oz 1 361 1 257 1 273 1 236 989 all in sustaining costs1 oz 1 559 1 539 1 598 1 497 1 158 all in sustaining margin1 oz 287 232 160 285 599 asanko gold mine 100 basis q1 2022 q4 2021 q3 2021 q2 2021 q1 2021 all in sustaining margin1 m 12 0 11 9 7 8 15 2 37 7 revenue m 77 5 91 1 85 3 95 2 110 8 income loss from mine operations m 10 6 8 9 13 0 18 1 35 9 adjusted net income loss 1 m 7 4 11 4 7 7 12 7 29 7 cash provided by operating activities m 3 9 14 0 26 5 10 8 35 4 the agm produced 42 343 ounces of gold during the quarter as the processing plant achieved milling throughput of 1 5mt of ore processed at a grade of 1 3g t with metallurgical recovery averaging 69 refer to the company s news release dated february 25 2022 for further details on lower plant recovery for further details on lower plant recovery sold 41 929 ounces of gold in q1 2022 at an average realized gold price of 1 846 oz for total revenue of 77 5 million including 0 1 million of by product silver revenue a decrease of 33 3 million from q1 2021 the decrease in revenue quarter on quarter was a function of a 33 reduction in sales volumes partly offset by a 5 increase in realized gold prices relative to q1 2021 oz for total revenue of including of by product silver revenue a decrease of from q1 2021 the decrease in revenue quarter on quarter was a function of a 33 reduction in sales volumes partly offset by a 5 increase in realized gold prices relative to q1 2021 total cost of sales including depreciation and depletion and royalties amounted to 67 0 million in q1 2022 a decrease of 7 9 million from q1 2021 the decrease in cost of sales was primarily due to fewer gold ounces sold and a 4 5 million positive net realizable value nrv adjustment on stockpile inventory due to higher gold prices in q1 2022 which were partly offset by higher ore transportation costs 2 0 million increase in q1 2022 a decrease of from q1 2021 the decrease in cost of sales was primarily due to fewer gold ounces sold and a positive net realizable value nrv adjustment on stockpile inventory due to higher gold prices in q1 2022 which were partly offset by higher ore transportation costs increase total cash costs per ounce 1 were 1 361 in q1 2022 compared to 989 in q1 2021 a 38 increase cash costs were higher in q1 2022 due in part to lower gold sales volumes which had the effect of increasing fixed production costs on a per unit basis higher ore transportation costs and general inflationary pressures on fuel and consumables and government levies these factors were partially offset by the above mentioned positive nrv adjustment on stockpile inventory in q1 2022 that was credited against production costs were in q1 2022 compared to in q1 2021 a 38 increase cash costs were higher in q1 2022 due in part to lower gold sales volumes which had the effect of increasing fixed production costs on a per unit basis higher ore transportation costs and general inflationary pressures on fuel and consumables and government levies these factors were partially offset by the above mentioned positive nrv adjustment on stockpile inventory in q1 2022 that was credited against production costs income from mine operations for q1 2022 totaled 10 6 million compared to income from mine operations of 35 9 million in q1 2021 the reduction in income from mine operations was due to a 33 3 million decrease in revenue partly offset by a 7 9 million decrease in cost of sales as described above compared to income from mine operations of in q1 2021 the reduction in income from mine operations was due to a decrease in revenue partly offset by a decrease in cost of sales as described above the agm generated 3 9 million of cash flows from operating activities during q1 2022 compared to 35 4 million of cash flows from operating activities during q1 2021 the decrease in cash flows from operations was primarily due to lower revenues from lower gold production and higher aisc 1 of cash flows from operating activities during q1 2022 compared to of cash flows from operating activities during q1 2021 the decrease in cash flows from operations was primarily due to lower revenues from lower gold production and higher aisc in light of the changing nature of operations at the agm the jv has undertaken a process of rationalizing its workforce severance notifications were issued resulting in a 21 0 million severance liability recorded by the agm at march 31 2022 and personnel necessary to maintain current operations have been retained with new employment contracts despite the upfront cost associated with the restructuring management expects to realize near term and sustainable costs savings and a more streamlined and efficient operation going forward as well as ensuring the severance liability is permanently eliminated over the next two years galiano gold inc summary q1 2022 financial results galiano gold inc consolidated q1 2022 q4 2021 q3 2021 q2 2021 q1 2021 net loss income after tax m 1 5 91 0 4 1 5 0 13 0 net loss income after tax per share 0 01 0 40 0 02 0 02 0 06 adjusted net loss income1 m 1 5 14 5 4 1 5 0 13 0 adjusted net loss per share1 0 01 0 06 0 02 0 02 0 06 the company reported a net loss after tax of 1 5 million in q1 2022 compared to net income after tax of 13 0 million in q1 2021 the decrease in earnings during q1 2022 was due to a reduction in the jv s net earnings in q1 2022 compared to net income after tax of in q1 2021 the decrease in earnings during q1 2022 was due to a reduction in the jv s net earnings cash used in operating activities in q1 2022 was 3 2 million compared to 4 7 million in q1 2021 the decrease in cash used in operations was primarily due to an increase in accounts payable and accrued liabilities partly offset by an increase in receivables related to the company s jv service fee compared to in q1 2021 the decrease in cash used in operations was primarily due to an increase in accounts payable and accrued liabilities partly offset by an increase in receivables related to the company s jv service fee as at march 31 2021 the company had cash on hand of 50 4 million and 8 7 million in receivables for a gross liquidity position of 59 1 million and no debt this news release should be read in conjunction with galiano s management s discussion and analysis and the unaudited condensed consolidated interim financial statements for the three months ended march 31 2022 and 2021 which are available at www galianogold com and filed on sedar 1 non ifrs performance measures the company has included certain non ifrs performance measures in this press release these non ifrs performance measures do not have any standardized meaning accordingly these performance measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with ifrs refer to the non ifrs measures section of galiano s management s discussion and analysis for an explanation of these measures and reconciliations to the company s and the jv s reported financial results in accordance with ifrs operating cash costs per ounce and total cash costs per ounce operating cash costs are reflective of the cost of production adjusted for share based payments and by product revenue per ounce of gold sold total cash costs include production royalties of 5 excluded from operating cash costs are one time severance charges and net realizable value adjustments on stockpile inventory resulting from lower expected gold recovery recorded in q4 2021 as the magnitude of such adjustments are not indicative of current period costs operating cash costs are reflective of the cost of production adjusted for share based payments and by product revenue per ounce of gold sold total cash costs include production royalties of 5 excluded from operating cash costs are one time severance charges and net realizable value adjustments on stockpile inventory resulting from lower expected gold recovery recorded in q4 2021 as the magnitude of such adjustments are not indicative of current period costs all in sustaining costs per gold ounce the company has adopted the reporting of all in sustaining costs per gold ounce aisc as per the world gold council s guidance aisc include total cash costs corporate overhead expenses sustaining capital expenditure capitalized stripping costs reclamation cost accretion and lease payments made to and interest expense on the agm s mining and service contractors per ounce of gold sold the company has adopted the reporting of all in sustaining costs per gold ounce aisc as per the world gold council s guidance aisc include total cash costs corporate overhead expenses sustaining capital expenditure capitalized stripping costs reclamation cost accretion and lease payments made to and interest expense on the agm s mining and service contractors per ounce of gold sold adjusted ebitda ebitda provides an indication of the company s continuing capacity to generate income from operations before taking into account the company s financing decisions and costs of amortizing capital assets accordingly ebitda comprises net income loss excluding interest expense interest income amortization and depletion and income taxes adjusted ebitda adjusts ebitda to exclude non recurring items and to include the company s interest in the adjusted ebitda of the jv other companies and jv partners may calculate ebitda and adjusted ebitda differently ebitda provides an indication of the company s continuing capacity to generate income from operations before taking into account the company s financing decisions and costs of amortizing capital assets accordingly ebitda comprises net income loss excluding interest expense interest income amortization and depletion and income taxes adjusted ebitda adjusts ebitda to exclude non recurring items and to include the company s interest in the adjusted ebitda of the jv other companies and jv partners may calculate ebitda and adjusted ebitda differently adjusted net loss income the company has included the non ifrs performance measures of adjusted net loss income and adjusted net loss income per common share neither adjusted net loss income nor adjusted net loss income per share have any standardized meaning and are therefore unlikely to be comparable to other measures presented by other issuers adjusted net loss income excludes certain non cash items from net income or net loss to provide a measure which helps the company and investors to evaluate the results of the underlying core operations of the company and its ability to generate cash flows and is an important indicator of the strength of our operations and the performance of our core business about galiano gold inc galiano s vision is to build a sustainable business capable of long term value creation for its stakeholders through a combination of exploration accretive m a activities and the disciplined deployment of its financial resources the company currently operates and manages the asanko gold mine located in ghana west africa which is jointly owned with gold fields ltd the company is strongly committed to the highest standards for environmental management social responsibility and health and safety for its employees and neighbouring communities for more information please visit www galianogold com cautionary note regarding forward looking statements certain statements and information contained in this news release constitute forward looking statements within the meaning of applicable u s securities laws and forward looking information within the meaning of applicable canadian securities laws which we refer to collectively as forward looking statements forward looking statements are statements and information regarding possible events conditions or results of operations that are based upon assumptions about future conditions and courses of action all statements and information other than statements of historical fact may be forward looking statements in some cases forward looking statements can be identified by the use of words such as seek expect anticipate budget plan estimate continue forecast intend believe predict potential target may could would might will and similar words or phrases including negative variations suggesting future outcomes or statements regarding an outlook forward looking statements in this news release include but are not limited to the operating plans for the agm under the jv between the company and gold fields plans to transition from mining to processing stockpiles and the benefits that may arise therefrom and with respect to the re start of mining operations thereafter and activities to be completed while mining activities are temporarily paused such forward looking statements are based on a number of material factors and assumptions including but not limited to the company and gold fields will agree on the manner in which the jv will operate the agm including agreement on development plans and capital expenditures the price of gold will not decline significantly or for a protracted period of time the accuracy of the estimates and assumptions underlying mineral resources estimates the ability of the agm to continue to operate produce and ship dor from the agm site to be refined during the covid 19 pandemic or any other infectious disease outbreak the company s ability to raise sufficient funds from future equity financings to support its operations and general business and economic conditions the global financial markets and general economic conditions will be stable and prosperous in the future the ability of the jv and the company to comply with applicable governmental regulations and standards the mining laws tax laws and other laws in ghana applicable to the agm and the jv will not change and there will be no imposition of additional exchange controls in ghana the success of the jv and the company in implementing its development strategies and achieving its business objectives the jv will have sufficient working capital necessary to sustain its operations on an ongoing basis and the company will continue to have sufficient working capital to fund its operations and contributions to the jv and the key personnel of the company and the jv will continue their employment the foregoing list of assumptions cannot be considered exhaustive forward looking statements involve known and unknown risks uncertainties and other factors which may cause actual results performance or achievements to differ materially from those anticipated in such forward looking statements the company believes the expectations reflected in such forward looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and you are cautioned not to place undue reliance on forward looking statements contained herein some of the risks and other factors which could cause actual results to differ materially from those expressed in the forward looking statements contained in this news release include but are not limited to the mineral resource estimates may change and may prove to be inaccurate mineral reserves may not be reinstated metallurgical recoveries may not be economically viable risks associated with the company ceasing its mining operations during 2022 the company does not currently have a lom estimate for the agm due to the withdrawal of the mineral reserve actual production costs returns and other economic and financial performance may vary from the company s estimates in response to a variety of factors many of which are not within the company s control agm has a limited operating history and is subject to risks associated with establishing new mining operations sustained increases in costs or decreases in the availability of commodities consumed or otherwise used by the company may adversely affect the company adverse geotechnical and geological conditions including geotechnical failures may result in operating delays and lower throughput or recovery closures or damage to mine infrastructure the ability of the company to treat the number of tonnes planned recover valuable materials remove deleterious materials and process ore concentrate and tailings as planned is dependent on a number of factors and assumptions which may not be present or occur as expected the company s operations may encounter delays in or losses of production due to equipment delays or the availability of equipment outbreaks of covid 19 and other infectious diseases may have a negative impact on global financial conditions demand for commodities and supply chains and could adversely affect the company s business financial condition and results of operations and the market price of the common shares of the company the company s operations are subject to continuously evolving legislation compliance with which may be difficult uneconomic or require significant expenditures the company may be unsuccessful in attracting and retaining key personnel labour disruptions could adversely affect the company s operations the company s business is subject to risks associated with operating in a foreign country risks related to the company s use of contractors the hazards and risks normally encountered in the exploration development and production of gold the company s operations are subject to environmental hazards and compliance with applicable environmental laws and regulations the effects of climate change or extreme weather events may cause prolonged disruption to the delivery of essential commodities which could negatively affect production efficiency the company s operations and workforce are exposed to health and safety risks unexpected costs and delays related to or the failure of the company to obtain necessary permits could impede the company s operations the company s title to exploration development and mining interests can be uncertain and may be contested geotechnical risks associated with the design and operation of a mine and related civil structures the company s properties may be subject to claims by various community stakeholders risks related to limited access to infrastructure and water the company s exploration programs may not successfully reinstate mineral reserves risks associated with establishing new mining operations the company s common shares may experience price and trading volume volatility the company has never paid dividends the company s revenues are dependent on the market prices for gold which have experienced significant recent fluctuations the company may not be able to secure additional financing when needed or on acceptable terms company shareholders may be subject to future dilution risks related to the control of agm cashflows and operation through a joint venture risks related to changes in interest rates and foreign currency exchange rates risks relating to credit rating downgrades changes to taxation laws applicable to the company may affect the company s profitability and ability to repatriate funds ability to repatriate funds risks related to the company s internal controls over financial reporting and compliance with applicable accounting regulations and securities laws non compliance with public disclosure obligations could have an adverse effect on the company s stock price the carrying value of the company s assets may change and these assets may be subject to impairment charges risks associated with changes in reporting standards the company s primary asset is held through a joint venture which exposes the company to risks inherent to joint ventures including disagreements with joint venture partners and similar risks the company may be liable for uninsured or partially insured losses the company may be subject to litigation damage to the company s reputation could result in decreased investor confidence and increased challenges in developing and maintaining community relations which may have adverse effects on the business results of operations and financial conditions of the joint venture and the company and the company s share price the company may be unsuccessful in identifying targets for acquisition or completing suitable corporate transactions and any such transactions may not be beneficial to the company or its shareholders the company must compete with other mining companies and individuals for mining interests risks related to information systems security threats the company s growth future profitability and ability to obtain financing may be impacted by global financial conditions and the risk factors described under the heading risk factors in the company s annual information form although the company has attempted to identify important factors that could cause actual results or events to differ materially from those described in the forward looking statements you are cautioned that this list is not exhaustive and there may be other factors that the company has not identified furthermore the company undertakes no obligation to update or revise any forward looking statements included in or incorporated by reference in this news release if these beliefs estimates and opinions or other circumstances should change except as otherwise required by applicable law neither toronto stock exchange nor the investment industry regulatory organization of canada accepts responsibility for the adequacy or accuracy of this release source galiano gold inc
a co founder of arm has criticised britain s technology illiterate politicians amid fears the firm will list its shares in new york rather than london hermann hauser one of the entrepreneurs who spun off the chip designer from acorn computers in 1990 said mps have only recently woken up to the importance of supporting uk technology and he called on arm s owner softbank to float arm on the stock market in london as well as new york in a so called dual listing rather than just in the us arm co founder hermann hauser pictured said mps have only recently woken up to the importance of supporting uk technology the japanese group bought cambridge based arm for 24billion in 2016 but is planning to sell it through a stock market float having seen a proposed sale to us giant nvidia collapse new york is the favoured destination for the float but no formal decision has been made hauser told the bbc technology sovereignty has become a key issue for the decade and even the technology illiterate politicians like johnson and the majority of parliament have woken up to the fact that it is important to support the local technology companies with local stock exchanges
sorrento therapeutics inc sp 102 semdexa tm is the first non opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain and it contains no preservatives surfactants solvents or particulates the study met its primary endpoint with a highly statistically significant reduction in average daily leg pain in patients receiving semdexa tm compared to placebo p 0 001 data demonstrated the utility of semdexa in rapidly reducing sciatica pain with an extended effect for up to 99 days following a single epidural injection of sp 102 semdexa safety analysis demonstrated a clean safety profile with no identified safety risks there were no serious adverse events related to the drug or injection procedure no adverse events of special interest such as hematoma and infection at the injection site or paraplegia were reported the c l e a r trial also established the safety of repeat injections as patients who experienced moderate to severe radicular pain between 4 and 20 weeks were allowed to receive open label additional sp 102 semdexa injection the key secondary endpoint of oswestry disability index the gold standard for measuring degree of disability and estimating quality of life showed a 28 improvement at 4 weeks on sp 102 semdexa compared to baseline minimal clinically meaningful improvement 8 12 1 the ls mean sem difference as compared to placebo was 6 28 1 49 with a p value 0 001 it has been a while since new drugs have been developed for interventional pain procedures we are anxiously awaiting a new injectable formulation of viscous gel dexamethasone with extended local effect and its fda approval for the treatment of radicular pain based on the results of this large randomized multicenter placebo controlled trial if approved by the fda it will be the first corticosteroid ever approved for epidural injections addressing safety issues with steroid medications that have been used off label in the past few decades this could be an important addition to treatment options for these patients a game changer said prof dr nebojsa nick knezevic m d ph d palo alto calif may 05 2022 globe newswire scilex holding company scilex a sorrento company nearly 100 or over 99 9 majority owned subsidiary of sorrento therapeutics inc nasdaq srne sorrento and a commercial biopharmaceutical company focused on developing and commercializing non opioid therapies for patients with acute and chronic pain announced pivotal phase 3 semdexatm data presentation at the american society of interventional pain 2022 annual meeting the pivotal phase 3 sp 102 semdexatm trial has a highly positive results evaluating semdexatm in sciatica patients following an epidural injection was presented at the innovation summit session of the 2022 american society of interventional pain asipp annual scientific meeting in las vegas nevada results from this multicenter randomized double blind placebo controlled study demonstrated that patients experienced rapid onset of pain reduction in sciatica pain and the effect lasted for up to 99 days following a single injection of semdexatm at the end of the procedure this is the first time this trial study data has been presented at a major north american medical meeting story continues the podium presentation described the phase 3 trial known as the c l e a r trial program randomized 401 lumbosacral radicular pain sciatica patients at 40 sites across 25 states in the u s which is the largest double blind randomized controlled epidural steroid injection clinical trial in sciatica presenting author prof dr nebojsa nick knezevic m d ph d professor of anesthesiology and surgery college of medicine university of illinois at chicago president of the illinois society of interventional pain physicians director at large of the north american society of neuromodulation vice chair for research and education advocate illinois masonic medical center department of anesthesiology and pain management the presentation at the innovation summit session asipp on may 5 2022 described the outcome of the c l e a r trial key findings from this study include the study met its primary endpoint with a highly statistically significant reduction in average daily leg pain in patients receiving semdexa tm compared to placebo p 0 001 a total of 401 sciatica patients were enrolled at 40 clinical sites in us the median time days to repeat injection in placebo group was 57 and 99 days in the semdexa tm group according to kaplan meier estimation p 0 001 safety analysis demonstrated a clean safety profile with no identified safety risks there were no serious adverse events related to the drug or injection procedure and no adverse events of special interest reported such as hematoma and infection at the injection site or paraplegia the c l e a r trial also established the safety of repeat injections as patients who experienced moderate to severe radicular pain between 4 and 23 weeks were allowed to receive open label additional sp 102 semdexa injection the key secondary endpoint of oswestry disability index the gold standard for measuring degree of disability and estimating quality of life showed a 28 improvement at 4 weeks on sp 102 semdexa compared to baseline minimal clinically meaningful improvement 8 12 these phase 3 data demonstrate that the median time to repeat injection for patients treated with semdexatm was significantly longer than those treated with placebo said dmitri lissin svp and cmo of scilex holding we believe these data coupled with phase 2 results from our repeat dose trial and earlier pk pd trial in sciatica patients will help support product registration with the fda and utility of semdexatm in a pain clinic setting this is the first time that these pivotal phase 3 data are being presented at a north american medical meeting and we believe this is another important milestone as we execute on our clinical and pre commercial strategies there is about 60 use of opioid pain medications for chronic back pain2 which is directly linked to many new persistent opioid users every year and up to many new cases of opioid use disorder annually making low back pain opioid use an important contributor to the opioid epidemic in the united states with more than 30 million low back pain and sciatica patients every year in the us3 4 there is enormous need for an approved treatment and a desperate need for effective non opioid alternatives said annu navani secretary asipp and medical director comprehensive spine sports center and adjunct clinical associate professor stanford university school of medicine epidural steroid injections have been used more than half a century for low back and leg pain and there has always been a need for safer longer lasting and more efficacious formulations scilex holding company and vickers vantage corp i nasdaq vcka vcka a special purpose acquisition company sponsored by vickers venture fund vi pte ltd and vickers venture fund vi plan pte ltd entered into a definitive business combination agreement bca on march 17 2022 upon the closing of the transaction the combined company the combined company will be renamed scilex holding company and its common stock is expected to be listed on nasdaq under the ticker symbol sclx the boards of directors of each of vcka scilex and sorrento have unanimously approved the proposed transaction the closing of the transaction which is expected to occur by the third quarter of 2022 is subject to the approval of vcka s shareholders and the satisfaction or waiver of certain other customary closing conditions a corporate presentation describing scilex s development plans can be found at www scilexholding com about scilex holding company scilex holding company a sorrento company nearly 100 or over 99 9 majority owned subsidiary of sorrento therapeutics inc is dedicated to the development and commercialization of non opioid pain management products for treatment of acute and chronic pain scilex is uncompromising in its focus to become the global pain management leader committed to social environmental economic and ethical principles to responsibly develop pharmaceutical products to maximize quality of life highly positive results from the phase iii pivotal trial c l e a r program for semdexatm its novel non opioid product for the treatment of lumbosacral radicular pain sciatica were announced in march 2022 scilex targets indications with high unmet needs and large market opportunities with non opioid therapies for the treatment of patients with moderate to severe pain scilex launched its first commercial product in october 2018 and is developing its late stage pipeline which includes a pivotal phase 3 candidate and one phase 2 and one phase 1 candidate its commercial product ztlido lidocaine topical system 1 8 or ztlido is a prescription lidocaine topical product approved by the u s food and drug administration for the relief of pain associated with postherpetic neuralgia which is a form of post shingles nerve pain scilex s three product candidates are sp 102 injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone or semdexa a phase 3 novel viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain or sciatica with fda fast track status sp 103 lidocaine topical system 5 4 a phase 2 triple strength formulation of ztlido for the treatment of low back pain and sp 104 4 5 mg delayed burst release low dose naltrexone hydrochloride dbr ldn capsule for the treatment of chronic pain fibromyalgia in multiple phase 1 programs expected to be initiated this year for further information regarding the sp 102 phase 3 efficacy trial see nct identifier nct03372161 corticosteroid lumbar epidural analgesia for radiculopathy full text view clinicaltrials gov scilex holding company is headquartered in palo alto california with operations in both palo alto and san diego california for further information please visit www scilexholding com about sorrento therapeutics inc sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer pain non opioid treatments autoimmune disease and covid 19 sorrento s multimodal multipronged approach to fighting cancer is made possible by its extensive immuno oncology platforms including key assets such as fully human antibodies g mab library immuno cellular therapies dar t antibody drug conjugates adcs and oncolytic virus seprehvec sorrento is also developing potential antiviral therapies and vaccines against coronaviruses including abivertinib covishield and covi msc and diagnostic test solutions including covimark sorrento s commitment to life enhancing therapies for patients is also demonstrated by our effort to advance a first in class trpv1 agonist non opioid pain management small molecule resiniferatoxin rtx and sp 102 10 mg dexamethasone sodium phosphate viscous gel semdexa a novel viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain or sciatica and to commercialize ztlido lidocaine topical system 1 8 for the treatment of postherpetic neuralgia phn rtx has been cleared for a phase ii trial for intractable pain associated with cancer and a phase ii trial in osteoarthritis patients positive final results from the phase iii pivotal trial c l e a r program for semdexa its novel non opioid product for the treatment of lumbosacral radicular pain sciatica were announced in march 2022 ztlido was approved by the fda on february 28 2018 for more information visit www sorrentotherapeutics com about vickers vantage corp i vickers vantage corp i is a blank check company formed for the purpose of effecting a merger share exchange asset acquisition share purchase reorganization or similar business combination with one or more businesses or entities important information for investors and stockholders this press release relates to a proposed transaction between scilex and vcka this press release does not constitute an offer to sell or exchange or the solicitation of an offer to buy or exchange any securities nor shall there be any sale of securities in any jurisdiction in which such offer sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction in connection with the transaction described herein vcka intends to file relevant materials with the sec including a registration statement on form s 4 which will include a document that serves as a prospectus and proxy statement of vcka referred to as proxy statement prospectus after the registration statement is declared effective by the sec the proxy statement prospectus will be sent to all vcka shareholders as of a record date for the meeting of vcka shareholders to be established for voting on the proposed business combination vcka will also file other documents regarding the proposed transaction with the sec this press release does not contain all of the information that will be contained in the proxy statement prospectus or other documents filed or to be filed with the sec investors and security holders of vcka are urged to read these materials including any amendments or supplements thereto and any other relevant documents in connection with the transaction that vcka files with the sec when and if they become available because they will contain important information about vcka scilex and the proposed transaction investors and security holders will be able to obtain free copies of the registration statement the proxy statement prospectus and all other relevant documents filed or that will be filed with the sec by vcka through the website maintained by the sec at www sec gov participants in the solicitation vcka and its directors and executive officers may be deemed participants in the solicitation of proxies from vcka s shareholders in connection with the transaction a list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the proxy statement prospectus when available you may obtain free copies of these documents as described in the preceding paragraph scilex and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of vcka in connection with the proposed transaction information about scilex s directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement prospectus for the proposed transaction non solicitation this press release is not a proxy statement or solicitation of a proxy consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of vcka the combined company or scilex nor shall there be any sale of any such securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction no offer of securities shall be made except by means of a prospectus meeting the requirements of the securities act of 1933 as amended forward looking statements this press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward looking statements related to vcka sorrento therapeutics inc and its subsidiaries including but not limited to scilex under the safe harbor provisions of section 21e of the private securities litigation reform act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected forward looking statements include statements regarding the efficacy and safety profile of sp 103 for treatment of lbp in patients the ability of sp 103 to address limitations of prescription lidocaine patches in treating acute lbp scilex s expected timeline to complete this phase 2 study and plans for subsequent phase 3 trial s the proposed business combination between scilex and vcka including the timing of such business combination the potential listing of the combined company s common stock on nasdaq or other major securities exchange and the anticipated stock ticker symbol for such shares the expectation that vcka will file a registration statement on form s 4 with the sec which would include a proxy statement prospectus the estimated or anticipated future results and benefits of the combined company following the proposed business combination including the likelihood and ability of the parties to successfully consummate the proposed business combination future opportunities for the combined company the timing of the completion of the proposed business combination scilex s and the combined company s proposed business strategies the expected cash resources of the combined company and the expected uses thereof scilex s and the combined company s current and prospective product candidates planned clinical trials and preclinical activities and potential product approvals as well as the potential for market acceptance of any approved products and the related market opportunity statements regarding sp 102 semdexa or sp 103 if approved by the fda scilex s development and commercialization plans and sorrento s products technologies and prospects and scilex s products technologies and prospects including the potential for scilex s product candidates to be best in class or first in class therapies risks and uncertainties that could cause sorrento s and scilex s actual results to differ materially and adversely from those expressed in our forward looking statements include but are not limited to the inability of the parties to consummate the proposed business combination transaction for any reason or the occurrence of any event change or other circumstances that could give rise to the termination of the bca including any failure to meet applicable closing conditions changes in the structure timing and completion of the proposed transaction between vcka and scilex vcka s ability to continue its listing on the nasdaq capital market until closing of the proposed transaction the combined company s ability to list its securities on nasdaq or other major securities exchange after closing of the proposed transaction the ability of the parties to achieve the benefits of the proposed transaction including future financial and operating results of the combined company the ability of the parties to realize the expected synergies from the proposed transaction risks related to the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed business combination general economic political and business conditions risks related to the ongoing covid 19 pandemic the risk that the potential product candidates that scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all risks relating to uncertainty regarding the regulatory pathway for scilex s product candidates the risk that scilex will be unable to successfully market or gain market acceptance of its product candidates the risk that scilex s product candidates may not be beneficial to patients or successfully commercialized the risk that scilex has overestimated the size of the target patient population their willingness to try new therapies and the willingness of physicians to prescribe these therapies risks that the results of the phase 2 trial for sp 103 may not be successful risks that the prior results of the clinical trials of sp 102 semdexa or sp 103 may not be replicated regulatory and intellectual property risks the risk that any requisite regulatory approvals to complete the transaction are not obtained are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed transaction or that the approval of vcka s shareholders is not obtained the risk of failure to realize the anticipated benefits of the proposed transaction the amount of redemption requests made by vcka s shareholders and other risks and uncertainties indicated from time to time and other risks set forth in sorrento s and vcka s filings with the sec investors are cautioned not to place undue reliance on these forward looking statements which speak only as of the date of this release and we undertake no obligation to update any forward looking statement in this press release except as may be required by law contacts for scilex holding company jaisim shah chief executive officer scilex holding company 960 san antonio road palo alto ca 94303 office 650 516 4310 email jshah scilexpharma com website www sorrentotherapeutics com and www scilexholding com investors and media contact contact brian cooley senior vice president corporate communications and investor relationships head of lymphatic drug delivery email mediarelations sorrentotherapeutics com website www sorrentotherapeutics com for vickers vantage corp i jeffrey chi chief executive officer 85 broad street 16th floor new york ny 10004 phone 646 974 8301 email jeff chi vickersventure com website www vickersvantage com investors and media contact nicolette ten senior account executive sprg email nicolette ten sprg com sg sorrento and the sorrento logo are registered trademarks of sorrento therapeutics inc g mab dar t seprehvec sofusa covishield covi msc and covimark are trademarks of sorrento therapeutics inc semdexa sp 102 is a trademark owned by semnur pharmaceuticals inc a wholly owned subsidiary of scilex holding company a proprietary name review by the fda is planned ztlido is a registered trademark owned by scilex pharmaceuticals inc a wholly owned subsidiary of scilex holding company all other trademarks are the property of their respective owners 2022 sorrento therapeutics inc all rights reserved references 1 yoshina et al 2019 and ostelo de vet clinically important outcomes in low back pain best practice research clinical rheumatology volume 19 issue 4 august 2005 pages 593 607 2 deyo weinstein 2001 3 decisions resources group chronic pain disease landscape and forecast 2016 76 80 4 decisions resources group chronic pain disease landscape and forecast 2016 40
alung technologies inc whose hemolung product developed out of the university of pittsburgh helps patients with acute respiratory distress has been acquired by a london based medical technology company livanova nasdaq livn acquired alung for 10 million with additional payments on sales based milestones in the future according to livanova s first quarter earnings report that was released wednesday the deal closed monday alung products are complementary to livanova s acs portfolio and as such the business and financial results will be included in the company s acs advanced circulatory support segment livanova said it s the second acquisition in the pittsburgh region for livanova which acquired cardiopulmonary support maker tandemlife in 2018 tandemlife is also in the same division as alung peter decomo chairman and ceo of alung retired from the company after the deal closed along with the company s cfo decomo had led alung through the long process of getting the hemolung respiratory assist system to u s food and drug administration approval hemolung received clearance from the fda in november 2021 after years of development in pittsburgh and clinical trials in the united states and the united kingdom acquisition or strategic partnership was always one of alung s potential outcomes given the long road it takes not only for fda approval of a medical device but also then marketing and selling it the transaction i think is a very positive transaction for the company for the company and for the people decomo told the business times on thursday afternoon livanova and tandemlife especially the advanced circulatory support system and alung it s a very synergistic merger they are like products very similar calling points to who you would call on in the hospital to sell these technologies decomo said that hemolung will get a boost by being part of a larger medical device company that knows the space and it won t have to continue to raise capital on its own it s a benefit because alung doesn t have to go out and build that commercial infrastructure that livanova has in place decomo said alung has weathered challenges throughout its existence but prevailed not only with the de novo clearance from the fda but also through the covid 19 pandemic and the challenges that it brought to medical device companies hemolung although not developed for covid 19 was also used to treat some people with acute respiratory distress due to covid it was also a company featured in the business times small business big mission package in 2020 livanova didn t immediately respond to a request for comment more alung was featured in the pittsburgh business times award winning small business big mission series in 2020
u s a ammoland com given the large variety of ar 15 barrel lengths gas system lengths bolts and buffer weights it s no surprise that there s a wide range of gas pressures kicking back into the upper receiver this normally isn t much of a concern to the shooter so long as reliability is unaffected when you screw on a suppressor however backpressure is increased and can often lead to the shooter inhaling an obnoxious amount of pew exhaust the new silencerco gas defeating charging handle gdch isn t the first product to address this issue but it may be the last you ll need to hear about before we get into hands on testing let s cover tech specs as provided by silencerco uses a gasket seal to redirect blowback machined from aircraft grade 7075 aluminum type iii hard anodize finish features ambidextrous design for intuitive manipulation and smooth charging msrp of 114 00 on initial inspection the gas defeating charging handle looks just like any upper echelon charging handle out there today ambidextrous handles held with fat roll pins to prevent shearing the usual hard anodized finish the gdch looks like most flip it over and inspect the underbelly and you ll see what makes this different a u shaped gasket lives where the rear flat of the charging handle mates up with the upper receiver normally there s a tiny gap there enough for high pressure gas to vent out right next to your nose and eyes if you ve shot a rapid string of fire from a suppressed rifle that runs on the gassy side you ll know why this is a problem if you haven t let me tell you why the gdch and other products of its ilk exist once that gas gets into your eyes they can start watering to the point where it s hard to see in your nose it can induce coughing and sneezing when you least need to deal with that some will say if a gun is that gassy you should use a regulated bolt carrier or adjustable gas block sometimes though the guns runs extremely well the way it is set up and the solution least likely to change how the gun operates is best so how much does the gdch reduce this obnoxious issue to find out i took my most excessively gassy upper to the range i fired five rounds quickly then took notes on how bad the gas was i swapped in the gas defeating charging handle and did it again five more rounds with a normal charging handle and then another five with the gdch i really didn t need to have bothered taking notes the result is pretty obvious with a stock charging handle it s a gassy mess the gdch is like a good haircut you don t notice it because everything is as it should be gas is vented out the ejection port away from the shooter and the air he she needs to breathe o rings do wear out eventually though in this application it doesn t seem like a severe wear point silencerco does include a spare gasket with every gas defeating charging handle it s a simple review for a simple product you don t need to dump a thousand rounds to figure out if it works or not it s evident immediately if i had the ear of the tech at silencerco i d suggest that in v2 0 they add porting holes  la radian s raptor sd charging handle as it stands the gas defeating charging handle is an effective tool that can help reduce the primary drawback of shooting suppressed with an msrp of 114 some may opt to keep breathing gas for a while or slap on some rtv silicone until the street price comes down to double digits if you re building a rifle designed around suppressed shooting i d suggest you buy once cry once or cry every few gassy rounds about rex nanorum rex nanorum is an alaskan expatriate living in oregon with his wife and kids growing up on commercial fishing vessels he found his next adventure with the 2nd bn 75th ranger regt after 5 tours to afghanistan and iraq he adventured about the west coast becoming a commercial fishery and salvage scuba diver rated helicopter pilot instructor cfii and personal trainer before becoming a gear reviewer and writer
cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation while scotts miracle gro might seem cheap on a price to earnings basis management doesn t have a handle on how bad it s going to get the mad money host said cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation historically this is a great time of year for anything garden related because it s planting season and scotts is a name that we used to get a ton of questions about but over the past thirteen months these shares have been obliterated the mad money host said get southern california news weather forecasts and entertainment stories to your inbox sign up for nbc la newsletters while scottsmiracle gro might seem cheap on a price to earnings basis the problem is that the earnings forecast keeps coming down and management doesn t have a handle on how bad it s going to get he later added scottsmiracle gro stock fell 6 on thursday the company reported better than expected earnings in its previous quarter two days before jpmorgan upgraded scottsmiracle gro to overweight from neutral on wednesday pointing to the stock s valuation high margins and market leadership stifel downgraded the stock from overweight to hold cramer said that he agrees with stifel s more bearish stance on scotts particularly because of the company s struggles with rising raw costs lack of confidence regarding an earnings target of 8 a share and his concerns with the performance of scotts hawthorne division hawthorne operates in cannabis an industry cramer says has been beaten down for the last year on top of that scotts has an ugly enough balance sheet that they don t see management embracing an aggressive buyback either in short business is bad and there s not much scotts can do to make it better cramer said sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
mannkind corporation nasdaq mnkd q1 2022 earnings conference call may 5 2022 5 00 pm et company participants michael castagna  chief executive officer steven binder  chief financial officer conference call participants brandon folkes  cantor fitzgerald gregory renza  rbc capital markets thomas smith  svb securities bert hazlett  btig operator good afternoon and welcome to the mannkind corporation first quarter 2022 earnings call as a reminder this call is being recorded on may 5 2022 and will be available for playback on the mannkind corporation s website shortly after the conclusion of this call until may 19 2022 this call will contain forward looking statements such forward looking statements are subject to risks and uncertainties which could cause actual results to differ materially from the stated expectations for further information on the company s risk factors please see their 10 k report filed with the securities and exchange commission this afternoon the earnings release and the slides prepared for this presentation joining us today from mannkind are chief executive officer michael castagna and chief financial officer steven binder i would now like to turn the conference over to mr castagna please go ahead sir michael castagna thank you and thank you all for dialing into our earnings call today we re in unprecedented times as we look at the volatility in the stock market as well as our biotech sector having lots of unfortunately mishaps these days in terms of companies employing on a daily basis which from a mannkind perspective we re expanding and hiring so we re able to find great talent but from an industry perspective we see lots of change ahead when i think about q1 we had some great opportunities to continue to advance our transformation in afrezza which i ll talk about today as well as advance our pipeline progress with clofazimine and we ll give an update we know today on tyvaso so those will be the three focuses of our conversation i personally just got back from our attd diabetes conference in europe and i was able to meet about 10 15 of the top regional thought leaders in those countries that are represented in the european union to really talk about afrezza the potential of afrezza as well as the pediatric trial and the studies that we re doing and i walked back invigorated on opportunities on how we can continue to advance the science within diabetes we ve also had several fda interactions on afrezza in the pipeline trying to think about the label change as well as preparing to go to advance clofazimine into phase 2 and we also had advisory board with roughly 10 of the top thought leaders in nontuberculous mycobacteria for the first time where we could really assess how we think about ntm how we re positioning clofazimine and to confirm our strategic direction relative to where we re going in our clinical trial before we go to the fda so within the ut collaboration here on the slide our pdufa date is may of 2022 we eagerly await for the fda to give us notification on actually ut we are focused on preparing to support the expected commercial launch of ut in june on the pipeline our sad trial is almost complete i ll describe that in a second we expect full results from the mad section in q3 on mnkd 201 and mnkd 501 both of these are progressing nicely we re in doing animal inhalation studies and really looking at the levels as well as the bleomycin induced lung models here in q2 and q3 on the afrezza side we had 9 8 million of revenue for the quarter 21 growth year over year our afrezza pediatric trial site certification continued to increase each month and were on track for our patient goals for 2022 we also kicked off the afrezza basal combination study which i ll show you some progress on that very shortly and finished a quarter with 233 million in cash on a tyvaso dpi update we are deferring the unitor on any questions related to indications fda approval timelines any questions on the label that will all go through unitor they are handling the day to day communications with the fda we do look at the decision and we are excited to continue to focus on what we can control which is manufacturing commercial products for launch in q2 as well building out the plant expansion to support the additional readouts that ut expects for copd and ipf on mnkd 101 which is our clofazimine product we have completed part a yesterday thank god so we have done cohorts a 1a2 and a3 leave out those patients up to 90 milligrams which is the highest dose we thought we should go and we ve so far have seen great tolerability with no safety signals we ll now wait for the full data set to be analyzed along with pk and pd and assess the proper doses here for part b well now on the low end we ll go to 30 milligrams which we think is more than enough to overcome any mics and we are debating whether to go to 90 or 60 based on the data coming out of part a we think we can go to 90 and it would probably make sense to go to 90 just to have the max tolerated dose top lines are expected here in q3 from the mad part obviously in part a we know the safety and tolerability of clofazimine looks very strong in the nebulized formulation i m now going to bridge a little bit over to the afrezza because we haven t spent a lot of time on afrezza last few earnings calls but i thought we should share with you some of the activities we re doing and what s changed over the last few months starting in february we had a refocused effort and that effort is starting to show early signs of impact on driving nrx ultra acting share so on the left side you can see here this is our patient funnel we look at all patients coming into afrezza assist which is our reimbursement hub as well as our cash program as well as our free goods program which takes out a lot of the costs that used to exist in our old program and you can see on average we re at about 187 patients a week now involved in one of these three programs up from 122 so these are patients that don t necessarily show up in the symphony if they are free goods or cash pay but this is activity that s showing continued growth and momentum of the diabetes franchise when we look on the right side we started refocusing our efforts on ultra acting share which is defined as and afrezza and we ve had a multi year decline in share and this year we changed our field incentive comp as well as our target list to really focus on moving market share back in the right direction we had our first sales meeting in person in the last three years due to covid and that meeting happened and you can see early on nrxs which is where you ll see that progress we ve gained almost 1 market share through april since january with this new focus we ll continue to watch this closely this is one of our key metrics for 2022 and we re excited about what that can bring on inhale 1 this is our pediatric trial we now have 18 sites confirmed these are high quality us investigators from leading academic centers as well as some of the top private practice doctors we met with our colleagues in europe and there was some interest in a couple countries such as germany israel and italy to add a pediatric site in those countries to get experience for those investigators who have a strong desire to learn more about inhaled insulin as we think about filing in europe sometime down the road what you can see here on the u s only focused so far is we are meeting and exceeding our target enrollment and we the randomization there s a delay of a couple weeks between time we get enrolled in the time they actually randomize so it s not that we ve lost 16 or 17 patients in these numbers there s just a delay from the time they actually enter the trial to the time they re actually randomized i think only one randomization failure has happened so far but otherwise this trial is on track to continue to hit our goals for this year the next trial i want to talk about which again we haven t given much focus on we ve referred this previously as the pump switch trial if you look up on clinicaltrials gov it s called the afrezza with basal combination study and one of the things we ve realized about afrezza is a lot of people enjoy their insulin pumps that have type 1 diabetes and a lot of them when we get questions about our script refill trends it turns out a good proportion of type 1 used afrezza for special occasions or their mealtime on top of their pump and so we have no clinical data in showing what afrezza plus an aid pump looks like in greater than one dose for some of the trials were done years ago we also have zero data on switching a patient often insulin pump so we can show people safely how to switch from their insulin pump to afrezza tresiba and show that they can have hopefully equal or better glucose control and quality of life this is the first time in history that we can see that there s a pump switch from a pump over to afrezza and we also decided to maintain a control group so we can see what happens if we take people on a pump and continue them on the pump for the duration of the 12 weeks so we ll really be able to compare in this pilot study staying on your pump adding afrezza to your pump only for your mealtime using the pump just for your basil and or switching off calling a detached lifestyle over to afrezza plus tresiba and the reason this is important as we do see an opportunity in the future where we see once weekly basils coming that s a very compelling proposition for patients as well as oral basil potentially watching what do later this year with their readout and type 2s so i want to understand how best to use afrezza in different combinations this trial s primary output is no difference in a1c between the three treatment options the good news is pretty much by the end of this month this trial will be fully enrolled and we should have the results here in late q3 early q4 i think when you look at clinical trials the excitement around enrollment tells you the excitement around the trial and the fact is this trial enrolled literally in 60 days these 25 patients so we re very excited about it its two sites very focused effort here and we we ll await these results very shortly in the next quarter or two now i m going to turn it over to our cfo steve binder steven binder thanks mike and good afternoon please to review select first quarter financial results please supplement this call by reading the condensed consolidated financial statements and mdna contains our 10 q which is being filed with the sec this afternoon let s start by looking at revenues for first quarter of 2022 afrezza net revenue was 9 8 million versus 8 1 million in 2021 a growth rate of 21 the increase was driven by wholesaler inventory ordering patterns during the first quarter of 2021 which were adversely impacted as wholesalers decreased inventory levels plus price including a more favorable growth to net deduction of 38 7 and underlying trx growth moving to collaboration services revenue for the first quarter was 2 2 million versus 9 3 million for 2021 the revenue in the first quarter was mainly associated with united therapeutics specifically the next gen r a efforts clinical supplies for patients in the brief study extension and some pass through expenses we did not have and did not expect to have revenue from our commercial supply agreement with united therapeutics in the first quarter we expect to start recognizing revenue associated with the ut commercial supply agreement in the second quarter revenue associated with the manufacturing activity in the first quarter of 2022 was deferred on the balance sheet in the amount of 7 4 million which i will discuss in greater detail in a few minute from a cash standpoint we were able to invoice and collect from united therapeutics for these manufacturing activities the graph on our next slide shows the quarterly of afrezza gross margin trend from the first quarter of 2021 through the first quarter of 2022 our gross margin for the first quarter of 2022 was a record 77 which in fact increasing afrezza net revenue and lower cost of goods mainly related to the absorption of indirect and overhead costs at our factory where we now produce two products we expect the gross margin for afrezza to be at least 70 for the full year 2022 but it can fluctuate quarter to quarter based on manufacturing activity and spend across both products the next slide is similar to one that i showed last quarter and that we have been deferring the revenue associated with our tyvaso dpi manufacturing activities since the second quarter of 2021 and will not be able to recognize this revenue until we sell product to ut which we expect in the second quarter of 2022 for the first quarter of 2022 we have 7 4 million in manufacturing expenses recognized in our p l without a corresponding revenue offset since the second quarter of 2021 the amount of manufacturing expenses recognized in our p l without a corresponding revenue offset totaled 21 million which sits on our balance sheet as of march 31 2022 deferred revenue will be recognized over the manufacturing services agreement life which currently runs to 2031 united therapeutics is funding this cost as we ve been invoicing and collecting from ut now that we have looked at afrezza and collaboration services separately let s look at the gross profit and gross margin for both side by side please note that collaborations and services is mostly associated with our agreements with ut afrezza gross margin increased from 47 in the first quarter of 2021 to 77 in the first quarter of 2022 we discussed earlier and the gross profit associated with afrezza increased almost 100 to a record 7 5 million the collaboration services was loss for the first quarter of 2022 was mainly due to the revenue deferral i just spoke about we expect this to term positive once revenue is allowed to be recognized when we start selling product to ut let me conclude with some final comments having done our convertible debt and sale lease back financings in 2021 before the capital market downturn this year we are in a strong financial position to fund our growth with a cash and investments balance of 233 million as of march 31st in addition with rising interest rates which are likely to continue for some time we are well positioned with minimized interest rate risk the vast majority of our debt which includes the convertible mann debts are at a fixed rate of 2 5 also anticipating a rising interest rate environment we negotiated an interest rate ceiling for our floating rate debt with midcap about a year ago with a maximum exposure of only 1 over the current rate operationally we are showing continued progress in turning afrezza into a money making brand and we are preparing to support the expected commercial launch of tyvaso dpi as the fda action date approaches thank you now i turn back over to mike for some additional comments michael castagna you re saying the money making brand was a great comment steve steven binder all right michael castagna thank you everyone so talking about the pipeline here so we remain very excited about the pipeline we talked about afrezza and tyvaso dpi and clofazimine the next couple things we ll start to hear about over the coming quarters will imatinib going forward and the outcome of bleomycin model as well as dna alpha and thirona these programs take a little more time in the beginning and then once we get them through and get the cmc part working these programs progress quite rapidly in the coming years additionally on the cannabinoid side receptor life sciences received fd  and ind for the fda to progress their development and we continue to keep in touch with fosun around their small molecule inhibitor and how that s progressing in development we ll continue to look for more collaborations on our technology platform as we continue move forward post the next fda action date with tyvaso when we look at our milestones for 2022 we clearly lay out every year and you can see so far we re on track to meet and most of these milestones exceed them we obviously did not hit the first one which we think was very important on the tyvaso dpi pdufa date that s been extended to may and we remain optimistic about that date and our ability to hopefully get tyvaso to patients here in q2 so one i think important thing when we come to you on our next earning call will be two additional sources of revenue as related to out back in q4 earning s call on tyvaso manufacturing and tyvaso royalties the bars of revenue growth for mannkind continue to grow and we look very look  look out very forward about the exciting opportunities we have to exponential grow revenue over the coming years between afrezza collaboration services business development as well as manufacturing and royalties we re going to stop there and open it up for questions question and answer session operator thank you your first question comes from the line of brandon folkes from cantor fitzgerald your line is open brandon folkes hi thanks for taking my questions and congratulations on another good quarter brandon folkes obviously confident on the tyvaso dpi approval but how should we think about optic spending just in the case where tyvaso dpi does not get approved this month perhaps pushed off a little bit just any color in of how we should think about maybe some levers in your current opex spend that may come down and then secondly maybe just on afrezza can you just elaborate and apologize if i missed this but where was wholesaler inventory at the end of this quarter thank you michael castagna okay i think the first one i would say and steve correct me afrezza and tyvaso even there was a delay that s mostly picked  this is all picked up by ut and that s why i see some of the deferred revenue on our p l so that doesn t impact our particular cash burn or anything around mannkind and also inventory steve steven binder yes inventory remained constant between december of 2021 and march of 2022 so it wasn t much of a wholesaler inventory channel change brandon folkes great thanks and one more if i may obviously just with that very strong cash balance you have how do you think about maybe bringing in licensing a few more pipeline products obviously you pull through pretty robust pipeline but i guess do you have the capacity maybe asked in different way to bring in additional products just given valuations for in licensing maybe coming down thank you michael castagna yes brandon i think m a is going to be something we continue to evaluate as a company we ve had a lot of inbound interest on looking at different opportunities so far in 2022 obviously a lot of companies i think there is about 170 companies trading for less than cash value so there s opportunities in that space there s also opportunities for companies continuing to streamline their  the products that they re going to focus on and then there s plenty of pipeline opportunities to go but i think on the pipeline we feel pretty good about the shots on goal that we have in progressing those on the ability to find additional cash generating assets i think is where our focus is because we think we can continue to harmonize the g a expense and the p l that we have as well as the infrastructure we ve built up so i think we ll continue to watch out for those as valuations have become more normal in the last couple of years things were just ridiculous but i do think things are finally coming in a good range that we re sitting in a good spot as a company to continue to look at these things brandon folkes thanks that s very helpful i appreciate it congrats again michael castagna thank you operator your next question comes from the line of gregory renza from rbc capital markets your line is open gregory renza hey good afternoon michael and steve congratulations on the progress and thanks for taking my question maybe just building on the previous question with respect to tyvaso dpi decision coming up and maybe just around scenario planning i think you answered the question just around opex i m just curious how various scenarios playing out whether of course it s approval but as mentioned delay or otherwise how you think about the potential permutations of your strategy that you earlier mentioned of business development are there accelerants that we would see or other things to contemplate with respect to that that decision coming with tyvaso coming up thank you michael castagna hey greg i don t want to comment too much i think we re literally within weeks of the fda decision i think we just got to wait for that to come through and i think that ll bring a lot of clarity around the anxiety i hear from our shareholders what does this mean from indication what does this mean from the platform what does this mean from mannkind and like i said i think our focus is making sure we have product supply available upon launch and approval and i think that s what we want to make sure we re ready for ut but i want to really defer a lot of tyvaso related questions for us we have enough cash we show out the balance sheet last year even if there was another delay it doesn t fundamentally change how mannkind s operating we look at this as all upside to the current operating plan that we have and that s some of the decisions we made last year around the sale lease back and the convertible debt was so that we can fund our pipeline and fund our growth and not be fully dependent on the unit the decisions and the fda some of the interactions there but obviously want this we think it s important to get the patients we re excited to partner with ut they ve been an incredible partner and we want to get this to patients as soon as possible we want to make sure we can supply and be there and so hopefully that gives you some clarity but i think if things are delayed it doesn t shift anything we do that much we still want to go up inventory we still want to be ready day one of launch and we re focused on our pipeline and our platform equally as much right now gregory renza great that s really helpful appreciate all the color and looking forward to the update operator your next question comes from the line of thomas smith from svb securities your line is open thomas smith hey guys good afternoon thanks for taking the questions and congrats on the progress just on tyvaso dpi i understand ut is handling all the fda communications directly but i was wondering if you could comment on whether there s been any other requests where you ve had to provide data to the agency since the last submission i think it was back in february that led to the major amendments michael castagna i would thomas i don t want to speak on behalf of ut they re the ones having face to face request i  from my knowledge and perspective i don t think there s been anything major that s come in since the initial request but i d have to refer to ut to answer that properly thomas smith okay okay michael castagna coming out prior to mannkind i can tell you that thomas smith okay that s helpful and then just on the tyvaso dpi commercial manufacturing preparations could you just give us an update on where you are in terms of scale up activities has there been any changes to your plans or your forecast on manufacturing here over the last couple of months as we get closer to the anticipated launch later this year michael castagna no i think the only thing we continue to try to do is we re purposed a lot of equipment over the years that we had and we want to make sure that equipment s operating optimally how we increase yield how do we increase product loss in the process so i think we re just trying to continue to improve everything that this team has set out to do and honestly a lot of it s been operator training and so they are more proficient they make a lot of clinical batches they made some practice runs they obviously go through validation so i think that s helping all the new employees gain a lot of experience with our process and our equipment and that s probably the biggest thing we can be doing is just continue to build proficiency because the operation is going to be running 24x7 for the foreseeable future so i think that s number one is making sure we re keeping our talent we re training our talent and we re getting them proficient in how to operate it s a very multiple step process with different teams involved so i think just getting each of those teams on a 24x7 basis operating running equipment properly is really important thomas smith okay got it and then just one last one maybe on the afrezza pediatric study can you just remind us how many sites you re ultimately targeting and then as you think about expanding your sites here into europe how are you thinking about the balance the regional enrollment between the u s versus ex u s sites michael castagna yes i think on the sites we ve gone back and forth but somewhere between 25 and 40 is  i think 40 is probably the max you would go to we ve got a couple investigators who have seven patients eight patients and growing so i think it s just a matter if we had 25 sites each getting 10 patients we will be done in the next nine months excuse me in terms of enrollment so i just think it s how are we enrolling how are we tracking and it takes time to get a lot of these academic centers up and running from a contractual basis so several great sites like in boston stanford these guys are just coming on board right now so we haven t even really started a lot of the academic centers so i think let s see how they re progressing i think in europe we don t have a target number i think it was more nice to hear some thought leaders that are really podium type presenters want to be involved in the trial and so we re looking to see we weren t trying to go to europe but it doesn t hurt us to have a few sites in europe collect some patients there and i think in that market medtronic 7ag was all the hype at attd and thinking about an alternative opportunity to those patients who aren t on pumps is a real market opportunity in new york that we got to look at and i think some of these countries have decent reimbursement and many of them don t have decent reimbursement so i think it s just trying to understand what is the value proposition of afrezza for example can you justify the cost of insulin pump or avoidance of a pump and that cost is equal to afrezza versus mdi injection so i think really understanding our pump switch trial that we re doing how that s going to show outcomes and efficacy as well as the efficacy we get in peds will start to drive some of the the strategy for ex u s but ultimately just getting peds done and getting good results will be important and but we think probably 25 to 35 sites is going to get us there thomas smith got it that makes sense all right guys thanks for taking the questions appreciate it michael castagna thank you operator your next question comes from the line of bert hazlett from btig your line is open bert hazlett yes thanks congrats on all the progress and my apologies if some of this has been touched upon but i came on late but just with regard to afrezza and the focus on the ultra acting share nice to hear everybody has been able to get back together with salesforce meetings is there any contemplation of potential salesforce expansion should this gain traction down the road or is that something that maybe really not under contemplation you re really trying to find out more about what strategies are working or what could work at this point michael castagna i think bert like we will always  if we see ways to grow the company faster we now have the capital to deploy so if alejandro and ben and our team leading efforts over there we can start to show some consistent week over week and month over month growth trends and marketing programs are starting to work i think we have a good plan for ada and aace so we have some good conferences this year some good podium presentations so again if the noise is positive we re seeing the momentum we re happy to fuel that fire to make it grow faster we re not looking to spend more than we are in a meaningful way until we start to see some additional progress but we are willing to in the event we do see that continue bert hazlett okay great and then just with regard to tyvaso dpi maybe you touched on it but apologies if you have have you talked about expectations for the label of this and then could you just comment on potential competitive landscape as you think about dpi rolling out again obviously you are with a great partner but love to hear your thoughts on competitive positioning of the molecule or the program thanks michael castagna yes i think bert i m not going to comment on the label i think ut had their earnings call yesterday they were pretty silent about that so i m going to defer to them on any comments on that question and i think on the competitive landscape again i know there s some patent wars between ut and liquidia i m going to defer ultimately to the experts over there on those questions so i don t want to  too much comment only because we re so close to the pdufa date let s get that date across the finish line and then happy to talk further around those things bert hazlett okay head to try though thank you michael castagna if you did it will be bert so thank you thank you bert operator your next question comes from the line of steven lichtman from oppenheimer your line is open unidentified analyst hey this is david on for steve thanks for taking the questions just one for me regarding what s your latest outlook on sort of the macro landscape are you seeing any supply disruptions or inflationary pressures and if so how does that impact your gross margin outlook for the rest of the year thank you michael castagna yes i think overall the company we had to give slightly higher raises than historical we know some of our suppliers are going up a little bit but i ll let steve comment but obviously inflation is impacting everybody but fortunately a lot of our operations are fixed costs and a little bit of variable but steve steven binder yes and a lot of our large supply agreements we had locked in for a period of time some of them will expire during the year and we ll have to renegotiate them so i don t expect right now a huge increase but there is definitely a slight increase over the previous year but we re pretty well locked in for period of time michael castagna and if you think about on the flip side the euro and the dollar has gone in our favor and we have this large insulin supply commitment so that s actually coming down from a cost perspective nicely so fortunately it probably balances each other out but we re not seeing any major supply disruptions we ve bought lot of safety stock where we can see risk and there s things here that pop up but we want to make sure a 2 pump or hose doesn t cause us to have a delay so the biggest impact honestly has been our bluhale device that we ve been working on the chips are going out of stock and there s free manufacturing we got to redo the mother board other boards that s been probably the biggest headache but again that s not impacting afrezza or tyvaso these are launch opportunities enhancements to accelerate growth but they re not on the critical timeline yet but those are probably little things that annoy us unidentified analyst okay great appreciate the color guys steven binder okay thank you dave michael castagna thank you steve operator and there are no other question at this time let me turn the call back to mr michael castagna ceo for closing remarks michael castagna i just want to say thank you to everyone for listening today i know it s a turbulent time and we re on a tremendous amount of stress to continue to perform and fortunately we re coming out of covid but we re entering into an inflationary period with a volatile stock market mannkind is in a really good position to whether the storm we weathered worse over the last five years and we feel very optimistic about the position we re in as well as the opportunity to continue to grow the company on behalf of shareholders and help patients so i just want to say thank you to everyone for all the work and really looking forward to executing the rest of this year and hopefully having a great 2022 thanks again and we ll look forward to  i think we have a couple of investor conferences coming up in the month of may so you ll be hearing about those very shortly operator this concludes today s conference call thank you all for participating you may now disconnect
developing multiple unique cannabinoid psychedelic medicine therapies targeted for u s fda approval and registration completed loyalty option program to raise a 23 6m primarily allocated to clinical r d program plans underway to acquire apirx pharmaceuticals usa llc substantial reduction in ahi in preliminary results of clinical trial assessing ihl 42x in patients with osa incannex healthcare limited nasdaq ixhl is an australian based clinical stage pharmaceutical company that is developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders obstructive sleep apnoea osa traumatic brain injury tbi concussion lung inflammation ards copd asthma bronchitis rheumatoid arthritis and inflammatory bowel disease u s fda approval and registration subject to ongoing clinical success is being pursued for each ixhl drug and therapy under development each indication represents major global markets and currently have no or limited existing registered pharmacotherapy drug treatments available to the public ixhl has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners ixhl completes loyalty option program to raise a 23 6m current cash is approximately a 40 0m on april 28th ixhl announced that it has finalized its loyalty option offer to shareholders to raise a 23 6m ixhl loyalty options expired on april 22 2022 and a total of 67 3m new shares are to be issued shortly as a result of the entitlement program for every two 2 new shares that will be issued one 1 piggy back option will be granted to participants piggy back options will be issued shortly and have an exercise price of a 1 00 equivalent to approx us 18 25 per ads on nasdaq expiring april 28 2023 a total of 33 7m piggy back options will be issued and incannex does not intend to seek approval to list the piggy back options on asx or nasdaq the directors of ixhl collectively hold 175 9m shares in the company and permitted their entitlement of approximately 11 7m shares representing a 4 1m in investment capital to be allocated to a strategic investor group that intend to enhance liquidity via the company s ads program on the nasdaq exchange the additional capital will primarily be allocated to ixhl clinical research and development activities that are significantly ramping up in 2022 and 2023 ixhl to acquire apirx pharmaceuticals usa llc highlights apirx has twenty two 22 active clinical and pre clinical research and development projects therapeutic candidates are targeted at treating pain dementia parkinson s disease restless leg syndrome gastrointestinal diseases periodontitis addiction disorders skin conditions and ophthalmic conditions therapeutic candidates are underpinned by an extensive intellectual property portfolio that includes 19 granted patents and 23 pending patents proposed acquisition price of us 93 3m in all scrip transaction the transaction affirms ixhl position as a global leader in the fields of cannabinoid psychedelic and combination pharmaceuticals on march 24th ixhl announced that it has executed a term sheet with binding commercial terms to wholly acquire apirx pharmaceutical usa llc apirx subject to shareholder approval under asx listing rule 7 1 about apirx first mover in pharmaceutical medicinal product development apirx is an innovative biotechnology company focused on research development and production of prescription pharmaceutical cannabinoid medicines it has twenty two 22 active clinical and pre clinical research and development projects utilizing proprietary technologies the acquisition of apirx brings to ixhl a diverse portfolio of promising therapeutic candidates targeted at treating an extensive range of conditions including pain dementia parkinson s disease restless leg syndrome gastrointestinal diseases periodontitis addiction disorders skin conditions and ophthalmic conditions apirx was established as a corporate entity in the netherlands to amalgamate the intellectual property assets of medicinal cannabis pioneers and apirx co founders dr george anastassov and mr lekhram changoer dr anastassov and mr changoer have collaborated since 2003 to develop the largest privately held patent portfolio pertaining to pharmaceutical cannabinoid inventions globally they previously licensed their technology to axim biotechnologies inc where they were part of the lead management team overseeing a peak market capitalization of approximately us 1 2b in 2017 prior to the assets being privatized by apirx numerous pre clinical studies and clinical trials over the apirx therapeutic candidates have been undertaken to justify the intellectual property portfolio which includes 19 granted patents and 23 pending patents key patents relate to sustained oral mucosal delivery of cannabinoids and cannabinoid combinations through chewing gum oral care cannabinoid compositions cannabinoid ophthalmic solutions topical compositions containing cannabinoids and cannabinoid extraction technologies medicated chewing gum mcg is a novel drug delivery system growing in favor amongst the medical community due to widespread potential applications as an extended release dosage form that provides a continuous release of the medicine contained mcgs are fast acting as they release the active ingredients into the oral mucosa reducing the potential for gastric intolerance amongst patients these qualities amongst others make mcgs an excellent delivery system for medicinal combinations designed to treat sustaining pain and addiction disorders strategic rationale the acquisition of apirx will significantly strengthen the ixhl position as a market leader at the forefront of treatment development it will add a large portfolio of intellectual property with granted and pending patents expand the ixhl addressable markets globally and addressable market sizes by over us 400bn per annum addressable markets globally and addressable market sizes by over us 400bn per annum further enhance the ixhl technical and drug development capability by adding some of the industry s longest standing and best known scientists to the ixhl team technical and drug development capability by adding some of the industry s longest standing and best known scientists to the team expand the ixhl drug delivery capability to include apirx s patented delivery technologies for more information on incannex healthcare limited nasdaq ixhl visit www incannex com au disclaimer the products mentioned are thc free and or compliant with the 2018 farm bill this article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks media contact company name incannex healthcare limited contact person michael miller email send email phone 1 917 633 6086 country united states website
at the start of 2022 it often seemed as if nothing could bring the world together but russia has now managed to change that the country s brutal attack on ukraine is condemned across the board it is uniting people left and right and across national borders that unity is good the time for talk is long past and effective action is necessary meaningful dialogue as we strived for before is not an option for russia which is so blatantly violating international law which is using military force against an independent sovereign nation as ukraine and which is responsible for atrocities for the suffering we see taking place in ukraine every day nato secretary general jens stoltenberg told reporters the action so far has been in sanctions imposed by countries across europe and across the atlantic russian oil and gas are now off limits as is most trade there are more steps ahead at nato and the european union and at the state department the pentagon and allied ministries blueprints are being drawn up to enshrine new policies across virtually every aspect of the west s posture toward moscow from defense and finance to trade and international diplomacy the washington post writes but while the sanctions are starting to bring down the russian economy and hopefully grinding its war machine to a halt one european company disagrees with the policy we don t think sanctions on imports will be appropriate guillaume faury chief executive officer of airbus told reporters this will be a small impact on russia and would have large consequences on the rest of the countries and the industry so we think the no sanction policy actually is the most meaningful one airbus a major weapons producer has an agenda here it imports about half of the titanium it uses from russia it needs titanium to build its planes titanium pairs well with modern carbon frames and wants to secure its russian supply in other words airbus is focused on kissing up to russia and staying on putin s good side in order to maintain its access to russian titanium even though that means turning a blind eye toward the deaths of thousands of innocent ukrainians bloomberg notes the policy is working to date airbus a major customer of russia s vsmpo avisma corp has so far been able to keep importing which hasn t been directly targeted by a growing list of european union sanctions aimed at punishing president putin that is a major mistake weapons manufacturers should follow national policy not make it for the governments they work for by weakening sanctions airbus endangers the entire sanction regime while at the same time trying to grow business with the pentagon by proposing to sell tanker refueling jets to the air force airbus is not the only european company flouting sanctions the christian science monitor reported on may 2 the giant french owned auchan hypermarket has bursting shelves and full stocks of almost everything from toilet paper to fresh meats and vegetables citrus fruits and bananas to a wide range of domestic cheeses and dairy products several american fast food chains such as burger king and subway are still operating in some locations in russia while the heads of those companies wisely closed up shop in russia some franchise owners have kept individual restaurants open internationally the sanctions on are working russia s annual inflation rate is almost double what the united states is encountering economics columnist sebastian mallaby wrote in the washington post in battle you take casualties to inflict larger casualties on the other guy economic warfare is no different he is calling for more and deeper sanctions even as some companies want them removed these companies are on the wrong side of history american policymakers should be taking steps to limit their use of its products and should instead focus on winning the sanctions battle against russia
san diego may 5 2022 prnewswire tusimple nasdaq tsp a global self driving technology company based in san diego california today announced its participation in the following investor conferences on wednesday may 18 2022 at 12 00 p m eastern time management will present in a panel at the bank of america 2022 transportation airlines and industrials conference in boston ma at management will present in a panel at the bank of america 2022 transportation airlines and industrials conference in on tuesday may 24 2022 at 1 00 p m beijing hong kong time management will present in a virtual track presentation at the morgan stanley virtual china summit 2022 at hong kong time management will present in a virtual track presentation at the morgan stanley virtual china summit 2022 on tuesday may 24 2022 at 2 50 p m eastern time management will present in a fireside chat at the j p morgan 50th annual global technology media and communications conference in boston ma at management will present in a fireside chat at the j p morgan 50th annual global technology media and communications conference in on wednesday may 25 2022 management will virtually participate in the 2022 ubs global truck commercial vehicle and powertrain conference management will virtually participate in the 2022 ubs global truck commercial vehicle and powertrain conference on thursday may 26 2022 at 1 05 p m eastern time management will present in a virtual panel at the wolfe 15th annual global transportation industrials conference management will be available for one on one or group meetings with institutional investors at all the conferences above portfolio managers and analysts who wish to request a meeting should contact their institutional sales representative at each sponsoring bank about tusimple tusimple is a global autonomous driving technology company headquartered in san diego california with operations in arizona texas europe and china founded in 2015 tusimple is developing a commercial ready fully autonomous sae level 4 driving solution for long haul heavy duty trucks tusimple aims to transform the 4 trillion global truck freight industry through the company s leading ai technology which makes it possible for trucks to drive safely autonomously operate nearly continuously and reduce fuel consumption by 10 relative to manually driven trucks global achievements include the world s first fully autonomous driver out semi truck run on open public roads and development of the world s first autonomous freight network afn visit us at www tusimple com source tusimple holdings inc
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed corecivic inc let s just stay away inmode ltd if you want med tech you just want edwards lifesciences western midstream partners lp this one s got a great yield really good story get southern california news weather forecasts and entertainment stories to your inbox sign up for nbc la newsletters sghc limited they are doing well and i don t say that idly enterprise products partners lp they are the best in what they do united states steel corp if you re going to own a steel company which i don t honestly recommend right now you re going to own nucor teva pharmaceutical industries ltd i would prefer to see you in something like a ast spacemobile inc i do not know that company but we will do homework on it sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
new york may 5 2022 prnewswire consolidated edison inc con edison nyse ed today reported 2022 first quarter net income for common stock of 602 million or 1 70 a share compared with 419 million or 1 23 a share in the 2021 first quarter adjusted earnings were 522 million or 1 47 a share in the 2022 period compared with 491 million or 1 44 a share in the 2021 period adjusted earnings and adjusted earnings per share in the 2022 and 2021 periods exclude the effects of hypothetical liquidation at book value hlbv accounting for tax equity investments in certain renewable and sustainable electric projects of con edison clean energy businesses inc the clean energy businesses and the net mark to market effects of the clean energy businesses adjusted earnings and adjusted earnings per share in the 2022 period exclude the tax impact on the parent company of hlbv accounting and mark to market effects of the clean energy businesses adjusted earnings and adjusted earnings per share in the 2021 period exclude the impact of the impairment loss related to con edison s investment in stagecoach gas services llc stagecoach our innovative and engaged employees are enabling us to lead the transition to a clean energy future while delivering safe reliable service to our customers and providing strong stable returns to our investors said timothy p cawley the chairman and chief executive officer of con edison during the quarter we helped our customers surpass 400 megawatts of solar capacity placed another battery project into service and continued installing curbside chargers with new york city we are building transmission lines under our reliable clean city program to support renewable energy in new york city and proposing solar investments to benefit our low income customers for the year of 2022 con edison reaffirmed its previous forecast of adjusted earnings per share to be in the range of 4 40 to 4 60 per share adjusted earnings per share exclude the effects of hlbv accounting for tax equity investments in certain renewable and sustainable electric projects of the clean energy businesses and the related tax impact of such hlbv accounting on the parent company approximately 40 million or 0 11 a share after tax and the net mark to market effects of the clean energy businesses and the related tax impact of such mark to market effects on the parent company the amounts of which will not be determinable until year end con edison is considering strategic alternatives with respect to its clean energy businesses con edison s forecast of adjusted earnings per share for the year of 2022 does not include the impact if any that may result from such evaluation see attachment a to this press release for a reconciliation of con edison s reported earnings per share to adjusted earnings per share and reported net income for common stock to adjusted earnings for the three months ended march 31 2022 and 2021 see attachment b for the estimated effect of major factors resulting in variations in earnings per share and net income for common stock for the three months ended march 31 2022 compared to the 2021 period the company s 2022 first quarter form 10 q is being filed with the securities and exchange commission a first quarter 2022 earnings release presentation will be available at www conedison com select for investors and then select press releases this press release contains forward looking statements that are intended to qualify for the safe harbor provisions of section 27a of the securities act of 1933 as amended and section 21e of the securities exchange act of 1934 as amended forward looking statements are statements of future expectations and not facts words such as forecasts expects estimates anticipates intends believes plans will target guidance potential consider and similar expressions identify forward looking statements the forward looking statements reflect information available and assumptions at the time the statements are made and accordingly speak only as of that time actual results or developments might differ materially from those included in the forward looking statements because of various factors such as those identified in reports con edison has filed with the securities and exchange commission including but not limited to that con edison s subsidiaries are extensively regulated and are subject to substantial penalties its utility subsidiaries rate plans may not provide a reasonable return it may be adversely affected by changes to the utility subsidiaries rate plans the failure of or damage to its subsidiaries facilities could adversely affect it a cyber attack could adversely affect it the failure of processes and systems and the performance of employees and contractors could adversely affect it it is exposed to risks from the environmental consequences of its subsidiaries operations including increased costs related to climate change its ability to pay dividends or interest depends on dividends from its subsidiaries changes to tax laws could adversely affect it it requires access to capital markets to satisfy funding requirements a disruption in the wholesale energy markets or failure by an energy supplier or customer could adversely affect it it has substantial unfunded pension and other postretirement benefit liabilities it faces risks related to health epidemics and other outbreaks including the covid 19 pandemic its strategies may not be effective to address changes in the external business environment and it also faces other risks that are beyond its control including inflation and supply chain disruptions con edison assumes no obligation to update or revise any forward looking statements whether as a result of new information future events or otherwise except as required by law this press release also contains financial measures adjusted earnings and adjusted earnings per share that are not determined in accordance with generally accepted accounting principles in the united states of america gaap these non gaap financial measures should not be considered as an alternative to net income for common stock or net income per share respectively each of which is an indicator of financial performance determined in accordance with gaap adjusted earnings and adjusted earnings per share exclude from net income for common stock and net income per share respectively certain items that con edison does not consider indicative of its ongoing financial performance such as the impairment loss related to con edison s investment in stagecoach the effects of the clean energy businesses hlbv accounting for tax equity investors in certain renewable and sustainable electric projects and mark to market accounting and only for the 2022 period exclude the tax impact on the parent company of hlbv accounting and mark to market accounting management uses these non gaap financial measures to facilitate the analysis of con edison s financial performance as compared to its internal budgets and previous financial results and to communicate to investors and others con edison s expectations regarding its future earnings and dividends on its common stock management believes that these non gaap financial measures are also useful and meaningful to investors to facilitate their analysis of con edison s financial performance consolidated edison inc is one of the nation s largest investor owned energy delivery companies with approximately 14 billion in annual revenues and 64 billion in assets the company provides a wide range of energy related products and services to its customers through the following subsidiaries consolidated edison company of new york inc cecony a regulated utility providing electric service in new york city and new york s westchester county gas service in manhattan the bronx parts of queens and parts of westchester and steam service in manhattan orange and rockland utilities inc o r a regulated utility serving customers in a 1 300 square mile area in southeastern new york state and northern new jersey con edison clean energy businesses inc the second largest owners of solar electric projects in north america which through its subsidiaries develops owns and operates renewable and sustainable energy infrastructure projects and provides energy related products and services to wholesale and retail customers and con edison transmission inc which falls primarily under the oversight of the federal energy regulatory commission and through its subsidiaries invests in electric transmission projects supporting its parent company s effort to transition to clean renewable energy con edison transmission manages through joint ventures both electric and gas assets while seeking to develop electric transmission projects that will bring clean renewable electricity to customers focusing on new york new england the mid atlantic states and the midwest attachment a for the three months ended march 31 earnings per share net income for common stock millions of dollars 2022 2021 2022 2021 reported earnings per share basic and net income for common stock gaap basis 1 70 1 23 602 419 impairment loss related to investment in stagecoach pre tax 0 51 172 income taxes a 0 16 52 impairment loss related to investment in stagecoach net of tax 0 35 120 hlbv effects pre tax 0 14 48 1 income taxes b 0 05 15 hlbv effects net of tax 0 09 33 1 net mark to market effects pre tax 0 19 0 19 68 65 income taxes c 0 05 0 05 21 16 net mark to market effects net of tax 0 14 0 14 47 49 adjusted earnings and adjusted earnings per share non gaap basis 1 47 1 44 522 491 a the amount of income taxes was calculated using a combined federal and state income tax rate of 30 for the three months ended march 31 2021 b the amount of income taxes was calculated using a combined federal and state income tax rate of 31 and 25 for the three months ended march 31 2022 and 2021 respectively adjusted earnings and adjusted earnings per share for the 2022 period exclude the tax impact on the parent company of hlbv accounting 3 million and 0 01 for the three months ended march 31 2022 of the clean energy businesses adjusted earnings and adjusted earnings per share for the 2021 period do not exclude the tax impact on the parent company of hlbv accounting immaterial for the three months ended march 31 2021 of the clean energy businesses c the amount of income taxes was calculated using a combined federal and state income tax rate of 31 and 25 for the three months ended march 31 2022 and 2021 respectively adjusted earnings and adjusted earnings per share for the 2022 period exclude the tax impact on the parent company of the mark to market effects 4 million and 0 01 for the three months ended march 31 2022 of the clean energy businesses adjusted earnings and adjusted earnings per share for the 2021 period do not exclude the tax impact on the parent company of the mark to market effects 4 million and 0 01 for the three months ended march 31 2021 of the clean energy businesses attachment b variation for the three months ended march 31 2022 vs 2021 net income for common stock net of tax millions of dollars earnings per share cecony a higher gas rate base 29 0 08 resumption of the billing of late payment charges and other fees to allowed rate plan levels 14 0 04 higher electric rate base 6 0 02 higher interest expense 10 0 03 lower incentives earned under the electric and gas earnings adjustment mechanisms eams 9 0 03 higher stock based compensation costs 6 0 02 higher payroll taxes 4 0 01 weather impact on steam revenues 3 0 01 dilutive effect of stock issuances 0 05 other 7 0 01 total cecony 10 0 02 o r a electric base rate increase 2 0 01 gas base rate increase 2 0 01 other 1 0 01 total o r 3 0 01 clean energy businesses hlbv effects 37 0 10 higher operating revenue 26 0 08 lower operation and maintenance expense 17 0 05 net mark to market effects 2 0 01 higher gas purchased for resale 29 0 09 other 5 0 01 total clean energy businesses 58 0 16 con edison transmission impairment loss related to investment in stagecoach in 2021 125 0 36 other 3 0 01 total con edison transmission 122 0 35 other including parent company expenses impairment tax benefits related to investment in stagecoach in 2021 5 0 01 hlbv effects 3 0 01 other 2 0 01 total other including parent company expenses 10 0 03 total reported gaap basis 183 0 47 impairment loss related to investment in stagecoach in 2021 120 0 35 hlbv effects 34 0 09 net mark to market effects 2 total adjusted non gaap basis 31 0 03 a under the revenue decoupling mechanisms in the utilities ny electric and gas rate plans and the weather normalization clause applicable to their gas businesses revenues are generally not affected by changes in delivery volumes from levels assumed when rates were approved in general the utilities recover on a current basis the fuel gas purchased for resale and purchased power costs they incur in supplying energy to their full service customers accordingly such costs do not generally affect con edison s results of operations source consolidated edison inc
global markets were plunged into chaos last night after central banks ramped up their fight against inflation on a bleak day for the economy the bank of england raised interest rates to a 13 year high while warning inflation will top 10 per cent plunging britain into recession the grim analysis came just a day after the federal reserve raised rates in the us by the most in 22 years in an attempt to get a grip on rising prices the pound plunged more than 2 per cent to a low of 1 2326 a level not seen for nearly two years as officials on threadneedle street sketched out a gloomy forecast of soaring inflation and stalling growth the ftse 100 index gave up most of its gains yesterday afternoon as the bad news sunk in and was trading down 0 5 per cent or 38 7 points early this morning at 7 464 6 wall street in new york stock markets tumbled with more than 1 000 points was wiped off the dow jones industrial average as it fell 3 1 and in new york stock markets tumbled yesterday with more than 1 000 points was wiped off the dow jones industrial average as it fell 3 1 per cent the tech heavy nasdaq index sank by 5 per cent while the s p 500 index of america s top companies slid by 3 6 per cent it was one of the worst days for us stocks since the covid crash of 2020 investors feared a string of rate hikes were on the way despite attempts by the fed on wednesday to downplay its aggressiveness central banks around the world are attempting to push inflation down by raising rates encouraging saving rather than spending but if they hike rates too fast they risk depressing the covid recovery and even tipping economies back into recession this is a worry for high growth companies such as amazon facebook owner meta and netflix as much of their valuation is based on the belief that they will rake in money over the future this could be under threat if the economy slumps and spending falls or if interest rates are higher making borrowing more expensive david madden an analyst at equiti capital said investors were in for a choppy period he added it seems that fears about lower growth in the us are still in circulation despite the fed not acting excessively hawkish investors were relatively sanguine about the fed s 0 5 percentage point rate hike on wednesday evening but this was flipped yesterday as traders digested the dreary economic outlook randy frederick of the schwab center for financial research in the us said the extreme reversal in sentiment was truly extraordinary meta dropped by 7 per cent amazon by 7 6 per cent microsoft by 4 4 per cent and google parent alphabet by 4 7 per cent three bank of england economists vote for a bigger rate hike despite the looming threat of a recession three members of the bank of england s monetary policy committee voted for an even bigger interest rate hike jonathan haskel catherine mann and michael saunders all argued rates should rise from 0 75 per cent to 1 25 per cent they were outvoted by their six colleagues on the mpc including governor andrew bailey who settled on a hike to 1pc bailey said the bank was toeing a narrow line between trying to curb rampant inflation and supporting the economy while rate hikes should help to keep a lid on prices they also run the risk of throwing the covid recovery into reverse as businesses and households face higher borrowing costs the bank itself is forecasting a slump in economic activity from the end of this year as rising prices dampen spending in the uk sterling tanked as investors sold the currency worried that its value would be eroded by rising inflation and an economic slump gloomy forecasts from the bank of england predicted inflation would soar to 10 25 per cent in the fourth quarter its highest level since 1982 in response officials at the central bank hiked interest rates from 0 75 per cent to 1 per cent a level not seen since 2009 bond yields or how much investors expect to be paid to lend rallied in response the yield on 10 year gilts issued by the government was close to 2 per cent a near six year high find the best mortgage or savings deal for you the cost of new mortgages has risen rapidly over the past six months but rates remain low by historic standards savings rates have also risen and best easy access and fixed deals are considerably higher than they were this is money s mortgage finder powered by l c can help you compare rates meanwhile our independent best buy savings tables show the top deals on offer and our savings platform round up has details of how to manage your money in one place and earn boosters mortgages compare rates savings best buy tables savings platforms manage savings in one place the yield on the equivalent us treasury stayed firmly above 3 per cent a level not seen since 2018 the bank warned inflation in britain would once again be pushed higher by rising energy costs when regulator ofgem lifts the price cap on household bills again this autumn oil and gas has become increasingly expensive since vladimir putin s invasion of ukraine as western countries tried to shun russian supplies this means households and businesses will have less to spend elsewhere causing economic output to shrink by 1 per cent in the fourth quarter of this year it will contract by 0 25 per cent across the whole of 2023 the bank said but despite the worries about falling output threadneedle street said it was pushing ahead with plans to end its 895billion money printing programme the scheme involved the bank using its own cash to buy gilts and bonds loans handed by investors to the government and companies bank governor andrew bailey has now instructed employees at the bank to work on a strategy for uk government bond sales he chose not to kick off the sales yesterday instead saying they would start in september at the earliest
shares in asia pacific declined on friday hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 shares on wall street declined sharply overnight with the dow jones industrial average seeing its worst day since 2020 singapore shares in asia pacific largely declined on friday after an overnight drop on wall street sent the dow jones industrial average to its worst day since 2020 hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 in mainland china the shanghai composite slipped 2 16 to end the trading day at 3 001 56 while the shenzhen component shed 2 141 to 10 809 88 in asia of course we re very much influenced by what the u s fed does and the u s economy but now we face the zero covid problem from china richard martin a business consultant and managing director at ima asia told cnbc s street signs asia on friday get dfw local news weather forecasts and entertainment stories to your inbox sign up for nbc dfw newsletters data shows china s recent covid lockdowns are hitting more than just beijing and shanghai where the bulk of new infections have been found a lot of the components and materials come out of china so in addition to weak demand from china we re going to have a shortage of components from china which on the supply side into the markets across asia will stop factories running martin said technology stocks in the region sold off following the tech heavy nasdaq composite s nearly 5 drop overnight stateside shares of tencent declined 4 69 while alibaba fell 6 57 and meituan slipped 4 68 hong kong s hang seng tech index dropped 5 23 to 4 036 26 the broader risk off sentiment also extended to electric vehicle stocks with xpeng plunging 9 84 while nio shed 11 47 in japan shares of conglomerate softbank group dropped 2 27 south korea s kakao slipped 5 28 while industry heavyweight samsung electronics declined 2 06 other asia pacific markets mostly dip south korea s kospi dropped 1 23 on the day to 2 644 51 the s p asx 200 in australia shed 2 16 to close at 7 205 60 singapore s straits times index slipped 1 39 as of 4 20 p m local time japanese stocks bucked the overall trend regionally as they returned to trade on friday after being closed for holidays much of this week the nikkei 225 closed 0 69 higher at 27 003 56 while the topix index gained 0 93 to 1 915 91 msci s broadest index of asia pacific shares outside japan fell 2 74 overnight on wall street the dow jones industrial average plunged 1 063 09 points or 3 12 to 32 997 97 the s p 500 fell 3 56 to 4 146 87 thursday s moves on wall street were a sharp reversal from a wednesday rally after the u s federal reserve increased its benchmark interest rate by half a percentage point in line with market expectations and also the biggest hike in two decades fed chairman powell also indicated raising rates by 75 basis points at a time is not something the committee is actively considering with no obvious news flow to explain the sharp reversal it seems instead that the relief of powell indicating 75bp moves were likely a step too far gave way to a renewed focus on high inflation and a challenging growth outlook taylor nugent an economist at national australia bank wrote in a friday note currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 103 617 after a recent jump from below 103 the japanese yen traded at 130 50 per dollar weaker as compared to levels below 130 seen against the greenback earlier in the week the australian dollar was at 0 7081 after yesterday s decline from levels above 0 721 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 54 to 111 50 per barrel u s crude futures also gained 0 49 to 108 79 per barrel
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
sir martin sorrell put investors on alert after s4 capital said it would finally publish its long awaited full year results the advertising tycoon 77 was forced to delay publication twice in march sending shares in the company tumbling but s4 said it will at last release the figures today shares rose 12 per cent or 35p to 326p ad guru sir martin sorrell pictured was forced to delay publication of s4 capital s full year results twice in march sending shares in the company tumbling the digital advertising agency has come under increased scrutiny over the delay to publishing its results the figures were due on march 18 but its auditor pwc said it was unable to complete the work necessary and pushed back publication to the last day of the month then in an update on march 30 s4 said pwc had refused to sign off its accounts which led to its results being delayed for a second time sorrell who is the largest shareholder in the digital advertising company with a near 10 per cent stake launched s4 in 2018 following his acrimonious departure from wpp clients include tech giants google apple and netflix and german car maker bmw the digital advertising agency employs more than 7 500 people across 33 countries and reached the 1billion unicorn milestone in just over a year sorrell has previously warned he was considering moving his digital advertising agency from london to wall street as it would get a better valuation shares in wpp fell 0 3 per cent or 3p to 1009 5p stock watch helios towers shares in helios towers climbed after revenues for the first three months of this year rose more than a fifth compared with a year earlier in its trading update the phone mast operator s sales for the first quarter reached 103million up from 84million in the same period in 2021 the ftse 250 operates masts that provide mobile signal in eight african countries and hailed success in three new markets senegal madagascar and malawi shares rose 3 5 per cent or 3 9p to 114p while sorrell s announcement created ripples through the market the day belonged to the bank of england threadneedle street grabbed the headlines by raising rates to a 13 year high of 1 per cent and warning that britain was heading towards recession as inflation soars above 10 per cent the update from the bank came after america s central bank the federal reserve raised rates by 0 5 percentage points on thursday night it was the biggest increase in us rates since 2000 despite the interest rates rise the ftse 100 index was up 0 1 per cent or 9 82 points to 7503 27 but the ftse 250 fell 0 6 per cent or 129 52 points to 20089 96 canadian london listed endeavour mining was among the winners on the blue chip index after it beat analysts first quarter estimates in its trading update for the first three months of the year the gold miner s adjusted net earnings reached 98 32million up from 81 41million a year earlier sebastien de montessus president and chief executive said the company started the year on a strong footing and hailed the fact more than 80 84million has been returned to shareholders over the period through dividends and buybacks shares climbed 4 2 per cent or 81p to 2022p also on the up was packaging firm mondi which said it would divest its russian operations in light of the war in ukraine the group s trading update beat market expectations and led to its rating being upgraded to overweight with shares up 4 3 per cent or 64 5p to 1566 5p but it was mixed fortunes for barratt developments shares in the ftse 100 housebuilder rose 0 8 per cent or 3 7p to 488 1p after the group reiterated its desire to complete between 18 000 and 18 250 homes for the full year despite this barratt s trading update also hit out at the unjust and disproportionate way the government plans to expand a levy to finance fire safety repairs it labelled the plans as further punishing housebuilders who were not responsible for most of the historical buildings or building safety issues being addressed shares in pharmaceutical group hikma fell heavily by 9 per cent or 167p to 1685 5p after it announced a delay to the launch of the narcolepsy drug xyrem
khristi zimmeth special to the detroit news more backyard butterflies guest speaker mary ellen van slembrouck and the meadow brook garden club share tips on how to attract more butterflies to your garden at 10 a m may 20 at meadow brook hall van slembrouck will show common butterflies often found in southeast michigan and how gardeners can attract them by planting michigan natives and providing shelter and resources coffee and refreshments will be served reservations are not required but visitors must follow pandemic protocols this presentation is also available through zoom there is a 5 non member fee for more information to confirm that the event is being held in person or to request a zoom link by may 19 that includes a link to make a 5 guest donation email mbgcmembers gmail com call 248 364 6210 or visit meadowbrookhall org mdc helps you plan for the future wondering what your next home will be like as you get older and wishing you had someone to guide you in the many choices bigger or smaller one story or two interior designer renea m lewis from design by choice will guide you in design decisions as you age in your next home offered at 10 a m may 19 at the michigan design center she ll share advice on creating a safe and comfortable home and tips on what to consider when purchasing your next home the event is complimentary but space is limited contact emily at emcdonald michigandesign com to reserve a place visit michigandesign com stock up at bookstock may 15 22 it s back stock up for spring and summer reading at metro detroit s largest used book and media sale after a two year absence bookstock will return to livonia s laurel park place from may 15 22 you ll find deals on more than 400 000 gently used books dvds cds books on tape and vinyl collectors flock to the presale at 8 15 a m may 15 20 presale only which continues through 11 a m proceeds benefit literacy and education projects throughout detroit and oakland and wayne counties and counties in northern michigan the sale has raised more than 2 25 million for literacy and education and includes more than 700 volunteers hours are 11 6 sunday and 11 7 mon through sat new merchandise is added daily visit bookstockmi org clean up with mother s day giveaway feeling lucky don t have a mother s day gift lined up yet there s still time to enter molly maid s clean home for mother s day giveaway which expires at 11 59 p m central time may 8 the company is giving hard working moms the gift they really want this mother s day free time and a clean home according to a press release this is the eighth year they ve offered families the chance to win free cleaning service for their moms the giveaway will award five winners with a 500 gift certificate this is our way of showing appreciation to moms everywhere says molly maid president vera peterson visit mollymaid com spring show at epiphanyglass looking for something different to do on mother s day weekend tap into your creative side or help your mom tap into hers with diy workshops at the annual free spring show at pontiac s epiphany glass offered saturday sunday from 10 a m 5 p m the event features renowned master glass artist april wagner and her team offering hourly glass blowing workshops discounts on artwork and special pet themed items that will benefit the michigan humane society create a vibrantly colored glass flower or sculpted heart and learn about the creation of glass art and its man forms or just enjoy exploring the gallery when it s filled with colorful sculpture and art of all sizes workshops are 95 100 per person registration in advance at is recommended visit epiphanyglass com
cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation while scotts miracle gro might seem cheap on a price to earnings basis management doesn t have a handle on how bad it s going to get the mad money host said cnbc s jim cramer on thursday told investors to resist the urge to add scottsmiracle gro to their portfolios despite the stock s low valuation historically this is a great time of year for anything garden related because it s planting season and scotts is a name that we used to get a ton of questions about but over the past thirteen months these shares have been obliterated the mad money host said get dfw local news weather forecasts and entertainment stories to your inbox sign up for nbc dfw newsletters while scottsmiracle gro might seem cheap on a price to earnings basis the problem is that the earnings forecast keeps coming down and management doesn t have a handle on how bad it s going to get he later added scottsmiracle gro stock fell 6 on thursday the company reported better than expected earnings in its previous quarter two days before jpmorgan upgraded scottsmiracle gro to overweight from neutral on wednesday pointing to the stock s valuation high margins and market leadership stifel downgraded the stock from overweight to hold cramer said that he agrees with stifel s more bearish stance on scotts particularly because of the company s struggles with rising raw costs lack of confidence regarding an earnings target of 8 a share and his concerns with the performance of scotts hawthorne division hawthorne operates in cannabis an industry cramer says has been beaten down for the last year on top of that scotts has an ugly enough balance sheet that they don t see management embracing an aggressive buyback either in short business is bad and there s not much scotts can do to make it better cramer said sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
laval qc and vaughan on may 5 2022 prnewswire bausch lomb corporation bausch lomb a wholly owned subsidiary of bausch health companies inc nyse tsx bhc bausch health today announced the pricing of its initial public offering ipo of 35 000 000 common shares at a public offering price of 18 00 per share a wholly owned subsidiary of bausch health the selling shareholder is offering all of the common shares and bausch lomb will not receive any of the proceeds from the ipo the selling shareholder has granted the underwriters a 30 day option to purchase up to an additional 5 250 000 common shares of bausch lomb to cover over allotments if any at the initial public offering price less underwriting commissions the common shares have been approved for listing on the new york stock exchange nyse and conditionally approved for listing on the toronto stock exchange tsx the common shares are expected to begin trading on the nyse and on an if as and when issued basis on the tsx on may 6 2022 in each case under the ticker symbol blco the offering is expected to close on may 10 2022 subject to customary closing conditions following the ipo bausch health together with its subsidiaries will hold approximately 90 of the common shares of bausch lomb or 88 5 of the common shares of bausch lomb if the underwriters over allotment option is exercised in full morgan stanley and goldman sachs co llc are acting as joint lead book running managers for the ipo citigroup j p morgan barclays bofa securities guggenheim securities jefferies evercore isi wells fargo securities and deutsche bank securities are acting as joint book running managers for the ipo and dnb markets hsbc truist securities amerivet securities loop capital markets ramirez co inc r seelaus co llc siebert williams shank and stern are acting as co managers for the ipo a registration statement relating to these securities has been filed with and declared effective by the u s securities and exchange commission sec on may 5 2022 and a receipt has been obtained for a final base prep prospectus that has been filed with the securities regulatory authorities in each of the provinces and territories of canada other than quebec on may 5 2022 the ipo is only being made by means of a prospectus when available copies of the final prospectus and the supplemented prep prospectus containing pricing information and other important information relating to the common shares and the offering may be obtained from morgan stanley co llc attn prospectus department 180 varick street 2nd floor new york n y 10014 or goldman sachs co llc attn prospectus department 200 west street new york n y 10282 by telephone at 866 471 2526 or by email at a copy of the supplemented prep prospectus will be filed and will become available on sedar at www sedar com by may 9 2022 no securities regulatory authority has either approved or disapproved of the contents of this news release this news release does not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state province territory or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state province territory or jurisdiction about bausch lomb bausch lomb a leading global eye health business of bausch health companies inc is dedicated to protecting and enhancing the gift of sight for millions of people around the world from the moment of birth through every phase of life its comprehensive portfolio of more than 400 products includes contact lenses lens care products eye care products ophthalmic pharmaceuticals over the counter products and ophthalmic surgical devices and instruments founded in 1853 bausch lomb has a significant global research and development manufacturing and commercial footprint with more than 12 000 employees and a presence in nearly 100 countries bausch lomb is headquartered in vaughan ontario with corporate offices in bridgewater new jersey about bausch health bausch health companies inc nyse tsx bhc bausch health is a global company whose mission is to improve people s lives with our health care products bausch health develops manufactures and markets a range of pharmaceutical medical device and over the counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology bausch health is delivering on its commitments as it builds an innovative company dedicated to advancing global health forward looking statements this news release may contain forward looking statements about the potential distribution of the common shares of bausch lomb that bausch health will continue to hold following completion of the bausch lomb ipo which may generally be identified by the use of the words anticipates hopes expects intends plans should could would may believes subject to and variations or similar expressions including statements about the closing of the ipo whether the underwriters will exercise their over allotment option the number of shares to be held by bhc following the ipo and the expectations relating to the listing of the common shares on the nyse and tsx these statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward looking statements in addition actual results are subject to other risks and uncertainties that relate more broadly to bausch health s overall business including those more fully described in bausch health s most recent annual report on form 10 k and detailed from time to time in bausch health s other filings with the u s securities and exchange commission and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forward looking statements these forward looking statements speak only as of the date hereof bausch health undertakes no obligation to update any of these forward looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes unless required by law source bausch lomb corporation bausch health companies inc
shares in asia pacific declined on friday hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 shares on wall street declined sharply overnight with the dow jones industrial average seeing its worst day since 2020 singapore shares in asia pacific largely declined on friday after an overnight drop on wall street sent the dow jones industrial average to its worst day since 2020 hong kong s hang seng index led losses regionally as it fell 3 81 to close at 20 001 96 in mainland china the shanghai composite slipped 2 16 to end the trading day at 3 001 56 while the shenzhen component shed 2 141 to 10 809 88 in asia of course we re very much influenced by what the u s fed does and the u s economy but now we face the zero covid problem from china richard martin a business consultant and managing director at ima asia told cnbc s street signs asia on friday get southern california news weather forecasts and entertainment stories to your inbox sign up for nbc la newsletters data shows china s recent covid lockdowns are hitting more than just beijing and shanghai where the bulk of new infections have been found a lot of the components and materials come out of china so in addition to weak demand from china we re going to have a shortage of components from china which on the supply side into the markets across asia will stop factories running martin said technology stocks in the region sold off following the tech heavy nasdaq composite s nearly 5 drop overnight stateside shares of tencent declined 4 69 while alibaba fell 6 57 and meituan slipped 4 68 hong kong s hang seng tech index dropped 5 23 to 4 036 26 the broader risk off sentiment also extended to electric vehicle stocks with xpeng plunging 9 84 while nio shed 11 47 in japan shares of conglomerate softbank group dropped 2 27 south korea s kakao slipped 5 28 while industry heavyweight samsung electronics declined 2 06 other asia pacific markets mostly dip south korea s kospi dropped 1 23 on the day to 2 644 51 the s p asx 200 in australia shed 2 16 to close at 7 205 60 singapore s straits times index slipped 1 39 as of 4 20 p m local time japanese stocks bucked the overall trend regionally as they returned to trade on friday after being closed for holidays much of this week the nikkei 225 closed 0 69 higher at 27 003 56 while the topix index gained 0 93 to 1 915 91 msci s broadest index of asia pacific shares outside japan fell 2 74 overnight on wall street the dow jones industrial average plunged 1 063 09 points or 3 12 to 32 997 97 the s p 500 fell 3 56 to 4 146 87 thursday s moves on wall street were a sharp reversal from a wednesday rally after the u s federal reserve increased its benchmark interest rate by half a percentage point in line with market expectations and also the biggest hike in two decades fed chairman powell also indicated raising rates by 75 basis points at a time is not something the committee is actively considering with no obvious news flow to explain the sharp reversal it seems instead that the relief of powell indicating 75bp moves were likely a step too far gave way to a renewed focus on high inflation and a challenging growth outlook taylor nugent an economist at national australia bank wrote in a friday note currencies and oil the u s dollar index which tracks the greenback against a basket of its peers was at 103 617 after a recent jump from below 103 the japanese yen traded at 130 50 per dollar weaker as compared to levels below 130 seen against the greenback earlier in the week the australian dollar was at 0 7081 after yesterday s decline from levels above 0 721 oil prices were higher in the afternoon of asia trading hours with international benchmark brent crude futures up 0 54 to 111 50 per barrel u s crude futures also gained 0 49 to 108 79 per barrel
some states previously passed laws banning or restricting access to abortions those laws are now set to go into effect example video title will go here for this video example video title will go here for this video on friday the supreme court ruled in favor of mississippi s anti abortion law in dobbs v jackson women s health organization overturning the 1973 roe v wade decision that made abortion legal nationwide a copy of the supreme court s decision leaked to politico in may led to questions from many of our verify viewers and people on social media asking whether this changes abortion access nationwide some claimed that the decision doesn t make abortion illegal throughout the country and instead sends the issue to individual states by the way if you actually read the decision it doesn t outlaw abortion it sends the legality question of abortion to states and their legislatures to decide tim young timrunshismouth may 3 2022 the question is abortion illegal in all states now that the supreme court overturned roe v wade the sources the answer no abortion isn t illegal in all states now that the supreme court overturned roe v wade states can still pass their own abortion laws to either restrict or guarantee the right to abortions what we found in its 1973 ruling on roe v wade the supreme court found that a fundamental right to privacy is inherent in the fourteenth amendment s due process clause and a person s right to choose whether to have an abortion falls within the right to privacy the court s 1973 decision made it illegal for states to regulate abortion in the first trimester of pregnancy in the second trimester states could impose some regulations on abortion that are reasonably related to maternal health once the fetus reached the point of viability in the third trimester or the point where it could survive outside the womb with medical support a state could regulate or ban abortions so long as the laws contain exceptions for cases when abortion is necessary to save the life or health of the mother however supreme court justice samuel alito wrote in the majority opinion on dobbs v jackson women s health organization which overturns roe v wade that the constitution makes no reference to abortion and no such right is implicitly protected by any constitutional provision including the fourteenth amendment now that roe v wade is overturned the right to an abortion in the first trimester is no longer federally protected but that doesn t mean abortion is illegal in every state in the u s liza fuentes a senior research assistant at the guttmacher institute previously told verify that individual states can make their own laws about abortions benjamin barton a law professor at the university of tennessee knoxville agrees if the draft opinion becomes the actual majority opinion there would no longer be a federal constitutional right to an abortion so the decision as to whether to allow abortions or not would be up to individual states he wrote in an email to verify before the supreme court issued its official ruling about a dozen states have trigger laws to ban all or nearly all abortions set to go into effect now that roe v wade is overturned according to the guttmacher institute more than two dozen u s states are certain or likely to ban abortions in the absence of roe on the other hand some states have passed laws guaranteeing the right to have an abortion without state interference south dakota gov kristi noem said in may that she will call for a special legislative session to restrict access to abortions the state already has a trigger law on the books to ban most abortions following the supreme court s decision in january 2022 new jersey gov phil murphy signed the freedom of reproductive choice act into law codifying the constitutional right to freedom of reproductive choice in the state
new york may 5 2022 prnewswire consolidated edison inc con edison nyse ed today reported 2022 first quarter net income for common stock of 602 million or 1 70 a share compared with 419 million or 1 23 a share in the 2021 first quarter adjusted earnings were 522 million or 1 47 a share in the 2022 period compared with 491 million or 1 44 a share in the 2021 period adjusted earnings and adjusted earnings per share in the 2022 and 2021 periods exclude the effects of hypothetical liquidation at book value hlbv accounting for tax equity investments in certain renewable and sustainable electric projects of con edison clean energy businesses inc the clean energy businesses and the net mark to market effects of the clean energy businesses adjusted earnings and adjusted earnings per share in the 2022 period exclude the tax impact on the parent company of hlbv accounting and mark to market effects of the clean energy businesses adjusted earnings and adjusted earnings per share in the 2021 period exclude the impact of the impairment loss related to con edison s investment in stagecoach gas services llc stagecoach our innovative and engaged employees are enabling us to lead the transition to a clean energy future while delivering safe reliable service to our customers and providing strong stable returns to our investors said timothy p cawley the chairman and chief executive officer of con edison during the quarter we helped our customers surpass 400 megawatts of solar capacity placed another battery project into service and continued installing curbside chargers with new york city we are building transmission lines under our reliable clean city program to support renewable energy in new york city and proposing solar investments to benefit our low income customers for the year of 2022 con edison reaffirmed its previous forecast of adjusted earnings per share to be in the range of 4 40 to 4 60 per share adjusted earnings per share exclude the effects of hlbv accounting for tax equity investments in certain renewable and sustainable electric projects of the clean energy businesses and the related tax impact of such hlbv accounting on the parent company approximately 40 million or 0 11 a share after tax and the net mark to market effects of the clean energy businesses and the related tax impact of such mark to market effects on the parent company the amounts of which will not be determinable until year end con edison is considering strategic alternatives with respect to its clean energy businesses con edison s forecast of adjusted earnings per share for the year of 2022 does not include the impact if any that may result from such evaluation see attachment a to this press release for a reconciliation of con edison s reported earnings per share to adjusted earnings per share and reported net income for common stock to adjusted earnings for the three months ended march 31 2022 and 2021 see attachment b for the estimated effect of major factors resulting in variations in earnings per share and net income for common stock for the three months ended march 31 2022 compared to the 2021 period the company s 2022 first quarter form 10 q is being filed with the securities and exchange commission a first quarter 2022 earnings release presentation will be available at www conedison com select for investors and then select press releases this press release contains forward looking statements that are intended to qualify for the safe harbor provisions of section 27a of the securities act of 1933 as amended and section 21e of the securities exchange act of 1934 as amended forward looking statements are statements of future expectations and not facts words such as forecasts expects estimates anticipates intends believes plans will target guidance potential consider and similar expressions identify forward looking statements the forward looking statements reflect information available and assumptions at the time the statements are made and accordingly speak only as of that time actual results or developments might differ materially from those included in the forward looking statements because of various factors such as those identified in reports con edison has filed with the securities and exchange commission including but not limited to that con edison s subsidiaries are extensively regulated and are subject to substantial penalties its utility subsidiaries rate plans may not provide a reasonable return it may be adversely affected by changes to the utility subsidiaries rate plans the failure of or damage to its subsidiaries facilities could adversely affect it a cyber attack could adversely affect it the failure of processes and systems and the performance of employees and contractors could adversely affect it it is exposed to risks from the environmental consequences of its subsidiaries operations including increased costs related to climate change its ability to pay dividends or interest depends on dividends from its subsidiaries changes to tax laws could adversely affect it it requires access to capital markets to satisfy funding requirements a disruption in the wholesale energy markets or failure by an energy supplier or customer could adversely affect it it has substantial unfunded pension and other postretirement benefit liabilities it faces risks related to health epidemics and other outbreaks including the covid 19 pandemic its strategies may not be effective to address changes in the external business environment and it also faces other risks that are beyond its control including inflation and supply chain disruptions con edison assumes no obligation to update or revise any forward looking statements whether as a result of new information future events or otherwise except as required by law this press release also contains financial measures adjusted earnings and adjusted earnings per share that are not determined in accordance with generally accepted accounting principles in the united states of america gaap these non gaap financial measures should not be considered as an alternative to net income for common stock or net income per share respectively each of which is an indicator of financial performance determined in accordance with gaap adjusted earnings and adjusted earnings per share exclude from net income for common stock and net income per share respectively certain items that con edison does not consider indicative of its ongoing financial performance such as the impairment loss related to con edison s investment in stagecoach the effects of the clean energy businesses hlbv accounting for tax equity investors in certain renewable and sustainable electric projects and mark to market accounting and only for the 2022 period exclude the tax impact on the parent company of hlbv accounting and mark to market accounting management uses these non gaap financial measures to facilitate the analysis of con edison s financial performance as compared to its internal budgets and previous financial results and to communicate to investors and others con edison s expectations regarding its future earnings and dividends on its common stock management believes that these non gaap financial measures are also useful and meaningful to investors to facilitate their analysis of con edison s financial performance consolidated edison inc is one of the nation s largest investor owned energy delivery companies with approximately 14 billion in annual revenues and 64 billion in assets the company provides a wide range of energy related products and services to its customers through the following subsidiaries consolidated edison company of new york inc cecony a regulated utility providing electric service in new york city and new york s westchester county gas service in manhattan the bronx parts of queens and parts of westchester and steam service in manhattan orange and rockland utilities inc o r a regulated utility serving customers in a 1 300 square mile area in southeastern new york state and northern new jersey con edison clean energy businesses inc the second largest owners of solar electric projects in north america which through its subsidiaries develops owns and operates renewable and sustainable energy infrastructure projects and provides energy related products and services to wholesale and retail customers and con edison transmission inc which falls primarily under the oversight of the federal energy regulatory commission and through its subsidiaries invests in electric transmission projects supporting its parent company s effort to transition to clean renewable energy con edison transmission manages through joint ventures both electric and gas assets while seeking to develop electric transmission projects that will bring clean renewable electricity to customers focusing on new york new england the mid atlantic states and the midwest attachment a for the three months ended march 31 earnings per share net income for common stock millions of dollars 2022 2021 2022 2021 reported earnings per share basic and net income for common stock gaap basis 1 70 1 23 602 419 impairment loss related to investment in stagecoach pre tax 0 51 172 income taxes a 0 16 52 impairment loss related to investment in stagecoach net of tax 0 35 120 hlbv effects pre tax 0 14 48 1 income taxes b 0 05 15 hlbv effects net of tax 0 09 33 1 net mark to market effects pre tax 0 19 0 19 68 65 income taxes c 0 05 0 05 21 16 net mark to market effects net of tax 0 14 0 14 47 49 adjusted earnings and adjusted earnings per share non gaap basis 1 47 1 44 522 491 a the amount of income taxes was calculated using a combined federal and state income tax rate of 30 for the three months ended march 31 2021 b the amount of income taxes was calculated using a combined federal and state income tax rate of 31 and 25 for the three months ended march 31 2022 and 2021 respectively adjusted earnings and adjusted earnings per share for the 2022 period exclude the tax impact on the parent company of hlbv accounting 3 million and 0 01 for the three months ended march 31 2022 of the clean energy businesses adjusted earnings and adjusted earnings per share for the 2021 period do not exclude the tax impact on the parent company of hlbv accounting immaterial for the three months ended march 31 2021 of the clean energy businesses c the amount of income taxes was calculated using a combined federal and state income tax rate of 31 and 25 for the three months ended march 31 2022 and 2021 respectively adjusted earnings and adjusted earnings per share for the 2022 period exclude the tax impact on the parent company of the mark to market effects 4 million and 0 01 for the three months ended march 31 2022 of the clean energy businesses adjusted earnings and adjusted earnings per share for the 2021 period do not exclude the tax impact on the parent company of the mark to market effects 4 million and 0 01 for the three months ended march 31 2021 of the clean energy businesses attachment b variation for the three months ended march 31 2022 vs 2021 net income for common stock net of tax millions of dollars earnings per share cecony a higher gas rate base 29 0 08 resumption of the billing of late payment charges and other fees to allowed rate plan levels 14 0 04 higher electric rate base 6 0 02 higher interest expense 10 0 03 lower incentives earned under the electric and gas earnings adjustment mechanisms eams 9 0 03 higher stock based compensation costs 6 0 02 higher payroll taxes 4 0 01 weather impact on steam revenues 3 0 01 dilutive effect of stock issuances 0 05 other 7 0 01 total cecony 10 0 02 o r a electric base rate increase 2 0 01 gas base rate increase 2 0 01 other 1 0 01 total o r 3 0 01 clean energy businesses hlbv effects 37 0 10 higher operating revenue 26 0 08 lower operation and maintenance expense 17 0 05 net mark to market effects 2 0 01 higher gas purchased for resale 29 0 09 other 5 0 01 total clean energy businesses 58 0 16 con edison transmission impairment loss related to investment in stagecoach in 2021 125 0 36 other 3 0 01 total con edison transmission 122 0 35 other including parent company expenses impairment tax benefits related to investment in stagecoach in 2021 5 0 01 hlbv effects 3 0 01 other 2 0 01 total other including parent company expenses 10 0 03 total reported gaap basis 183 0 47 impairment loss related to investment in stagecoach in 2021 120 0 35 hlbv effects 34 0 09 net mark to market effects 2 total adjusted non gaap basis 31 0 03 a under the revenue decoupling mechanisms in the utilities ny electric and gas rate plans and the weather normalization clause applicable to their gas businesses revenues are generally not affected by changes in delivery volumes from levels assumed when rates were approved in general the utilities recover on a current basis the fuel gas purchased for resale and purchased power costs they incur in supplying energy to their full service customers accordingly such costs do not generally affect con edison s results of operations source consolidated edison inc
new york after breathing a sigh of relief when the federal reserve held off on signaling more aggressive measures ahead to fight inflation wall street tumbled on thursday amid renewed anxiety over rising interest rates while the pound slumped on fears of a uk recession the sell off was new york s worst since 2020 and saw the nasdaq dominated by tech firms that are particularly sensitive to higher rates lose five per cent while the dow and s p 500 fell more than three per cent with us inflation at levels not seen since the 1980s the fed on wednesday hiked the key lending rates by half a per centage point but cheered markets at least at first by saying a three quarter point increase was not in the cards that message was not as hawkish as feared but the fed still is engaged in one of the most aggressive tightening cycles that we have seen in decades said angelo kourkafas investment strategist at edward jones it didn t necessarily change the narrative that economic growth is slowing while the fed will tighten monetary policy at a fast pace pound slips in britain the pound suffered after the bank of england released an updated forecast predicting annual inflation would rise above 10 per cent and the economy would contract later this year while hiking its main rate by an as expected quarter point the pound plunged more than two per cent due to the changes in the economic forecasts which pointed to a potential recession by year end and the warnings that rates may not rise as high as markets had been expecting in the months ahead said market analyst michael hewson at cmc markets uk the boe said uk output was expected to contract in the final quarter of the year when inflation is likely to enter double digits as household energy prices rise sharply although the central bank does not forecast a full blown recession for the moment uncertainty over inflation and growth puts rate setters in a tricky dilemma city index analyst fawad razaqzada said the key risk facing the uk is not necessarily tighter policy but uncertainty over monetary policy and more to the point stagflation central banks worldwide are raising interest rates to fight inflation that is sitting at the highest levels in decades as economies ease pandemic restrictions while dealing with the war in ukraine which increased already high energy costs news that turkish inflation soared to 70 per cent in april highlighted the battle policymakers face in controlling prices
it s that time again mad money host jim cramer rings the lightning round bell which means he s giving his answers to callers stock questions at rapid speed corecivic inc let s just stay away inmode ltd if you want med tech you just want edwards lifesciences western midstream partners lp this one s got a great yield really good story get dfw local news weather forecasts and entertainment stories to your inbox sign up for nbc dfw newsletters sghc limited they are doing well and i don t say that idly enterprise products partners lp they are the best in what they do united states steel corp if you re going to own a steel company which i don t honestly recommend right now you re going to own nucor teva pharmaceutical industries ltd i would prefer to see you in something like a ast spacemobile inc i do not know that company but we will do homework on it sign up now for the cnbc investing club to follow jim cramer s every move in the market disclaimer questions for cramer call cramer 1 800 743 cnbc want to take a deep dive into cramer s world hit him up mad money twitter jim cramer twitter facebook instagram questions comments suggestions for the mad money website madcap cnbc com
listen to this article listen to this article washington ap the federal reserve intensified its fight against the worst inflation in 40 years by raising its benchmark short term interest rate by a half percentage point wednesday its most aggressive move since 2000 and signaling further large rate hikes to come the increase in the fed s key rate raised it to a range of 0 75 to 1 the highest point since the pandemic struck two years ago the fed also announced that it will start reducing its huge 9 trillion balance sheet which consists mainly of treasury and mortgage bonds those holdings more than doubled after the pandemic recession hit as the fed bought trillions in bonds to try to hold down long term borrowing rates reducing the fed s holdings will have the effect of further raising loan costs throughout the economy all told the fed s credit tightening will likely mean higher loan rates for many consumers and businesses over time including for mortgages credit cards and auto loans speaking at a news conference wednesday chair jerome powell made clear that further large rate hikes are coming there is a broad sense on the committee he said referring to the fed that additional half point increases should be on the table in the next couple of meetings but powell also sought to downplay any speculation that the fed might be considering a rate hike as high as three quarters of a percentage point a 75 basis point hike is not something that the committee is actively considering he said a remark that appeared to cause stock indexes to rise with prices for food energy and consumer goods accelerating the fed s goal is to cool spending and economic growth by making it more expensive for individuals and businesses to borrow the central bank hopes that higher borrowing costs will slow spending enough to tame inflation yet not so much as to cause a recession it will be a delicate balancing act the fed has endured widespread criticism that it was too slow to start tightening credit and many economists are skeptical that it can avoid causing a recession at his news conference powell stressed his belief that restoring price stability that is curbing high inflation is essential to sustaining the economy s health in their statement wednesday the central bank s policymakers noted that russia s invasion of ukraine is worsening inflation pressures by raising oil and food prices it added that covid related lockdowns in china are likely to exacerbate supply chain disruptions which could further boost inflation inflation according to the fed s preferred gauge reached 6 6 last month the highest point in four decades inflation has been accelerated by a combination of robust consumer spending chronic supply bottlenecks and sharply higher gas and food prices exacerbated by russia s war against ukraine starting june 1 the fed said it would allow up to 48 billion in bonds to mature without replacing them a pace that would reach 95 billion by september at september s pace its balance sheet would shrink by about 1 trillion a year powell has said he wants to quickly raise the fed s rate to a level that neither stimulates nor restrains economic growth fed officials have suggested that they will reach that point which the fed says is about 2 4 by year s end the fed s credit tightening is already having some effect on the economy sales of existing homes sank 2 7 from february to march reflecting a surge in mortgage rates related in part to the fed s planned rate hikes the average rate on a 30 year mortgage has jumped 2 percentage points just since the start of the year to 5 1 yet by most measures the overall economy remains healthy this is especially true of the u s job market hiring is strong layoffs are few unemployment is near a five decade low and the number of job openings has reached a record high powell has pointed to the widespread availability of jobs as evidence that the labor market is tight to an unhealthy level that would tend to fuel inflation the fed char is betting that higher rates can reduce those openings which would presumably slow wage increases and ease inflationary pressures without triggering mass layoffs for now with hiring robust the economy has added at least 400 000 jobs for 11 straight months and employers grappling with labor shortages wages are rising at a roughly 5 annual pace those pay raises are driving steady consumer spending despite spiking prices in march consumers increased their spending 0 2 even after adjusting for inflation even if the fed s benchmark rate were to go as high as 2 5 by year s end powell said last month the policymakers may still tighten credit further to a level that would restrain growth if that turns out to be appropriate financial markets are pricing in a rate as high as 3 6 by mid 2023 which would be the highest in 15 years shrinking the fed s balance sheet will add another layer of uncertainty surrounding how much the fed s actions may weaken the economy
example video title will go here for this video example video title will go here for this video some states previously passed laws banning or restricting access to abortions those laws are now set to go into effect on friday the supreme court ruled in favor of mississippi s anti abortion law in dobbs v jackson women s health organization overturning the 1973 roe v wade decision that made abortion legal nationwide a copy of the supreme court s decision leaked to politico in may led to questions from many of our verify viewers and people on social media asking whether this changes abortion access nationwide some claimed that the decision doesn t make abortion illegal throughout the country and instead sends the issue to individual states by the way if you actually read the decision it doesn t outlaw abortion it sends the legality question of abortion to states and their legislatures to decide tim young timrunshismouth may 3 2022 the question is abortion illegal in all states now that the supreme court overturned roe v wade the sources the answer no abortion isn t illegal in all states now that the supreme court overturned roe v wade states can still pass their own abortion laws to either restrict or guarantee the right to abortions what we found in its 1973 ruling on roe v wade the supreme court found that a fundamental right to privacy is inherent in the fourteenth amendment s due process clause and a person s right to choose whether to have an abortion falls within the right to privacy the court s 1973 decision made it illegal for states to regulate abortion in the first trimester of pregnancy in the second trimester states could impose some regulations on abortion that are reasonably related to maternal health once the fetus reached the point of viability in the third trimester or the point where it could survive outside the womb with medical support a state could regulate or ban abortions so long as the laws contain exceptions for cases when abortion is necessary to save the life or health of the mother however supreme court justice samuel alito wrote in the majority opinion on dobbs v jackson women s health organization which overturns roe v wade that the constitution makes no reference to abortion and no such right is implicitly protected by any constitutional provision including the fourteenth amendment now that roe v wade is overturned the right to an abortion in the first trimester is no longer federally protected but that doesn t mean abortion is illegal in every state in the u s liza fuentes a senior research assistant at the guttmacher institute previously told verify that individual states can make their own laws about abortions benjamin barton a law professor at the university of tennessee knoxville agrees if the draft opinion becomes the actual majority opinion there would no longer be a federal constitutional right to an abortion so the decision as to whether to allow abortions or not would be up to individual states he wrote in an email to verify before the supreme court issued its official ruling about a dozen states have trigger laws to ban all or nearly all abortions set to go into effect now that roe v wade is overturned according to the guttmacher institute more than two dozen u s states are certain or likely to ban abortions in the absence of roe on the other hand some states have passed laws guaranteeing the right to have an abortion without state interference south dakota gov kristi noem said in may that she will call for a special legislative session to restrict access to abortions the state already has a trigger law on the books to ban most abortions following the supreme court s decision in january 2022 new jersey gov phil murphy signed the freedom of reproductive choice act into law codifying the constitutional right to freedom of reproductive choice in the state
stocks fell thursday in response to looming fallout from the federal reserve s stepped up fight against inflation a sharp sell off left the dow jones industrial average more than 1 000 points lower thursday wiping out the gains from wall street s biggest rally in two years as worries grow that the higher interest rates the federal reserve is using in its fight against inflation will derail the economy the benchmark standard poor s 500 index fell 3 6 marking its biggest loss in nearly two years a day after it posted its biggest gain since may 2020 the nasdaq composite slumped 5 its worst drop since june 2020 the losses by the dow and the other indexes offset the gains from a day earlier yesterday s sharp rally was not rooted in reality and today s dramatic sell off is a reversal of that misplaced exuberance said ben kirby co head of investments at thornburg investment management advertisement wall street s breakneck reversal reflects the degree of investors uncertainty and unease over the array of threats the economy is facing starting with inflation running at the highest level in four decades and how effective the federal reserve s bid to tame higher prices by jacking up interest rates will be on wednesday the fed raised its benchmark interest rate by half a percentage point as part of an effort to slow consumer borrowing and tamp down inflation the market rallied when fed chair jerome h powell dismissed the possibility the fed could resort to a more aggressive three quarter point hike in the future now traders are starting to fret more about the effect of the fed s moves to damp demand and slow the economy the fed is between a rock and a hard place and because of instant information investors are experiencing both fear and greed at the exact same moment said sam stovall chief investment strategist at cfra the fed s aggressive shift to raise interest rates has investors worrying about whether it can pull off the delicate dance to slow the economy enough to halt high inflation but not so much as to cause a downturn the pace and size of interest rate increases are being scrutinized closely on wall street investors realized that by the fed continuing to take a very measured approach it could actually allow inflation to remain out of control stovall said advertisement business as inflation soars how is arizona iced tea still 99 cents tall cans of arizona iced tea have cost 99 cents since 1992 the family behind the company says it s committed to that price even as the prices of aluminum and corn syrup climb higher the fed s half point increase had been widely expected the central bank also announced that on june 1 it will start reducing its huge 9 trillion balance sheet which consists mainly of treasury and mortgage bonds those large holdings are a policy tool the fed uses to keep long term interest rates such as those on mortgages low powell s assurance that a 0 75 point increase is not in the offing doesn t mean the fed is done raising rates as it fights to tame inflation economists at bnp paribas expect the fed to keep raising the federal funds rate until it reaches a range of 3 to 3 25 up from zero to 0 25 earlier this year we do not think this was chair powell s intention economists at bnp paribas wrote in a report citing the market s jubilance wednesday and we reckon we could see coming fedspeak seek to retighten financial conditions the bank of england on thursday raised its benchmark interest rate to the highest level in 13 years its fourth rate hike since december as u k inflation runs at 30 year highs energy markets remain volatile as the conflict in ukraine continues and demand remains high amid tight supplies of oil european governments are trying to replace energy supplies from russia and are considering an embargo opec and allied oil producing countries decided thursday to gradually increase the flows of crude they send to the world higher oil and gas prices have been contributing to the uncertainties weighing on investors as they try to assess how inflation will ultimately affect businesses consumer activity and overall economic growth advertisement the latest corporate earnings reports are also being closely watched by investors trying to get a better picture of inflation s effect on the economy cereal maker kellogg rose 3 5 after reporting encouraging financial results etsy stumbled 16 8 after giving a weak forecast twitter rose 2 7 after elon musk said he had secured more backing for his bid to take over the company technology companies had some of the biggest losses and weighed down the broader market in a reversal from the solid gains they made a day earlier internet retail giant amazon slumped 7 6 and google s parent company fell 4 8 home builders fell broadly as average long term home loan rates climbed d r horton slid 5 9 the average rate on a 30 year fixed rate mortgage rose to 5 27 this week its highest level since 2009 according to mortgage buyer freddie mac a year ago it averaged 2 96 mortgage rates tend to follow moves in the 10 year treasury yield the sharp increase in mortgage rates has strained affordability for home buyers after years of sharply rising prices associated press writer stan choe contributed to this report
framingham mass business wire clinical enterprise inc d b a empowerdx today announced the launch of a revolutionary at home celiac risk gene test the launch combined with becoming a sponsor of the celiac disease foundation puts empowerdx in a unique position to help a large population of americans in debilitating physical and mental pain without clear answers the celiac disease foundation leads the fight to increase the rate of diagnosis improve treatments and find a cure celiac disease is a genetic autoimmune condition where the body s immune system attacks the small intestine when gluten is consumed more than 99 of people who develop celiac disease carry one of the genetic variants identified in our test symptoms can range from abdominal issues and joint pain to brain fog depressed mood and concentration issues if left untreated celiac disease can lead to serious health complications including heart disease intestinal cancers and fertility issues an estimated three million americans have celiac disease with increased risk awareness and accessible testing more of these individuals can be properly diagnosed currently 60 70 of individuals with celiac disease are misdiagnosed or undiagnosed on average it takes 6 10 years for a symptomatic individual to be diagnosed with celiac disease celiac disease can present with a spectrum of gastrointestinal and non gastrointestinal symptoms which can make early diagnosis challenging knowledge of disease risk facilitates the path to proper diagnosis for physicians and healthcare providers the empowerdx celiac risk gene test provides access to high quality hla genetic testing which requires specialized equipment and rare expertise at a remarkable value unlike most blood based celiac disease genetic tests the empowerdx assay uses a sample taken from two non invasive mouth swabs to analyze hla markers results for each marker are provided to individuals through a secure online portal ten business days after sample receipt at the company s clia certified lab the test is 199 and available for ages 3 susceptibility to celiac disease is strongly associated with the hla alleles dqa1 05 02 and dqb1 02 01 but these markers alone do not necessarily mean people have or will develop the disease individuals with the presence of genetic markers should consult with their physician on how to monitor for celiac disease and improve their overall gut health testing negative for all three markers means the lifetime risk of developing celiac disease is less than one percent the revolutionary at home celiac risk gene test is characteristic of the ethos defining the mission of empowerdx celiac disease affects the lives of millions of people in the us and this test bridges to the gap between demand and access to a test critical to lifetime risk assessment eurofins donor product testing inc performs the molecular testing and carries extensive experience to test and interpret hla results boston area based empowerdx now has a robust portfolio of more than 20 products including the first at home pfas test as well as mthfr coq10 vitamin d apoe and one of the most sensitive at home covid pcr tests on the market the start up strives to make testing for a wide range of issues including heart sexual and mental health thyroid and vitamin deficiencies affordable and accessible to the consumer for more information on the empowerdx celiac risk gene test please visit empowerdxlab com about empowerdx launched in 2019 empowerdx is the online shop for easy at home health testing empowerdx specializes in fda authorized covid 19 testing women s health men s health sexual health and general wellness testing along with its affiliated clia certified clinical laboratories in the u s empowerdx is positioned to lead the market for cutting edge self collected diagnostic and non diagnostic testing all clinical tests are reviewed by empowerdx s licensed ordering physician to eliminate the need for a phlebotomist or a telemedicine observed sample collection welcome to health clarity with just a few clicks the company is based outside of boston in framingham ma and is a subsidiary of the eurofins group to learn more please visit empowerdxlab com about eurofins the global leader in bio analysis eurofins is testing for life with 58 000 staff across a network of 900 laboratories in 54 countries eurofins companies offer a portfolio of over 200 000 analytical methods eurofins shares are listed on euronext paris stock exchange ________________________________
listen to this article listen to this article boeing co said thursday it will move its headquarters from chicago to the washington d c area where company executives would be closer to key federal government officials the company said it will use its campus in arlington virginia as the new headquarters and it plans to develop a research and technology hub in the area the region makes strategic sense for our global headquarters given its proximity to our customers and stakeholders and its access to world class engineering and technical talent boeing ceo david calhoun said the move marks a win for virginia s republican gov glenn youngkin who campaigned last year on a promise to bring new jobs to the state youngkin retired in 2020 as co ceo of private equity giant the carlyle group he was personally involved in discussions about the move and had a prior business relationship with calhoun who also was an executive in the investment industry according to a person familiar with the matter who was not authorized to discuss the negotiations publicly a spokeswoman for the state s economic development agency didn t immediately respond to questions about whether the state had offered the company any tax or other incentives boeing is a major defense contractor and the move will put executives close to pentagon leaders rival defense contractors including general dynamics lockheed martin and northrop grumman already are based in the d c area company executives would also be near the federal aviation administration which certifies boeing passenger and cargo planes boeing s relationship with the faa has been strained since deadly crashes of its best selling plane the 737 max in 2018 and 2019 the faa took nearly two years far longer than boeing expected to approve design changes and allow the plane back in the air certification of new boeing planes will take longer too the company has suffered financial setbacks in building a refueling tanker for the air force and it has been hurt by the pandemic which undercut travel and demand for new planes boeing lost 1 2 billion in this year s first quarter boeing s roots are in the seattle area and it has assembly plants in washington state and south carolina the company moved its headquarters to chicago in 2001 after an unusually public search that also considered dallas and denver cai von rumohr an aerospace analyst for cowen said there were advantages for boeing moving its headquarters to the washington d c area or back to seattle where leaders again would be closer to the company s important commercial operations chicago does nothing for them von rumohr said boeing had 142 000 employees at the end of 2021 including 12 based outside the united states according to a regulatory filing the filing did not say how many work in chicago richard aboulafia an analyst with consultant aerodynamic advisory said boeing s chicago work force is minimal making the move easier u s rep peter defazio chairman of the house transportation committee which investigated boeing and the faa after the max crashes criticized boeing s move to be closer to federal policy makers boeing should focus on making safe airplanes not lobbying federal regulators and congress he said meanwhile many of virginia s elected officials celebrated the news democratic state senate majority leader dick saslaw called it one hell of a catch democratic u s sen tim kaine a member of the senate armed services committee said boeing s decision was a testament to virginia s skilled workforce and strong national security community u s sen mark warner also a democrat indicated the deal had been in the works for quite some time for well over a year i ve been making my case to boeing senior leadership that virginia would be a great place for its headquarters and late last year i was happy to learn that my efforts were successful he said in a statement the company s statement thanked both youngkin and warner boeing will be following in the footsteps of amazon which decided to put a second headquarters in arlington last month local officials approved amazon s plans to erect a 350 foot helix shaped building
some states previously passed laws banning or restricting access to abortions those laws are now set to go into effect example video title will go here for this video example video title will go here for this video on friday the supreme court ruled in favor of mississippi s anti abortion law in dobbs v jackson women s health organization overturning the 1973 roe v wade decision that made abortion legal nationwide a copy of the supreme court s decision leaked to politico in may led to questions from many of our verify viewers and people on social media asking whether this changes abortion access nationwide some claimed that the decision doesn t make abortion illegal throughout the country and instead sends the issue to individual states by the way if you actually read the decision it doesn t outlaw abortion it sends the legality question of abortion to states and their legislatures to decide tim young timrunshismouth may 3 2022 the question is abortion illegal in all states now that the supreme court overturned roe v wade the sources the answer no abortion isn t illegal in all states now that the supreme court overturned roe v wade states can still pass their own abortion laws to either restrict or guarantee the right to abortions what we found in its 1973 ruling on roe v wade the supreme court found that a fundamental right to privacy is inherent in the fourteenth amendment s due process clause and a person s right to choose whether to have an abortion falls within the right to privacy the court s 1973 decision made it illegal for states to regulate abortion in the first trimester of pregnancy in the second trimester states could impose some regulations on abortion that are reasonably related to maternal health once the fetus reached the point of viability in the third trimester or the point where it could survive outside the womb with medical support a state could regulate or ban abortions so long as the laws contain exceptions for cases when abortion is necessary to save the life or health of the mother however supreme court justice samuel alito wrote in the majority opinion on dobbs v jackson women s health organization which overturns roe v wade that the constitution makes no reference to abortion and no such right is implicitly protected by any constitutional provision including the fourteenth amendment now that roe v wade is overturned the right to an abortion in the first trimester is no longer federally protected but that doesn t mean abortion is illegal in every state in the u s liza fuentes a senior research assistant at the guttmacher institute previously told verify that individual states can make their own laws about abortions benjamin barton a law professor at the university of tennessee knoxville agrees if the draft opinion becomes the actual majority opinion there would no longer be a federal constitutional right to an abortion so the decision as to whether to allow abortions or not would be up to individual states he wrote in an email to verify before the supreme court issued its official ruling about a dozen states have trigger laws to ban all or nearly all abortions set to go into effect now that roe v wade is overturned according to the guttmacher institute more than two dozen u s states are certain or likely to ban abortions in the absence of roe on the other hand some states have passed laws guaranteeing the right to have an abortion without state interference south dakota gov kristi noem said in may that she will call for a special legislative session to restrict access to abortions the state already has a trigger law on the books to ban most abortions following the supreme court s decision in january 2022 new jersey gov phil murphy signed the freedom of reproductive choice act into law codifying the constitutional right to freedom of reproductive choice in the state
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
updated may 5 2022 at 5 40 pm et it was an ugly day on wall street with stocks going from one of their best days in recent memory to one of their worst on thursday the dow fell by 1 063 points just a day after gaining nearly 1 000 points the s p 500 and the tech heavy nasdaq suffered similar swings after they had one of their best days since 2020 the sharp turnaround denotes the incredible volatility in markets and the deepening fears that the economy may be headed to a recession as the federal reserve embarks on one of its most aggressive fights against inflation in years i think we need to prepare ourselves for a volatile market said savita subramanian head of u s equity and quantitative strategy at bank of america securities subramanian said markets are adjusting for a new environment of higher interest rates after enjoying historically low rates for years i mean for the last 30 or 40 years we have seen rates slowly grinding down to zero and we are embarking now on the opposite of that she said it mainly hinges on the fed on wednesday the fed raised interest rates by half a percentage point as wall street expected the fed said more rate hikes of that size are on the table as the central bank intensifies its fight against persistently high inflation but investors were relieved after fed chair jerome powell appeared to rule out increases larger than half a percentage point at future meetings the positive feelings did not last just hours later markets went the opposite way as investors reckoned with the hard reality that interest rates are going up which is bound to raise borrowing costs across the economy from mortgages to bank loans jim watson afp via getty images afp via getty images federal reserve chair jerome powell takes questions from reporters during a news conference in washington dc on wednesday the fed wants to engineer a soft landing for the u s economy by raising rates just enough to cool inflation without kickstarting a recession but investors are worried the central bank will overdo its rate hikes tipping the economy into a deep downturn in its quest to bring down inflation those fears are leading to the dramatic swings in markets an ugly ugly year for markets the falls on thursday extend what has been an ugly year for markets the fed s rate hikes also come at a time of deep uncertainty about the global economy as russia s invasion of ukraine continues and china is in the midst of lockdowns to tamp down a covid outbreak technology stocks had quite a run during the pandemic but they were among the biggest decliners on thursday netflix amazon and meta facebook s parent company all slumped by about 7 higher interest rates put pressure on high growth technology stocks in particular because they are more dependent on debt other companies that saw their shares surge during the pandemic are experiencing a reversal this year peloton closed down 9 wayfair ended down 25 7 and carvana the used car retailer was off almost 18 bonds were also hit hard on wednesday with the yield on the 10 year treasury trading over 3 its highest level since 2018 copyright 2023 npr to see more visit
using the term white privilege puts people off campaigning for social justice a study has found the phrase made discussions less constructive more polarised and less supporting over racially progressive policies researchers said a more inclusive term such as racial inequality was found to be better at creating a sense of shared purpose white privilege refers to the idea that white people enjoy unearned benefits over other ethnicities due to biases in society using the term white privilege puts people off campaigning for social justice a study has found stock image the university of michigan spoke to nearly 1 000 people 82 per cent of whom were white they were asked should colleges rename buildings that were named after people who actively supported x for half the group x was replaced with the phrase racial inequality and for the others it was replaced with white privilege the research in the journal plos one found the number supporting the cause fell by 26 percentage points when the latter was used the university of michigan pictured spoke to nearly 1 000 people 82 per cent of whom were white the study s lead author christopher quarles said mentioning white privilege was enough to flip white support for renaming college buildings from primarily supportive to primarily opposing the term first appeared in academia in the 1980s but became more widely used over the past decade amid heightened racial tensions the study said it came under the spotlight in the uk last year after a parliamentary report suggested teaching it in schools was divisive and pitted pupils against each other last year education secretary nadhim zahawi said schools must not teach children about white privilege as if it were fact last year education secretary nadhim zahawi said schools must not teach children about white privilege as if it were fact he warned it was a contested view and teachers who promote it risk pushing partisan politics on to pupils the minister spoke out after a report by the commons education committee suggested that teaching white privilege could be against the equality act it highlighted how white working class pupils had been neglected by the education system for decades
